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Chronic viral hepatitis, caused by Hepatitis B (HBV) or Hepatitis C (HCV) infection is a global public 
health concern, and contributes considerable health burdens from chronic liver disease, liver 
cirrhosis, hepatocellular carcinoma and death. The advent of new curative directly-acting antiviral 
drugs for HCV, and better treatment and management for HBV, offers an opportunity to improve 
outcomes for more than 300 million affected individuals. 
In the UK approximately 0.4% of the population are infected with chronic HBV or chronic HCV, but 
prevalence is higher in immigrant populations.  
Primary care can provide an important opportunity for case-finding infected individuals by offering 
testing to high-risk populations.   
The HepFREE Trial: “Chronic Viral Hepatitis in First and Second Generation Immigrants from ‘At Risk’ 
Countries. A controlled randomised cross sectional cluster trial to assess the impact of identifying, 
screening and treating immigrants with viral hepatitis” reports on screening of immigrants in 
Bradford, London and Oxfordshire in the UK, and subsequent follow-up care. 
In this thesis, I outline the background to viral hepatitis screening in primary care and the 
methodology of the HepFREE Trial.  I analyse screening outcomes, disease staging and follow-up care 
of positive subjects, as well as qualitative research on the experience of healthcare professionals 
involved in trial delivery.  I analyse a pre-screening survey exploring demographics, knowledge of 
viral hepatitis and treatment experience of a population of eligible individuals before the screening 
began. 
I present current knowledge about viral hepatitis screening in primary care, the outcomes of a large 
multicentre national screening and follow-up trial, and the barriers and facilitators to screening as 
identified by healthcare providers and the high-risk patient population.    I discuss my findings and 
how they contribute to our current understanding and future strategies for improvement of case-
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Chronic Viral Hepatitis caused by infection with the Hepatitis B virus (HBV) or Hepatitis C virus (HCV) 
is an ongoing global public health concern, despite the advent of new curative directly-acting 
antiviral (DAA) therapies for HCV and protocols for the monitoring and suppression of HBV.  
Approximately 257 million people are infected with chronic HBV (1), and 71 million are infected with 
HCV (1) , with more than 1.34 million deaths in 2015 attributable to chronic active hepatitis, cirrhosis 
or primary liver cancer due to infection by these viruses (1).   
Over the last two decades there has been a marked increase in morbidity and mortality due to viral 
liver disease.  Low testing and diagnosis rates, as well as the poor efficacy and multiple adverse 
events associated with interferon based therapy, led to many individuals with chronic HBV and HCV 
infection progressing to advanced liver disease(2).  However, access to new National Institute for 
Health and Care Excellence (NICE)-approved DAA therapies for HCV, along with better treatment and 
surveillance management for HBV, offers an opportunity to reduce end stage liver disease, 
hepatocellular carcinoma and mortality rates related to chronic infection with these viruses. With 
the development of highly efficacious DAA treatment, the focus for reducing morbidity and mortality 
from viral hepatitis is now on case-finding and engagement. 
In the United Kingdom, seroprevalence studies in 2014-15 estimated 0.4% of the population are 
infected with chronic HBV (3) , and 0.4% infected with chronic HCV (2).  Surveillance and research 
studies in England have found that of those screened for HCV, 2.2% of individuals of South Asian 
origin and 5.0% of eastern Europeans tested positive (2).  However, there is a lack of robust, 
quantitative studies on identifying, testing and treating HBV and HCV among immigrant populations 
living in the UK (3). 
Late diagnosis is major contributor to the mortality and morbidity caused by these viruses – 17% of 
HCV infections are diagnosed late (i.e. at a time of concurrent liver cirrhosis or hepatic 
decompensation within 12 months of diagnosis) (4).  Early diagnosis provides an opportunity to 
prevent progression to liver fibrosis or cirrhosis and to test contacts and vaccinate those at risk of 
hepatitis B.  Patients who are diagnosed late have often presented to healthcare professionals 
(HCPs) and have not been offered a viral hepatitis test on multiple opportunities (4). 
Primary Care HCPs can play a key role in case-finding infected individuals.  Screening of patients from 
high-risk groups has been shown to be cost-effective (5)  and is estimated to be so in primary care 
settings (6) .The HepFREE Trial : “Chronic Viral Hepatitis in First and  Second Generation Immigrants 
from ‘At Risk’ Countries. A controlled randomised cross sectional  cluster trial to assess the impact of  
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identifying, screening and treating immigrants with viral hepatitis” reports on screening of one high-
risk group, immigrants who reside in Bradford, London and Oxfordshire in the UK, and the 
subsequent follow-up care of those who test positive in standard care versus primary care settings. 
In this thesis, I outline the background to viral hepatitis screening in primary care and the 
methodology of the HepFREE Trial and describe my role in managing the trial in its final 3 years.  I 
analyse screening outcomes, disease staging and follow-up care of those who tested positive.   
My substudy “The HepFREE Provider Experience” is qualitative research on the experience of 
healthcare professionals involved in the provision of primary care screening for viral hepatitis. 
I also analyse the pre-screening surveys of patients from the immigrant populations who were 
subsequently invited to participate in the HepFREE Study.  These surveys explored demographics, 
knowledge of viral hepatitis and testing, vaccination and treatment experience of a population of 
eligible individuals before the screening was launched. 
I discuss my findings in the context of current challenges in HBV and HCV care and future strategies 
for viral hepatitis case-finding in primary care.  In this thesis I present the current knowledge about 
viral hepatitis screening in primary care, the outcomes of a large multicentre national screening and 
follow-up trial, and the barriers and facilitators to screening as identified by healthcare providers 
and the at-risk patient population.  These findings contribute to our current understanding of how to 
improve case-finding for viral hepatitis in primary care in the UK. 
 
1.2 Background 
Approximately 257 million people are infected with HBV and 71 million with HCV worldwide (1).  In 
the UK, approximately 175,000 people are living with HBV and 200,000 with HCV.  Around 75% of 
these individuals are undiagnosed (2,7). Infection with HBV or HCV can lead to swelling and scarring 
(fibrosis) of the liver, which over time increases the risk of progression to liver cirrhosis and liver 
failure.  Annual deaths from HCV have almost quadrupled in the last 20 years, in contrast to many 
other important chronic conditions (8). There is also a risk of communicating HBV or HCV to others, 
via mother-to-child transmission, sexual contact, and sharing of needles and injecting materials.  As 
such the Lancet Commission launched the UK Liver Disease Crisis highlighting the importance of a 
joined-up approach to liver care.  Three key points focussed on the role of primary care in improving 
the public’s liver health: (i) improving expertise and facilities in primary care to strengthen detection 
of early disease and screening of high-risk patients in the community, (ii) eradication of chronic HCV 
from UK by 2030 and major reduction in the burden of HBV disease, (iii) increasing awareness of 
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liver disease in the general population and NHS.  Improved screening programmes in primary care, 
more effective pathways to treatment and ensuring ongoing engagement with therapy should be 
the focus if we are to achieve a reversal in the current escalating rates of viral hepatitis disease (8). 
To understand the challenges in meeting the goal of improving viral hepatitis care amongst 
immigrants in England, we must first understand the current background to viral hepatitis care.  
 
1.3 Brief History of Hepatitis B and Hepatitis C Viruses 
Although it was the 20th Century before molecular components of viral hepatitis were understood, 
“epidemic jaundice” was first described by Hippocrates in De Morbus Internis in 4th Century BC 
(9,10).  
Hepatitis B Virus (HBV) is a blood-borne DNA virus which was first discovered in 1967 by Blumberg 
(11) although as early as 1908 viruses were proposed as having a causative role in liver disease (12).  
By the 1940s the existence of two hepatitis viruses had been posited – hepatitis A, transmitted by 
the faecal-oral route and hepatitis B, transmitted by blood (13).  
In the late 1950s, Baruch Blumberg, an American physician and geneticist, began collecting multiple 
serum samples from various ethnicities around the world in order to understand the associations 
between disease, genetics and environment.   
By the early 1960s, Blumberg and Anthony Allison, biochemist at the National Institute of Health 
(NIH) in the USA, developed agar gel diffusion techniques to detect novel polymorphisms (genetic 
variations).  They focussed their studies on detecting the presence of a novel antigen-antibody 
complex which formed in samples from patients who had received multiple blood transfusions 
compared to those who had received none.  The presence of this complex suggested that transfused 
patient’s blood now contained antibodies previously exposed to protein polymorphisms in other 
transferred blood products.  Blumberg and Allison reasoned that these polymorphisms may be 
antigenic.  Therefore patients receiving multiple blood transfusions could develop antibodies against 
variants that they themselves had not inherited or acquired (11). 
Harvey Alter, working at the NIH transfusion service, collaborated with Blumberg on agar gel 
diffusion testing samples from Blumberg’s global collection and samples from patients who had 
received multiple blood transfusions.  
One antibody found in a transfused haemophiliac patient reacted with the serum from a native 
Australian Aborigine.  As the Aborigine’s sample did not react with any other transfused samples this 
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raised the possibility that the rare reaction was due to infection rather than genetic variation.   
Testing the serum of the haemophiliac patient against thousands of other samples showed around 
10% of samples from leukaemia patients reacted to the sample compared to 1 in 1000 non-
haemophiliac blood donor samples.  This new protein was named the “Australia” Au antigen.  
At first Blumberg and Alter hypothesised that the Au antigen (Au Ag) increased the risk of developing 
leukaemia, and so tested for Au Ag in patients with Down’s Syndrome (who have increased risk of 
developing leukaemia).  Although Au Ag was found in up to one third of patient’s with Down’s, 
newborn babies from the same population tested negative compared to older children and adults 
housed in large institutions.  Also, one young boy who had initially tested positive showed the 
presence of Au Ag when tested again a few months later.  The boy was noted to have developed 
hepatitis at the time of repeat testing.  On testing of further samples by Blumberg and other 
researchers in New York and Tokyo a clear link between the presence of the Au Ag in patients who 
developed hepatitis was made.   
Subsequent isolation by electron microscopy and description of the whole virus in sera of patients 
testing positive for Au Ag, and in liver cells of patients with hepatitis by Dane et al led to the Au 
antigen as being renamed the Hepatitis B (transmission via blood) Surface antigen (HBsAg) (14).  
HBsAg became the marker of HBV infection. 
The development of diagnostic markers for hepatitis A and B led to the recognition that some clearly 
infectious hepatitis was caused by another virus – originally named non-A, non-B hepatitis. 
Hepatitis C virus (HCV) was first isolated as non-A non-B in 1989 by Choo et al (15) and found to be 
the cause of more than 90% of non-A non B hepatitis in the USA (16).    Anti-HCV antibody is the 
marker of Hepatitis C infection, with further testing for HCV ribonucleic acid (RNA) as a marker of 










1.4 Viral Structure 
1.4.1 HBV Structure 
HBV is a hepadnavirus: a small enveloped-virus with double stranded circular deoxyribonucleic acid 
(DNA) (17).  Replication is by reverse transcription: HBV virions deliver their DNA into hepatocytes at 
the time of infection (18).  Viral DNA is then converted to covalently closed circular DNA (cccDNA).  
This serves as a transcriptional template for ribonucleic acid (RNA) and messenger RNA (mRNA) for 
HBsAg, HBV e Antigen and core antigen (HBeAg, HBcAg)(19). Multiple factors impact upon the 
clinical course of chronic HBV infection – these include host immune response, HBV viral strain and 
level of HBV DNA replication.  In particular, age of acquisition is a key factor – the earlier the age of 
exposure, the more likely lifelong infection incurs (20).  Presence of HBeAg is an indicator of active 
viral replication, and individuals with high levels (>107 IU/mL) of replicating HBV DNA are highly 
contagious (21). 
 
Figure 1: Hepatitis B virus structure 
Copyright-free image of virus taken from Shutterstock 
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1.4.2 HCV Structure 
Hepatitis C virus (HCV) is an RNA virus belonging to the fabiviridae family (9). HCV is found in 
hepatocytic cytoplasm where it replicates at a rate of between 1010 to 1012 virions per day.  Rapid 
viral replication is one of the reasons that the HCV genome mutates frequently, resulting in high 
genetic diversity characterised by regional variations in genotype prevalence (9). 
Seven HCV genotypes have been described (known as Genotypes 1-7), with genotype 1 (G1) being 
the most common across the globe affecting 40% of those infected, and genotype 3 (G3) the second 




Figure 2: Hepatitis C virus structure 











1.5 Natural History of HBV Infection and HCV Infection 
1.5.1 Natural History of HBV Infection 
Acute Hepatitis B Infection 
HBV replicates in hepatocytes, disrupting normal liver function.  The subsequent immune response 
generates inflammatory damage in the liver tissue, leading to fibrosis, cirrhosis and in susceptible 
individuals may lead to development of Hepatocellular Carcinoma (HCC). (23) 
The clinical course of Hepatitis B can be extremely variable and may be asymptomatic.  During acute 
infection (within 6 months of exposure) patients may experience nausea, vomiting diarrhoea, 
jaundice and fever.  The vast majority of adult patients will recover within 8 weeks and clear the 
virus, however up to 10% may become asymptomatic carriers (HBcAb positive) or develop chronic 
hepatitis B infection (23). 
Chronic Hepatitis B 
Chronic HBV infection is defined by WHO as 6 or more months of persistent HBsAg infection(23).  
The natural course of chronic HBV infection was, until 2017, divided into immune tolerance, immune 
clearance, immune control and immune escape phases.  These phases have now been renamed 
HBeAg positive chronic infection, HBeAg positive chronic hepatitis, HBeAg negative chronic infection 
and HBeAg chronic hepatitis respectively, in order to better reflect pathological processes (21).  All 
these phases are found in the HBsAg positive state and are dependent on clinical state and 
serological markers alanine aminotransferase (ALT) and HBV DNA levels to be identified.  The highest 
risk of developing liver cirrhosis occurs in the immune clearance and immune escape phases 
indicating active viral replication which lead to liver necroinflammation and hepatocellular damage.  
Table 1 outlines the biochemical and virological findings in each of these disease states, and Box 1 
outlines the natural history of HBV infection. 
Risk of developing HCC is highest in patients with one or more factors that relate to the host 
(cirrhosis, chronic hepatic necroinflammation, older age, male sex, African origin, alcohol abuse, 
chronic co-infection with other hepatitis viruses or human immunodeficiency virus (HIV), diabetes or 
metabolic syndrome, active smoking, positive family history) and/or to HBV properties (high HBV 






Table 1: HBV Chronic Infection Terminology EASL Guidelines 2017 (21) 
 HBeAg Positive HBeAg Negative 
 Chronic Infection Chronic Hepatitis Chronic 
Infection 
Chronic Hepatitis 
HBsAg High High/Intermediate Low Intermediate 
HBeAg Positive Positive Negative Negative 




Normal Elevated Normal Elevated* 
Liver Disease None/minimal Moderate/severe None Moderate/severe 
Old terminology Immune Tolerant Immune 
Clearance 
Inactive carrier Immune Escape 
EASL Guidelines Viral Hepatitis 2017 Table 1: Natural history and assessment of patients with 
chronic HBV infection based upon HBV and liver disease markers.  *Persistently or intermittently.  







Box 1 Natural History by chronology after HBV infection 
1. Immune Tolerant Phase (now known as HBeAg Positive Chronic Infection) 
- HBeAg positive with high serum levels of HBV DNA.   
- Normal or minimally elevated ALT and normal liver histology and function.   
- These patients are highly contagious due to high levels of HBV DNA. 
2. Immune Clearance (now known as HBeAg Positive Chronic Hepatitis) 
- Fluctuating but progressively increasing HBV DNA levels.   
- Increased ALT and histological activity.   
- Immune mediated histologic damage – increasing inflammatory hepatic necrosis. 
3. Immune Control/ Inactive Carrier (now known as HBeAg Negative Chronic Infection) 
- Decrease in HBV DNA levels.   
- Inactive liver disease, with normal ALT.   
- No necroinflammation.   
- Inactive carrier state (for years or decades).   
- May be seen after spontaneous HBeAg seroconversion:  the development of antibodies 
against the eAntigen.   
- When HBeAg cleared, HBeAb develops and HBV DNA is <2000 IU/mL.   
- Spontaneous seroconversion rate is 5-10% per year, although this varies among 
populations 
4. Immune Escape (now known as HBeAg Negative Chronic Infection) 
- Reactivation of viral replication of mutated virions that do not express HBeAg, 
associated with high levels of HBV DNA and active necro-inflammation and progression 
to fibrosis. Progression to cirrhosis occurs at an annual rate of 2-5.5% (cumulative 5-year 





1.5.2 Natural History of HCV Infection 
Acute Hepatitis C 
Acute hepatitis C infection is usually asymptomatic or presents as a mild flu-like illness.   Up to one 
third of patients may experience jaundice.  The most common outcome in in 60-85% of cases is 
chronic HCV infection, detected by the persistence of HCV RNA after 6 months following infection. 
The range of resolution is largely based on retrospective studies of post-transfusion patients.  
Factors which can determine resolution or chronic infection include genetic factors (such as 
interleukin IL28b inheritance) immune response, gender, mode of acquisition, severity of acute 
illness, jaundice on presentation, immunosuppression, co-infection with HBV or HIV. (25) (26) 
Chronic Hepatitis C 
Chronic HCV infection is a leading cause of end-stage liver disease, hepatocellular carcinoma and 
liver-related death globally.  The infection can cause persistent hepatocellular inflammation, leading 
to fibrosis and subsequent cirrhosis in at a rate of 10% per decade infected (26).  HCV is an indolent 
infection with many individuals remaining asymptomatic until they present with end stage liver 
disease and its associated complications.  The presence of cirrhosis also increases the risk of HCC to 
1-5% per annum, with increased risk of liver failure and death.  (25,26) 
 
1.6 Impact of Chronic Viral Hepatitis on Morbidity and Mortality Risks 
1.6.1 HBV Infection 
The triggering of host and viral factors to end the HBeAg positive chronic infection phase, 
modulating the course of immune-clearance/inflammatory phase, HBeAg/HBsAg seroclearance and 
seroconversion, and even the occurrence of HBeAg-negative hepatitis flare are the key determinants 
to the life-long risk of liver injuries, liver cirrhosis and HCC (27). 
The age at which HBeAg seroconversion occurs, and the severity of liver damage sustained during 
the HBeAg positive chronic infection phase are both important outcome determining factors during 
the natural course of chronic HBV infection (28). 
There are two main age groups in which risk of HCC increases due to seroconversion: (i) very early 
HBeAg seroconversion in childhood (at < 3 years of age), along with severe liver damage, increases 
the risk of childhood HCC (29,30) (ii) delay in occurrence of HBeAg seroconversion until after the 4th 




Conversely, HBeAg seroconversion during childhood without severe liver damage is associated with 
a relatively uneventful course with a low viraemia profile, lower incidence of hepatitis reactivation 
after HBeAg seroconversion, and higher chance of spontaneous HBsAg seroconversion (28,31,32). 
Wu et al have noted that earlier transition to HBeAg positive chronic hepatitis phase, and earlier 
HBeAg seroconversion in children with chronic HBV infection are both important predictors of 
spontaneous HBsAg seroconversion (31). 
Chronic HBV has a significant impact on life expectancy: a US study showed that individuals who are 
infected with chronic HBV die on average 22 years earlier than those not infected, due to 
complications of liver cirrhosis, HCC and liver failure (33).   
1.6.2 HCV Infection 
Due to multiple confounders, cohort studies of heterogenous populations have not been able to 
fully clarify the natural history of chronic HCV infection.  Development of cirrhosis in the context of 
hepatitis C infection is multi-factorial and risk factors for increasing the risks of fibrosis or cirrhosis 
include age at infection, male gender, alcohol consumption, obesity, insulin resistance, type 2 
diabetes, co-infection with HBV or HIV, or immunosuppressive therapy (34). 
Hepatitis infection can cause persistent hepatitis, but as the RNA viral genome in not integrated into 
the host, viral replication can be suppressed and cure achieved with virological treatment.  Cure is 
defined as undetectable serum HCV RNA (known as sustained virological response) at 12 weeks 
following completion with treatment by Directly Acting Antiviral (DAAs) drugs (aka SVR12).  For 
those treated with pegylated interferon and ribavirin, cure is defined as achieving SVR24, measured 
at 24 weeks following completion of therapy. (35,36). 
Without treatment, HCV can persist in some individuals without causing abnormal liver function or 
change in biochemical markers such as a raised serum ALT.  However these individuals can still 
progress to fibrosis, and will show a decline in ALT following curative treatment (37).  This is a key 
consideration in who to test for the virus, as asymptomatic patients with apparently normal liver 
function tests may be still be infected with HCV and at risk of liver disease with the passing of time. 
Approximately 16% of patients infected with chronic HCV will develop liver cirrhosis over a 20 year 
period (34), increasing to 41% by 30 years of infection.  Rates of fibrosis progression are also related 





1.7 Co-infection with other Blood-Borne Viruses 
In those who are HBV infected, co-infection with Hepatitis Delta virus (HDV) can lead to rapid 
progression to liver fibrosis and cirrhosis (38).  HDV is not an infective virus but is a satellite virus that 
can only lead to hepatitis in the presence of HBV infection.  HDV is a single-stranded RNA genome in 
the deltaviridae family.  It can be acquired either by co-infection or superinfection of individuals 
already infected with HBV.   In a minority of individuals, co-infection will lead to a clearance of both 
viruses, however the majority of patients will develop chronic co-infection (9,38).   
Co-infection with HBV-HDV leads to a more progressive course than monoinfection with HBV. Co-
infected patients have a higher risk of earlier development of liver fibrosis and cirrhosis, and also an 
increased risk of hepatocellular carcinoma. (21). 
Co-infection of HBV-HCV, and co-infection with HIV (e.g. HBV-HIV or HCV-HIV) also leads to a more 
progressive course than monoinfection with HBV or HCV.  Co-infected patients are at higher risk of 
earlier development of liver fibrosis and cirrhosis (21,35,36). 
 
1.8 Transmission  
HBV transmission is via vertical (maternofetal), exposure to infected blood, and unprotected sexual 
intercourse.   Individuals at risk of infections include those from high-prevalence countries, men who 
have sex with men (MSMs), people who inject drugs and healthcare workers (1). 
HCV transmission is the same as HBV, and also includes anyone exposed to infected blood or in 
receipt of infected blood products prior to 1991, people who inject (or who have ever injected) 
drugs, individuals with tattoos or body piercings, and intra nasal cocaine users (1). 
1.8.1 Immigrants as a particular At-Risk Population 
More than 250 million people globally are estimated to be persistently infected with HBV, many of 
whom are from low and middle income countries (LMIC) in eastern Asia and sub-Saharan Africa. 
More than 1 million deaths occur each year due to chronic HBV infection.  Approximately 2% per 
year of long-established chronic carriers terminate their active infection and become HBsAg-
negative (1,7). 
For chronic HCV infections there are large variations in estimates of prevalence across large global 
regions.  The WHO Global Hepatitis report estimated chronic HCV infections at 71 million worldwide 
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(a lower figure than previous estimates), with the majority of infections occurring in the Eastern 
Mediterranean and Western Pacific regions (1). 
At risk populations for HBV/HCV include anyone exposed to infected blood or receipt of infected 
blood products prior to 1991, people who inject (or who have ever injected) drugs, those born in 
higher prevalence countries, vertical (maternofetal transmission), men who have ever had sex with 
men, healthcare workers, dialysis patients, individuals with tattoos or body piercings, and intra nasal 
cocaine users.  
Migrant populations are also more likely to be at risk of chronic viral hepatitis, particularly those 
from areas of known high prevalence (>2%) such as South East Asian (India, Pakistan, and 
Bangladesh), East Asia (China, Japan), Sub-Saharan Africa (Nigeria, Sierra Leone, and Somalia etc) 
and Eastern Europe (Poland, Romania etc).  Appendix 2 includes the WHO’s full list of high 
prevalence countries. 
Patients from these LMICs may have been exposed to HBV and/or HCV at a young age due to 
mother-to-child transmission during pregnancy, poor infection control practices e.g. reusable or 
poorly sterilised vaccination needles, or shared use of razors.  High prevalence in these areas had led 
to substantial morbidity, for example in  West Africa where up to 15% of the population are chronic 
HBV infected (8) and Pakistan where HCV can exceed 20% in some regions (39).   
In many high income countries (HICs) the overall prevalence is less than 1%, but remains high in the 
populations who were born abroad in a LMIC and migrated to the HIC (40–42).  Amongst migrant 
populations in European countries, estimated HBsAg prevalence ranges from 1-15.4% (up to 6 times 
higher than the general population), and estimated HCV Ab prevalence ranging from 0-23.4% (up to 
2 times higher than the general population) (43).  
Screening for viral hepatitis in HICs has historically been informed by the risk behaviours of the local 
indigenous populations (such as injecting drug use, sexual risks) and not upon those within migrant 
populations, who are more likely to have been at risk of vertical transmission or vulnerable to 
healthcare exposure in their country of origin (44). 
Screening for viral hepatitis in HICs may often neglect to offer appropriate testing to the migrant 
population, and migrants themselves may not prioritise testing.  It has been shown that engagement 





1.9.1 HBV Immunisation 
Subsequent to the discovery of HBV, development of sensitive tests and the screening of donor 
blood prior to transfusion led to a dramatic drop in post-transfusion hepatitis from the late 1970s 
onwards.  An immunisation was developed based on HBsAg and is now one of the most widely used 
across the globe.  Blumberg was awarded the Nobel Prize for Medicine in 1975 for his work in 
identifying HBV and developing an effective immunisation (11).    
In the UK, immunisation has been recommended to specific at risk groups: injecting drug users, 
MSMs, commercial sex workers, close family or household contacts of an individual with chronic 
hepatitis B, families adopting or fostering children from countries with a high or intermediate 
prevalence of HBV, individuals receiving regular blood or blood products and their carers, patient 
with chronic renal failure, patients with chronic liver disease, individuals living with HIV, inmates of 
custodial institutions, individuals at occupational risks and those travelling to areas of high or 
intermediate prevalence (3).  In August 2017, immunisation for all neonates was introduced as part 
of routine immunisations in the UK (45).  Those who are not immunised, or do not mount an 
adequate immune response after vaccination but are subsequently identified as being at risk of 
recent exposure may be offered post-exposure prophylaxis with HBV immunoglobulin +/- 
immunisation. 
1.9.2 HCV Vaccine Research 
A vaccine for HCV has proved more elusive. With 6 known genotypes and more than 50 subtypes 
and frequent mutations, the search for a vaccine is has remained challenging. Phase I and Phase II 
human trials are currently in progress and development of prophylactic or therapeutic vaccine 




1.10 Management and Treatment of Chronic Viral Hepatitis Infection 
1.10.1 Assessment of Chronic HBV Disease in Primary Care 
In the UK, the National Institute of Clinical Excellence (NICE) who publish guidelines on evidence-
based best practice, have produced guidelines for the assessment and management of chronic HBV 
(47).  Although specific UK guidelines for HCV have not yet been published, European guidelines 
have been issued.  These have been combined in the section below. 
Initial assessment of chronic HBV or HCV infection should include a full history and examination to 
identify risk factors for viral hepatitis and other causes of liver disease (including country of birth, 
alcohol and smoking history, history of recreational and injecting drug use, and family history of 
HCC).   
Initial investigations for patients testing HBsAg positive should include serology for  
• full blood count including platelets 
• urea and electrolytes 
• liver function tests including Alanine Aminotransferase (ALT), aspartate aminotransferase 
(AST), Alkaline Phosphatase (ALP), Bilirubin, Albumin, full globulins, prothrombin time and 
International Normalised ratio (INR) 
• HBV specific tests (HBeAg, anti-HBE, anti-HBc IgM, HBV DNA levels) 
• tests for co-infection with other BBVs such as HCV (anti-HCV), HDV (anti-HDV) and HIV (anti-
HIV) 
• and Hepatitis A Virus (HAV) immunity status.   
For those testing HCV Antibody positive, serum HCV RNA should also be tested. The HCV RNA should 
be done as a reflex test at the local laboratory level – this will clarify whether the patient has active 
ongoing infection.  A negative HCV RNA indicates that the virus has either been therapeutically cured 
or self-cleared.  If the RNA test is positive the patient remains infected and the other serological 
tests should be completed. 
NICE advise that all the above can be performed in primary care, and the results should be 
forwarded with a referral to a hepatologist, or to a gastroenterologist or infectious diseases 
specialist with an interest in hepatology.  If the patient is a pregnant woman, she should be referred 
within 6 weeks of receiving the screening test result to allow treatment in the third trimester.  Adults 
with decompensated liver disease should be referred immediately to a hepatologist or 
gastroenterologist with an interest in hepatology (47). 
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1.10.2 Assessment and Staging of Chronic Viral Hepatitis Disease in Secondary Care 
In the secondary care setting, information about chronic HBV should be provided to patients and to 
family members or carers (if appropriate) before assessment.  This information should include: 
• the natural history of chronic hepatitis B / hepatitis C, including stages of disease and long-
term prognosis 
• lifestyle issues such as alcohol, diet and weight  
• family planning  
• monitoring 
• routes of viral hepatitis transmission 
• the benefits of antiviral treatment, including reduced risk of serious liver disease and death 
and reduced risk of transmission to others 
• treatment options and contraindications based on the patient's circumstances 
• causes of treatment failure, including non-adherence to prescribed medicines, and options 
for re-treatment 
• Patients should be advised that their general practitioner should arrange testing and HBV 
immunisation (if appropriate) of sexual and household contacts.   
• Patients should be offered HAV and/or HBV immunisation if appropriate. 
As well as ensuring the initial serological investigations above have been completed, baseline 
imaging of the liver should include ultrasound scan (USS) liver and transient elastography (aka 
Fibroscan®) to assess for hepatocellular carcinoma and liver fibrosis stage respectively.  Further 
investigation will be dependent upon this disease staging. 
The staging of chronic Hepatitis B infection is dependent upon the natural chronology of HBV, 
various factors including age, ALT value, fibrosis score and the presence or absence of cirrhosis.  
Dependent on local guidelines, a liver biopsy may be indicated (see box 2 for further information).  
However biopsy is increasingly being superseded by non-invasive measures of cirrhotic change such 








Box 2 HBV Liver Biopsy Indicators 
Transient elastography score below 6 kiloPascals (kPa) 
Adults with a transient elastography score less than 6 kPa should be offered liver biopsy if they are < 
30 years and have HBV DNA > 2000 IU/ml and abnormal ALT (greater than or equal to 30 IU/L for 
males and greater than or equal to 19 IU/L for females) on 2 consecutive tests conducted 3 months 
apart. 
Adults with a transient elastography score less than 6 kPa are unlikely to have significant fibrosis, 
and should not be offered a liver biopsy if they have a normal ALT and HBV DNA <2000 IU/mL, as 
they are unlikely to have advanced liver disease or need antiviral treatment.  
Transient elastography score between 6 and 10 kPa 
Liver biopsy should be considered for adults with a transient elastography score between 6 -10 kPa 
to confirm the level of fibrosis, which cannot be accurately predicted in scores within this range. 
 
 
In chronic HCV infection, the cumulative risk of cirrhosis after 20 years is approximately 16%, and 
rises to more than 40% at 30 years (34). Chronic Hepatitis C infection is disease staged as being 
either non-cirrhotic or cirrhotic dependent on findings from ultrasound scan, transient elastography 
or liver biopsy (21).  Progression of fibrosis is non-linear however, and transition rates are highest at 
the F2-F3 progression (see section 1.9.3).  Therefore identifying and treating patients at this 
progression is crucial in reducing risk of cirrhosis (34). 
Dependent on local guidelines, HCV-related cirrhosis may be prioritised for treatment with DAA 
therapies.   
 
1.10.3 Assessment of Liver Fibrosis and Cirrhosis 
Historically, liver biopsy has been the gold-standard of investigation and staging of fibrosis/cirrhosis 
in liver disease.  This is an invasive procedure whereby a skilled operator takes a percutaneous 
biopsy from the patient under local anaesthetic for histological examination.  This procedure carries 
moderate risks including bleeding and haemorrhage, pain and discomfort during and after the 
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procedure, and is higher risk in those individuals who have liver cirrhosis and therefore poor control 
of clotting factors which may lead to significant bleeding (48).   
The METAVIR score is a scoring system used to assess the extent of inflammation and fibrosis in 
chronic hepatitis C infection based on histopathological evaluation via biopsy (49).  The METAVIR 
score is composed of a two-letter and two-number scoring system: A = histological activity (A0 = no 
activity, A1 = mild activity, A2 = moderate activity and A3 = severe activity) and F= fibrosis (F0 = no 
fibrosis, F1 = portal fibrosis without septa, F2= portal fibrosis with rare septa, F3 = numerous septa 
without cirrhosis and F4 = cirrhosis). 
Over the past 10 years, there has been increasing use of transient elastography (aka Fibroscan®) a 
non-invasive shear wave technology to assess liver stiffness as a surrogate marker of the presence of 
liver fibrosis and cirrhosis (50).  Vibrations of low amplitude and frequency are delivered by an 
ultrasound transducer probe and delivered through liver tissues.  The resultant elastic shear wave 
propagates through the intrabdominal organ and it the probe measures its velocity.  The velocity of 
the shear wave is directly related to tissue stiffness which correlates with fibrosis (51,52).  This 
technique has the benefit of being more agreeable for patients than the liver biopsy procedure and 
offers a reliable non-invasive assessment of fibrosis stage equivalent to the METAVIR score which is 
independent of operator (49,51).  Transient elastography detects significant fibrosis or cirrhosis with 
acceptable accuracy and offers incremental diagnostic value in detecting significant fibrosis, but not 
cirrhosis (53).  Therefore it should be used as adjunct to serology and other imaging such as 
ultrasound if used in place of biopsy. 
Fibroscanning® Procedure 
The use of a Fibroscan® can be performed by a trained operator in an outpatient setting and is a 
straightforward and safe non-invasive test.  The patient is asked to attend having fasted for 3-4 
hours (to reduce the degree of liver stiffness caused by post-prandial blood flow).  The patient lies 
on their left side with the right arm in maximal abduction. The probe is placed along a lower 
intercostal space to obtain a view of the right lobe of the liver (54–56). Once an area of at least 6 cm 
thick and free of large vascular structures or gallbladder has been identified, ten measurements are 
obtained using the Fibroscan® probe. A reliable exam should result in ten measurements with a 70% 










METAVIR Score Fibrosis Stage Histological Findings 
1.5-7.4 kPa F0-F1 No or Mild Fibrosis Indicates no or 
minimal liver fibrosis 
and no evidence of 
progressive liver 
disease 
7.5-9.4 kPa F2 Moderate Fibrosis Indicates significant 




9.5-12.4kPa F3 Severe Fibrosis Indicates severe liver 
fibrosis and high-risk 
progression to 
cirrhosis 
>12.5kPa F4 Cirrhosis Indicates extensive 
liver fibrosis consistent 
with cirrhosis 
 
1.11 Antiviral Treatment for Chronic HBV Infection 
All major guidelines recommend pegylated interferon (PEG-IFN), or nucleoside analogues (NA) such 
as Entecavir or Tenofovir as first-line monotherapy in patients with chronic HBV (21,47,57).  Choice 
of treatment is based on factors which include host, virus and drug-related considerations including 
duration of treatment, plans for pregnancy and potential side effects (58). 
 
1.11.1 Interferon Monotherapy  
Pegylated-interferon is a cytokine based immunomodulator which also has antiviral activity.  It 
shows most benefit in the treatment of those with low HBV DNA levels and high ALT without 
advanced disease.  Benefits include a finite duration of therapy, possible anti-HBe/antiHBs 
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seroconversion within 12 months and absence of resistance.  However, it carries considerable 
adverse effects such as myalgia, fatigue, nausea, weight loss, bone marrow suppression and thyroid 
disease.  It is delivered as a weekly injection which the patient can be taught to self-administer.  It is 
contraindicated in pregnant women, those with a history of psychiatric illness, severe leucopoenia or 
thrombocytopenia and decompensated cirrhosis (21,59). 
Desired treatment endpoints for interferon therapy in chronic HBV infection are defined as 
sustained serum HBV DNA < 2000 IU/mL, HBsAg loss together with ALT normalisation as well as 
HBeAg seroconversion in HBeAg positive patients (21).  
 
 
1.11.2 Nucleoside Analogue Therapy  
Entecavir and tenofovir (available as tenofovir disoproxil or the pro-drug tenofovir alafenamide) are 
NAs of the class nucleoside reverse transcriptase inhibitors (NRTI) which act by inhibiting HBV DNA 
polymerase.  They are both delivered as oral tablets, taken once daily.  Adverse events are rare and 
can include renal insufficiency and long-term use of tenofovir disoproxil (TDF) can lead to Fanconi’s 
syndrome (hypophosphataemia and glycosuria) as well as decreased bone density.  TDF should be 
dose adjusted according to creatinine clearance in patients with established renal disease (60–62).  
Both NRTIs have potent antiviral effects but the main disadvantages include lifelong therapy, and 





The EASL 2017 antiviral treatment guidelines are summarised in Boxes 3, 4 and 5. 
 
Box 3 When to Offer Antiviral Treatment for Chronic Hepatitis B (21) 
 
1. Any Age / Disease Stage 
– HBV DNA > 20, 000 IU/mL 
– AND abnormal ALT (>30 IU/ml in males, >19 in females) 
on 2 tests, 3 months apart 
2. Adults with Cirrhosis and detectable HBV DNA 
3. Co-Infection with HDV, HCV, or HIV 
4. Age >30 
• AND HBV DNA > 2000 IU/mL 
• AND abnormal ALT (>30 IU/ml in males, >19 in females) 
 on 2 tests, 3 months apart 
5. Age <30 
• AND HBV DNA > 2000 IU/mL 
• AND abnormal ALT (>30 IU/ml in males, >19 in females) 
 on 2 tests, 3 months apart 
• AND evidence of necroinflammation or fibrosis on Liver biopsy, or TE score > 6kPa 
Consider Treatment 
• HBV DNA > 2000 IU/mL 







Box 4 HBV Treatment Options (21) 
HBeAg-positive & HBeAg- Negative Chronic HBV 
First Line: Pegylated-Interferon for 48 weeks 
Contraindicated in Pregnancy 
At 24 weeks if: 
– HBV DNA decreased by less than 2 log10 IU/mL  
– or if HBsAg >20,000 IU/mL  
STOP & offer 2nd line treatment 
Second Line:  
Tenofovir Disoproxil if no HBeAg seroconversion, or relapse after PEG IFN 
Entecavir, if Tenofovir contraindicated 
Review adherence if detectable HBV DNA at 48 weeks 
Add Lamivudine at 96 weeks if still detectable 
If no cirrhosis – consider stopping at 12 months after HBeAg seroconversion 
If HBeAg negative and no cirrhosis, consider stopping at 12 months after achieving undetectable HBV 




Box 5 Monitoring Chronic HBV (21) 
Patients not on treatment: 
• Immune Tolerant (HBeAg positive, active viral replication + normal ALT) → Monitor ALT 
every 24 weeks 
– Increase to every 12 weeks if ALT ↑ 
• Immune Control (HBeAg negative, normal ALT, HBV DNA <2000)→ monitor ALT and HBV 
DNA every 48 weeks or 12-24 weeks if cirrhosis 
Patients on treatment: 
Immune Tolerant Phase 
ALT levels should be monitored every 24 weeks and increased to every 12 weeks if there is an 
increase in ALT levels. 
Immune-control phase in Adults 
ALT and HBV DNA levels should be monitored every 48 weeks  
Consider more frequent monitoring (12-24 weeks) in patients with cirrhosis 
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1.12 Current Treatments for HCV 
From the late 1990s until 2014, the mainstay of therapy for Hepatitis C treatment was a combination 
of injectable pegylated-interferon and oral ribavirin (a nucleoside analogue).  This was an 
unsatisfactory treatment option for several reasons: the therapy achieved poor cure rates of 15-40% 
(63), both drugs are associated with multiple serious adverse effects (such as pancytopenia, 
abnormal thyroid function tests, associated psychiatric disorders) and required up to 72 weeks of 
twice daily oral therapy and weekly injections (59,64). 
In the early 2010s, the development of directly acting antivirals (DAAs) revolutionised hepatitis c 
therapies as they are oral short duration (either 8, 12 or 16 weeks once daily) medication which 
provide cure rates of more 95% and highly tolerable by most patients.  Ongoing studies have also 
shown DAAs are highly efficacious in patients who have failed on previous non-DAA therapies, or 
who have cirrhosis at the time of treatment (65–74). 
Current DAAs are derived from three main classes: 
• NS3/4A Inhibitors (e.g. Paritaprevir) 
• NS5A Inhibitors (e.g. Ledipasvir) 
• NS5B Inhibitors (e.g. Sofosbuvir) 
Newer generation therapies are now pangenotypic and can be used without prior knowledge of viral 
genotype (73,74) . 
 
1.13 Surveillance for Hepatocellular Carcinoma in adults with Viral Hepatitis Infection 
6-monthly surveillance for hepatocellular carcinoma by hepatic ultrasound and alpha-fetoprotein 
serology testing should be performed for patients with significant fibrosis (METAVIR stage greater 
than or equal to F2 or Ishak stage greater than or equal to 3) or cirrhosis. 
In HBV-infected without significant fibrosis or cirrhosis, 6-monthly surveillance for HCC should be 
considered if the person is older than 40 years and has a family history of hepatocellular carcinoma 
and HBV DNA greater than or equal to 20,000 IU/ml (21). 
Patients who have been successfully cured of HCV infection only require ongoing 6-monthly HCC 




1.14 Benefits of Achieving Viral Suppression 
Suppression of HBV replication with oral NRTIs prevents complications improves outcomes and can 
also reverse cirrhosis (75,76). 
The health benefits of achieving SVR has been documented in both the Interferon treatment era (77) 
and the DAA era (78).  The vast majority of HCV-infected patients will see an improvement in fibrosis 
and necro-inflammation scores and also a reduction in all-cause mortality outcomes as well as 
likelihood of liver-related mortality and morbidity and progression to liver transplant (see figure 3). 
 
Figure 3: Outcomes for All-Cause Mortality, Liver-associated mortality, Hepatocellular carcinoma and 






1.15 Access to Viral Hepatitis Treatments amongst the Migrant Population 
1.15.1 Limited Access to Treatments 
As discussed earlier, many migrants from LMIC who have migrated to HICs carry a higher risk of viral 
hepatitis and have been identified as at-risk populations.  Despite the NICE, EASL and WHO 
Guidelines regarding testing at-risk populations, access to treatment for HBV and HCV infected 
patients remains limited (79).   
Multiple retrospective studies have highlighted the undertreatment of patients in various settings.  
Giannini et al followed a cohort of 363 patients chronically monoinfected with HBV for at least 1 year 
in tertiary referral centres.  After 12 months, 84% potential treatment candidates (41 of 49 patients) 
were not treated, despite having elevated serum HBV DNA (>20,000 IU/mL) or being HBeAg positive 
with an elevated HBV DNA. Although there were limitations to this study such as a lack of uniform 
serum ALT work-up, low rate of disease staging (by imaging or biopsy) and no measurement of 
patients refusal of treatment, it does underline that even patients with chronic infection in specialist 
care may not receive timely therapy (80). 
In a 2010 US study, 84% of low-income and immigrant patients with HBV infection who were 
followed in a publicly‐funded health‐care system did not receive HBV treatment between 1994 and 
2006. Interestingly, in this study the strongest predictor of treatment was HBV-HIV co-infection, due 
to dual effect of NRTIs and use of tenofovir to treat both infections.  When HIV-HBV co-infected 
patients were removed from the results, 90% of HBV mono-infected patients were not on 
treatment, and therefore at a disadvantage compared to co-infected patients.  One of the 
documented reasons for nontreatment was that only 28% of had HBeAg and HBV DNA serology, 
highlighting the importance of serological markers in disease staging.  However, barriers to 
treatment were rarely documented. (81) 
Other studies suggest underdiagnosis could lead to up to half of eligible HBV patients not being 
offered treatment.  (82,83)  HCV infection has historically been underdiagnosed and undertreated:  
in 2004, of the total UK population that had been infected with hepatitis C, only 19% had been 
diagnosed and less than 10% of those went on to receive treatment. (84) 
The consequences of delayed treatment for chronic HBV and HCV infection increases health burden 




1.15.2 Barriers to Care 
Possible barriers to high risk immigrant populations accessing treatment were explored in a USA 
2011 review (79).  These were grouped into Personal and Environmental barriers: 
Personal barriers were noted to be:   
- lack of information or misinformation about the disease;  
- cultural beliefs regarding physician usage when not feeling ill;  
- fear of stigmatization and discrimination by family, friends and community 
members  
- HBV knowledge deficits regarding transmission, prevention, diagnosis and 
treatment outcomes of HBV  
Environmental Barriers: 
Some of these were specific to the US healthcare system. But provider barriers can also 
occur in any healthcare setting.  The authors noted the following issues: 
- lack of access to routine, ongoing medical care because of lack of insurance or 
being under‐insured  
- provider‐related barriers: providers are often unaware of the risk groups that 
should be screened for HBV, or there is a communication breakdown with high‐
risk individuals that stems from language and cultural barriers, especially with 
foreign‐born persons from endemic regions. 
1.16 Screening for Viral Hepatitis 
Although there are screening recommendations for viral hepatitis testing, there is no formal 
screening programme in the UK.   This is even though HBV and HCV infections fit the Wilson and 
Junger criteria for a screening programme (85), which are: 
• The condition is an important problem with a natural history characterised by a latent or 
early symptomatic stage 
• There is a suitable acceptable diagnostic test 
• There is accepted an established treatment 
• Case-finding is cost-effective. 
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Screening for viral hepatitis has been shown to improve outcomes and be cost-effective (5).  A 2010 
Dutch study used a Markov chain statistical model (describing a sequence of events where the 
probability of each event is dependent on the state attained by the previous event) to assess the 
cost and health outcomes of a cohort of HBV-infected individuals in the Netherlands.  For a one-off 
screening test, liver-related mortality was reduced by 10% and the intervention was found to be cost 
effective.  However, this assumed patients would be more likely to attend a specialist appointment 
after participating in a screening programme rather than being opportunistically tested, and that 
they would be offered treatment if they were eligible (which as has been discussed above is not 
always the case).  A 2015 systematic review of the cost-effectiveness of HBV and HCV screening 
noted that the arrival of DAAs has considerably changed the landscape in making HCV screening 
cost-effective, even with the higher costs of the new drugs (86), supporting earlier findings (87). 
 
1.16.1 Prevalence of Viral Hepatitis amongst immigrants outside of the UK 
Several European studies have investigated the prevalence of viral hepatitis amongst migrants to HIC 
outside of the UK.  In Malta, 500 asylum seeking migrants were tested for HBsAg and HCV Ab (as well 
as being tested for Tuberculosis and syphilis).  83.2% of participants were from Somalia, with the 
rest from Eritrea (8.2%), Ethiopia (2.4%) and Western Africa countries (5.6%).  HBsAg was positive in 
31 subjects (6.1%) and HCV Ab positive in 3 (0.6%). (88)   
Several Dutch studies have looked at the prevalence of viral hepatitis in immigrant populations.  A 
wide-ranging retrospective study looked at the prevalence of viral hepatitis in 4 surveys in 
Amsterdam (i) 3895 heterosexual visitors at STI clinics (ii) random samples of 4563 pregnant women 
(iii) 1309 inhabitants of Amsterdam (iv) population-based random sample of 4428 people living in 
the Netherlands.  In total 4860/14,195 (34%) of subjects were non-Western.  Overall HCV Ab 
seroprevalence was low (0.3-0.6%).  First-generation non-Western immigrants were up to five times 
more likely to be HCV-positive (0.7-2.3%) than Western participants (0.1-0.4%). Except for survey 3, 
second-generation non-Western immigrants had a lower HCV prevalence than first-generation 
immigrants, comparable to Western migrants and the Dutch population. Phylogenetic analysis 
showed that the majority of the HCV-positive, first-generation non-Western non-European 
immigrants were infected with endemic strains which are rarely observed in Europe. (89)  
Another Dutch study looked at the prevalence of HCV Ab and RNA amongst 465 first generation 
Egyptian migrants (from a country of known high HCV prevalence) to the Netherlands.  11 (2.4%) 
participants had HCV Ab, 10 of whom were HCV RNA positive.  HBsAg prevalence was 1.1%.  Most 
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(9/10 HCV; 3/5 HBV) chronic infections were newly diagnosed. (90)  A further Dutch study based in 
Arnhem tested 709 first generation migrants of Turkish origin for HBsAg and HCV Ab.  3.0% were 
HBsAg positive and 0.4% HCV Ab positive.  (91) 
In Finland, a random sample of 3000 migrants from Kurdish, Russian or Somali origin who had lived 
in Finland for at least one year were invited to test for HBV, HCV, syphilis and HIV.  Seroprevalence 
of hepatitis B surface antigen (HBsAg) was 2.3%, hepatitis C antibodies 1.7%.  Among the Somali 
population (n = 261), prevalence of previously undiagnosed chronic hepatitis B diagnosis was 3.0%. 
(92) 
Outside of Europe, a large Chinese study tested 17,377 (95% of whom were Han Chinese ethnicity) 
migrant workers who had moved location within the country. The prevalence of HCV infections was 
0.40% (95%CI: 0.31%-0.51%).  (93) 
A meta-analysis of 50 studies collated from four electronic databases representing 38,635 
immigrants looked at the prevalence of HCV Ab.  Overall HCV Ab prevalence was 1.9% (95% CI 1.42-
2.7%).  Older age and region of origin, particularly Sub-Saharan Africa, Asia, and Eastern Europe were 
the strongest predictors of HCV seroprevalence. The estimated HCV seroprevalence of immigrants 
from these regions was >2% and higher than that reported for most host populations.(94)  
 
1.16.2 Prevalence of Viral Hepatitis amongst immigrants to the UK 
In the UK, although several studies have looked at HBV and HCV prevalence amongst higher risk 
groups including people who inject drugs (PWIDs), Homeless persons and men who have sex with 
men (MSMs)(95–97), fewer studies have investigated prevalence amongst migrants to the UK.  
Testing for viral hepatitis may be part of wider infectious disease screening for at-risk patients.  In 
the UK, over 80% of cases of tuberculosis are non-UK born (98), , a migrant population that is also at 
risk of viral hepatitis.  Between 2008-2011, Nooredinvand et al investigated the prevalence of 
chronic HBV and HCV in 429 newly diagnosed Tuberculosis patients (both active and latent TB)  
attending a tertiary care centre (St Mary’s Hospital, Imperial College Healthcare Trust)  in central 
North West London.  Patients were tested for for HBcAg, HBsAg, HCV IgG antibody and HIV antibody.  
Prevalence of HBsAg was 2.6%, and 1.6% were HCV Ab positive. The prevalence of chronic HBV or 
HCV in this predominantly migrant population was significantly higher than the estimated United 
Kingdom prevalence of 0.3% for each. (99)  In 2009, Uddin et al undertook community-based testing 
at five sites in England. (40) A total of 4998 people attending community centres were screened for 
viral hepatitis using oral fluid testing. The overall prevalence of anti-hepatitis C virus (HCV) in people 
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of south Asian origin was 1.6% but varied by country of birth being 0.4%, 0.2%, 0.6% and 2.7% in 
people of this ethnic group born in the UK, India, Bangladesh and Pakistan, respectively. The 
prevalence of HBsAg was 1.2%-0.2%, 0.1%, 1.5% and 1.8% in people of this ethnic group born in the 
UK, India, Bangladesh and Pakistan, respectively.  The increased prevalence in subjects from Pakistan 
(compared with those originally from the UK, and also those from other parts of South Asia) noted in 
this study indicated that prevalence cannot by easily predicted from ethnicity and country of birth.  
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1.17 Screening for Viral Hepatitis in Primary Care 
Screening for viral hepatitis has been trialled in various secondary care settings such as Emergency 
Departments (100–104) and outpatients colonoscopy services (105,106).  In sub-Saharan Africa, 
community healthcare services have provided testing opportunities for HBV and HCV.  (107) 
Primary Care has an important role in providing screening for many national programmes such as 
cervical cancer (108) and bowel cancer (109).  There has been an increasing interest in the 
opportunity to use general practice as a location for viral hepatitis testing, particularly as general 
practitioners (GP)s may already be offering the tests as part of a panel of liver investigations, or as 
part of antenatal care.   
NICE has provided guidance on screening for viral hepatitis in primary care for targeted groups, but 
implementation is not uniform at a national level (3).  High prevalence of hepatitis markers have 
been detected in immigrant populations in Germany  (110) and in the UK (111,112), particularly 
those originally from countries of known high prevalence, likely due to poor infection control 
practices e.g. mother-to-child transmission, reusable needles for vaccination, shared use of barbers’ 
razors in countries of origin.  Case finding of both HBV and HCV in at risk populations is cost-effective 
(5) and this is estimated to be the case in primary care settings (6).  General Practitioners and 
primary care health professionals can play an important role in finding infected individuals and 
ensuring they are part of a care pathway which offers cure or surveillance.  Closing the gap between 
the diagnosed and undiagnosed remains one of the major challenges in viral hepatitis care (113) and 
primary care offers an opportunity to recognise viral hepatitis risks in order to offer targeted 
screening.  Migrant populations may face potential barriers to screening, such as stigma related to 
viral hepatitis infection, language barriers, and poor knowledge of the effects of chronic hepatitis B 
& C.  Most infected individuals will be asymptomatic and may also have normal liver function tests, 
making their identification difficult for non-specialist clinicians (114). 
Implementation of primary care screening programmes has shown an increase in case-finding and 
linkage to care in the US and Europe (115,116) but as yet such strategies are not yet standard 
practice in the UK.  A brief risk screener with a clinical reminder has been shown to be effective in 
increasing HCV screening rates in primary care  (117). 
 A review of 2988 cases of viral hepatitis from 12 EU countries showed that the most common 
reported place of testing was general practice (26.9%), with 35.6% of chronic cases being detected 
via this source. (118) 
55 
 
General Practice Trends in 2015 (119) reports that 57,170,000 patients are registered to a primary 
care practice in the England, with an average 7,183 patients at each practice.  This presents an 
excellent opportunity for a wide range of patients to be invited for testing, including those from 
migrant populations who are asymptomatic and have normal liver function. 
Areas of denser migrant populations are more likely to have a higher prevalence of viral hepatitis 
and therefore primary care in urban settings has been the focus of numerous case-finding initiatives. 
As part of the EU funded project “HEPScreen” in 2015, an online survey amongst GPs was conducted 
across 6 EU countries (the UK, Germany, the Netherlands, Hungary, Italy and Spain) to assess how 
commonly risk groups are offered a viral hepatitis test (120).   
Five to ten GPs were surveyed in each country (except for Hungary n=1 and Germany n=4).  In the 
majority of cases, immigrants were variably or not routinely screened for HBV/HCV, although routine 
testing was offered to PWIDs.  Testing for HBV amongst MSMs was common practice in the UK, but 
HCV testing was only occasionally offered to this group.  More than 44% of GPs in all countries 
(except Hungary) offered routine viral hepatitis screening to patients living with HIV.  GPs were 
unlikely to monitor clinical outcomes (apart from side effects) in patients undergoing treatment.   
In addition to the testing survey, knowledge of viral hepatitis guidelines amongst healthcare 
professionals was also assessed (121).  Of 268 respondents, 80% were aware of the HBV guidelines, 
and 73% aware of the HCV guidelines in their countries. 
The role of GPs involved in the management of chronically infected patients was not clear to the 
professional groups surveyed, and raising awareness of viral hepatitis disease amongst GP was 
recommended for more effective implementation of testing guidelines.  These guidelines should be 
specifically designed for and actively promoted among those who follow them and accompanied by 
diverse training for different professional groups. 
In order to improve the offering of viral hepatitis tests to at risk groups, an Australian study 
implemented four interventions during a 15 month period at a primary care practice with 
approximately 3000 registered patients.  The interventions were: staff education, quality 
improvement (audit and feedback), review of electronic records to assess HBV risks and patient-
triggered activities (a reminder card for each consultation).  Although the interventions increased 
testing rates by 60% (up from 15 to 24 tests per month), the proportion of patients from Africa and 




1.18 Keeping patients engaged in care 
Testing for viral hepatitis in Primary Care is one part of an ongoing continuum care of care, which 
starts with a serology test.  The second stage after a positive result is confirmation testing and 
disease staging (continuing care), with the third stage being treatment or monitoring in the context 
of chronic infection.  Patients (especially those from migrant populations) may be lost at each stage, 
highlighting the need to raise awareness amongst both healthcare professionals providing the care 
and at-risk populations (123). 
A study looking at the outcomes for the various stages of the care continuum for HCV infection in 
Philadelphia, USA between 2010-2013 estimated 2.9% of the adult population would be HCV Ab 
positive (47,525 / 1,585,848) based on seroprevalence studies (123). 
During the study period the Health Department received HCV test results for 28,990 unique 
individuals, 13,596 (47%) of which were HCV Ab positive and 6,383 (22% of total) were HCV RNA 
positive.  Of those in whom disease was confirmed, only 1,745 (6% of estimated total morbidity) 
were in care – defined as two tests within 6 months or a test ordered by a specialist.  956 (3% of 
total) were, by 2013, estimated to have received or were currently receiving HCV therapy. 
Recommendation of offering a one-off HCV Ab test to all US patients born between 1945-1965 (the 
“baby-boomers”) was made in September 2012 and a significantly higher number of individuals 
received their first positive HCV test in the months after this (p<0.001).   
Figure 4 shows the engagement of patients in the HCV care continuum at each stage.  In addition, it 
was noted that older (>40 years) male patients were more likely to remain engaged through to stage 
4 of the continuum.  Race and ethnicity was not available for all patients, but for those in which it 









Figure 4 The continuum of hepatitis C testing, referral to care and treatment in Philadelphia from 




1.19 Delivering Care 
Although there has been a drive to expand viral hepatitis screening and case-finding in primary care 
as noted above, the role of the general practice in delivering care is less understood.  With the 
opportunity to offer patients all oral therapy for a short, fixed time period, many primary care 
providers who see multiple patients with HCV could provide curative therapy in an environment 
where patients are potentially less likely to default from care (124).  Community based clinics have 
been a mainstay of HCV service delivery for PWIDs but these are usually not related to primary care 
providers, and the same model has not been trialled for other at-risk groups.  (125,126)   
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Challenges in providing a primary care-based model include whether general practitioners have the 
skills to manage viral hepatitis and also whether the primary care surgery is equipped with 
appropriate staff skillsets and tools to function as a setting for viral hepatitis care.   
A US survey in 2001 was amongst the first to assess the knowledge base and practice patterns of 
primary care physicians in the era of interferon-based therapies (127).   
4000 primary care physicians in the US were surveyed to assess knowledge of risk factors for HCV, 
management of HCV patients and attitudes towards HCV testing.  1412 (39%) responded and the 
vast majority (>90%) correctly identified common risk factors for HCV.  59% reported asking all 
patients about HCV risk factors, and 70% reported testing those with risk factors for HCV.  78% 
tested all patients with elevated liver enzymes for HCV infection.  At the time of the survey, 72% of 
US GPs referred HCV-positive patients with elevated liver enzyme patients to specialists but only 
28% would refer HCV-positive patients with normal liver function.  25% reported that they did not 
know what treatment to recommend for HCV.   
Recruiting and training GPs to provide treatment for HCV could be a key component in the 
eradication of the virus. (128) One non-randomised, open-label US study in 2015 assigned 600 HCV 
RNA positive patients to receive treatment at either (i) Nurse Practitioner, (ii) Primary Care Physician 
or (iii) Specialist, who had all received uniform training prior to the trial.  96% of patients were black, 
69% male, 72% had HCV G1 infection 1a infection and 20% had cirrhosis.  82% of patients were 
treatment naïve.  All patients were treated with ledipasvir-sofosbuvir, with the outcome of the study 
being achievement of SVR.  516 patients achieved SVR, a response rate of 86% (95% CI, 83.0% to 
88.7%), with no major safety signals. Response rates were consistent across the 3 provider types: 
NPs, 89.3% (CI, 83.3% to 93.8%); PCPs, 86.9% (CI, 80.6% to 91.7%); and specialists, 83.8% (CI, 79.0% 
to 87.8%). Patient loss to follow-up was the major cause of non-SVR.  SVR outcomes were equivocal 
in those with cirrhosis and those without.  (129) 
A caveat to primary care management of HCV is that cirrhotic patients achieving SVR will still need 
ongoing monitoring for HCC and regular follow-up, a pathway of care that is best suited to secondary 
care setting where imaging and Fibroscan® are available on site.  However, for non-complex HCV 
patients it has been postulated that GPs could offer curative therapy in a community setting, and 
indeed use of this resource will be essential in achieving elimination of the virus (124). 
Although there is limited data suggesting HCV RNA positive patients can be managed by GPs there 
remains an absence of evidence that migrant populations with chronic viral hepatitis can be 
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managed in primary care settings, and no RCT evidence comparing this with the current standard of 
care in hospital services. 
1.20 Patient Perceptions of Viral Hepatitis, Screening and Treatment 
An important consideration in developing a new screening intervention is understanding the 
attitudes and knowledge of the at-risk population about the disease process, which may be crucial 
contributors to uptake.  
There is limited knowledge and understanding about HBV and HCV in high-risk communities, 
especially regarding modes of transmission, the asymptomatic nature of chronic infection, and the 
potential for infection to increase the risk of hepatocellular carcinoma, mortality and morbidity. 
(130–132).There may also be ongoing stigmatisation around liver disease amongst the immigrant 
population because of perceived associations with alcoholism and commercial sex workers. (133) 
These illness perceptions, combined with other barriers to screening such as language, may 
contribute to an individual decision as to whether or not to accept a screening test for viral hepatitis 
infection.  However, little is known about the relative contribution of these various factors to 
screening uptakes. 
Prior to the commencement of the HepFREE trial, the study team presented a systematic review 
aimed at collating evidence on knowledge (illness perception or explanatory models) on HBV and 
HCV infections among first and second-generation migrants from high or intermediate prevalence 
countries to low prevalence countries.  
Illness perceptions are organised cognitive representations or beliefs patients have about illness, 
which more inform their behaviours and determine outcomes such as treatment adherence.  (134)  
The explanatory model (EM) of illness has been defined as “notions about an episode of sickness and 
its treatment that are employed by all those engaged in the clinical process”. (135) EMs allow 
exploration of how illness perceptions are informed by the patient’s social and cultural backgrounds.  
There are several EM models, with common components including aetiology, symptoms, 
pathophysiology, history and severity (course), and treatment. The Barts Explanatory Model 
Inventory (BEMI) was compiled through the analysis of studies looking at patients’ experience of 
mental health problems and can be used as either interview (BEMI-I) or questionnaire format (BEMI-
C).  The latter alone distinguishes amongst explanatory models of ethnic groups and therefore is 
useful in assessing illness perceptions of large populations from varied backgrounds.  (136,137) 
The HepFREE team of Owiti et al reviewed 261 studies, of which 51 were found to meet the eligibility 
criteria of being full text studies focussed on the knowledge of migrants who have moved from 
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high/intermediate to low prevalence countries.   Data was extracted on the knowledge of HBV and 
HCV infections (including screening, vaccination and treatment) organised around the following 
themes: concepts of HBV and HCV infection, signs and symptoms, causes, transmission, prevention, 
consequences and treatment. (131) 
Most studies were based in the US (64%) and focussed on the views and experiences of South East 
Asian immigrants from China, Korea, Cambodia and Vietnam who had moved to the USA, Canada or 
Australia.  Most surveys used a convenience sample (i.e. canvassing the views of attendees at health 
clinics or community events).  There were diverse data collection methods which included focus 
groups, semi-structured interviews, observational and in-depth interviews and ethnography.  
Therefore, comparing data across the studies and the various ethnic groups was limited. 
 
1.20.1 Viral Hepatitis Perceptions 
Concepts of viral hepatitis for South East Asians included “liver sickness/cancer/disease” and 
“bad/contaminated/unclean blood” and “yellow skin”.  Two survey and three qualitative studies 
noted participants’ confusion about the types of viral hepatitis and their progression (for example 
some participants believed that Hepatitis A/B/C referred to the stages of linear progression through 
severity of liver disease).  Causes of HBV/HCV were attributed to multiple factors such as a “weak 
liver” (caused by triggers such as smoking, alcohol, stress, hormones).  Transmission routes were 
stated to be contact with contaminated blood/other body fluids (61-90% of participants), pre-
masticated food (63-82%), contaminated drug injecting equipment (59-86%) and sharing of 
toothbrushes and razors (33-86%).  Knowledge of vertical transmission ranged widely across the 
studies with 34-91% of participants being aware of mother-to-child transmission. 
Between 54-96% of participant were aware of the HBV vaccine, although there has been evidence 
that uptake in the Asian-American population has been low (138–145).   
1.20.2 Screening Perceptions 
Some immigrants expressed general motivation to seek screening (138,145–150).  Amongst 
Cambodian, Chinese and Vietnamese participants screening caused anxiety due to lack of 
information from HCPs prior to screening (149).  Better knowledge of screening processes and 





1.20.3 Treatment Perceptions 
In nine surveys, 44-96% of participants were aware of treatments for HBV.  One study reported 
knowledge of a lack of effective treatment for HCV. (153)  Personal experiences with HBV infection 
(138,139,148,149,154), having a family member with HBV or liver cancer (31,145,154–156), 
screening (20,145,157–162), and vaccination (158,162) were associated with better knowledge; 
though in one study, individuals who had a personal or family history of HBV or liver cancer were 
more likely to have been screened, but they did not have better knowledge of HBV (145). 
 
This review of the evidence on illness perception and explanatory models showed that the bulk of 
the evidence emerged from studies on South East Asians in the USA and Canada, and to a lesser 
extent Australia.  There was little evidence of attitudes and understanding amongst migrants from 
other ethnicities or territories such as South Asia, Africa, Middle East and Eastern Europe and no 
evidence from those who migrated to the UK.  Most of the studies were focussed on knowledge and 
understanding of HBV infection.  One limitation was that the majority of the studies were surveys, 
with few qualitative studies.   
The overall picture was that many (though not all) migrants lack adequate knowledge of the 
aetiology, symptoms, transmission risk factors, prevention strategies, consequences and treatment 
of HBV and HCV infections.  There was a confusion about various hepatitis types, disconnect in 
awareness of viral hepatitis and its health implications (especially liver cancer) and poor knowledge 
of transmission risks, with false attribution to cultural and social factors as well as foodstuffs.  
There remains an opportunity to explore the knowledge and understanding in other ethnic migrant 
groups in the UK, and develop intervention and strategies which could increase uptake in screening 
programmes for these populations. (131) 
 
1.21 Healthcare Provider Perceptions of Screening and Treatment of Viral Hepatitis 
The healthcare provider is a key facilitator to any new health intervention, and general practitioners 
and other primary healthcare staff can provide a valuable insight into the implementation of a viral 
hepatitis testing programme and provision of follow-up care in the community.  There have been a 
small number of qualitative studies investigating the primary care providers’ perception of HCV case-




Qualitative researchers completed semi-structured interviews with 12 PCPs and 12 hepatology 
providers in Pittsburgh, USA regarding the facilitators and barriers to HCV treatment and adherence.  
Key barriers were identified as being patients' substance use disorders, mental health, 
transportation availability, history of non-adherence, and concern about side effects, with PCPs 
identifying treatment cost as a system-based barrier.  The main facilitators were provider education 
and encouragement, with PCPs also noting patient-based facilitators including past adherence, 
media exposure to information about HCV medications, a desire to clear the virus, and positive 
feedback regarding treatment response.  (163) 
 
A US study sought the opinions of PCPs on provision of HCV screening as part of the “baby boomer” 
screening programme offering a one-off test for all those born between 1945-1965.  22 PCPs in six 
states participated in qualitative semi-structured interviews.  Three themes related to primary care 
provider HCV testing and linkage were identified: (i) evaluating cues to HCV testing 
(innovation/evidence), (ii) framing HCV testing decisions (recipients), and (iii) HCV testing and 
linkage to care in the new treatment era (context).  The most frequently reported HCV testing cue 
was an electronic clinical reminder alert, followed by clinical markers and the presence of 
behavioural risk factors.  PCPs indicated a high motivation to test and link patients to specialist 
therapy.  (164) 
 
In New Zealand, one nurse-led practice providing integrated care participated in a qualitative 
investigation of staff experiences.  24 stakeholders (including 4 clinic staff members and other 
service providers) were interviewed in depth regarding implementation if the service and 
interprofessional relationships within the clinic.  Participants generally endorsed the clinic model 
which was thought to support more effective use of health resources.  Some participants expressed 
concerns regarding the potential 'poaching' of patients from other services (particularly general 
practice) and indicated a preference for HCV treatment services to be restricted to hospital settings. 
(165) 
A large postal survey of 3817 general practitioners in New Zealand assessed perceived barriers to 
HCV treatment in primary care.  925 (24.2%) surveys were returned. 187 (21%) GPs stated they 
currently prescribe Hepatitis C medications. 620 (70%) indicated that no general practitioner in their 
practice had interest in managing Hepatitis C therapy. Hepatitis C training was associated with 
increased prescribing activity-29% in those with training versus 10% in those without training.  
Barriers to treatment were identified as inadequate reimbursement (44%), too few Hepatitis C 
patients (40%), and caseload with other patients (40%),  Other barriers included difficulty in 
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obtaining transient elastography (35%) prior to treatment, lack of training (32%), and the perception 
that Hepatitis C therapy should be done by a specialist (30%).  Also, general practitioners 
consistently underestimated the prevalence of Hepatitis C in their practice by a factor of 4.3 to 13.6 
(based on an estimated prevalence of 1.9%).  (166) 
 
All of these studies were focussed on HCV testing and treatment in primary care in either the US or 
New Zealand.  There remains a knowledge gap on the opinions of PCPs in the UK on management of 
HBV or HCV and whether they believe the migrant population would benefit from the opportunity to 






















1.22 Aims and Objectives of the Research 
The HepFREE trial was designed to explore the feasibility of testing migrant populations for viral 
hepatitis in primary care.  As Clinical Research Fellow and Trial Manger I collected data and set up 
community based follow-up clinics for East and South London GP Practices in the trial. 
By analysing the HepFREE testing data I aimed to explore the following: 
1. To determine the screening rate at practices where GPs are supported and incentivised to 
screen migrants for viral hepatitis, compared to standard screening rates 
and through my own substudy analysis 
2. To determine the range of disease staging of those testing positive for viral hepatitis in 
primary care  
3. To determine if community-based follow-up and management is superior to standard 
hospital based follow-up 
4. To analyse the outcomes of the pre-trial survey of eligible patients on their understanding 
and knowledge of viral hepatitis, and if this influenced their attendance for screening 
5. to explore the views and opinions of healthcare professionals on their experience in 
delivering the HepFREE trial.   
In the following chapters I will outline the methodology of the HepFREE trial and each of the 
substudies, present the data and discuss my research findings, and consider how the findings explain 













2. Materials and Methods 
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2.1 The HepFREE Trial 
The HepFREE Trial (2013-17) was developed in order to assess the value of screening immigrants for 
viral hepatitis in a primary care setting, to clarify the prevalence of viral hepatitis amongst this group 
and to evaluate clinical and cost effectiveness of such a screening programme.   
The study involved a preliminary phase of qualitative work examining attitudes to testing and illness 
perception in several immigrant communities, followed by a randomised controlled cross-sectional 
cluster trial to assess the feasibility and cost-effectiveness of case identification and subsequent 
treatment of viral hepatitis in immigrants originating from countries with a known prevalence of viral 
hepatitis of more than 2%. The trial was developed by Professor Graham Foster and funded by the 
National Institute for Health and Research (NIHR) through the Programme Grants for Applied 
Research. 
I worked as the London based Clinical Research Fellow (2015-2017) and also the HepFREE trial 
manager (2016-2017). 
This thesis comprises the outcomes of my original analysis of the HepFREE trial data, the outcomes 
and my original analysis of a community based substudy which was set up and performed by myself.  
It also includes my original data collection and analysis of disease staging and engagement 
outcomes, an original qualitative research substudy to the trial which I designed and performed, and 
my original analysis of patient illness perceptions studies.  
In this chapter I discuss the methodology of the main HepFREE Trial, and the HepFREE sub-studies.  
These are presented below: 
(i) Testing for Viral Hepatitis 
1. Overall HepFREE Results 
2. Disease Staging 
3. Engagement and Outcomes in London Community & Standard Care Clinics 
 
(ii) Factors influencing Screening Uptake 
4. Patient Pre-Screening Survey 
5. The HepFREE Provider Experience Study 
In this chapter I will describe the trial design, aims and objectives of the HepFREE trial, from which I 
developed my original research into engagement and outcomes in London Community Viral 
Hepatitis Clinics, qualitative research into facilitators and barriers to testing for viral hepatitis in 
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Primary Care, and further exploratory analysis of the HepFREE outcomes and pre-trial patient 
survey. 
 
2.2 HepFREE Trial Methodology 
HepFREE was a multicentre, open-label, cluster-randomised controlled clinical trial in UK immigrant 
subjects examining the hypothesis that incentivising and supporting primary care physicians 
increased screening rates for viral hepatitis in immigrants in areas of high immigrant density 
(Bradford, North East London and South London).  Nested sub-studies examined whether bespoke 
invitation letters were beneficial and whether community care increased engagement.  A parallel 
non-randomised substudy of screening in a region of low migrant density (Oxford) was also 
conducted (known as HepFREE 2). 
The HepFREE project was initiated with a literature review and qualitative assessment of attitudes to 
testing and knowledge of viral hepatitis in a variety of immigrant groups. Following completion of 
these studies, culturally appropriate awareness and information leaflets were developed and used in 
the communities where testing was to be introduced.  
 
HepFREE Trial Hypotheses: 
 
The trial protocol described the trial hypotheses as follows: 
Hypothesis 1 
Targeted interventional screening is superior and more cost-effective than control (opportunistic) 
screening for the detection of viral hepatitis in first and second generation ethnic minority patients 
in primary care 
 
Hypothesis 2 
Provision of an enhanced patient information invitation letters which include additional information 




Community based therapy and follow-up is superior to conventional delivery of treatment (based on 
referral to local hospital treatment centres) as measured by engagement with management and 




(1) HepFREE Screening Trial 
(2) HepFREE Follow-Up Trial : Standard vs Community Based Clinical Care Trial 
(3) HepFREE 2 
 
1. The HepFREE Screening Trial 
The main HepFREE trial tested the impact of screening for viral hepatitis in immigrants in General 
Practices (GP) in three areas of high density of immigrants in England (Bradford, North-east and 
South-east London). The trial was designed to invite up to 48,000 eligible participants.  Practices 
were randomised to participate in either the intervention arm or the control arm of the trial. 
 
Practices in the targeted intervention arm were further randomised to either the enhanced 
invitation arm (invitation letters with additional information viral hepatitis) arm or standard 
invitation letters arm (trial invitation letters are included in Appendix 4), as well as standard or 
community based follow-up (see details under “2. Follow-Up Trial” below) 
 
Potential participants were identified from all registered patients on the clinical computer systems 
within the practice by using pre-existing demographic data stored within individual electronic 
medical records. Once identified, potential study participants were sent an invitation by post to 
attend for a screening test.   Each GP Practice was asked to recruit trial participants over an 18 
consecutive calendar months period. 
 
The HepFREE Screening Trial commenced screening on 31 Oct 2013. To avoid a strain on resources, 
screening start dates were staggered across the practices, with the initial practices commencing 
screening in Oct 2014, and final practices commencing screening in August 2015.  All intervention 
and control practices were closed to recruitment by 4 February 2017. 
 
2. Follow-up and treatment in Standard vs Community Based Viral Hepatitis Clinics Trial 
examine the compliance with clinical follow up and to determine whether or not community care for 
viral hepatitis was clinically and financially viable we conducted a second trial of different treatment 
options – therapy in the hospital setting (standard of care) versus therapy in community based viral 
hepatitis clinics.  
This trial was nested within the first screening trial with practices in the targeted screening arm of 
the first trial randomised to either community care or standard (hospital-based care) in the event of 
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a positive diagnosis of hepatitis. From the fifty practices that were randomised to the targeted 
screening arms of the trial, twenty-one were assigned to standard care follow-up and twenty-nine to 
community care follow-up.  
 
The HepFREE Follow-Up Trial commenced in mid-2014 after patients testing positive for viral 
hepatitis were identified in the HepFREE Screening Trial. 
 
3. HepFREE 2 
A parallel trial was set up in rural Oxfordshire, an area with low density migrant population.  GP 
practices in Oxfordshire were invited to participate as intervention practices only.  GPs were asked 
to invite eligible patients by letter and opportunistically, and recruitment from each practice was not 
capped.  Practices invited patients over an 18 month period, the first practice opened to recruitment 
in May 2015, and the final practice opened in August 2015. 
Patients testing positive for viral hepatitis were referred to secondary care for their ongoing 
management, but were not followed up by the HepFREE trial. 
Data outcomes from HepFREE 2 are included with screening outcomes from the HepFREE trial but 
are not analysed by me as this work lies outside the scope of this thesis.  
 
 
2.2.1 Aims and objectives of the HepFREE TRIAL 
 
Aims: 
The main aims of the HepFREE trial were:-  
1) To complete a literature review of knowledge and attitudes to viral hepatitis in immigrant 
communities in England  
2) To complete a mixed methods assessment of community needs to inform the development of 
appropriate tools to increase awareness of, and compliance with, testing for chronic viral hepatitis in 
immigrant communities at high risk of infection  
3) To develop a culturally sensitive patient information letter with the potential to increase 
engagement in testing and treatment  
4) To assess the most cost effective method of screening for chronic viral hepatitis in primary care 
patients within ‘at risk’ ethnic minority communities.  
5) To assess the impact of the interventional approach based strategy to screening.  
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6) To establish whether the involvement of community therapy is likely to have an impact on a 
patient’s engagement after having been positively tested for viral hepatitis.  
7) To assess differences in treatment adherence between patients groups receiving treatment within 
the community against those who have standard hospital care.  
 
Aims 1-3 were addressed with qualitative studies which have been published (131,132)and aims 4 to 
7 were addressed in a cluster randomised trial (see below).  
 
For Chapters 3-5 of this thesis, I have analysed data arising from aims 4-7. 
 
Objectives and Outcomes: 
 
The primary and secondary objectives and outcomes from the cluster randomised controlled trial 
were:-  
Primary Objectives  
HepFREE Screening Trial 
• To determine whether interventional screening is more cost-effective than control screening 
in the detection of viral hepatitis in ethnic minority patients in primary care.  
• To determine the screening rate of intervention practices compared to the screening 
rate in control GP practices  
 
HepFREE Standard vs Community Based Clinical Care Trial  
• To determine whether community based therapy is superior to conventional delivery of 
treatment (based on referral to local hospital treatment centres) as measured by 
engagement with management).  
 
Secondary Objectives  
• To determine the range and prevalence of different beliefs, attitudes and barriers to 
screening.  
• To assess the impact of contextual variables and demographics as well as health literacy in 
the uptake rate of screening and subsequent treatment engagement.  
• To assess treatment adherence between patient groups receiving treatment within the 
community care setting against standard hospital care.  
• To determine the cost effectiveness of the interventions  
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• To determine the prevalence of viral hepatitis in different ethnic groups living in the UK  
• To determine the number of eligible patients across the participating GP practices  
• To determine the overall level of compliance with diagnostic and prognostic events for all 
patients that test viral hepatitis positive as part of this trial 
• To determine the level of compliance with the management plan for patients that test 
positive for viral hepatitis.  
 
The Primary and Secondary Outcomes of the HepFREE trial were: 
 
Primary outcomes  
• In control GP practices, the number of patients eligible to be screened (determined by a 
review of the number of immigrants registered at the GP practice at the initiation of the 
study). In intervention GP practices: the number of patients eligible for this study that are 
invited to screen (determined by a review of the number of invitation letters sent to eligible 
immigrants registered at the GP practice at the initiation of the study).  
• The proportion of potential participants that attended for testing 
• The proportion of viral hepatitis positive participants that comply with the clinical diagnostic 
and prognostic assessments in the different treatment arms. Engagement is defined as:  
• completion of three diagnostic and prognostic events (including diagnostic assessment 
visit, a Fibroscan® and/or ultrasound and a statement of clinical management plan from 
the hepatology team).  The schedule of these events was dictated by local policy.  
• For patients who are HCV antibody positive or equivocal but HCV RNA negative 
attending the GP practice or the local hospital on two separate occasions.  
• The costs associated with delivering the intervention were recorded and used for the cost 
effectiveness analysis.  
 
Secondary outcomes  
• Proportion of new registrants who agreed to undergo testing for viral hepatitis.  
• The proportion of patients compliant with their prescribed clinical management plan in the 
different treatment arms (community care vs standard hospital care). Compliance with the 
clinical management plan is defined as attending at least one visit after the management 
plan has been agreed by the participant and the clinicians  
• Patients that test positive for viral hepatitis and were prescribed medication to treat their 
viral hepatitis were monitored for their adherence to therapy. Patients were considered to 
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have adhered to therapy if they successfully complete 80% or more of their prescribed 
therapy.  
• The ‘outcome of therapy’ was also monitored. A successful outcome of therapy was defined 
as sustained viral response 12 weeks after treatment completion for hepatitis C patients. 
The definition of successful outcome of therapy for hepatitis B treatment is a reduction in 
viral load to <80% of starting value within 12 weeks.  
 
 
2.2.2 HepFREE Trial Team 
 
The HepFREE trial team were as follows: 
Chief Investigator (CI) – Prof Graham R. Foster 
Trial Manager  
Data Manager 
Clinical Research Fellow (London) 
Clinical Research Fellow (Bradford) 
Research Assistant (London) 
Research Assistant (Bradford) 
Research Assistant (Oxford) 
Data Manager 
 
The Trial team were all based in London, apart from the Clinical Research Fellow (CRF) and Research 
Assistant based in Bradford. 
I joined the HepFREE Trial team in August 2015 as Clinical Research Fellow (London) and took on the 
additional role of Trial Manager from Sept 2016 until August 2017. 
When I joined the trial, the GP practices in Bradford had been initiated for recruitment (i.e. trained 
for this research trial and eligible patients identified) by the local CRF.  Some practices had started 
screening in London; however I initiated the majority of GP practices in East London and South 
London.  I also performed a monthly review of testing outcomes at each London practice with the 
assistance of the Trial Manager and Research Assistant (London).   
For the community based clinical care trial I set up new Hepatology clinics at the Royal London 
Hospital (RLH) and King’s College Hospital (KCH) London, and liaised with GP practices to set up new 
community based Hepatology clinics at 3 practices in East London and 4 in South London. 
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When I became Trial Manager I also oversaw the collection and cleaning of screening data from 
interventional and control practices in London, and also the HepFREE2 trial in Oxford.  I collected all 
the research data from the standard and community clinics.  At the end of recruitment, I cleaned all 
the research data with a data manager and assisted in data analysis with the trial statisticians.  At 
the end of the analysis, I wrote the NIHR trial report with Prof G. R. Foster.    
 
 
2.2.3 Trial Funding, Ethics and Governance  
HepFREE was funded by the NIHR through the Programme Grants for Applied Research, after a grant 
application by CI Prof Foster.  
The first version of the Trial protocol was written by the CI and Trial Manager in 2012 and underwent 
several modifications during the Trial set-up. 
 
The study was sponsored by Bart’s Health NHS trust and Queen Mary University London.  An 
Integrated Research Application System (IRAS) form for the trial was completed, and all documents 
submitted for internal peer review at the Blizard Institute, 4 Newark Street, London, City of London, 
E1 2AT and external review by the Bart’s Health NHS Trust Research Development team, Joint 
Research Management Office, Queen Mary Innovation Centre, Lower Ground Floor, 5 Walden 
Street, London, E1 2EF.  
The study protocol was approved by the National Research Ethics Service Committee London – 
Fulham based at HRA NRES Centre Manchester, Barlow House, 3rd Floor, 4 Minshull Street, 
Manchester, M1 3DZ on 24 December 2012, REC reference number 12/LO/1768. 
 
During 2013 the data for qualitative studies looking at patient illness perception and healthcare 
providers’ experience was collected by qualitative researchers. 
 
During 2013 the HepFREE Trial team was assembled and local co-ordinating leads in Bradford, North 
East & South East London and Oxford were identified.  A Trial Steering committee including of the CI, 
trial manager, lead statistician, lead qualitative researcher, research fellows and primary care and 
public health leads was also put together.  The trial steering committee was chaired by Prof William 
Irving (Chairman), supported by Dr Moira Kelly and Dr Alan Montgomery. 
2.2.4 Amendments to the HepFREE Protocol 
Several modifications were made to the HepFREE protocol during set-up and prior to the 
commencement of screening.  These included the inclusion of the pre-screening survey, and 
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inclusion of the enhanced letter nested study.   However some amendments were made after 
recruitment had begun (such as the addition of cost-effectiveness analysis), the most significant of 
which was capping of eligible participants at some interventional GP practices. 
 
2.2.5 Capping of Eligible patients 
Several modifications were made to the HepFREE protocol during set-up and prior to the 
commencement of screening. It was initially planned to test all eligible patients in each practice, on 
basis that this would be an estimated 500 patients per practice based on prior pilot studies.  
However between proposal and trial initiation it became clear from eligibility reports that practice 
mergers had created much larger patient registries, with more than 500 eligible patients at each 
practice.  Between proposal and trial initiation, changes in general practice, specifically the merger 
of practices to form larger practices with greatly increased numbers of patients, led to a marked 
increase in the number of patients per practice. A scoping exercise indicated that recruiting from the 
58 primary care practices would have led to enrolment of over 100,000 patients –i.e. a doubling of 
the trial size. As HepFREE is a cluster randomised trial it was not advisable to substantially reduce the 
number of participating practices. Following discussions with the trial steering committee and 
funders it was agreed that some practices (35 of the 50) should be ‘capped’ and recruitment should 
only involve a total of 500 patients. To determine whether recruitment of all patients from a practice 
was feasible, the 15 practices that had already initiated recruitment prior to the amendment 
continued to recruit all eligible patients.  
 
For all 50 practices randomised to the interventional arm, the Clinical Effectiveness Group (London) 
and Commissioning Support Unit (Bradford) created a search that would enable practice staff to 
query the GP database (EMIS or SystmOne) to assess the total number of patients fitting the 
eligibility criteria at the  practice. For uncapped practices this list was used to invite all the patients 
who were flagged as being eligible. For capped practices, a functionality on the GP practice database 
was exploited to select 500 patients at random who were on the full eligibility list. In capped 
practices, GP practices invited the 500 patients that were randomly selected by the GP database, 
and these patients were the eligible cohort at that practice. 
 
For practices where no cap was applied, all identified patients formed the eligible cohort. Patients 




At the end of the intervention period, in control and uncapped practices, the eligibility search was 
repeated and eligible patients who joined the practice during the study (i.e. present on final but not 
initial eligibility lists) were included as new registrants. Data was not collected for the number of 
patients who registered and subsequently left the practice within the 18-month study period. 
 
This amendment was approved in Aug 2014 as part of Protocol version 6.0. 
 
2.2.6 Randomisation of GP Practices 
 
Trial randomisation was performed using the method of online minimisation. The programme 
managing allocations was web-based, and developed using Java at the Pragmatic Clinical Trials Unit 
(PCTU), Queen Mary University of London (QMUL) in London, UK. 
 
Practices in areas with a high density of migrants were randomly assigned by a trial statistician in the 
ratio 1:2:2:2:2 to an opportunistic screening (control) group or to one of four targeted screening 
(interventional) groups: standard (i.e., hospital-based) care and a standard invitation letter; standard 
care and an enhanced invitation letter; community care and a standard invitation letter; or 
community care and an enhanced invitation letter.  
 
There were therefore five treatment groups, which were first stratified by area (Bradford, southeast 
London, or northeast London) and then minimised by number of eligible patients per practice. This 
method was used in preference to minimisation with a random element, which has limitations when 
it is required to allocate different numbers of clusters to different trial groups, as in this case.  
 
Practices were divided into three groups according to the number of eligible patients: fewer than 
1600 patients, 1600–3300 patients, or more than 3300 patients. Randomisation was done with an 
online minimisation system that was developed by, and hosted at, the PCTU, QMUL.  This cluster 
randomisation study design minimised training and spillover effects. Clusters consisted of all 
migrants registered at a practice (or a random subset of such patients) and interventions were 
delivered at the cluster level in parallel interventions. Patients registered with the practice were not 
informed of their allocation, but the practices were aware. 
The trial manager emailed the details of which GP practices needed to be randomised directly to an 
independent PCTU statistician (who had no other involvement in the trial), who used the 
randomisation software to allocate the practice, and the project coordinator was then notified by 
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email of the allocation group. The analysis team were masked to the allocation groups. Patients who 
tested positive for viral hepatitis were not informed of the group to which their practice was 
allocated until after they consented to enter the embedded trial of community versus standard care. 
 
 








The HepFREE Screening Trial was a cluster randomised trial of screening. Therefore, there was no 
individual participant consent to participation. Participants gave written consent to the blood test 
used for screening and for access to data. At this stage they were blinded to their practice’s 
treatment allocation in the second trial so were unaware of their treatment in the event of a positive 
screening result.  
Consent to participate in the HepFREE Follow-Up Trial was sought from all participants who had a 
positive viral hepatitis screening test at the time of their diagnostic assessment in secondary care. 
Once this consent to the second trial had been obtained, participants were un-blinded and informed 
of their practice’s treatment and monitoring allocation, either hospital treatment and follow-up, 
referred to as standard care, or treatment and follow-up at a satellite clinic in the community. Any 
participant who withdrew consent for the second trial was treated as per standard care. Treatment 
allocation was concealed until after the initial consent to participate in the second trial had been 
obtained, in an effort to prevent bias from being created between recruitment in the two arms of 





















2.2.8 HepFREE Screening Trial Methodology 
2.2.8.1 The control arm  
Practices randomised to the control arm received detailed written information about the trial aims, 
objectives and methods and a single face-to-face meeting with the trial team at a site initiation visit 
(SIV). The SIV was attended by general practitioners (GPs), the practice manager, practice nurse and 
healthcare assistants and consisted of an education session on viral hepatitis delivered by the local 
Clinical Research Fellow with the use of PowerPoint presentation.  Information included indications 
for screening and consequences of long-term infection.   
 
The purpose of the session was to encourage practitioners to offer screening to individuals 
considered at risk of viral hepatitis, including individuals who would have been eligible if the practice 
had been randomised to targeted screening. Clinicians were encouraged to consider offering the 
screening test to eligible individuals who attended the practice for a consultation or when 
registering as a new patient.  
 
A copy of the slides and documents provided in the SIV is found the in Appendix 3. 
 
2.2.8.2 The targeted screening (intervention) arm 
Practices in the intervention arm were allocated to be given a financial incentive for every patient 
tested, and patients received either a standard or enhanced invitation letter.  Practices were visited 
by the trial team at an SIV where members of staff received the same education session provided to 
control practices, as well as teaching on additional trial procedures. In practices assigned to targeted 
screening, potential study participants were invited to attend for screening using one of the two trial 
invitation letters (see appendix 4).  
Administrative staff were taught how to generate and distribute personalised screening invitation 
letters using the practice computer system. Allied healthcare professionals were taught how to 
obtain consent, perform blood sampling for analysis, complete the sample request form, and how to 
locate and complete the trial specific template that had been published on the electronic records 
system used by the practice. Finally, staff were taught to input Read codes denoting the results of 
the screening blood tests on to each participant’s electronic medical record and instructions were 






2.2.8.3 Practice payment  
Practices received monetary incentives for trial related activities. For time taken to set up the trial 
and to produce a data extract, control practices received £250. In practices performing targeted 
screening financial support was provided by NIHR. Table 1 summarises the payments made to 
targeted screening practices for trial related activities. 
 
Table 4: Study support costs provided to targeted screening practices by the Clinical Research 
Network 
Trial related activity Cost (pound sterling) 
Set up costs 475.28 
GP check on participant list for suitability 160.00 
Reminder set up 12.44 
Text Message reminder service set up 11.00 
Consent and Screening 7.32 
Book appointments (per appointment) 2.07 
Invites (per invite) 0.41 
Exclusions Nurse 0.37 
Text message reminder (per SMS) 0.15 
 
 
2.2.8.4 Eligibility criteria 
Potential study participants included anyone registered within one of the designated targeted 
screening practices that:  
• Originated from a country with a prevalence of viral hepatitis of more than 2% (List of 
countries available at the in appendix 2). 
• Had a parent who originated from a country with a prevalence of viral hepatitis of more than 
2% 
• Was eighteen years of age or older.  
• Had capacity to consent to participate  
• Had no documented evidence of previous viral hepatitis screening within the last five years.  




Due to uncertainty surrounding whether subjects had historically been screened for HBV infection 
prior to immunisation, we did not exclude patients immunised for HBV.  
Patients could withdraw from the trial at any time and data up to the time of withdrawal was 
retained and analysed.  
2.2.8.5 Patient selection  
In London and Bradford each practice manager ran a bespoke eligibility search report on their GP 
database (the SystmOne database for Bradford practices and some London practices and the EMIS 
database for all other London practices). The reports were designed in conjunction with the data 
quality team at the Yorkshire and Humber Commissioning Support Unit (CSU and the Clinical 
Effectiveness Group (CEG) at the Centre for Primary Care and Public Health, QMUL.  
For GP databases using SystmOne (S1), the eligibility search consisted of two reports that were 
combined and when run at the same time on S1 created the final list of trial participants.  Report 
one searched for Read codes in electronic medical records that related to the following demographic 
data fields:  
• Country of birth  
• Main spoken language  
• Ethnicity  
 The second report (Report Two) was designed to exclude ‘eligible’ individuals, who had either 
already been diagnosed with chronic viral hepatitis or had undergone testing for viral hepatitis in the 
previous five years.  The two reports, when run together produced a final report containing the 
details of all individuals that fulfilled the criteria for enrolment.  This list was used by practice 
administrative staff to generate and distribute letters. Practices recruited to comprehensive 
enrolment were instructed to send an invitation letter to all potential study participants that 
appeared within the eligibility report during the eighteen month screening period.    
At practices using EMIS a single eligibility search was run at the start of the study and identified 
eligible patients based on   
• Country of birth 
• Main spoken language 
• Ethnicity  
Patients were excluded who had either already been diagnosed with chronic viral hepatitis or had 
undergone testing for viral hepatitis in the previous five years.   In practices assigned to test all 
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patients a second report (Final Eligibility) was run at the end of screening and identified patients on 
the same basis as the initial report and therefore included new patients who had registered at the 
practice during the 18 months study period and were eligible for screening.  At the end of the 
screening period a final screening report was run at each practice to capture date invitation letter 
sent, patient consent to trial recruitment, date of HBsAg and anti-HCV testing, and outcome of 
testing.   For practices recruited to perform selective, capped enrolment, the process described 
above was used to identify potential study participants registered at the practice.  Once the list of 
study participants had been generated, a function within either SystmOne or EMIS was used to 
produce a list of five hundred individuals that were selected at random from the original eligibility 
report.  An additional Read code was entered into the electronic medical record of all five hundred 
participants, and a new search was created in SystmOne or EMIS to produce a report using this Read 
code.  The report produced was a modified list of potential study participants from which the 
practice could send invitation letters.     
At control practices using EMIS a screening report was run at the end of the 18 month period to 
identify date of HBsAg and/or anti-HCV testing and outcomes.  
In summary the reports were: 
SystmOne Practices:  
(i) Report 1 – identifying eligible patients  
(ii) Report 2 – excluding previously screened/known positive patients from Report 1.  
(iii) Combined report – combining outcomes from Reports 1 & 2 
(iv) Random 500 Report – selecting 500 randomised patients from (iii) 
(v) Screening Report (based on either (iii) or (iv)  
EMIS Practices:  
(i) Initial Eligibility report – those patients eligible for screening on Day 1 of the 18 month 
screening period  
(ii) Final Eligibility Report – those patients eligible for screening on final day of 18 months 
screening period  
(iii) Random 500 report – selecting 500 randomised patients from (i)  





Control Practices  
(i) Initial Eligibility report – those patients eligible for screening on Day 1 of the 18 month 
screening period  
(ii) Final Eligibility Report – those patients eligible for screening on final day of 18 months 
screening period  
(iii) Screening report – based on (ii)  
It was accepted that there may have been a small number of eligible patients who joined and left 
practices within the eighteen months of the screening period and therefore would not appear on 
either (i) or (ii) at Uncapped or Control practices.  
For patients identified as eligible for the study an invitation letter was sent inviting attendance and 
participation in the trial. In addition the patient’s electronic letter was ‘flagged’ to identify them as 
eligible for testing and when such patients attended the surgery they were asked if they wished to 
participate.  
 
2.2.8.6 Data capture during the screening   
A trial-specific template that incorporated and collected data required for analysis was designed by 
CEG and was built and published on SystmOne (Bradford) and EMIS web (London) for data capture. 
The template was used to collect and record specific trial-related activities using Read codes.  The 
following data was recorded in the template either by using a tick box (with attached Read code) or 
free text entry.  
• The date the person either agreed or declined the offer to give blood for testing  
• The date consent to give blood for testing was obtained from the trial participant. 
• The tests requested on the study specific proforma. 
• The ethnicity of the trial participant. 
• The country of birth of the trial participant. 
• The main spoken language of the participant and whether an interpreter was used for 
consent.  
There were two fields on the template to record a positive HBV or HCV screening test result and 
either this could be used or the Read codes could be entered manually without opening the 
template. Monthly cumulative reports for each practice including all of the data collected in the 
template, the number of invitation letters sent, the number of individuals that had consented for 
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screening and the results of all screening tests were sent to London by secure email for cleaning by 
the trial study team and storage by the trial data manager.   
  
2.2.8.7 Testing of patients in the HepFREE Trial 
Patients were identified as eligible for HepFREE screening using the bespoke trial eligibility search 
and invited by letter to participate in the trial at their GP practice.  Additionally, an electronic alert 
was placed on the patients’ electronic records system (either EMIS or SystmOne) identifying them as 
eligible for testing, so that patients could be opportunistically asked to participate if they attended 
the GP practice for another reason.  
Patients who responded to invitation were asked for written consent to take blood and use the 
results in the trial. Following consent, 6 millilitres of venous blood was obtained by venepuncture 
and sent in a VACUETTE® sample tube with a study specific proforma requesting for the sample to be 
tested for HBsAg and anti-HCV to the local virology laboratory (Leeds General Infirmary for Bradford, 
Barts Health Virology for NE London and Kings College Hospital virology for SE London).  
 
HepFREE study samples were tested and reported as follows: 
HBsAg  
Blood samples were tested using the Abbott ARCHITECT HBsAg qualitative assay.   This is a two-step 
chemiluminescent microparticle immunoassay (CMIA) for the quantitative determination of hepatitis 
B surface antigen (HBsAg) in human serum and plasma. 
 
Samples that tested positive underwent confirmatory testing using the Diasorin Liason XL assay in 
addition to testing for the following markers to confirm chronic infection: total core, core IgM, 
Hepatitis B e-antigen and hepatitis B e-antibody.  
 




Samples were tested for anti-HCV using the Abbott ARCHITECT Anti-HCV assay (Abbott Laboratories. 
Abbott Park, Illinois, U.S.A.). ARCHITECT Anti-HCV assay is a CMIA for the qualitative detection of 
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immunoglobulin G (IgG) and immunoglobulin M (1gM) antibodies to hepatitis C virus (anti-HCV) in 
human adult serum and plasma. 
Anti-HCV Positive 
 If the result obtained from the ARCHITECT anti-HCV test was positive, the sample was referred for 
confirmatory testing using the Diasorin Liason XL assay.  This test also uses CMIA technology for 
qualitative detection of anti-HCV. If there was a discrepancy in the results obtained from the first 
and second tests, a third test was performed on samples using the Orthogenics HCV antibody kit. 
The sample was also automatically referred for RNA testing using the COBAS® AmpliPrep/COBAS® 
TaqMan® HCV Test, Roche Molecular Diagnostics (4300 Hacienda Drive, Pleasanton, CA 94588, USA).  
This is an in vitro nucleic acid amplification test for the quantification of HCV RNA in human plasma 
or serum.  The results of this test were reported to the referring GP. 
 
Anti-HCV negative  
The screening test for HCV was negative and reported to the referring GP.  No further action was 
required. 
 
Low level anti-HCV  
For those samples reported as either low level anti-HCV or anti-HCV indeterminate, the study 
participant was recalled for repeat anti-HCV testing after seven days. If the repeat sample was 
positive for anti-HCV, RNA testing was performed, and if it was either negative, or indeterminate 
again, no further action was taken.  
 
 
2.2.8.8 Management of patients identified with chronic viral hepatitis and individual consent for 
participation in the HepFREE follow-up trial  
 
Participants with a positive screening result were contacted by a member of staff in the practice and 
an appointment made with a practice clinician. As the Clinical Research Fellow, I generated a referral 
for the participant to attend secondary care and notified the patient by letter to their home address 
and also by mobile phone text reminder. 
Irrespective of the patient’s further participation in the Follow-up Trial all diagnostic investigations 
were scheduled at the patient’s local Hepatology Secondary Care Centre to be seen by the Clinical 
Research Fellow (myself in North-east and South-east London).  All subsequent follow-up 
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appointments in either standard or community care in London were arranged and conducted by 
myself. 
 
2.2.8.9 Data Capture 
Data capture for patients with a positive test result was recorded on the OpenClinica open source 
clinical trial software for Electronic Data Capture Clinical Data Management. This allowed the 
recording of case report forms for study events such as:  
• Patient Demographics (Ethnicity, Country of Birth, Study location, Date of positive results, 
anonymised identifiers)  
• Diagnostic Assessment (documentation of supplementary consent, blood results including 
full blood counts, Liver function tests, INR, renal function and HIV viral hepatitis screen)  
• Fibrosis Assessment (documentation of liver ultrasound, liver biopsy and Fibroscan®  results) 
• Management (approved therapy, observation, wait for new therapies or refer to clinical trial 
for treatment)  
• Extra Visits (summary of additional clinic visits in hospital or community setting)  
• Adverse Events  
Demographics 
Patient demographics recorded for all those testing positive for HBsAg and HCV Ab were 
- Gender 
- Ethnicity  
- Country of birth 
Some of the above were included in GP records, but full documentation was recorded at the time of 
the patient’s presentation to diagnostic screening appointment in secondary care. 
Tests and staging for HBV infection 
For patients testing HBV sAg positive, staging investigations were: 
- Hepatitis B specific serology tests:  Hep B core antibody, Hepatitis B e-antigen, Hepatitis 
B e-antibody, Hepatitis B DNA levels and Hepatitis delta co-infection 
- General serology tests: full blood count, urea and electrolytes, liver function tests, HIV 
antibody. 
- Imaging investigations:  liver transient elastography and liver ultrasound.   
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- Liver Biopsy: Some patients based in the Bradford arm of the study were offered a liver 
biopsy as per local protocol 
Staging for Hepatitis B infection is dependent on HBV viraemia, and imaging.(21)   
Tests and staging for HCV infection 
HCV Ab positive, HCV RNA negative status reflects patients who have either been treated and cured 
of HCV, or have self-cleared the virus (approx. 20% of those infected). (36) 
For those testing positive for HCV Ab, a negative HCV PCR test confirmed by a repeat negative test 
confirms a non-viraemic status.  These patients can be discharged without follow-up, requiring a 
HCV RNA test only if they are at further risk.   
For patients testing HCV-antibody and HCV RNA positive, staging investigations were: 
- Hepatitis C specific serology tests:  HCV Genotype, HCV RNA levels. 
- General serology tests: full blood count, urea and electrolytes, liver function tests, HIV 
antibody. 
- Imaging investigations:  liver transient elastography and liver ultrasound.   
NB: Liver Biopsy: - Some patients based in the Bradford arm of the study were offered a liver biopsy 
as per local protocol at the time of the study.  However, this was not a measured outcome for the 
HepFREE trial. 
Staging for Hepatitis C infection is dependent on imaging. (3,36)  
HIV Testing 
HIV Antibody testing was routinely offered to all patients testing positive for HBV or HCV or both as 
part of local protocols. 
 
2.2.8.10 Data Collection Process 
Trial 1: The following information was collected from participating GP practices at the end of the 18 
months screening period:  
• Number of eligible patients [patients WITHOUT a positive Hepatitis B and C status on file] at 
this GP Practice (over total screening period) and their ethnicity and gender breakdown. For 
capped practices the number of eligible patients was 500 and the number of eligible patients 
varied in the other practices.  
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• Total numbers of eligible patients contacted for screening (over the 18 months screening 
period)   
• Total numbers of patients screened at a new patient appointment   
• Total numbers of new registrants screened – i.e. patients registering with the practice after 
the practice was initiated and has not left the practice up until the practice was closed for 
screening  
• Total numbers of patients test positive for viral hepatitis  
The data was collected by running bespoke HepFREE eligibility searches which were prepared by the 
Primary Care Trials Unit, QMUL for use on SystmOne and EMIS systems.  The searches were powered 
to look for patients fitting the above parameters at set timepoints (start and end of screening 
period).  They also allowed collection of anonymised patient demographics. 
 
Patient level data was collected from patients who agreed to be tested. This included:   
• Age  
• Gender  
• Ethnicity  
• Country of birth  
• Country of parents’ birth  
• Blood testing results  
  
2.2.8.11 Data Management   
Clinical fellows and research assistants were responsible for collecting cumulative monthly reports 
from each intervention practice for storage and cleaning.  At the end of the trial, a final screening 
report was run at each control and intervention practices.  All of these reports included the Read 
codes and outcomes for the parameters described above in Data Capture section 2.2.8.9.   Initial 
data cleaning was undertaken by a data manager and myself in my role as the clinical research 
fellow.  We ensured that all patients identified as eligible fit criteria of at least one of (i) country of 
birth, (ii) main language spoken or (iii) ethnicity, in both control and intervention practices.   Patients 
belonging at intervention practices required evidence of eligibility (from the eligibility reports) 
presence of a consent form or electronic consent code, date of invitation, date of testing and 
outcome of screening.  The patient’s practice was contacted for relevant missing data.  
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For missing test outcomes, the virology laboratory was contacted and a result of negative, positive 
or sample missing was recorded.  Missing data were then manually entered.   For patients screened 
at Control practices, they required evidence of eligibility (from the eligibility reports), date of testing 
and outcome of screening to be included as a screened participant.  Again, if any results fields were 
missing, the virology laboratory was contacted to clarify outcomes. Final cumulative reports of 
eligible patients from SystmOne practices, from uncapped EMIS practices and from capped EMIS 
practices were produced.  A final cumulative screening report for SystmOne and for EMIS practices 
was also produced and cross referenced with the eligibility reports to produce a final outcome of 
eligible, screened patients from each practice. Patients with positive test results were identified 
from the monthly screening reports and positive READ codes from the virology laboratories.  
Therefore there were two possible routes of identification for positive results which were applied to 
both control and active practices. Results that were positive at the surgery but negative in the 
virology laboratory were reviewed and, where appropriate, the GP result was deleted. Results that 
were positive in the virology laboratory but reported negative at the GP surgery were reviewed and, 
if appropriate, the GP record was amended and the patient contacted to inform them of the positive 




2.2.9 HepFREE Trial Data Analyses 
The following statistical methodology is from the HepFREE protocol version 9 (see appendix 1) and 
statistical analysis plan.  This analysis was completed by an independent statistician from PCTU, and 
is included here for completeness. 
2.2.9.1 Trial definitions  
HepFREE Screening Trial: 
Screening rates = standard screening vs interventional screening (8 v 50 practices)  
Denominator = the number of individuals deemed eligible to be screened at each GP practice over 
the 18 months screening period. (In standard and interventional screening practices where all 
eligible individuals were invited, the number deemed eligible was the number of individuals fulfilling 
the eligibility criteria over the 18 months screening period and in intervention practices where only 
500 individuals were randomly selected for inviting, the denominator was 500).   
Numerator = number of patients attending a blood test and for whom the GP practice received their 
results over the 18 months trial period.  
HepFREE Follow-Up Trial: 
Engagement with Clinical Assessment rates (binary outcome) in community care vs standard care:   
Numerator – number of patients engaged with clinical assessment.  
Engagement with diagnostic and prognostic assessment was defined as completion of three 
diagnostic and prognostic events (including diagnostic assessment visit, a Fibroscan® and/or 
ultrasound and a statement of clinical management plan from the HepFREE Clinical Research 
Fellow).  
The schedule of these events was dictated by local policy. For patients who were HCV antibody 
positive but HCV RNA negative, attending the GP practice or the local hospital on two separate 
occasions was deemed as adherence with diagnostic and prognostic assessments. 
Denominator – number of patients tested positive for viral hepatitis.  Patients who tested positive, 
but did not come to receive their results after contacting them on three separate occasions were 





Compliance to Clinical Management Plan and Prescribed Therapies: community vs standard care   
Compliance with the clinical management plan was defined as attending at least 1 visit within 6 
months after the management plan was been agreed by the participant and the clinicians.  Patients 
that tested positive for viral hepatitis and were prescribed medication to treat their viral hepatitis 
were monitored for their adherence to therapy. Patients were considered to have adhered to 
therapy if they successfully completed 80% or more of their prescribed therapy.   
Secondary Outcomes 
HepFREE Screening Trial: 
(i) for each ethnic group estimated prevalence rates of viral hepatitis. Calculated as number of 
patients screening positive in the first trial over number of patients screened 
(ii) for each ethnic group positive screening rate of viral hepatitis. Calculated as number of 
patients screening positive in the first trial over number eligible for screening 
(iii) Screening rates in new registrants for viral hepatitis (only applicable for practices offering 
‘uncapped’ interventional screening or standard screening).  Numerator = number of new 
registrants attending a blood test and for whom the GP practice has received their results 
over the 18 months trial period. Denominator = the number of new registrants deemed 
eligible to be screened at each GP practice over the 18 months screening period.  (A new 
registrant is any person registering with the practice after the initiation date and has not left 
the practice up until the date practice was closed for screening).   
HepFREE Follow-Up Trial: 
(iv) Sustained virological response (SVR):  For patients with hepatitis C, SVR is defined as 
undetectable HCV RNA (i.e. viral load below 18IU/ml) 12 weeks after DAA treatment 
completion, or 24 weeks after Interferon based treatment. The definition of SVR for 
hepatitis B treatment is a reduction in viral load by >80% of starting value within 12 weeks. 
Denominator – number of patients went on to have at-least one dose of anti-viral therapy.  
Numerator – number of patients deemed successfully treated based on SVR outcomes. 
  
2.2.9.2 Sample size calculations  
In our original sample size calculation, we assumed that there are 500 eligible (i.e. high risk because 
of country of birth/ethnicity) patients per practice, on average. However, as the practice recruitment 
progressed it was clear that the number of eligible patients in some practices could be 3 to 4 times 
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(approximately 2000 eligible patients) more than what we had anticipated, and revised our original 
calculations accordingly.   
Original sample size calculation 
We powered our study to detect a difference of 25% (from 15% for opportunistic screening to 40% 
for targeted screening) in testing rate for screening trial, and a difference of 20% in engagement 
rates (from 50% for usual care to 70% for community care) for the nested treatment trial. For the 
nested trial we assumed an average of 500 eligible patients per practice, 40% screened and 3% 
testing positive (5% prevalence for 50% born abroad, 1% prevalence for 50% UK born), hence an 
average of 6 identified infected patients included in the nested treatment trial per practice. We use 
an intra-cluster correlation coefficient of 0.05 and a coefficient of variation of cluster size of 0.65. 
This resulted in 185 patients or 31 clusters being required in each arm for a power of 90% and alpha 
of 5%. Thus we required 62 practices altogether in the nested trial.  
For the screening trial, with 500 eligible patients per practice, an ICC of 0.05 and coefficient of 
variation of cluster size of 0.65, 2666 individuals or 6 practices are required in each arm. With 62 
practices in the targeted screening arm, 6 further practices in the opportunistic testing (control) arm 
would have given us more than 90% power to detect our specified difference. We increased the 
number of practices on the control arm of the screening trial to allow for drop-outs.  
Revised sample size calculation.    
We continued to assume an intra-cluster correlation coefficient of 0.05 for all outcomes, a 
coefficient of variation of cluster size of 0.65, and that 40% of eligible patients would be screened 
and of these 3% would test positive. In practices where there were 2000, rather than 500, eligible 
participants this would result in 24 participants included in the nested treatment trial. To detect a 
difference from 50% to 70% engaged with 90% power at the 5% significance level requires 134 
participants in each arm without allowing for clustering, or 268 altogether. As described in section 8, 
following the realisation that the number of eligible participants in practices was on average 2000 
and not 500, we decided to approach all eligible participants (i.e. on average 2000) from 15 
practices, and then re-estimated the number of additional practices needed in the nested treatment 
trial to reach an effective sample size of 268. We estimated that we would need an additional 31 





2.2.9.3 Statistical Analyses  
All analyses were documented in a detailed analysis plan that was signed off by the senior 
statistician and chief investigator prior to the release of allocation codes to the statistician. We used 
statistical analyses for two comparisons in trial 1 (HepFREE screening trial) and three in trial 2 
(HepFREE follow-up trial). Other potential comparisons were not undertaken because of small 
numbers of participants.    In trial 1 loss to follow-up and missing data was not relevant. In trial 2 for 
the analysis of overall engagement with diagnostic and prognostic events withdrawals, patients lost 
to follow-up were recorded as not engaged. Only those who withdrew consent for use of their data 
were excluded from the analyses. For the treatment compliance, treatment adherence and viral 
response in stage 2, patients lost to follow-up or withdraw consent were retained and used in the 
analysis up to the point of withdrawal. Where feasible, reason for withdrawal were documented and 
presented in the CONSORT diagram. Patients who died were excluded from analysis. In trial 1, and in 
the embedded trial of invitation letters, comparisons of screening rates were modelled using Poisson 
regression models. Our dependent variable was number of patients screened in each GP practice. 
The number of eligible patients was included as the exposure and practice as a random effect. The 
stratification factor, area, was included as a covariate in the model. The model was checked for over-
dispersion. Intra-cluster correlation coefficients (ICCs) calculated. If ICCs were found to be negative, 
the intervention effects from the analysis not adjusting for clustering are presented.  
In the Follow-up Trial: 
1) engagement in community based therapy compared to hospital based therapy 2) engagement 
with diagnostic and prognostic events in community based therapy compared to hospital based 
therapy  3) compliance with clinical management plan in community based therapy compared to 
hospital based therapy  
For the engagement outcome, generalised estimating equations using logit link to account for binary 
outcome, accounting for area, cluster size (number of eligible patients group), age and sex (xtgee 
command in Stata) were fitted. Model based ICCs are presented. Exchangeable correlation matrix 
and robust standard errors were used. Where ICCs were negative, the intervention effects from the 
analysis not adjusting for clustering is presented.   
 
2.3 Disease Staging Outcome Analysis 
Patients who tested positive in the intervention of the HepFREE screening trial had also consented to 
the ongoing collection of data regarding their disease stage and management.  This data was 
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collected on the OpenClinica platform and collated on Microsoft Excel for descriptive and 
exploratory analysis by me.  This included demographics (gender/age/country of birth) and 
serological results, Transient Elastography score and ultrasound reports.   
Statistical analysis was performed on Stata program version 14. 
 
2.4 London Standard Care Community & Clinics Follow-Up Trial 
Patients testing positive for viral hepatitis at primary care practices employing interventional 
screening were cluster randomised into two follow-up arms: standard hospital clinic follow-up, or 
community based follow-up.  In both arms, patients who tested positive were referred to their local 
hospital for an initial diagnostics appointment.  At this visit, the patients were provided with a 
detailed information sheet explaining the follow-up phase of the trial, and were asked to provide 
written consent to be for progression to Stage 2 of the Hep FREE study. 
2.4.1 London GP practices 
In London, as the 32 interventional practices were spread across East London (17 practices) and 
South London (15 practices), patients testing positive were referred to either Royal London Hospital 
(North East London) or King’s College Hospital (South East London).   
Any patient who tested positive in East London was referred for diagnostic and prognostic tests at 
the Royal London Hospital (RLH), Whitechapel. East London is defined as the boroughs of Tower 
Hamlets, Newham and Redbridge and their associated Clinical Commissioning Groups (CCGs). 
Any patient who tested positive in South London was referred for diagnostic and prognostic tests at 
King’s College Hospital (KCH), Denmark Hill.  South London is defined as the boroughs of Lambeth 
and Southwark and their associated Clinical Commissioning Groups (CCGs).   CCGs are responsible 
for commissioning hospital and community services in their local areas and assured by NHS England.  
Tables 5 and 6 list the London GP practices, their boroughs and CCGs, and nominated Community 
Care centres.  Figures 6 and 7 show the geographical distribution of GP practices in East and South 














EAST London 1 Stroudley Walk 
Health Centre 
E3 3EW 




EAST London 2 Royal Docks Medical 
Practice 
E6 5NA 




EAST London 3 Dr Driver & Partners 
(aka Forest Practice) 
E7 0EP 




EAST London 4 Star Lane Medical 
Centre 
E16 4QH 




EAST London 5 Greengate Medical 
Centre 
E13 8PS 




EAST London 6 Ilford Lane Surgery 
IG1 2SN 




EAST London 7 Queen Mary Practice 
E18 2QS 




EAST London 8 Jubilee Street 
Practice 
E1 0LS 






EAST London 9 Dr Patel’s Surgery 
E7 8LZ 






EAST London 10 Stratford Village 
Medical Practice 
E15 4BZ 










EAST London 11 Dr Abiola Practice 
(aka Forest Practice) 
E7 0EP 






EAST London 12 E12 Health Centre 
E12 6AQ 






EAST London 13 Leytonstone Road 
E15 1LH 






EAST London 14 Cumberland Medical 
Centre 
E13 8LS 






EAST London 15 York Surgery 
IG1 3AF 






EAST London 16 St Andrews Health 
Centre 
E3 3FF 






EAST London 17 XX Place Health 
Centre 
E1 4DG 













Table 6:  South London GP Practices and associated Secondary and Community Care Centres 
Area Clinic Map 
Number 






1 Minet Green 
SW9 6AF 






2 Riverside Medical 
Practice 
SW8 2JB 















4 Acorn & Gaumont 
House Surgeries 
SE15 5SL 






5 Dr Bradford and 
Partners 
(aka East Street 
Surgery) 
SE17 2SX 






6 Paxton Green 
Group Practice 
SE21 8AU 






7 Hurley Clinic 
SE11 4HJ 








8 Manor Place 
Surgery 
SE17 3BD 








9 Lambeth Walk 
Group Practice 
SE11 6SP 












Lambeth King’s College 
Hospital 
SE5 9RS 







11 The Iveagh Surgery 
SW9 6AF 
Lambeth King’s College 
Hospital 
SE5 9RS 





12 Herne Hill Road 
Medical Practice 
SE24 0AU 
Lambeth King’s College 
Hospital 
SE5 9RS 





13 Sir John Kirk Close 
Surgery 
SE5 0BB 
Southwark King’s College 
Hospital 
SE5 9RS 





14 Albion Street 
Practice 
SE16 7JX 








15 Crown Dale 
Practice 
SE19 3NY 
Lambeth King’s College 
Hospital 
SE5 9RS 






Figure 7 Geographical Distributions of the South London GP Practices   
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2.4.1.1 Distribution of Community Care Centres 
Due to the wide geographical spread of practices, 3 practices were used for community care in East 
London and 4 in South London.  Several factors dictated which practices would be suitable as 
community care centres: 
(i) The practice must be a cluster randomised to a community care follow-up 
(ii) The practice lead GP must be agreeable to the practice being used as a community care 
location 
(iii) The practice should be geographically nearer to the patient’s original practice than the 
local secondary care centre 
The East London community practices were: 
• Dr Abiola Practice, Lord Lister Health Centre, 121 Woodgrange Road, London E7 0EP 
• Jubilee Street Practice, 367-374 Commercial Road, London E1 0LS 
• St Andrews Health Centre, 2 Hannaford Walk Bow, London E3 3FF 
 
The South London community practices were: 
• Albion Street Group Practice, 87 Albion St, London SE16 7JX 
• Manor Place Surgery, 1 Manor Place, London, SE17 3BD 
• Sir John Kirk Close Surgery, 3 Sir John Kirk Close, London, SE5 0BB 
• Crown Dale Medical Centre, 61 Crown Dale, London, SE19 3NY 
 
As above, Tables 1 & 2 show the GP practices and their linked community centres.  Figures 5-8 show 
the geographical distribution of the GP community centres and the locally linked practices.  Jubilee 




Figure 8:  St Andrews’ Health Centre and associated linked practice 
 
 








Figure 11: Sir John Kirk Close Surgery and associated linked practices 
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2.4.2 Follow-up for Positive Patients 
2.4.2.1 Standard Operating Procedures 
To ensure a consistent approach to the delivery of care, I wrote standard operating procedures 
(SOPs) for the provision of community based care by the Viral Hepatology services in East London 
and South London.  SOPs are stepwise instructions on the execution of complex but routine services 
within healthcare.  They aim to maintain quality by adhering to local and national guidelines, and 
provide uniformity of care regardless of which individual staff members are delivering the service.  
SOPs for East and South London services are found in appendices 9 & 10. 
2.4.2.2 Referral process for patients testing positive in Primary Care 
Patients who tested positive for HBsAg, HCV Ab or both were referred to their local hospital by 
clinical or administrative staff at the GP practice emailing an autopopulated referral letter to a 
dedicated HepFREE email address.  The letter included patients details (name, address, date of 
birth), HepFREE screening test results, medication list and past medical history.  
Referred patients were then booked into a dedicated HepFREE clinic list at either the RLH or KCH by 
myself. 
2.4.2.3 Measurement of engagement and outcomes in HepFREE Follow-Up Trial 
One of the primary objectives of the HepFREE study was to determine whether community based 
therapy is superior to conventional delivery of treatment as measured by engagement with 
management and treatment. 
 
Engagement with the study was defined completion of at least three visits for diagnosis, 
investigation and management in a 12 month period: 
o For patients who tested HBsAg positive, or HCV Antibody, RNA positive this was 
attending (i) diagnostic visit (i) prognostic investigation: ultrasound and/or 
Fibroscan®  (iii) management visit 
o For patients who tested HCV antibody positive or equivocal but HCV RNA negative, 
engagement was defined as attending the GP practice or the local hospital on two 
separate occasions. 
Compliance with the clinical management plan was defined as attending at least one follow-up visit 
after the management plan was agreed by participant and clinicians. 
 
Adherence to therapy in the study was defined as 80% completion of prescribed therapy. 
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The outcome of therapy was monitored. A successful outcome of therapy was defined as sustained 
viral response 12 weeks after treatment completion for HCV infected patients. The definition of 
successful outcome of therapy for HBV treatment was a reduction in viral load by >80% of starting 
value within 12 weeks.  
 
Data relating to engagement, compliance with management plan and outcome of therapy was 
monitored until the end of data collection in February 2017 for all patients that screened positive as 
part of Stage 1 of HepFREE. Due to due to rapid developments in treatment availabilities for hepatitis 
C and changes in NHS policy, with regards to prescribing new hepatitis therapies, the ‘clinical 
management plan’ for some patients was variable throughout the course of the trial. Continuing to 
collect outcome data for all HepFREE patients that screened positive until Feb 2017 enabled the 
collection of ‘adherence to therapy’ and ‘outcome of therapy’ information for patients whose 
treatment options changed during the trial period.   
Patients who were randomised to community care continued to receive their hepatology care, if 
appropriate, in the community until the HepFREE data collection stopped in February 2017. This was 
to allow the patients enough time to adjust to their treatment regimes in the community before 
moving their care back to ‘standard of care’ based at the local hospital once their study visits have 
been completed. 
2.4.2.4 Supplementary consent to participating in HepFREE Follow-Up Trial 
Patients testing positive for viral hepatitis were invited to participate in stage 2 of the HepFREE trial 
at their diagnostics appointment.  The patients were provided with a detailed information sheet 
explaining the follow-up phase of the trial, enabling participants to make an informed decision as to 
whether they would like to remain in the trial or not.  They were then asked to provide 
supplementary written consent to further participation.  Consent was obtained by a GCP trained 
viral hepatology specialist who was blinded to the cluster randomisation of the patient’s referring GP 
practice. 
2.4.2.5 Patient Information Leaflet for HepFREE Follow-Up Trial 
The patient information sheet did not indicate whether the patient’s GP practice was randomised to 
standard care (care in hospital as per standard practice) or intervention (care at a local community 
care practice) arm, and explained the follow-up visits in community and standard care.  A copy of the 




2.4.2.6 Process of taking consent 
The healthcare professionals who consented eligible patients for the HepFREE Follow-Up trial at their 
diagnostic out-patient appointment (in North East and South East London this was a delegated 
member of the local Hepatology Research team), were not aware of the patient’s practice’s allocation 
at the time when consent was sought.  In general, this investigator was a local specialist hepatology 
nurse who had received GCP training and was on the HepFREE delegation log but not involved in 
provision of care for HepFREE patients. This individual was blinded to the allocation of the referring 
GP practice cluster randomisation, and therefore bias to recruitment of one or either arm of the trial 
could be minimised.   
After joining the HepFREE trial team in August 2015 I started the process of setting up community-
based follow-up clinics.  Therefore from this point I was no longer blinded to allocation of referring GP 
practice cluster randomisation and so I trained local specialist hepatology research nurses at the RLH 
(North East London) and KCH (South East London) in taking consent for the HepFREE follow-up trial.  
This training involved a one hour session outlining the aims and objectives of the HepFREE Screening 
and Follow-Up Trials, reviewing the Follow-up Trial consent form and discussing questions patients 
may have regarding the consent process. 
During the consent process, the participant was informed that if they chose to continue in the trial 
they would be randomised to receive monitoring and/or treatment for viral hepatitis (if required), at 
all subsequent follow-up appointments either in hospital (standard care) or in the community.  Prior 
to giving consent, participants were provided with a further information leaflet which outlined the 
nature of the HepFREE Follow-Up trial and randomisation to community or hospital care. For 
participants randomised to community care follow-up, after the initial diagnostic assessment and 
any appointments required for radiological examinations that formed part of the diagnostic 
assessment, all follow-up appointments were conducted in the community.   For participants 
randomised to standard care follow-up, all appointments were based in the Hospital out-patients 
department.   
 
Participants that consented to take part in the HepFREE follow-up trial, were subsequently informed 
of their treatment/monitoring allocation by the Viral Hepatology Specialist (VHS) who managed their 
treatment/active monitoring. For London participants, this VHS was myself as London Clinical 
Research Fellow.   
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Those participants who declined to participate in follow-up trial randomisation were followed up in 
standard care, however as per their previous consent to the HepFREE screening trial, their data 
would still be collected to form part of the Follow-Up Trial analysis. 
Treatment allocation was concealed until after consent to participate in the trial was been obtained, 
in an effort to prevent bias between recruitment into the two arms of the trial (community vs hospital 
care).  Patients were explicitly informed of their right to withdraw from the study if they were not 
comfortable with their treatment allocation at any point. If a participant subsequently withdrew 
consent to the trial completely, they were to be treated as per standard of care and data would be no 
longer be collected.  
Follow-Up consent to remain on the study was sought at the first visit to secondary care subsequent 
to a referral. However, consent could also be sought at the subsequent visit to secondary care (e.g. 
the management planning visit) only if conditions did not allow for the consent to be sought at the 
first visit to the local hospital (e.g. no specialist nurse with GCP training was available). It was a pre-
requisite that the consent must be stated (written) prior to the patient adopting their trial allocation 
(community care Vs standard (hospital) care).  
The consent form was approved by the Research Ethics Committee as part of version 7.0 of the 
HepFREE Trial protocol (submitted 12 March 2015 and acknowledged 05 May 2015).  A copy of the 
consent form can be found in Appendix 8. 
 
2.4.3 HepFREE Clinics in Secondary Care 
The HepFREE clinics at the Royal London Hospital and at King’s College Hospital were new services 
set up in addition to and as part of the already well-established viral hepatitis outpatients clinics at 
both sites.  As the London HepFREE CRF I was the HepFREE Viral Hepatitis Specialist (VHS) clinician at 
both sites.  Clinics appointments were on set days of the week (Wednesday afternoons for RLH and 
Friday afternoons for KCH). 
2.4.3.1 Diagnostics Appointment 
At both sites, positive patients would be given an initial 30 minute appointment (diagnostic visit) to 
be seen by me.  At this appointment, the patient’s relevant history would be reviewed, past medical 
history discussed, medications reviewed, allergies noted and an abdominal examination performed.  
History and findings were documented on the patient’s electronic health record (EPR) at the hospital 
(Cerner Millennium EPR at RLH and Sunrise EPR at KCH).   
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Onsite phlebotomy for baseline bloods test including full blood count (FBC), urea and electrolytes 
(U&E), liver function tests (LFTs), coagulation screen, International Normalised Ratio (INR), full 
blood-borne virus screen (including HBsAg level, e-antigen, e-antibody, core-antibody, HCV Ab and 
RNA if needed and HIV Ab) and other liver markers such as immunoglobulins, caeroplasmin and 
alpha-fetoprotein were performed.   
The patient was invited to participate in the HepFREE Follow-Up trial and was asked to provide 
written consent to be randomised by cluster-based approach to either secondary or community 
care.  As CRF I was aware of the randomisation outcome for each patient (as this was traceable to 
their referring GP practice), and so consent was performed by a local specialist nurse with GCP 
training in asking for research consent.  
2.4.3.2 Prognostic and Imaging Appointments 
The patient would then be referred for transient elastography (also known as Fibroscan®) and 
ultrasound to allow imaging of the liver and assessment of fibrosis/cirrhosis (severity of disease 
assessment).   
At KCH, Fibroscan® was usually performed by a specialist nurse on the same day as the initial 
appointment, with ultrasound being performed by a sonographer during a dedicated liver clinic list 
on the same day as the follow-up (management) appointment.   
At the RLH, Fibroscan® and ultrasound were performed separately to the outpatients clinics but 
completed by the time of the next follow-up (management appointment).   
2.4.3.3 Multi-Disciplinary Team Meetings and Operational Delivery Networks 
At both hospitals, between the initial diagnostics and prognostics visit and the management visit, 
patients were discussed at the local Viral Hepatitis Multi-disciplinary meeting, which was attended 
by Consultant Hepatologists, specialists pharmacists, HIV Physicians and Virologists, Hepatology 
trainees, and specialist nurses from various local sites. 
The recommendations made by the MDT also acted as the recommendations of the local 
Operational Delivery Network (ODN) who would approve new directly acting antivirals (DAA) 
therapies for Hepatitis C positive patients.  ODNs are the structures through which hepatitis C 
treatment is England has been delivered since 2015.  The networks involve regional centres which 
manage treatment decisions and prescribing, and which have a dispersed treatment model which 
aims to support partnership working and access for local patients. 
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The RLH ODN is the hub of the London North East network and named lead is Prof Graham R. Foster 
(Professor of Hepatology at QMUL).  The KCH ODN is the hub of the South Thames Hepatitis 
Network and named lead is Dr. Kosh Agarwal (Consultant Hepatologist at KCH). 
2.4.3.4 Management Visit 
At the patient’s management visit (usually scheduled 4-8 weeks following their initial appointment) 
they were advised of their baseline results, the outcome of their randomisation to either hospital or 
community based follow-up and their individual management plan (active monitoring or treatment) 
would be discussed and agreed with the patient. 
If the patients were randomised to hospital care, they would be given up a follow-up appointment 
within 3 months.   
For those patients randomised to community based care, their details were noted (including a 
contact phone number) and advised they would be given a date for their community-based follow-
up appointment at their particular practice which would be within 3 months.   
If patients declined to consent to the HepFREE Follow-Up randomisation, follow-up defaulted to 
secondary care.   
 
2.4.4 HepFREE Community Clinics 
2.4.4.1 Arranging Community Clinic Appointments 
The next steps were to arrange a suitable clinic day at the designated community practice.  Follow-
up appointments were located at a practice near to the patient’s original screening practice – in 
some cases this was the same practice, in others it was a nearby practice.  In all cases, the 
community clinic was closer to the patient’s home address at the time of screening than the local 
hospital.  When patients had consented to community follow-up, the local GP practice managers 
were contacted in order to arrange a suitable date for a viral hepatitis follow-up clinic at the 
practice.  
The main challenge at each practice was finding a spare room suitable to use for the HepFREE Viral 
Hepatitis Clinic.  Each practice usually had a spare room on a particular session (morning or 
afternoon) on a particular day of the week and was happy for the HepFREE team to use the room at 
this time.  A computer was not required as notes from the consultations were documented on the 
local hospital EPR system shortly after the clinic rather than on the local GP EMIS system.  As VHS, I 
also took my own phlebotomy kit (disposable needles with vacutainers, alcohol wipes, gauze 
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plasters and tourniquet) and blood bottles (for virology, biochemistry and haematology samples) 
from the local hospital.   
As there were small numbers of positive patients randomised to each practice, patients were asked 
by telephone to attend on the day and time when a practice room was free.  Most patients were 
agreeable to these set days, however a small number of patients requested specific times or days to 
be seen – they felt they would be unable to attend at other times due to work or family 
commitments.  The HepFREE Community Clinic practices and myself were in each case able to 
arrange a mutually suitable time and day for the patients to be seen.  However this was in contrast 
to those patients who were randomised to hospital follow-up who were asked to attend on specific 
clinical days at each site. 
Patients were notified of their community clinic appointment dates by telephone call and by letter 
from the referring hospital.  The community GP practice played no role in contacting the patients – 
this was because many of the patients were not being seen at the practice where they were 
registered.  Subsequently, none of the community clinic patients received a reminder text as they 
would have done for either a standard hospital appointment or a standard GP appointment.   
Therefore, this group of patients were phoned 48 hours prior to their appointment by me as a 
reminder. 
 
2.4.4.2 Follow-Up Visits 
At both the community clinic and standard hospital appointments patients’ histories were reviewed 
and management plan followed.  For those patients who were being monitored (for example those 
who were HBeAg negative chronic infection HBV) blood tests and six-monthly ultrasound HCC 
scanning was arranged.  Patients were follow-up on a 3-6 monthly basis.  For those patients starting 
HBV or HCV treatment, the agreed treatment (from the ODN) was issued at the hospital pharmacy 
and transported by the VHS to the community practice.  Any bloods taken at the community practice 
were transported back to the local hospital either by me or by courier (with arrangement with the 
practice).   
At both hospital and community based clinics, patients’ blood and imaging results were checked by 
myself within 7 days and a letter issued to the patient and their GP of the findings, management 
plan and date and location for the next appointment. 
Patients on HBV monitoring were seen 4 times within 12 months and then 6 monthly.   
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Patients attending secondary care follow-up may also have been offered liver biopsy and 
participation in a research trial.  This is because this cohort of patients was offered standard of care 
management.  No community follow-up patients entered other research trials during the HepFREE 
period.   
 
2.4.5 Treatments Offered in HepFREE Follow-Up Clinics 
HBV Treatment 
All patients with chronic HBV infection were assessed for the degree of disease activity in line with 
standard practice.  Patients with active disease starting HBV treatment in London were all 
commenced on interferon-free regimens  with third generation oral once-daily antiviral agents 
(either tenofovir or entecavir) and reviewed at one month after commencing therapy (for bloods 
including full blood count, U&E, LFTs and HBV DNA levels plus urinalysis) and then again for the 
same tests at 3 months and 6 months.  Adherence was monitored at each visit and viral suppression 
was defined as a fall in DNA level of 80% or more from the baseline. 
HCV treatment 
All patients with chronic HCV infection underwent an assessment of the degree of liver fibrosis 
(either by liver biopsy or Fibroscan®) and were offered treatment in accordance with NHSE and NICE 
guidelines. 
For patients treated for Hepatitis C, during the early stages of the HepFREE trial period (March 2014-
Jan 2015), interferon-free therapies were not widely available for prescription on the NHS.  Access to 
therapy was also dependent on disease stage and HCV genotype.  Therefore patients were offered 
treatment with interferon-based therapies, or the option to await DAAs (which were deemed to be 
likely to be available within a few months).   
From the initiation of HepFREE screening trial at the first group of intervention practices in March 
2014 until September 2016, treatment for patients with genotype 1 HCV was with 
sofosbuvir/ledipasvir and treatment for patients with genotype 3 and cirrhosis was with pegylated 
interferon, ribavirin and sofosbuvir. All other patients with genotype 3 HCV were offered therapy 
with pegylated interferon and ribavirin and given the option of delaying therapy until all oral DAA 
agents were approved and funded by NHSE. From September 2016 until study recruitment closure in 
February 2017 patients with Genotype 1 HCV were offered paritaprevir, ombitasvir and dasabuvir 
and all patients with genotype 3 HCV were offered sofosbuvir/velpatasvir. 
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Patients commencing HCV Interferon based therapy were reviewed at Weeks 2,4,8,12, 16, 20, 24, 
28, 36 and 48.  Patients commencing DAAs for HCV treatment were reviewed at weeks 1,2,4,8,12,16 
and 24.  Adherence to therapy was monitored at each visit and viral suppression was defined as 
achieving SVR12 (for DAAs) or SVR24 (for interferon based therapy). 
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2.4.6 Analysis of London Community Clinic Outcomes 
Data collected in the OpenClinica platform regarding follow-up engagement and treatment was 
collated in Microsoft Excel and descriptive and exploratory analysis performed using this program.  








2.5 Patient Pre-Screening Survey 
As part of the HepFREE study, in 2014 a pre-screening survey of patients eligible for viral hepatitis 
screening was performed by the qualitative researcher John Owiti.  The survey was designed by the 
HepFREE Research team (including Prof Foster and John Owiti) and Owiti collected the data.  I data 
cleaned the 2014 data and linked it to the HepFREE screening outcomes.  I also undertook original 
analysis of the data. 
A subset of potential participants from interventional screening practices in North East London, 
South East London and Bradford were identified using the bespoke HepFREE eligibility searches run 
on Primary Care electronic patient records.  This subset of patients formed the sample for a 
population based survey of eligible patients in order to assess the characteristic of individuals who 
accept or decline at all stages of the trial. 
Potential participants were contacted by letter of invitation, with further information detailing the 
project (in English or appropriate translation), including the voluntary nature of involvement, and a 
choice of mode of participation by either (1) telephone, (2) face-to-face interview, or (3) postal 
survey completion. Two weeks after initial contact, potential participants were contacted by the GP 
practice, via telephone (up to 3 times) to confirm if they received the letter and whether they have 
any questions for the GP or the research team, indicating that they were happy to continue and 
participate. 
For those participants indicating a willingness to participate by phone, verbal consent was sought in 
the presence of a witness, with appropriate language translation (as required) and documented. 
Those indicating a preference for completion by post had all documents with instructions forwarded 
to them with a self-addressed envelope with a contact telephone number for any enquiries. Finally, 
individuals requesting face-to-face interview were invited to attend an appointment at their host GP 
surgery with appropriate language translation (as required) to complete the survey.  It was 
highlighted to participants that involvement was voluntary and the interview could be stopped at 
any time, if a participant did not wish to continue. The interview was concluded with a documented 
verbal consent. 
The patients were asked about their illness perceptions and narratives (explanatory models) about 
hepatitis using an adapted version of the Barts Explanatory Model Interview checklists. These were 
developed from focus groups and literature review information, following the methods set out in the 
original development for use in common mental disorders. Two other validated patient-reported 
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outcomes were completed by interview: patient health questionnaire (PHQ-9) and the generalized 
anxiety disorder 7-item (GAD-7) scale. 
Data collected from the pre-screening database was linked, using the pseudonymised identifier 
generated by the GP database, to HepFREE data collected as the part of the screening trial. This was 
to ascertain whether there are certain beliefs of perceptions about hepatitis that indicate whether a 
patient is more or less likely to screen for viral hepatitis when offered a screen.   
2.5.1 Data processing and analysis 
Survey data were initially gathered by completion of paper questionnaires and then manually 
uploaded to the OpenClinica database by John Owiti.  I cleaned the data completing an “other” entry 
for any question responses that were not completed (i.e. left blank).   
Outcomes of the data were then collated by myself with the assistance of a Barts Health 
Gastroenterology Fellow and analysed by myself and a statistician from the Centre of Psychiatry, 
Wolfson Institute of Preventive Medicine, Queen Mary University of London, using version 14 of the 




2.6 HepFREE Provider Experience Substudy 
2.6.1 Study Design 
My HepFREE Provider Experience substudy was a Qualitative Research Study which was designed to 
investigate the barriers and facilitators to offering testing for viral hepatitis in primary care, as 
perceived by the healthcare providers who participated in the HepFREE trial.  This followed on from 
qualitative research performed by Sweeney et al in 2014 prior to the launch of the HepFREE 
screening trial, which interviewed key informants, patients and general practitioners regarding the 
implementation and running of the HepFREE trial in practice. (132)  I wanted to expand on one 
aspect of this work in order to understand the views of general practitioners over an extended 
period of time from the early stages of trial implementation and after closure of recruitment to the 
HepFREE screening trial.  I also wanted to collect the views and experiences of other members of the 
Primary care practice teams who were involved in the HepFREE trial, including Primary Care Nurses 
and administrative and reception staff. 
2.6.2 Identifying Practices and Interviewees 
In my HepFREE Provider Experience substudy I, interviewed 1-2 members of the practice healthcare 
staff groups, at 12 practices (out of 50 intervention practices).  The staff members included general 
practitioners, practice nurses, healthcare assistants and healthcare administrators or practice 
managers.   I completed the interviews with the support of another independent researcher Dr 
Dania Shoeb.  The focus of the interviews was to explore the views of healthcare professionals in 
their experience of running a large trial testing for viral hepatitis, and to assess their attitudes to viral 
hepatitis testing in primary care following completion of the trial.  
These practices were purposively sampled based on their hepatitis screening rates in the HepFREE 
study, and their location. (167)  Practices were divided into high performers (screening more than 
20% of eligible patients), low performers (less than 10% of those eligible) and intermediate 
performers (10-20%). 
All interviewees were adult healthcare workers, interviews were semi-structured, allowing the 
researchers to ask open-ended questions which may lead to further exploration of a specific topic.  
(168)  The interview method of qualitative research has been used with both patient groups and 
healthcare professionals in regards to provider experiences and perspectives on delivering screening 
and treatment interventions for HIV  and sexually transmitted infections in primary care settings, but 




Along with Dr Shoeb, I conducted the interviews in person, or by telephone between November 
2016 and February 2017.  All interviews were audio-recorded (with consent) on dictaphone and 
transcribed verbatim. Any identifiable data was anonymised during transcription. No patient data 
was recorded for this study.  Both researchers had no previous direct contact with their allocated 
primary care practices. 
An interview topic guide was prepared with the assistance and advice of Dr Moira Kelly and Dr Lorna 
Sweeney, that aimed to be open-ended, neutral, sensitive and clear to the interviewee. (168,172)  
The initial pre-trial interviews focussed on setting up and implementing a viral hepatitis screening 
trial.  For my follow-up qualitative study, I was interested in staff perception of the trial process and 
outcomes at the end of the testing period. 
I wanted to understand the motivations and challenges of running a screening programme 
(perceived benefits to patients and to practice, impact on time and resources, impact of payment 
and the prioritisation of the study in a busy practice), the practical implications of being involved in a 
research study (local trial training, use of trial dataset) and the challenges of recruiting and 
consenting patients to the trial and therefore the interview questions were designed to explore 
these issues (see Appendix 14 for the interview questions).  
Interviewees were contacted initially by email and supplied with a written information leaflet and 
asked to provide written consent at the time of the interview (see appendices 12 and 13).   
Interviewees were asked for written consent to link answers from the 2014 study to the new study 
where applicable.   
Interviews were performed by myself and Dr Dania Shoeb, a GP trained in Qualitative Research. Both 
interviewers had no previous direct contact with their allocated primary care practices. All 
interviews were audio-recorded (with consent) on dictaphone and transcribed verbatim. Any 
identifiable data was anonymised during transcription. No patient data was recorded for this study.  
Thematic analysis was used to identify important commonalities and differences within provider 
accounts. 
The interview data was analysed using a framework method, and findings were interpreted in light 






2.6.3 Data Analysis 
Datasets from the 2017 interviews were analysed using the Framework method.  The Framework 
method is widely used by qualitative researchers and is a matrix based analytic method.  The 
thematic framework is used to classify and organise data according to key themes, concepts and 
categories.  Therefore the outcomes of the study can be comprised of main themes with related 
subtopics.   
The process of framework analysis is made up of five steps (173): 
(i) Familiarisation 
(ii) Thematic framework identification 
(iii) Indexing 
(iv) Charting 
(v) Mapping and interpretation 
The themes and subtopics evolve and are refined through familiarisation with the data and cross-
sectional labelling. 
My analysis process involved the transcription of all interviews in word documents to familiarise 
myself with the raw data.  After printing out the interviews, I then read through each interview 
several times, both in linear form and again in parallel with the other interviews.  During this reading 
process I used highlighter markers and margin notes to identify key themes and ideas from each 
interview response, which formed a framework.  On reviewing these notes I charted each theme 
within a Microsoft Excel spreadsheet with each theme and subtopic allocated a row and each 
respondent a column.  I then used the transcriptions to collate data from each interview into the 
appropriate theme and subtopic, to build a framework with themes and subthemes. 
I then reviewed the 2014 interviews framework analysis.  As the 2016-2017 interviews were 
following up with healthcare staff on the same project at different time points, I looked to analyse 








2.6.4 Ethics Approval 
This 2014 early trial primary care staff interviews research study was approved by the Research 
Ethics Committee at Queen Mary, University of London (No. QMREC2012/02).   After discussing with 
the Queen Mary Research Ethics Committee team it was felt that the 2017 substudy is intrinsically 
linked to the main HepFREE study and would be best placed seeking ethical approval as an 
amendment to the study protocol, rather than as a separate research study via QMREC.  Ethics 


















The results of the HepFREE screening trial as published are presented here.  The data from Bradford, 
London and Oxford were merged by the statistician and are presented here to provide a complete 
picture of the trial. As previously noted the data in Bradford and Oxford were collected by others 
and my role for these sites was to clean the data. The London data was, chiefly, collected by me. 
Data analysis was performed by myself and the trial statistician – I provided the clinical oversight, 
worked to define which data should, or should not be included, and discussed with the statistician 
the analyses that were to be performed. The write up of the data for the published manuscript was 
completed by myself with assistance from Prof. Foster 
 
3.2 Screening Outcomes 
Recruitment and testing ran from Feb 7th 2014, to Feb 4th 2017, and each practice recruited for 18 
consecutive calendar months. In a parallel, observational study we examined the impact of screening 
in area of low immigrant diversity (Oxford). In nine Oxford practices, recruitment and testing ran 
from May 22, 2015, to April 16, 2017, and each practice recruited for 18 consecutive calendar 
months.  
For the main study we approached 70 general practices in three areas with a high density of 
migrants, of which 63 general practices agreed to participate. Five practices withdrew before 
contributing data and 58 practices were randomly assigned to groups: eight practices were allocated 
to the control group, in which no intervention beyond a single teaching session was given to GPs, 
and 50 practices were allocated to receive an intervention, in which doctors were given a financial 
incentive and patients received a combination of a standard or enhanced letter and hospital-based 
or community care. 15 intervention practices were asked to invite all eligible patients (which were 
referred to as uncapped) and 35 intervention practices were capped to only approach 500 eligible 
patients for screening. 31 738 patients were assessed in the control practices, including 26 046 
(38·4%) patients who were deemed eligible of 67 820 patients who were originally registered and 
5692 new patients, and 58 512 patients from the interventional groups were assessed, including 51 
773 (14·7%) patients who were deemed eligible of 351 710 patients (some of whom had been 
randomly selected from a pool of 152 321 eligible, initially registered patients) and 6739 new 
patients.  
These patients were determined to be eligible for testing when assessing electronic records and at 
registration of new patients.  
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In Oxford, nine general practices comprising a total of 105,714 registered patients, were asked to 
test a total of 6,854 people (5022 registered and 1832 new registrants) and were paid for so doing. 
Testing rates were lower (515 of 6854, 7.5%) than those seen in areas of high immigrant density.  
seven (1·4%) patients positive for HBsAg and none for HCV Ab. There was no further analysis of 
engagement in the Oxford cohort. 
 
The flowchart of the 63 practices is shown in Figure 12, with the characteristics of all 63 practices 
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*GP practices allocated to standard screening arm do not take part in stage 2 of this trial 
Interventional screening-standard 
care-standard invitation 
number of practices randomised 
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number of practices randomised 
(n = 20) 
 
number of practices providing data 
= 8 
eligible patient pool = 26,046 
number of patients screened = 271 
number of practices providing data 
= 14 
eligible patient pool = 16,553 
number of patients invited = 
14,515 
number of patients consented = 
2,905 
number of patients screened = 
2,784 
number of practices providing 
data = 8 
number of patients tested positive 
(n = 10) 
number of practices providing data 
= 7 
eligible patient pool = 8,003 
number of patients invited = 6,183 
number of patients consented = 
2,336 
number of patients screened = 
2,276 
number of practices providing data 
= 11 
eligible patient pool = 11,034 
number of patients invited = 9,646 
number of patients consented = 
2,529 
number of patients screened = 
2,467 
number of practices providing data 
= 18 
eligible patient pool = 16,183 
number of patients invited = 
13,241 
number of patients consented = 
3,119 
number of patients screened = 
2,997 
number of practices providing 
data = 14 
number of patients tested positive 
(n = 43) 
number of practices providing 
data = 7 
number of patients tested positive 
(n = 42) 
number of practices providing 
data = 11 
number of patients tested positive 
(n = 54) 
number of practices providing 
data = 18 
number of patients tested positive 
(n = 59) 
 *Referred to standard care as per 
usual practice 
Stage 2 – treatment phase 
GP practices – (n=63) 
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(n = 8) 
Interventional screening Total  



















(n = 20) 
Site 
 Bradford 3 2 6 2 8 21 
 east London 3 2 7 5 5 22 
 South London 2 4 3 4 7 20 
Number of eligible patients  
 less than 1600 1 1 7 4 8 21 
 1600 – 3300 5 2 7 5 10 29 
 More than 3300 2 5 2 2 2 13 
 
 
Table 9: Characteristics of the 58 practices providing data 
Characteristics Standard 
screening 
(n = 8) 
Interventional screening Total  



















(n = 18) 
Site 
 Bradford 3 2 6 2 8 21 
 East London 3 2 5 5 5 20 
 south London 2 3 3 4 5 17 
Number of eligible patients  
 less than 1600 1 0 5 4 7 17 
 1600 – 3300 5 2 7 5 9 28 




The characteristics of the patients by randomised groups is shown in Table 10. A total of 90,250 
participants in 58 practices were included in the main HepFREE trial, 31,738 in the 8 control arm 
practices and 58,512 in the 50 intervention arm practices. The majority, 77,819, were registered in 
the practices at the start of the study. The rest were patients who registered with the practices 
during the 18 month period of the study. Within the intervention arm I have shown characteristics of 
participants in the four separate randomised groups for completeness. The tables show even 
matching of the different groups. Recording of first and second generation immigrants was very poor 
and within the practices and analysis by this metric was not possible. 
 
Participation in screening for viral hepatitis.  
In the eight standard screening practices, 543 participants were screened and in the 50 
interventional screening practices, 47,883 were invited for screening and 11,386 were screened. 





Table 10: Characteristics of all participants in study practices by randomisation group  
Characteristics Standard screening 
(n = 31,738) 
Interventional screening Total (n = 90,250) 
Standard care-
standard invitation 
(n = 8,501) 
Standard care-
enhanced invitation 
(n = 19,192)  
Community care-
standard invitation 




(n = 19,050) 
No % No % No % No % No % No % 
Gender                         
Female 16,549 52.1% 4,241 49.9% 10,283 53.6% 5,927 50.4% 9,736 51.1% 46,736 51.8% 
Male 15,189 47.9% 4,260 50.1% 8,908 46.4% 5,842 49.6% 9,314 48.9% 43,513 48.2% 
Missing - - - - 1 0.0% - - - - 1 0.0% 
Ethnicity             
Black 3,142 9.9% 847 10.0% 2,141 11.2% 1,966 16.7% 1,912 10.0% 10,008 11.1% 
Bangladeshi 3,289 10.4% 419 4.9% 761 4.0% 1,112 9.5% 1,065 5.6% 6,646 7.4% 
Indian 4,269 13.5% 420 4.9% 1,347 7.0% 575 4.9% 3,157 16.6% 9,768 10.8% 
Pakistani 8,771 27.6% 5,057 59.5% 6,016 31.4% 2,573 21.9% 5,355 28.1% 27,772 30.8% 
Other Asian 2,857 9.0% 216 2.5% 1,662 8.7% 873 7.4% 2,039 10.7% 7,647 8.5% 
Eastern Caucasian 1,309 4.1% 301 3.5% 1,558 8.1% 378 3.2% 889 4.7% 4,435 4.9% 
Other 8,101 25.5% 1,241 14.6% 5,707 29.7% 4,292 36.5% 4,633 24.3% 23,974 26.6% 
Age (years)             






Table 11: Characteristics of participants registered with study practices at the start of screening trial by randomisation group 
Characteristics Standard screening 
(n = 26,046) 
Interventional screening Total (n = 77,819) 
Standard care-
standard invitation 
(n = 8,003) 
Standard care-
enhanced invitation 
(n = 16,553) 
Community care-
standard invitation 




(n = 16,183) 
No % No % No % No % No % No % 
Gender                         
Female 13,351 51.3% 3,982 49.8% 8,860 53.5% 5,542 50.2% 8,164 50.4% 39,899 51.3% 
Male 12,695 48.7% 4,021 50.2% 7,692 46.5% 5,492 49.8% 8,019 49.6% 37,919 48.7% 
Missing - - - - 1 0.0% - - - - 1 0.0% 
Ethnicity             
Black 2,619 10.1% 846 10.6% 1,927 11.6% 1,881 17.0% 1,796 11.1% 9,069 11.7% 
Bangladeshi 2,837 10.9% 407 5.1% 735 4.4% 1,073 9.7% 933 5.8% 5,985 7.7% 
Indian 3,506 13.5% 397 5.0% 1,241 7.5% 560 5.1% 2,745 17.0% 8,449 10.9% 
Pakistani 7,874 30.2% 4,786 59.8% 5,697 34.4% 2,429 22.0% 4,785 29.6% 25,571 32.9% 
Other Asian 2,376 9.1% 199 2.5% 1,276 7.7% 812 7.4% 1,622 10.0% 6,285 8.1% 
Eastern Caucasian 965 3.7% 203 2.5% 1,267 7.7% 298 2.7% 663 4.1% 3,396 4.4% 
Other 5,869 22.5% 1,165 14.6% 4,410 26.6% 3,981 36.1% 3,639 22.5% 19,064 24.5% 
Age (years)             






Table 12: Characteristics of participants who joined the study during the study period 
Characteristics Standard screening 
(n = 5,692 ) 
Interventional screening Total (n =12,431 ) 
Standard care-
standard invitation 
(n = 498) 
Standard care-
enhanced invitation 
(n = 2,639)  
Community care-
standard invitation 




(n = 2867) 
No % No % No % No % No % No % 
Gender                         
Female 3,198 56.2% 259 52.0% 1,423 53.9% 385 52.4% 1,572 54.8% 6,837 55.0% 
Male 2,494 43.8% 239 48.0% 1,216 46.1% 350 47.6% 1,295 45.2% 5,594 45.0% 
Ethnicity             
Black 523 9.2% 1 0.2% 214 8.1% 85 11.6% 116 4.0% 939 7.6% 
Bangladeshi 452 7.9% 12 2.4% 26 1.0% 39 5.3% 132 4.6% 661 5.3% 
Indian 763 13.4% 23 4.6% 106 4.0% 15 2.0% 412 14.4% 1,319 10.6% 
Pakistani 897 15.8% 271 54.4% 319 12.1% 144 19.6% 570 19.9% 2,201 17.7% 
Other Asian 481 8.5% 17 3.4% 386 14.6% 61 8.3% 417 14.5% 1,362 11.0% 
Eastern Caucasian 344 6.0% 98 19.7% 291 11.0% 80 10.9% 226 7.9% 1,039 8.4% 
Other 2,232 39.2% 76 15.3% 1,297 49.1% 311 42.3% 994 34.7% 4,910 39.5% 
Age (years)             







Table 13a: Characteristics of all eligible, invited, and screened participants.  
Patient characteristics Standard screening 
(number of practices = 8) 
Interventional screening 
(number of practices = 50) 
Eligible patient pool 
(n = 31,738) 
Screened                                     
(n = 543) 
Eligible patient pool 
(n = 58,512) 
Invited for screening 
(n = 47,883) 
Screened                                    
(n = 11,386) 
No % No % No % No % No % 
Gender                 
Female 16,549 52.1% 304 56.0% 30,187 51.6% 24,401 51.0% 6,537 57.4% 
Male 15,189 47.9% 239 44.0% 28,324 48.4% 23,481 49.0% 4,848 42.6% 
Missing 0 0.0% 0 0.0% 1 0.0% 1 0.0% 1 0.0% 
Ethnicity           
Black 3,142 9.9% 112 20.6% 6,866 11.7% 6,153 12.9% 545 4.8% 
Bangladeshi 3,289 10.4% 61 11.2% 3,357 5.7% 2,974 6.2% 905 8.0% 
Indian 4,269 13.5% 25 4.6% 5,499 9.4% 4,563 9.5% 1,148 10.1% 
Pakistani 8,771 27.6% 38 7.0% 19,001 32.5% 15,570 32.5% 6,814 59.9% 
Other Asian 2,857 9.0% 55 10.1% 4,790 8.2% 3,656 7.6% 350 3.1% 
Eastern Caucasian 1,309 4.1% 9 1.7% 3,126 5.3% 2,213 4.6% 406 3.6% 
Other 8,101 25.5% 243 44.8% 15,873 27.1% 12,754 26.6% 1,218 10.7% 
Age (years)           







Table 13b: Characteristics of eligible, invited, and screened participants registered with study practices at the start of trial by randomisation group.  
Patient characteristics Standard screening Interventional screening 
Eligible patient pool 
(n = 26,046) 
Screened                                     
(n = 271) 
Eligible patient pool  
(n = 51,773) 
Invited for screening  
(n = 43,585) 
Screened                                    
(n = 10,524) 
No % No % No % No % No % 
Gender                 
Female 13,351 51.3% 142 52.4% 26,548 51.3% 22,131 50.8% 6,059 57.6% 
Male 12,695 48.7% 129 47.6% 25,224 48.7% 21,453 49.2% 4,464 42.4% 
Missing - - - - 1 0.0% 1 0.0% 1 0.0% 
Ethnicity                 
Black 2,619 10.1% 67 24.7% 6,450 12.5% 5,873 13.5% 537 5.1% 
Bangladeshi 2,837 10.9% 47 17.3% 3,148 6.1% 2,821 6.5% 821 7.8% 
Indian 3,506 13.5% 13 4.8% 4,943 9.5% 4,251 9.8% 1,024 9.7% 
Pakistani 7,874 30.2% 24 8.9% 17,697 34.2% 14,402 33.0% 6,414 60.9% 
Other Asian 2,376 9.1% 28 10.3% 3,909 7.6% 3,180 7.3% 324 3.1% 
Eastern Caucasian 965 3.7% 1 0.4% 2,431 4.7% 1,869 4.3% 306 2.9% 
Other 5,869 22.5% 91 33.6% 13,195 25.5% 11,189 25.7% 1,098 10.4% 
Age (years)                 







Table 13c: Characteristics of eligible, invited, and screened participants who joined the trial during the study period 
Patient characteristics Standard screening 
(number of practices = 8) 
Interventional screening 
(number of practices = 15) 
Eligible patient pool 
(n = 5,692) 
Screened                                     
(n = 272) 
Eligible patient pool 
(n = 6,739) 
Invited for screening 
(n = 3,944) 
Screened                                    
(n = 862) 
No % No % No % No % No % 
Gender                 
Female 3,198 56.2% 162 59.6% 3,639 54.0% 2,097 53.2% 478 55.5% 
Male 2,494 43.8% 110 40.4% 3,100 46.0% 1,847 46.8% 384 44.5% 
Ethnicity           
Black 523 9.2% 45 16.5% 416 6.2% 277 7.0% 8 0.9% 
Bangladeshi 452 7.9% 14 5.1% 209 3.1% 149 3.8% 84 9.7% 
Indian 763 13.4% 12 4.4% 556 8.3% 287 7.3% 124 14.4% 
Pakistani 897 15.8% 14 5.1% 1,304 19.4% 865 21.9% 400 46.4% 
Other Asian 481 8.5% 27 9.9% 881 13.1% 465 11.8% 26 3.0% 
Eastern Caucasian 344 6.0% 8 2.9% 695 10.3% 343 8.7% 100 11.6% 
Other 2,232 39.2% 152 55.9% 2,678 39.7% 1,558 39.5% 120 13.9% 
Age (years)           





Screening rates for viral hepatitis by age and ethnicity are shown in Tables 14a, 14b and 14c.  These 
overall screening rates were more than 10 times higher in the interventional screening practices but 
there was considerable variaiton by age and ethnicity. Screening rates were higher in women than in 
men. respectively. 
Table 14a Screening rates for viral hepatitis by ethnicity, gender and age in all participants 
  





















Total 31,738 543 1.7% 58,512 11,386 19.5% 
Ethnicity  
Black 3,142 112 3.6% 6,866 545 7.9% 
Bangladeshi 3,289 61 1.9% 3,357 905 27.0% 
Indian 4,269 25 0.6% 5,499 1,148 20.9% 
Pakistani 8,771 38 0.4% 19,001 6,814 35.9% 
Other Asian 2,857 55 1.9% 4,790 350 7.3% 
Eastern Caucasian 1,309 9 0.7% 3,126 406 13.0% 
Other 8,101 243 3.0% 15,873 1,218 7.7% 
Gender             
Female 16,549 304 1.8% 30,187 6,537 21.7% 
Male 15,189 239 1.6% 28,324 4,848 17.1% 
 Missing 0 0 0.0% 1 1 100.0% 
Age group 
18-19 882 6 0.7% 1,619 223 13.8% 
20-29 9,523 180 1.9% 16,816 2,029 12.1% 
30-39 10,023 185 1.9% 17,680 2,899 16.4% 
40-49 5,413 113 2.1% 10,457 2,606 24.9% 
50-59 2,846 38 1.3% 5,967 1,703 28.5% 
60-69 1,602 17 1.1% 3,133 1,130 36.1% 
70-79 935 2 0.2% 1,841 579 31.5% 
80-89 450 2 0.4% 896 206 23.0% 
90-99 60 0 0.0% 99 11 11.1% 













(number of practices = 8) 
Interventional screening 













Total 26,046 271 1.0% 51,773 10,524 20.3% 
Ethnicity  
Black 2,619 67 2.6% 6,450 537 8.3% 
Bangladeshi 2,837 47 1.7% 3,148 821 26.1% 
Indian 3,506 13 0.4% 4,943 1,024 20.7% 
Pakistani 7,874 24 0.3% 17,697 6,414 36.2% 
Other Asian 2,376 28 1.2% 3,909 324 8.3% 
Eastern Caucasian 965 1 0.1% 2,431 306 12.6% 
Other 5,869 91 1.6% 13,195 1,098 8.3% 
Gender             
Female 13,351 142 1.1% 26,548 6,059 22.8% 
Male 12,695 129 1.0% 25,224 4,464 17.7% 
 Missing - - - 1 1 100.0% 
Age group 
18-19 882 6 0.7% 1,619 223 13.8% 
20-29 7,107 56 0.8% 13,932 1,765 12.7% 
30-39 8,035 94 1.2% 15,382 2,631 17.1% 
40-49 4,681 66 1.4% 9,614 2,451 25.5% 
50-59 2,550 30 1.2% 5,561 1,606 28.9% 
60-69 1,472 16 1.1% 2,941 1,082 36.8% 
70-79 865 1 0.1% 1,764 558 31.6% 
80-89 397 2 0.5% 862 197 22.9% 
90-99 54 0 0.0% 94 11 11.7% 









Table 14c Screening for viral hepatitis by ethnicity, gender and age in patients registering with 
practices throughout the study period 
 
  













Total 5,692 272 4.8% 6,739 862 12.8% 
Ethnicity 
Black 523 45 8.6% 416 8 1.9% 
Bangladeshi 452 14 3.1% 209 84 40.2% 
Indian 763 12 1.6% 556 124 22.3% 
Pakistani 897 14 1.6% 1,304 400 30.7% 
Other Asian 481 27 5.6% 881 26 3.0% 
Eastern Caucasian 344 8 2.3% 695 100 14.4% 
Other 2,232 152 6.8% 2,678 120 4.5% 
Gender 
Female 3,198 162 5.1% 3,639 478 13.1% 
Male 2,494 110 4.4% 3,100 384 12.4% 
 Missing - - - - - - 
Age group 
18-19 - - - - - - 
20-29 2,416 124 5.1% 2,884 264 9.2% 
30-39 1,988 91 4.6% 2,298 268 11.7% 
40-49 732 47 6.4% 843 155 18.4% 
50-59 296 8 2.7% 406 97 23.9% 
60-69 130 1 0.8% 192 48 25.0% 
70-79 70 1 1.4% 77 21 27.3% 
80-89 53 0 0.0% 34 9 26.5% 
90-99 6 0 0.0% 5 0 0.0% 
100 and over 1 0 0.0% 0 0 0.0% 
 
In patients registered with the practice at the start of the study there was a marked increase in the 
proportion of older patients (>40 years old) who attended for screening – attendance was 14.9% in 
patients aged less than 39 but 28% in older patients. The difference was also present in patients 





We compared screening rates in patients in intervention and control practices and there was a 
significant increase in incidence rate ratios for all participants (IRR = 3.7) as well as participants 
present at the start of the study (IRR = 5.2) (Table 15).   
 
The difference in screening uptake between control and intervention groups was more marked in 
patients initially registered with the practice than new registrants; of the patients who were initially 
registered, 271 (1·0%) of 26 406 patients in the control practices were tested compared with 10 524 
(20·3%) of 51 773 patients in the intervention practices (IRR 5·20, 1·89–14·34; p=0·001). 
 
However, of newly registered patients, 272 (4·8%) of 5692 patients in control practices were tested 
compared with 862 (12·8%) of 6739 patients in intervention practices (1·52, 0·27–8·45; p=0·63).  
 
Table 15: Incidence rate ratios for interventional versus standard screening for all participants and 
those registered at the start of the study 
 
 Type of screening 
(number of 
practices) 
Numbers screened Incidence rate ratio* 
[95% confidence 
interval] 






543 / 31,738 
11,386 / 58,512 
1.7% 
19.5% 
3.697 [1.301 to 10.507] 0.014 
Participants 
present at 
start of study 
Standard (8) 
Interventional (50) 
271 / 26,046 
10,524 / 51,773 
1.0% 
20.3% 
5.201 [1.887 to 14.34] 0.001 
      
 
*adjusted for site and number of eligible patients  
*adjusted for site and number of eligible patients  
**Intracluster Correlation Coefficients, all participants = 0.028 (95% CI: 0.018 to 0.039)  
**Intracluster Correlation Coefficients, participants present at start of study = 0.029 (95% CI: 0.018 to 0.039)  
*** Screening rates were modelled using Poisson regression models. Dependent variable is number of patients screened in 
each GP practice. The number of eligible patients included as the exposure and practice as a random effect. The 







Table 16:  Screening rates in new registrants (as a % of new registrants deemed eligible for 
screening) 
 
Type of screening Numbers screened Tested positive 
Number % Number % 
Standard screening (number of practices = 8) 272 / 5,692 4.8% 7 / 5,692 0.1% 
Interventional screening (number of practices = 
15) 
862 / 6,739 12.8% 22 / 6,739 0.3% 
 
*New registrants are persons registering with the practice after the trial initiation date and has not left the practice up  
until the date practice was closed for screening. 
 
To examine the impact of a bespoke letter we compared screening rates in all patients who received 
the standard invitation letter. Table 17 details the analysis. There was no significant difference in 
screening rates with the two different letters. 
 
Table 17: Testing outcomes after standard invitation vs enhanced invitation  
Type of invitation Numbers screened 
within 31 days of an 
invitation been sent 
Incidence rate ratio* 
[95% confidence 
interval] 
p - value 
Number % 
Standard invitation (number of practices = 
18) 
720 / 15,844 4.5%   
Enhanced invitation (number of practices = 
32 ) 














Prevalence of chronic viral hepatitis in patients who were screened.  
The prevalence of chronic viral hepatitis in patients who were screened for infection is shown in 
Table 18. The prevalence in those originally registered with the practice and those who registered 
during the study is shown in Tables 12 and 13 respectively. 








HBsAg + ve HCV antibody  
+ ve 
HCV RNA + ve 
Number  % of 
number
s tested 
Number   % of 
number 
tested 
Number   % of 
number 
tested  









111 0.93 36 0.3% 
Ethnicity  
Black 657 11 1.7 9 1.37 2 0.30 0 0.00 
Bangladeshi 966 13 1.3 10 1.04 3 0.31 0 0.00 
Indian 1,173 11 0.9 7 0.60 4 0.34 2 0.17 
Pakistani 6,852 142 2.1 53 0.77 89 1.30 32 0.47 
Other Asian 405 12 3.0 11 2.72 1 0.25 0 0.00 
Eastern Caucasian 415 11 2.7 8 1.93 4 0.96 2 0.48 
Other 1,461 37 2.5 29 1.98 8 0.55 0 0.00 
Gender 
Female 6,841 104 1.5 41 0.60 63 0.92 20 0.29 
Male 5,087 133 2.6 86 1.69 48 0.94 16 0.31 
 Missing 1         
Age group 
18-19 229 0 0.0 0 0.00 0 0.00 0 0.00 
20-29 2,209 26 1.2 18 0.81 8 0.36 5 0.23 
30-39 3,084 69 2.2 34 1.10 35 1.13 16 0.52 
40-49 2,719 66 2.4 32 1.18 34 1.25 7 0.26 
50-59 1,741 39 2.2 20 1.15 19 1.09 5 0.29 
60-69 1,147 24 2.1 17 1.48 8 0.70 1 0.09 
70-79 581 10 1.7 5 0.86 5 0.86 1 0.17 
80-89 208 3 1.4 1 0.48 2 0.96 1 0.48 
90-99 11 0 0.0 0 0.00 0 0.00 0 0.00 
100 and over 0 0 0.0 0 0.00 0 0.00 0 0.00 
 
The prevalence of infection was slightly increased in those older than 40 years of age – prevalence in 
those <39 years old was 1.95% compared to 2.06% in older patients.
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Table 18b Prevalence of infection in patients registered with study practices at the start of trial  
 
Standard screening Interventional screening 
No. 
screened 





HBsAg + ve HCV antibody + ve HCV RNA + ve 
No. % of  
screened 
No % of 
total 
positive 









 % of 
total  
positive 
No % of 
positive 
No % of HCV +ve 
Total 271 10 
 




51.0% 98 49.5% 34 34.7% 
Ethnicity  
Black 67 3 4.5% 2 66.7% 1 33.3% 537 8 1.5% 7 87.5% 1 12.5% 0 0.0% 
Bangladeshi 47 2 4.3% 2 100.0% 0 0.0% 821 11 1.3% 8 72.7% 3 27.3% 0 0.0% 
Indian 13 0 0.0% 0 0.0% 0 0.0% 1,024 9 0.9% 5 55.6% 4 44.4% 2 50.0% 
Pakistani 24 2 8.3% 0 0.0% 2 100.0% 6,414 12
8 
2.0% 48 37.5% 80 62.5% 30 37.5% 
Other Asian 28 0 0.0% 0 0.0% 0 0.0% 324  2.5% 8 100.0% 0 0.0% 0 0.0% 
Eastern Caucasian 1 1 100.0% 1 100.0% 0 0.0% 306 8 2.6% 5 62.5% 4 50.0% 2 50.0% 
Other 91 2 2.2% 2 100.0% 0 0.0% 1,098 26 2.4% 20 76.9% 6 23.1% 0 0.0% 
Gender 
Female 142 5 3.5% 2 40.0% 3 60.0% 6,059 85 1.4% 32 37.6% 53 62.4% 20 37.7% 
Male 129 5 3.9% 5 100.0% 0 0.0% 4,464 11
3 
2.5% 69 61.1% 45 39.8% 14 31.1% 
 Missing 0 0 0.0% 0 0.0% 0 0.0% 1 0 0.0% 0 0.0% 0 0.0% 0 0.0% 
Age group 
18-19 6 0 0.0% 0 0.0% 0 0.0% 223 0 0.0% 0 0.0% 0 0.0% 0 0.0% 
20-29 56 2 3.6% 2 100.0% 0 0.0% 1,765 15 0.9% 10 66.7% 5 33.3% 4 80.0% 
30-39 94 4 4.3% 4 100.0% 0 0.0% 2,631 55 2.1% 22 40.0% 33 60.0% 15 45.5% 
40-49 66 2 3.0% 0 0.0% 2 100.0% 2,451 61 2.5% 32 52.5% 29 47.5% 7 24.1% 
50-59 30 2 6.7% 1 50.0% 1 50.0% 1,606 34 2.1% 17 50.0% 17 50.0% 5 29.4% 
60-69 16 0 0.0% 0 0.0% 0 0.0% 1,082 22 2.0% 15 68.2% 8 36.4% 1 12.5% 
70-79 1 0 0.0% 0 0.0% 0 0.0% 558 8 1.4% 4 50.0% 4 50.0% 1 25.0% 
80-89 2 0 0.0% 0 0.0% 0 0.0% 197 3 1.5% 1 33.3% 2 66.7% 1 50.0% 
90 and over 0 0 0.0% 0 0.0% 0 0.0% 11 0 0.0% 0 0.0% 0 0.0% 0 0.0% 
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Table 18c Prevalence of infection in patients screened who joined the study during the study period      
 
 











HBsAg + ve HCV antibody  
+ ve 
HCV RNA + ve 
No. % of  
screened 
No.   % of   
screened 
No  % of 
screened 




% of  
positive 
No.    % of  
positive 
No.  % of 
HCV +ve 
Total 272 7 2.6% 5 1.84% 2 0.74% 862 22 2.60% 1
4 
1.62% 8 0.93% 2 0.23% 
Ethnicity  
Black 45 0 0.0% 0 0.0% 0 0.0% 8 0 0.0% 0 0.0% 0 0.0% 0 0.0% 
Bangladeshi 14 0 0.0% 0 0.0% 0 0.0% 84 0 0.0% 0 0.0% 0 0.0% 0 0.0% 
Indian 12 0 0.0% 0 0.0% 0 0.0% 124 2 1.60% 2 1.61% 0 0.0% 0 0.0% 
Pakistani 14 2 14.3% 2 14.29% 0 0.0% 400 10 2.50% 3 0.75% 7 1.75% 2 0.50% 
Other Asian 27 2 7.4% 1 3.70% 1 3.70% 26 2 7.70% 2 7.69% 0 0.0% 0 0.0% 
Eastern 
Caucasian 
8 0 0.0% 0 0.0% 0 0.0% 100 2 2.00% 2 2.00% 0 0.0% 0 0.0% 
Other 152 3 2.0% 2 1.32% 1 0.66% 120 6 5.00% 5 4.17% 1 0.83% 0 0.0% 
Gender 
Female 162 4 2.5% 2 1.23% 2 1.23% 478 10 2.10% 5 1.05% 5 1.05% 0 0.0% 
Male 110 3 2.7% 3 2.73% 0 0.0% 384 12 3.10% 9 2.34% 3 0.78% 2 0.52% 
Age group 
18-19 0 0 0.0% 0 0.0% 0 0.0% 0 0 0.0% 0 0.0% 0 0.0% 0 0.0% 
20-29 124 2 1.6% 1 0.81% 1 0.81% 264 7 2.70% 5 1.89% 2 0.76% 1 0.38% 
30-39 91 5 5.5% 4 4.40% 1 1.10% 268 5 1.90% 4 1.49% 1 0.37% 1 0.37% 
40-49 47 0 0.0% 0 0.0% 0 0.0% 155 3 1.90% 0 0.0% 3 1.94% 0 0.0% 
50-59 8 0 0.0% 0 0.0% 0 0.0% 97 3 3.10% 2 2.06% 1 1.03% 0 0.0% 
60-69 1 0 0.0% 0 0.0% 0 0.0% 48 2 4.20% 2 4.17% 0 0.0% 0 0.0% 
70-79 1 0 0.0% 0 0.0% 0 0.0% 21 2 9.50% 1 4.76% 1 4.76% 0 0.0% 
80-89 0 0 0.0% 0 0.0% 0 0.0% 9 0 0.0% 0 0.0% 0 0.0% 0 0.0% 
90-99 0 0 0.0% 0 0.0% 0 0.0% 0 0 0.0% 0 0.0% 0 0.0% 0 0.0% 
100 and over 0 0 0.0% 0 0.0% 0 0.0% 0 0 0.0% 0 0.0% 0 0.0% 0 0.0% 
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3.3 Engagement in Care Outcomes 
Overall (including patients in the control group), of 11 929 patients who were tested, 237 (2·0%) 
patients, including one patient who tested positive for HBsAg and for HCV, tested positive for viral 
hepatitis (table 18a): 111 (0·9%) patients had antibodies against HCV, of whom 36 (32·4%; 0·3% of 
those tested) were viraemic, and 127 (1·1%) patients tested positive for HBsAg.  
A higher proportion of newly registered patients tested positive for viral hepatitis than registered 
patients: 29 (2·6%) of 1134 new patients compared with 271 (2·5%) of 10 795 registered patients. In 
post-hoc analyses, we noted a greater proportion of positive tests for viral hepatitis in patients 
screened in control practices, in which 17 (3·1%) of 543 patients were positive versus 220 (1·9%) of 
11 386 patients in the intervention practices, including one patient with a co-infection (i.e., 221 
diagnoses in 220 patients). 
 
The 220 (0·4%) of 58 512 patients who were eligible for testing and tested positive from intervention 
practices (1·9% of 11 386 patients tested) were eligible to enrol in the second embedded trial of 
community versus hospital care; the groups were well matched. Figure 13 outlines the engagement 
outcomes for these 220 patients. 
 
129 (58·6%) of the 220 patients with infections were randomly assigned to receive community care 
and 91 (41·4%) patients were assigned to receive standard, hospital-based care. Of the 220 patients 
included, nine were already receiving hospital care (which was not known to the general practices) 
and 21 (9·5%) did not attend for a diagnostic assessment.  
 
Of the 190 patients who attended for a diagnostic assessment, one (0·5%) patient died before 
completion of the tests, and nine (4·7%) patients did not attend for all the tests. 52 patients who 
were positive for HCV antibodies were not viraemic. 
 
128 (58·1%) of 220 patients engaged in diagnostic and prognostic assessment (93 patients with HBV 
and 35 patients with HCV).  
 
Engagement with the diagnostic and prognostic assessment did not differ significantly between the 
groups; in an intention-to treat analysis, 80 (87·9%) of 91 patients receiving standard care engaged 
with diagnostic and prognostic assessment compared with 105 (81·4%) of 129 patients receiving 
community care (94 patients with HCV and 89 patients with HBV; IRR 0·76, 95% CI 0·2–2·5; p=0·65). 
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Patient engagement by protocol is outlined in Figure 13.  Disease staging and treatment outcomes 





Patients testing HBsAg or HCV Antibody positive in intervention practices 
= 220 
4 patients DNA Hospital 
Imaging Appts 
190 patients testing HBsAg 
positive or HCV PCR positive at 
Intervention Practices who 
attended diagnostic appt 
128 Attended 3 appointments (ENGAGED): 
HBV: 93 
TOTAL ENGAGED = [HCV Pos, PCR neg attending 2 appts] + [HBsAg pos + 
HCV Pos attending 3 appts] = [58] + [93+ 35] = 186/220 
21 patients did not receive results or attend GP 
for further diagnostic investigations (i.e. repeat 
RNA) 
Figure 13: Patient engagement by protocol 
59 HCV Ab positive, RNA 
negative 
(1 of whom also HBsAg pos) 
= 58 engaged but not for 
follow-up 
9 patients previously diagnosed 
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In a per-protocol analysis, we found that, of the 13 patients with HBV who were randomly assigned 
to receive standard care, 12 (92%) patients complied with recommended management (observation) 
versus 22 (88%) of 25 patients randomly assigned to community care, in which one patient required 
therapy (and adhered to treatment). In the 55 patients who did not consent to be randomly assigned 
and were treated in the hospital setting, 49 (89%) patients complied with the recommended 
regimen.  
 
Of the 36 patients with HCV who were viraemic, 35 patients engaged with follow up: eight patients 
were treated in the community care group and all (100%) were adherent. 27 patients were treated 
in standard hospital settings (four patients in the trial group allocated to this setting and 23 by 
default), and all (100%) were adherent. 
 
Cost-effectiveness analysis was performed by the Healthcare Modelling team at Exeter University. 
In the base-case, the intervention was cost-effective at willingness to pay (WTP) thresholds in excess 
of £8540 per QALY. Treatment with pure direct-acting antiviral regimens for HCV made the joint 
intervention (screening and treatment) cost-effective at WTP thresholds between £6935 and £18 
185 per QALY dependent on pricing and the regimen or treatment duration applied.  
 
Treatment of people older than 40 years (mean age 50 years) was cost-effective at WTP thresholds 
in excess of £15 696.  
Screening based on ethnic background was cost-effective for Pakistani ethnicity at WTP thresholds in 
excess of £9523 per QALY. The intervention was unlikely to be cost-effective for cohorts with a mean 
age older than 56 years. Results from the probabilistic sensitivity analysis indicated that the 
intervention is likely to be cost-effective in the most scenarios, with a mean incremental cost-
effectiveness ratio of £5292. This result is lower than the deterministic mean, in part because the 
probabilistic analysis adjusts for the small numbers tested in some of the larger GP practices. 
 
This issue appears to have predominantly affected practices where HBV was the more prevalent 
infection. 
During the treatment phase, one patient who was treated with interferon developed thyroiditis, but 
no other trial-related harms were noted during the study. 515 (7·5%) of 6854 eligible patients in 
Oxford were tested for viral hepatitis, and a similar trend was observed to that of the main trial: 
older patients from the Indian subcontinent were most likely to attend screening. In Oxford, seven 




Current NICE guidelines recommend testing individuals at high risk of chronic viral hepatitis in the 
primary care setting.   This high-risk group includes immigrants.  Therefore, the HepFREE trial was 
designed to address the issues around testing immigrants in primary care. 
 
In control practices testing of patients registered with the practice was low (1%) but testing in new 
registrants was much greater (4.8%). By contrast testing in intervention practices that were 
incentivised to participate was much greater with 20% of registered patients undergoing testing 
whilst only 12.8% of new registrants were tested.  
 
Testing rates differed by ethnic group with people originally from Pakistan more likely to participate 
in screening.  There was also an important difference in uptake by age – older people (>40 years) 
were more likely to attend than younger people and the prevalence of viral hepatitis was slightly 
greater in these patients. These data suggest that screening may be more productive if it is focussed 
on older individuals.  
 
The overall prevalence of viral hepatitis was 2% but most patients with HCV had cleared virus. This 
may have been due to higher rates of viral clearance in elderly, healthy migrant patients compared 
to the indigenous, often younger, drug using population or whether this is an artefact of our 
selection criteria with people attending GP surgeries being more likely to have cleared virus, perhaps 
because their liver function tests are normal and therefore they have not been previously tested.   
However, the overall HCV viraemia of 0.3% was shown to be sufficient to justify screening using 
standard cost effectiveness calculations (not presented here).  
Generational risk was not specifically measured, but we can extrapolate that individuals born in the 
UK were at least 2nd generation migrants.  Of those testing positive (see chapter 4 Results) 4/128 
(3.1%) were UK-born.  This strongly suggests that high prevalence country of birth is a better 
indicator of viral hepatitis risk than ethnicity.  
 
The WHO goals of eliminating viral hepatitis by 2030 will require increased testing and treatment of 
high-risk communities. HepFREE shows that in areas of high migrant density testing for viral hepatitis 
in primary care is an effective strategy that leads to high rates of detection of infection that is 
associated with excellent therapeutic adherence. This is particularly marked for people over the age 


















In this chapter I report on the disease staging of patients who tested positive for HBsAg or HCV Ab in 
the HepFREE trial.  Staging of viral hepatitis liver disease is a key predictor of prognosis, as well as 
informing treatment and on-going management for patients with chronic HBV and HCV infection.  
Understanding the disease staging of patients who enrol in screening clarifies the need for screening 
for a condition and the health benefits of screening in further cost-effectiveness analysis. 
Data collection, collation and analysis were performed by me. 
4.2 Numbers of Positive Patients 
From the total 11,929 patient screened for HBsAg and HCV Ab in both control and intervention 
practices, 237 (2.0%) patients tested positive for HBsAg or HCV Ab (including one patient who tested 
positive for both). (See Table 18a, chapter 3). 
110 (0·9%) patients had antibodies against HCV, of whom 35 (31.8%; 0·3% of those tested) were 
viraemic, and 127 (1·1%) patients tested positive for HBsAg.  
 
In both control and intervention practices, a higher proportion of newly registered patients tested 
positive for viral hepatitis than registered patients: 29 (2·6%) of 1134 new patients compared with 
271 (2·5%) of 10,795 registered patients. (See Tables 18b and 18c, chapter 3). 
 
There was a greater proportion of positive tests for viral hepatitis in patients screened in control 
practices, in which 17 (3·1%) of 543 patients were positive versus 220 (1·9%) of 11,386 patients in 
the intervention practices, including one patient with a co-infection (i.e., 221 diagnoses in 220 
patients). 
 
We did not have ethical approval to collect follow-up data from patients diagnosed positive in the 
control arm of the HepFREE Screening trial, and therefore those 17 patients are not included in this 
disease staging analysis. 
 
220 (0·4%) of 58 512 tested patients from intervention practices tested positive (1·9% of 11,386 
patients tested) and were followed up regarding disease staging, and treatment and management.  
In this chapter I present my exploratory analysis of the viral hepatitis disease stage for this 
population.   
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4.3 Positive Results in the Intervention Arm 
As per the HepFREE trial protocol, if patients were already known to be HBsAg positive, or HCV Ab 
positive, they were not eligible for invitation to screening.  However, 9 patients of the 220 who 
tested positive were known to be HBsAg or HCV positive, and engaged appropriately in care.  This 
had not been recorded on their GP records and therefore they were not excluded by the HepFREE 
eligibility search.  Although these patients were not eligible for further follow-up, the GP records 
were amended so that their medical history was correctly coded. 
One patient tested positive for viral hepatitis but withdrew consent to the HepFREE trial prior to 
being referred to secondary care.  Their data has not been collected for further analysis.  Therefore, 
210 of the patients who tested positive for HBsAg or HCV Ab (or both) in intervention practices were 
eligible for follow-up analysis. 
4.3.1 GP Results Attendance 
As per the HepFREE protocol, all patients testing for viral hepatitis in the HepFREE trial were to be 
informed by their GP practice of the outcome of the screening test. 
8 patients who tested positive for viral hepatitis were not informed by their GP of the result, and 
therefore were not referred to Secondary Care for follow-up.  I had access to the virology laboratory 
results and an anonymous linking code for these patients, but no demographics data. 
8 patients who were not informed of their results had the following test results: 
- HBsAg Positive = 3 patients 
- HCV Positive, RNA negative = 3 patients 
- HCV Positive, RNA not done = 1 patient 
- HCV Positive, RNA Positive = 1 patient 
202 Patients required a diagnostic appointment after testing positive with newly confirmed viral 
hepatitis HBsAg positive or HCV antibody positive in intervention practices. 
4.3.2 Diagnostic Appointments 
Diagnostic Appointments fell into the one of the following four categories: 
1. GP appointment to repeat HCV RNA test after a previous HCV Ab, RNA negative result. 




3. Secondary Care appointment after a previous HCV Ab, RNA positive result to assess 
demographics, medical history and arrange serology testing for FBC, Urea & Electrolytes, 
LFTs, HCV genotype and HCV viral load, and to arrange Fibroscan®  and ultrasound imaging 
appointments. 
4. Secondary Care appointment after a previous HBsAg positive result to assess demographics, 
medical history and arrange serology testing for FBC, Urea & Electrolytes, LFTs, HBeAg and 
HBV viral load, and to arrange Fibroscan®  and ultrasound imaging appointments. 
12 patients Did Not Attend Secondary Care Diagnostic or repeat GP testing (if HCV RNA negative or 
equivocal x 1 sample). 
- HBsAg Positive = 7 patients 
- HCV Positive, RNA Positive & Deceased = 1 patient* 
- HCV Positive, RNA Positive = 2 patients 
- HCV Positive, RNA Negative (on 1 sample) = 1 patient 
- HCV Positive RNA unknown = 1 patient 
*The deceased patient died from causes unrelated to their HCV infection (prostate cancer) and 
were tested during their palliative care phase. 
9 of the patients were from Bradford, 1 from East London and 2 from South London. 8 were 
male and 4 female, with an age range of 27-61 years.  5 patients were from Pakistan and 4 from 
Eastern Europe, the other 3 patients did not have country of birth recorded on their GP records. 
 
4.3.2.1 Patients who Attended Diagnostic Appointments 
190 Patients tested HBsAg positive or HCV PCR positive at Intervention Practices and attended 
Diagnostic Appointments at Primary of Secondary Care 
131 of these patients were HBsAg positive or HCV Ab + RNA pos and attended their diagnostic 
appointment in Secondary Care. 
58 patients were HCV Ab Pos + RNA neg (on two samples) and attended their diagnostic 
appointment in either primary or secondary care.  These 58 patients were regarded as engaged 
although they did not require further disease staging.  
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1 patient was HBsAg positive and also HCV Ab pos and RNA neg (on two samples).  This patient 
attended their diagnostic appointment and was followed up for disease staging of Hepatitis B 
infection. 
 
4.3.2.2 Patients Not Attending Imaging Appointments 
Of the 132 attending the diagnostic appointment, 4 did not attend their Fibroscan® and/or 
ultrasound liver imaging appointments for disease staging. 
These 4 patients broke down as follows: 2 male, 2 female, 2 from Bradford and 2 from London.  All 4 
patients had tested HBsAg positive.  Age range was 32-72.  None of the patients had tested HBeAg 
positive or HDV positive on their baseline serology tests. 
 
4.3.2.3 Patients who Attended Diagnostic and Imaging Appointments 
A total of 186 (88.6%) of 210 patients testing positive for viral hepatitis in the HepFREE Screening 
trial who were eligible for follow-up engaged in diagnostic and prognostic assessment as per 
protocol.  93 patients were diagnosed with HBV, 58 with non-viraemic HCV and 35 patients with 
viraemic HCV. Figure 13 showing engagement for these patients was included in Chapter 3 but is 










Patients testing HBsAg or HCV Antibody positive in intervention practices 
= 220 
4 patients DNA Hospital 
Imaging Appts 
190 patients testing HBsAg 
positive or HCV PCR positive at 
Intervention Practices who 
attended diagnostic appt 
128 Attended 3 appointments (ENGAGED): 
HBV: 93 
TOTAL ENGAGED = [HCV Pos, PCR neg attending 2 appts] + [HBsAg pos + 
HCV Pos attending 3 appts] = [58] + [93+ 35] = 186/220 
21 patients did not receive results or attend GP 
for further diagnostic investigations (ie repeat 
RNA) 
Figure 13: Patient engagement by protocol 
 
59 HCV Ab positive, RNA 
negative 
(1 of whom also HBsAg pos) 
= 58 engaged but not for 
follow-up 
9 patients previously diagnosed 
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4.4 Demographics of Patients Testing HBsAg Positive 
 
93 (95·9%) of 97 patients with HBsAg completed a diagnostic and imaging assessment:  
65 patients were male, 28 female. 
- two (2·1%) patients had a coinfection with hepatitis D virus 
- five (5·4%) patients tested positive for HBeAg (a marker of HBV replication) 
- eight (8.6%) patients had severe fibrosis or cirrhosis on liver biopsy.  
 






























1 Female 56 Bradford 
Pakistan Negative Negative 
1.0 X 103 21 No 
cirrhosis 4.1 
Observe  
2 Male N/A Bradford 
Pakistan Negative Negative 
------ ------ No 
cirrhosis 7.5 
Observe  
3 Male 34 Bradford 
Bangladesh Negative Negative 
2.8 X 102 44 No 
cirrhosis 5.8 
Observe  
4 Male 33 Bradford 
Bangladesh Negative Negative 
1.1 X 103 36 No 
cirrhosis 7.8 
Observe  
5 Male N/A Bradford 
Afghanistan Negative Negative 
------ ------ No 
cirrhosis 7.3 
Observe  
6 Male 35 Bradford 
Gambia Negative Negative 
4.7 X 102 32 No 
cirrhosis 8.7 
Observe  
7 Male 36 Bradford 
Pakistan N/A Negative 
1.3 x 102 23 No 
cirrhosis 4.9 
Observe  
8 Male 36 Bradford 
Pakistan Negative Negative 





9 Male 41 Bradford 











10 Male 64 Bradford 
Africa Negative Negative 
------ ------ No 
cirrhosis 5.7 
Observe  
11 Male 39 Bradford 
Ghana Negative Negative 
1.6 X 103 34 No 
cirrhosis 4.7 
Observe  
12 Female 30 Bradford 
Pakistan Negative Negative 
------ ------ No 
cirrhosis 5.4 
Observe  
13 Male 47 Bradford 
Bangladesh Negative Negative 
1.1 x 103 23 No 
cirrhosis 5.4 
Observe  
14 Male 63 Bradford 
Pakistan Negative Negative 
1.3 x 102 24 No 
cirrhosis 6.8 
Observe  
15 Male 61 Bradford 
Pakistan Negative Negative 

































16 Male N/A Bradford Pakistani 
British Negative Negative 
83 20 No 
cirrhosis 5.3 
Observe  
17 Male 48 Bradford 
Pakistan Negative Negative 
7.5 x 102 24 No 
cirrhosis 3.2 
Observe  
18 Male 39 Bradford 
Pakistan Negative Positive 
71 79 No 
cirrhosis 9.4 
Observe  
19 Male 41 Bradford 
Pakistan Negative Negative 
2.0 x 103 21 No 
cirrhosis 3.3 
Observe  
20 Male 62 Bradford 
Pakistan Negative Negative 
7.2 x 102 22 No 
cirrhosis 4.5 
Observe  
21 Male 60 Bradford 
Pakistan Negative Negative 
2.0 x 102 32 No 
cirrhosis 2.0 
Observe  
22 Male 21 Bradford 
Pakistan Negative Negative 
1.6 x 103 32 No 
cirrhosis 5.6 
Observe  
23 Female 54 Bradford 
Pakistan Negative Negative 
------ ------ No 
cirrhosis 4.1 
Observe  
24 Female 59 Bradford 
India Negative Negative 






Pakistan Negative Negative 















Lithuania Negative Positive 






Pakistan Negative Negative 






Pakistan Negative Negative 






Pakistan Negative Negative 
------ ------ No 
cirrhosis 4.9 
Observe  




Pakistan Negative Negative 






Poland Negative Negative 












Latvia Negative Negative 






Pakistan Negative Negative 






India Negative Negative 






British Positive Negative 




































British Negative Negative 






India Negative Negative 






Pakistan Negative Negative 






Pakistan Negative Negative 






Latvia Negative Negative 






Pakistan Negative Negative 






Pakistan Negative Negative 








India Negative Negative 






Pakistan Negative Negative 






Pakistan Negative Negative 









Pakistan Negative Negative 






Pakistan Negative Negative 








British Negative Negative 






British Positive Negative 








Pakistan Negative Negative 






Pakistan Negative Negative 








Pakistan Negative Negative 
<20 62 No 
cirrhosis 11.4 
Observe  




Pakistan Negative Negative 
------ ------ No 
cirrhosis 6.3 
Observe  




Pakistan Negative Negative 








Pakistan Negative Negative 






London Romania Negative Negative 






London Romania Negative Negative 




































London Nigeria Negative Negative 






London India Negative Negative 






London Bangladesh Negative Negative 






London India Negative Negative 



















London Pakistan Negative Negative 






London Somalia Negative Negative 






London Pakistan Negative Negative 






London Pakistan Negative Negative 






London Bangladesh Negative Negative 






London Bangladesh Negative Negative 






London Pakistan Negative Negative 






















London Vietnam Negative Negative 








Leone Negative Negative 






























































London Nigeria Negative Negative 




































London Vietnam Positive Negative 
1.8 x 106 29 No 
cirrhosis 3.7 






















London Ghana Negative Negative 






London Albania Negative Negative 






London China Negative Negative 






London Ghana Negative Negative 































NB where Country of Birth is UK, patients are eligible by their ethnicity (e.g. Chinese British, Pakistani 
British). Data on Viral Load and ALT was not recorded on OpenClinica for 19/93 patients as their data 


















Figure 14b: Age Distribution of HBsAg positive patients 
 
 
69.9% of patients testing HBsAg positive were male, with the majority of patients originally from the 
Indian Subcontinent (ISC = Pakistan, India, Bangladesh).  This reflects the local demographics of the 
testing areas in Bradford and East London where in some GP practices up to 50% of the registered 
population were born in ISC, or born to parents from the ISC. 
The majority of patients were aged <50 years (57/93, 61.3%) which suggests that testing in this age 







4.5 Disease Staging Assessment for Patients Testing HBsAg Positive 
 
Of the 93 patients with HBsAg who completed diagnostic and imaging assessment:  
- two (2·1%) patients had a coinfection with hepatitis D virus 
- five (5·4%) patients tested positive for HBeAg (a marker of HBV replication) 
- eight (8.6%) patients had severe fibrosis or cirrhosis on transient elastography or liver 
ultrasound.  
 
4.5.1 Hepatitis Delta Virus coinfection 
Two patients were co-infected with Hepatitis Delta Virus (HDV): 1 male and 1 female patient, both 
located in Bradford.  
The patients were from Pakistan and Lithuania.   
Ages were 39 and 53 years. 
Both had no cirrhosis on US Liver.   
Fibroscan® scores were 5.9KpA and 9.4KpA.  
The management plan for both patients was for ongoing observation. 
 
 
4.5.2 HBeAg positive patients 
5 patients tested HBeAg positive (2 in Bradford, 2 in South East London and 1 in East London).   
All patients were male. 
None had cirrhosis on US Liver or on Fibroscan® (range of score 4.1kPa-9.2kPa) 
Country of Birth was 1 x Chinese British, 1 x Pakistani British, 1 x Moldova, 1 x Vietnam, 1 x Ghana. 
Age range was 22-59 years with the mode 22 years and the median 29 years. 
 
Management plans for the 5 patients were:  
1 patient to be treated with NRTIs:  as age >30 years, VL >20,000 copies/mL and ALT >30 Units/L.  
This patient did not attend for their treatment follow-up appointments, and therefore was not 
started on treatment. 
 
1 patient seroconverted to eAb positive during diagnostic and imaging investigations, and therefore 




1 patient was offered treatment with NRTIs (Tenofovir): as age >30 years, HBV DNA >2000 
copies/mL, ALT >30 Units/L on 2 tests.  This patient continued to engage in therapy and achieved a 
reduction in viral load by more than 80% within 3 months of starting treatment. 
 
For 2 patients the management plan was observation only.  Both these patients were aged <30 
years, had a viral load <2000 copies and normal LFTs. 
 
 
4.5.3 HBsAg positive, HDV negative and HBeAg negative patients 
86 patients without HDV co-infection or presence of eAg were assessed for chronic hepatitis B 
infection.  9 of these patients met the EASL criteria for treatment on the basis of ALT, HBV DNA viral 
load or presence of cirrhosis.  Of these 9 patients, 4 were offered treatment for HBV infection.  The 
other 82 patients were for ongoing observation. 
 
My disease analysis of patients testing positive for HBsAg was performed to understand the 
progression of liver disease in patients identified in the HepFREE trial.  In the trial, patients offered 
the screening test were not known to have abnormal liver function and therefore screening was 
performed in asymptomatic patients.  My expectation was that a majority of patients would have 
normal liver function biochemistry and normal liver architecture.  This was the case, however, the 
finding of severe liver fibrosis or cirrhosis in 8.6% of patients with hepatitis B indicates that a 
minority of patients in this population can develop significant disease without developing symptoms.  
The ongoing risk for these patients is considerable and there may be missed opportunities to offer 





Figure 15: Scatter graph of Transient Elastography (Fibroscan®) scores versus age in HBsAg positive 
patients.  A score ≥ 9.5kPa (red line) is considered severe fibrosis and carries an increased risk of 
progression to cirrhosis (TE score ≥ 12.5kPa).   
The Pearson correlation coefficient is 0.0407 – this shows no association between age and fibrosis 
score in this population which is not significant (p-value 0.71).   
Six patients were measured as having a TE score of ≥9.5 kPa (range 10-19.6 kPa).  5 patients were 
from Bradford and 1 from East London.  3 were born in Pakistan, 1 born in Nigeria, 1 born in Poland 













4.6 Demographics of Patients Testing HCV Ab Positive 
 
94 (94·6%) of 94 patients with an HCV Ab positive result completed a diagnostic assessment: 59 
were HCV RNA undetectable (one of whom was also HBsAg positive) and, of the 35 patients with 
viraemic HCV 35 attended imaging appointments.  Of these, 20 (57.1%) were female, and 15 (42.8% 
male.  30 (85.7%) patients had HCV genotype 3 and five (14·3%) patients had liver cirrhosis. 
 
Table 20: Demographic, Diagnostic and Imaging outcomes of HCV RNA positive Patients 
 







1 Female 32 Bradford Pakistan 3A No 
Cirrhosis 
5.1 IFN/Ribavirin Awaited 






3 Male 39 Bradford Pakistan 3A No 
cirrhosis 
10.8 IFN/Ribavirin SV24 
achieved 
4 Female 29 Bradford Pakistan 3A No 
cirrhosis 
4.2 IFN/Ribavirin SVR12 
achieved 
5 Male 36 Bradford Pakistan 1 N/A 1.5 DAAs SVR12 
achieved 
6 Male 40 Bradford Pakistan 3A N/A 9.9 Await DAAs  
7 Male 27 Bradford Pakistan 3A No 
Cirrhosis 
6.2 IFN/Ribavirin SVR24 
achieved 
8 Female 28 Bradford Pakistan 3A No 
Cirrhosis 
5.9 Await DAAs  




10 Male 37 Bradford Pakistan 3A No 
cirrhosis 
7.4 IFN / 
Ribavirin 
Awaited 
11 Male 43 Bradford Pakistan 3A No 
Cirrhosis 
6.0 IFN/Ribavirin SVR24 
achieved 
12 Female 82 Bradford Pakistan 3A No 
Cirrhosis 
13.1 Await DAAs  
13 Female 38 Bradford Pakistan 3A No 
cirrhosis 
6.1 IFN/Ribavirin SVR24 
achieved 
14 Female 22 Bradford Pakistan 3A No 
cirrhosis 
5.6 Await DAAs  
15 Female 49 Bradford Pakistan 3A No 
Cirrhosis 
7.7 IFN/Ribavirin Awaited 
16 Female 37 Bradford Pakistan 3A No 
Cirrhosis 
6.5 IFN/Ribavirin Awaited 
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17 Female 68 Bradford Pakistan 3A No 
cirrhosis 
7.1 IFN/Ribavirin SVR24 
achieved 
18 Female 47 Bradford Pakistan 3A No 
cirrhosis 
N/A IFN/Ribavirin Awaited 
19 Male 47 Bradford Pakistan 3A No 
Cirrhosis 
4.6 IFN/Ribavirin Awaited 
20 Female 51 Bradford Pakistan 1B No 
Cirrhosis 
3.6 IFN/Ribavirin SVR24 
achieved 
21 Female 27 Bradford Pakistan 3A No 
cirrhosis 
5 Await DAAs  
22 Male 27 Bradford Pakistan 3A No 
cirrhosis 
N/A IFN/Ribavirin SVR24 
achieved 
23 Female 41 Bradford Pakistan 3A No 
Cirrhosis 
N/A Await DAAs  
24 Female 70 Bradford Pakistan 3A No 
Cirrhosis 
6.2 Await DAAs  
25 Female 37 Bradford Pakistan 3A No 
cirrhosis 
5.8 IFN/Ribavirin SVR24 
achieved 












28 Female 40 Bradford Pakistan 3A No 
Cirrhosis 
7.4 IFN/Ribavirin SVR24 
achieved 
29 Female 51 Bradford Pakistan 3A No 
cirrhosis 
6.1 IFN/Ribavirin Null 
responder 
30 Male 38 Bradford Pakistan 3A No 
cirrhosis 
7.3 IFN/Ribavirin SVR24 
achieved 
31 Female 32 East 
London 
India 3A No 
Cirrhosis 
N/A IFN/Ribavirin SVR24 
achieved 
32 Female 34 East 
London 






33 Male 35 East 
London 
Pakistan 3A No 
cirrhosis 
20.6 IFN/Ribavirin SVR24 
achieved 
34 Male 42 East 
London 
Pakistan 3A No 
cirrhosis 
5.2 Await DAAs  
35 Male 34 East 
London 













Figure 16a: Birthplace of HCV RNA positive patients
 







Table 21: HCV Genotype Distribution by Birthplace 
Hepatitis C 
Genotype 
Country of Birth TOTAL 
 Pakistan India Poland  
G1 2 0 0 2 
G1B 1 1 0 1 
G3A 28 1 0 29 
G3K 1 0 0 1 
G4 0 0 1 1 









35 patients tested HCV Ab and RNA positive.  20/35 (57.1%) were female, with the vast majority of 
patients (32/35, 91.4%) from Pakistan. Again, this is reflective of the local demographics of Bradford, 
where the majority of patients tested.  The age distribution was skewed towards those aged <50 
years (30/35), suggesting that testing in this age range in migrant populations will detect chronic 






Figure 17: Scatter graph of Transient Elastography (Fibroscan®) scores versus age in HCV RNA 
positive patients.  A score ≥ 9.5kPa (red line) is considered severe fibrosis and carries an increased 
risk of progression to cirrhosis (TE score ≥ 12.5kPa).   
The Pearson correlation coefficient is 0.2116 – this shows weak association between age and fibrosis 
score in this population which is not significant (p-value 0.27).   
Five patients were measured as having a TE score of ≥9.5 kPa (range 9.9-20.6 kPa).  4 patients were 




4.7 Patients found to have Severe Liver Fibrosis or Cirrhosis on Imaging 
In total 13 /128 (10.1%) of patients were found to have liver cirrhosis on either liver ultrasound, 
Fibroscan® (value >9.5 kPa) or both. 
Cirrhosis = on US or FS > 9.5 or both = 13 patients 
US cirrhosis = 4 patients (two with FS > 9.5 kPa) – all HBsAg positive 
Fibroscan® score >9.5 kPa (cirrhosis) = 11 (9 with no cirrhosis on US) – 5 HCV RNA positive, 6 HBsAg 
positive 
 
Therefore total number = 2 with cirrhosis on FS and US, 2 with cirrhosis on US alone, 9 with cirrhosis 
on FS alone. 
 
4.7.1 Liver Biopsy 
22 patients (17 HCV positive, 5 HBsAg positive) underwent liver biopsy in Bradford, as per local 
protocols.  This was part of standard investigation in the early part of the trial, but no patients in 
London were offered biopsy, as non-invasive studies (i.e. ultrasound and transient elastography) had 
taken precedence for investigation of viral hepatitis.  As the intervention was not offered uniformly 
to all patients, the outcomes were not analysed for this dataset. 
 
4.7.2 Management Plans for Patients with Severe Liver Fibrosis or Cirrhosis and HBV infection 
The management plans for the 8 patients with HBV Infection and liver cirrhosis were: 
1 patient was offered treatment with NRTIs (Entecavir). This patient continued to engage in therapy 
and achieved a viral load reduction by >80% within 3 months of starting treatment. 
2 patients had cirrhosis on US but a low Fibroscan® score (4.5 kPa) with normal LFTs and VL<2000 
copies/mL.  Therefore the local MDT decision was for observation and repeat Ultrasound scan within 
3 months. 
5 patients with Fibroscan® score > 9.5 kPa but no cirrhosis on US, and normal LFTs and VL <2000 
copies/mL had a plan to observe only. 
  
4.7.3 Management Plans for Patients with Severe Liver Fibrosis or Cirrhosis and HCV Infection 
All 35 patients with viraemic HCV were offered treatment either with currently available therapies or 
to await DAA treatment when available on the NHS. 
 




3 patients were treated with Interferon-based therapies.  2 patients achieved SVR24 and cure, one 
patient had a responder-relapse outcome. 
The other 2 patients opted to wait for the availability of new DAA drugs and were observed. 
 
4.8 Discussion 
Screening for chronic disease is a valuable measure of disease prevalence but is not in itself a means 
to an end.  Screening should be offered in populations who are at risk of significant health problems 
from the condition.  For viral hepatitis, the health problems include development of liver fibrosis, 
cirrhosis and hepatocellular carcinoma. 
The HepFREE trial found a positivity rate of 1.98% (237 patients) for viral hepatitis in a population of 
11,929 tested patients from 58,512 eligible migrants (20.3% tested) living in Bradford and London. 
Of 220 positive patients from intervention practices, 84.5% (186/220) attended diagnostic 
assessments, of which 132 were invited to imaging assessments.  Of the 128 patients who engaged 
in diagnostic and imaging assessments, 13 (10.1%) were found to have severe fibrosis or cirrhosis on 
ultrasound or transient elastography.  An additional 2 patients (1.56%) were HDV co-infected, and 5 
patients (3.9%) tested positive for HBeAg (a marker of increased HBV replication). 
A majority of patients testing HCV Ab positive had cleared virus (58/93, 62.3%).  Of note, the 
viraemic patients (0.3% of all tested) skewed towards younger age groups with the majority aged 
<50 years (30/35, 85.7%).  It is not clear whether this is due to higher rates of viral clearance in 
elderly and otherwise healthy migrants or related to our eligible population being less likely to be 
tested for viral hepatitis in primary care as they have normal liver function tests. However, treating 
and curing a younger population will have impactful quality of life years (QALYs) for cost-
effectiveness calculations. 
All of the patients who tested positive had not previously been tested for viral hepatitis and did not 
have clinical markers indicative of liver disease (e.g. abnormal liver function tests) which may have 
led their GP to consider viral hepatitis screening.  In 10% of these patients their severe liver fibrosis 
or cirrhosis would have been missed without the testing offered in the HepFREE trial, putting them 
at risk of developing undetected hepatocellular carcinoma.  Testing asymptomatic migrant patients 
for viral hepatitis in primary care allows early detection of cirrhosis in this at-risk group. 
These results show that the vast majority of patients will attend diagnostic and prognostic 
assessment after testing positive in primary care screening.  This may be because they are self-
selecting population and are already engaged with health promotion.  Patients in this population 
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also attended for non-invasive staging by Fibroscan® which was an offered as an alternative to the 
more invasive liver biopsy procedure.   In East London, Fibroscan® and ultrasound appointments 
were on two additional days following the diagnostic appointment visit, whereas in South London all 
these visits could be arranged for the same date – however this did not affect the uptake of the 
imaging assessment at both sites. 
Engagement with diagnostic and prognostic appointments was 100% in patients with viraemic HCV 
patients.  The reasons for this may be that patients were encouraged to attend for the opportunity 
be offered a curative therapy, or that at this point in HCV treatment in the UK (2015-2017) there was 
a strong push for case-finding from healthcare professionals with increasing access to the new DAA 
drugs. 
During this timepoint, DAAs for the treatment of non-cirrhotic Genotype 3 HCV infection were not 
widely available in NHS services.  This led to a delay in therapy for 8 patients with G3A infection.  17 
patients with G3A infection opted to be treated with interferon-based therapy. 
This underlines that any screening programme should have safe and effective treatment available 
for the underlying condition should it be detected.  In the case of viraemic Hepatitis C, the treatment 
landscape has changed considerably in the UK in the last 5 years, with the NHS now entering an 
interferon-free treatment era, with DAAs now widely available and accessible for all genotypes.  
Better access to DAA therapy has been a strong promoter for increased case finding for hepatitis C in 
at-risk populations. 
Several patients who were eligible for HBV treatment according to EASL guidelines on their baseline 
serology were not offered treatment (or treatment was deferred).  This was due to local multi-
disciplinary team decisions following two sets of serological results 3 months apart and in one case a 
patient was lost to follow-up after the decision to offer treatment. 
Ongoing engagement in care in either secondary care or community care will be explored in the next 
chapter.  Facilitators and barrier to offering viral hepatitis serology testing in primary care will be 
explored in the qualitative research presented in Chapter 6.  The factors leading to patients 

















In this chapter I present the results for the HepFREE Follow-Up Trial which randomised patients to 
follow-up in community based viral hepatitis clinics or standard of care (hospital-based clinics). 
I will present a more detailed breakdown of outcomes at the London Community Clinics which was 
the aspect of HepFREE trial set-up and led by myself. 
5.2 HepFREE Follow-Up Trial Results 
A total of 128 pts tested positive for HBsAg (93) or HCV RNA (35), attended diagnostic and imaging 
appointments and progressed to ongoing follow-up in the HepFREE trial. 
Of these 128, 90 patients were in Bradford, 19 in East London and 19 in South London.  Initially it 
was planned that consent for the randomisation of each patient to their cluster allocation would be 
sought verbally.  However, the ethics committee recommended that patients should provide written 
consent for randomisation.  This required blinding of the clinical staff members in Bradford and 
London to the cluster allocations, so that they could consent patients.  The protocol amendment for 
the addition of consent prior to follow-up in HepFREE community trials was in version 7 (dated Sept 
2015), however some patients in Bradford and London had already tested positive and were not 
prepared to wait for cluster allocation prior to starting treatment or management.   Therefore no 
community clinics were set up prior to protocol amendment version 7 in September 2015.  Those 
patients had been randomised by cluster to community but declined to wait for the consent process 
were allocated to standard care.  This group of patients are considered “Pre-Consent” 
Therefore, by cluster randomisation: 
Bradford – 41 standard, 49 community 
East London – 8 standard (1 declined consent), 11 community (5 pre-consent and therefore standard 
by default, 1 declined and therefore standard by default, 5 community) 
South London – 5 standard (two declined consent), 14 community (2 declined consent, 1 pre-
consent). 
The breakdown of all the patients in the HepFREE trial who attended community care was analysed 
by myself for engagement and treatment outcomes and are presented in Flow Charts 01 and 02, 





Table 22 Breakdown of Randomisation / Declined Consent / Pre-Consent Patients 
 Bradford East London South London TOTALS 
Consented to 
Randomisation 
22 12 16 50 
Declined Consent 0 2 3 5 
Pre-Consent 68 5 0 73 







13 HBsAg positive 
randomised to secondary 
care 
-13 for observation   
1 did not comply with 
therapy 
55 HBsAg positive in 
secondary care by default 
-44 for observation 
-3 treated with Entecavir 
-2 treated with Interferon 
-5 treated with Tenofovir 
-1 initially treated with 
Interferon, then switched to 
Tenofovir 
6 did not comply with 
therapy 
25 HBsAg positive 
randomised to 
community care 
-24 for observation 
-1 treated with Tenofovir  
3 did not comply with 
therapy 
68 HBsAg patients in secondary care 
57 for observation – 51 (89.5%) compliant 
11 required therapy.  10 initiated therapy and 10 
(100%) were compliant.   3 had achieved 
undetectable VL.  1 was LTFU. 
Total  = 61 compliant patients in secondary care 
25 HBsAg patients in 
community care 
24 for observation – 21 
(87.5%) compliant 
1 for therapy – 1 (100%) 
compliant and achieved 
undetectable VL 
Total = 22 compliant in 
community care 
Figure 18 Management Plans and Outcomes for HBsAg positive 
patients   
Total HBsAg positive patients compliant with therapy = 




8 randomised to 
community care 
2 treated with DAAs 
5 treated with 
PegIFN/riba 
1 treated with 
PegIFN/riba/sof 
  
23 in secondary care by 
default 
-14  treated with 
PegIFN/riba 
-1 treated with 
PegIFN/Riba/Simeprevir 
-1 treated with DAAs 
-7 awaiting therapy 
4 randomised to 
secondary care 
-2 treated with 
PegIFN/riba 
- 1 treated with 
DAA 
- 1 awaiting DAA 
treatment 
27 patients in secondary care 
27 compliant with therapy plan 
19 treated – 19 (100%) compliant 
11 cured 
5 awaiting SVR 
2 responder‐relapser 
1 null responder 
Total  = 27 compliant patients in secondary 
care 
8 patients in community care 
8 treated  – 8 (100%) 
compliant 
6/8 cured 
1 awaiting SVR 
1 treatment failure (on IFN‐
Riba) 
Figure 19 Management Plans and Outcomes for HCV 
Ab and RNA positive patients 
Total Compliant with therapy = 27 + 8 = 35/35  
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5.3 Analysis of the HepFREE Follow-Up Trial 
 
128 (58·1%) of 220 patients testing positive for viral hepatitis engaged in diagnostic and prognostic 
assessment (93 patients with HBV and 35 patients with HCV). Engagement with the diagnostic and 
prognostic assessment did not differ significantly between the groups; in an intention-to treat 
analysis, 80 (87·9%) of 91 patients receiving standard care engaged with diagnostic and prognostic 
assessment compared with 105 (81·4%) of 129 patients receiving community care (94 patients with 
HCV and 89 patients with HBV; IRR 0·76, 95% CI 0·2–2·5; p=0·65). 
 
 
I then performed further exploratory analysis of the London based patients in the follow-up trial to 
look in more detail at the attendance and engagement of patients in this sub-cohort. 
 
5.4 London Cohort Results 
5.4.1 Randomisation per protocol vs Allocation in actuality 
Of 38 patients in London, 13 were cluster randomised as per protocol to Standard follow-up and 25 
to community follow-up. 
However, the allocation in actuality was  
(i) of 13 randomised to Standard follow-up – 3 declined to consent (but remained in 
Standard arm). 
(ii) of 25 in Community care – 6 were randomised to community follow-up pre-consent and 
therefore defaulted to standard care, 3 declined to consent and defaulted to standard 
care, and 16 remained in community care. 









5.4.2 Demographics of Patients testing HBsAg and HCV AB positive in London 
I analysed the 38 London patients by virus, gender, age and country of birth. 
Of 38 London patients, 33 were HBsAg positive, and 5 HCV RNA positive.  Prior to the introduction of 
consent for randomisation 25 (65.8%) of these patients would have been randomised to community-
based care.  The final allocation of patients saw 16 (42.1%) in the community-based care arm. 












1 Female 27 HBV Romania Standard Standard 
2 Male 20 HBV Romania Community Pre-Consent 
3 Male 75 HBV Nigeria Community Pre-Consent 
4 Male 29 HBV India Community Pre-Consent 
5 Male 39 HBV Bangladesh Community Community 
6 Male 39 HBV India Community Declined 
7 Male 29 HBV Moldova Community Community 
8 Male 73 HBV Pakistan Standard Standard  
9 Male 44 HBV Somalia Standard Declined 
10 Male 74 HBV Pakistan Community Community 
11 Male 62 HBV Pakistan Community Community 
12 Male 34 HBV Bangladesh Standard Standard 
13 Female 37 HBV Bangladesh Standard Standard 
14 Male 57 HBV Pakistan Standard Standard 
15 Male 41 HBV Ivory Coast Standard Standard 
16 Male 37 HBV Poland Community Standard 
17 Male 71 HBV Vietnam Community Standard 
18 Male 39 HBV Sierra Leone Community Community 
19 Female 41 HBV Bulgaria Community Community 
20 Male 43 HBV Sierra Leone Community Community 
21 Female 40 HBV Sierra Leone Community Community 
22 Male 48 HBV Ghana Standard Standard 
23 Female 63 HBV Sierra Leone Community Community 
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24 Male 53 HBV Nigeria Community Community  
25 Male 59 HBV Vietnam Community Community 
26 Male 49 HBV Ghana Community Declined 
27 Male 59 HBV Ghana Community Community  
28 Male 30 HBV Albania Community Community 
29 Female 46 HBV China Community Community 
30 Female 33 HBV Ghana Community Community 
31 Male 59 HBV Nigeria Standard Declined 
32 Male 41 HBV Ghana Standard Declined 
33 Male 47 HBV Nigeria Standard Standard 
34 Female 32 HCV India Community Pre-Consent 
35 Female 34 HCV India Community Pre-Consent 
36 Male 35 HCV Pakistan Community Community 
37 Male 42 HCV Pakistan Standard Standard 














5.4.3 HBsAg Positive Patients 
The 33 HBsAg positive patients in London were born in a total of 15 different countries – this is in 
contrast to the 10 countries of birth for the 60 HBsAg positive tested in Bradford. 26 were male and 
7 female.  The age range was 20-75 years with a median of 43 years. 
 












5.4.4 HCV RNA Positive Patients 
Of the 5 HCV RNA positive patients, 3 were male and 2 female.  The age range was 32-45 years, with 
a median of 34 years.  2 patients were born in India, 2 born in Pakistan and 1 born in Poland. 
 









5.4.5 Total Patients Randomised to Community Care Post-Consent 
Following the Follow-Up Trial Consent Amendment, 16 patients who consented to randomisation 
were randomised to the community arm of the follow-up trial.  5 patients were in East London and 
11 in South London, 11 were male and 5 female and 15 of the patients were HBV positive, and 1 was 
HCV RNA positive.   
5.4.6 Community Clinic Attendances 
The community clinics in East and South London were based at 6 GP Practices from November 2015 
until February 2017.  Engagement in Community Care was deemed to be attendance at one 
appointment after randomisation.  Further appointments for individual patients were scheduled for 
their ongoing viral hepatitis care during the duration of the trial, ending in February 2017.  This was 
in order to develop the scope of the trial to assess if patients would attend community 
appointments to for ongoing care. 
A total of 37 appointment slots were offered to the 16 patients across 28 clinical sessions on 27 
calendar days.  There were 30 attendance from the 37 appointment slots (81%). 
One patient who did not attend 2 appts in a row was deemed to be lost to follow-up to community 
care and subsequently defaulted to secondary care.  This patient also did not attend further 
secondary care appointments. Therefore 15/16 (93.8%) patients engaged in community care as per 
the trial protocol.  
5.4.7 Treatment Outcomes in the Community Clinics 
Of the 16 patients randomised to community clinic care, the management plans were: 
14 patients for observation (all HBsAg positive patients with no cirrhosis, normal LFTs and VL <2000). 
1 patient for treatment with NRTIs (HBsAg positive, no cirrhosis with age > 40, ALT>30 and 
VL>20,0000).  This patient was treated with Tenofovir and achieved a > 80 reduction in VL within 3 
months. 
1 patient for treatment with Interferon (HCV RNA positive, and cirrhosis on US and Fibroscan®).  This 
patient was seen at two community-based appointments whilst on Interferon treatment – however 
as this patient developed biochemical hyperthyroidism, as per protocol his follow-up care defaulted 
to secondary care. 




Table 24: Community-Based Viral Hepatitis Clinics in London  
Date of Clinic Venue of Clinics and number of patients  
(attended / appointments) 
 
Year Month Date East London South London 























Jan 19th  1/1     
Feb 25th 1/1      
March  4th    0/1   
April 8th    1/1   
May 6th     1/1  
 19th 1/1      
June 17th    0/2   
 28th    0/1 1/1  
July 29th     1/1  
Aug 11th    1/1   
Sept  9th    2/2   
 15th 1/1      
 29th   1/1    
Oct 4th  1/2     
 7th     1/1  
 11th     3/3  
 18th  0/1     
 20th      2/3 






Jan 12th    1/1   
 17th  1/1     
 19th      1/1 
Feb 3rd    2/2   
 4th     1/1  
 10th    1/1   
 17th     1/1  
 22nd   1/1    
TOTALS   3/3 4/6 2/2 8/12 10/10 3/4 





5.4.8 Standard Care Attendances 
The standard care clinics in East and South London were based at Barts Health in East London (Royal 
London Hospital, Whitechapel and Whipps Cross Hospital, Leytonstone) and King’s College Hospital 
from September 2015 until February 2017.  Engagement in Standard Care was deemed to be 
attendance at one appointment after randomisation.  Further appointments for individual patients 
were scheduled for their ongoing viral hepatitis care during the duration of the trial, ending in 
February 2017.  This was in order to develop the scope of the trial to assess if patients would attend 
standard care appointments to for ongoing care. 
A total of 41 appointment slots (see table) were offered across two sites in East London and one in 
South London. 
A total of 41 appointment slots were offered across 30 clinical sessions on 30 calendar days to the 22 
patients.  There were 35 attendance from the 41 appointment slots (85%). 
One patient who did not attend 2 appts in a row was deemed to be lost to follow-up to secondary 
care.  Therefore 21/22 (95.5%) patients engaged in standard care as per the trial protocol.  
 
5.4.9 Treatment Outcomes in the Standard Clinics 
Of the 22 patients randomised or defaulted to standard clinic care, the management plans were: 
15 patients for observation (all HBsAg positive patients with no cirrhosis, normal LFTs and VL <2000). 
2 patients for observation who did not attend appointments. 
2 patients for treatment with Interferon ( both HCV RNA positive), one of whom achieved SVR24 and 
the other achieved SVR12 by study end date. 
1 patient for treatment with NRTIs (HBsAg positive, HBeAg positive, no cirrhosis with age > 40, ALT 
28 and VL>20,0000).  This patient was treated with Tenofovir and achieved a > 80 reduction in VL 
within 3 months. 
1 patient (HCV RNA positive) opted to await treatment with DAAs dependent on NHS availability. 
1 patient (HCV RNA positive) was eligible for a Drug research trial with access to DAAs and opted to 





Table 25: Standard Care Viral Hepatitis Clinics in London  
 
Date of Clinic Venue of Clinics and number of patients  
(attended / appointments) 
 
Year Month Date East London South London 
   Royal London Hospital Whipps 
Cross 
Hospital 
King’s College Hospital 
 
2015 Sept 28th   1/1 











Jan 20th 3/3   
Feb 10th 1/1   
April  20th 3/4   
May 4th 1/1   
May 13th   1/1 
 1st 1/1   
June 22nd 2/2   
 6th 1/1   
July 8th   1/2 
 13th 1/1   
 27th 1/1   
Aug 5th   0/1 
 10th 1/1   
 24th 1/1   
 28th   1/1 
Sept 2nd   1/1 
 16th   0/1 
 30th   2/2 
Oct 5th 2/2   
Nov 1st  1/1  
 4th   1/1 
 9th   1/1 
 11th 1/1   
 17th   1/1 
Dec 7th 0/1   
 
2017 
Jan 6th   1/1 
 20th   2/2 
Feb 8th 1/2   
TOTALS 21/24 1/1 13/16 




Table 26: Comparison of Patient engagement in Standard and Community Care 
 Engaged Patients / Total Patients Totals 
 East London South London  
Standard Care 14/14 7/8 21/22 
Community Care 4/5 11/11 15/16 
 
 
Table 27: Comparisons of attendances in Standard and Community Care 
 Attendance / Appointments 
 East London South London TOTALS 
Standard Care 22/25 13/16 35/41 (85.4%) 




Patient engagement after diagnosis is an important consideration when developing a new case-
finding intervention.  Keeping patients engaged with ongoing care is particularly important for a 
chronic healthcare problem such as chronic Hepatitis B infection which involves six-monthly check-
ups for serology and/or ultrasound imaging.  Both Hepatitis B and C infection also represent a public 
health concern, and improving patient engagement in care reduces the wider public health 
exposure.  Patients living with viral hepatitis have traditionally represented a “hard-to-reach” group, 
often because they do not engage on an ongoing basis with healthcare services.  It is not clear if 
migrant populations also fall into a poorly engaging group, and so the HepFREE follow-up trial was 
devised to test the hypothesis that patients are more likely to attend locally provided viral hepatitis 
at a nearby primary care centre rather than standard care based in the local hospital. 
A total of 128 patients who attended their diagnostic and imaging appointments were eligible for 
randomisation for follow-up in the HepFREE follow-up trial.   
73/128 of the patients were not randomised for the follow-up trial as their engagement and 
management occurred before the protocol v7 amendment which required written consent for 
randomisation as part of the ethical approval for this part of the trial.  All of these patients defaulted 
to standard care and were followed-up and recorded as standard care patients.  5 patients 
expressed a strong preference for hospital care and declined to consent for randomisation.  In each 
case this was noted to be because they perceived that hospital-based care would be more specialist 
and suited to their needs, despite being advised that the same clinicians would be seeing them if 
they were randomised to community care within this trial. 
The remaining 50 patients were randomised after consent, and as a result 33 patients were 
randomised to the community arm of the trial.  As this was statistically underpowered, the data was 
analysed on an intention to treat basis.  Engagement in both arms was excellent at >80%, and there 
was no statistical difference in engagement between the two groups. 
It should also be noted that two patients who consented to randomisation and whose care was 
arranged for follow-up on the community were found in post-hoc analysis of the screening to have 
been not eligible for the trial.  This was because their country of birth was incorrect on GP records 
(stating UK instead of true country of origin) and they happened to have been tested 
opportunistically by their GP in uncapped intervention practices.  One of these patients was HCV 
RNA positive and eligible for DAA therapy, and achieved SVR12 in the community viral hepatitis 
clinic.  The other patient was HBsAg positive and treated with tenofovir in a community hepatitis 
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clinic, successfully achieving a viral load decay of >80% within 3 months.  Although their data has not 
been presented here, the process of arranging their care informed my experience in setting up novel 
community based viral hepatitis services. 
Setting up community care viral hepatology clinics allowed me to reflect upon the challenges and 
benefits posed by this novel way of delivering care.   
Benefits for the healthcare professionals included the involvement of the multi-disciplinary team 
and engagement with primary cares services.  In order to set up the 6 community clinics in London, I 
worked with specialist nurses, specialist pharmacists, local research teams and the Operational 
Delivery Network at Barts Health (Royal London and Whipps Cross) and King’s College London.  This 
included discussions about the patients’ management, arranging transfer of medication from 
hospital pharmacy to local GP practices, and ensuring the correct serology bottles were used for 
blood tests.  Medical management was a particular issue – at first it was thought that DAA drugs 
may be able to be stored on site at the GP practice, but when the numbers of patient appointments 
were 1-2 per sessions, it was felt to be too risky to leave expensive drugs in the community should 
the patients not attend for their appointments.  To avoid losing drugs, any transport of DAAs was 
done door-to door from hospital pharmacy to GP practice by myself by private taxi service.  Where 
transport of DAAs was not involved, public transport was used.  Although NRTI drugs are much 
cheaper than DAAs, their transport was handled in a similar way. 
The main difference between the set-up of community clinics and standard care clinics was that 
standard care hospital clinics were set in one site on one day of the week, and HepFREE patients 
were seen in one appointment of sixteen in a session (4 appointments in 4 hours).   
Community clinics, on the other hand, occurred on variable days of the week for a much smaller 
number of appointments (1-3).  These days and times were arranged for the patients’ convenience, 
but also involved liaising with the GP practice to ensure a room was available for the clinic.  On one 
occasion I arrived with a patient to a GP practice which was closed for the afternoon – the 
administrative staff who had confirmed the HepFREE session had forgotten that a clinic training 
session was arranged for the same time.  (Fortunately, on that occasion I was allowed to use a room 
for the purpose of the HepFREE appointment). 
Venepuncture was performed by myself in community clinics and involved transport of samples back 
to the hospital lab – for standard care patients their serological testing was performed by healthcare 
assistant on site. 
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Patients attending standard care were routinely sent a text reminder 48 hours prior to the 
appointment.  In the community care arm, patients may have been seen at a GP practice other than 
the one they were registered at – therefore they were reminded of the appointment and location by 
phone call by me 48 hours prior to the appointment.  This was an additional task to ensure 
community-based patients had a similar reminder to patients in standard care.  As patient numbers 
were low and the appointment times and dates not necessarily predictable, it was difficult to 
delegate this task to an administrative member of staff or another research team member.  
Managing the community cohort across 6 sites in London required organisation, planning and 
flexibility in re-arranging missed appointments. 
The data shows that there is no significant difference in engagement between the standard care and 
community care arms of the follow-up trial.  The main limitation of this analysis is the small numbers 
of patients who consented to randomisation and were seen in the community care arm.  However, 
the logistics, management and organisation required for arranging community care for small 
numbers of patients was much more involving for myself as their clinician than for patients seen in 
standard care.  The HepFREE Follow-Up trial suggests that community-based care is not required for 
this population who are health-engaged after being diagnosed with viral hepatitis, and its benefits 
are hard to ascertain when engagement with standard care follow-up was so good.  At this time-
point in HCV treatment there was also a perception from some patients that being seen in the 
community may lead them to “miss out” on treatment with the new DAA drugs, and there may be 
an ongoing perception in this population that community based care is somehow substandard to 
hospital care.   Patient perception would be an area worthy of qualitative research should the idea of 
primary care-based hepatitis clinics be explored in the future.  At present, our data suggests that 
clinical resources would be better used in standard based care for patients identified in general 



















In this chapter I present my analysis of the pre-screening survey of patients eligible for viral hepatitis 
from four interventional screening practices in North East London, South East London and Bradford. 
Prior to HepFREE screening beginning in 2014, a survey of patients eligible for viral hepatitis testing 
was performed by the qualitative researcher John Owiti to investigate patients’ illness perceptions 
regarding viral hepatitis.  I collated and cleaned the data and linked the survey data to the HepFREE 
outcomes I collected during the screening trial.  I then performed descriptive analysis and logistic 
regression of the survey data with the assistance of a statistician from QMUL.  The aim was to test 
the hypothesis that patients’ understanding of viral hepatitis and its impact on health indicates 
whether or not they will attend for screening when invited.  
For full methods please see section 2.5 of Chapter 2.  
6.2 Participation Outcomes 
1935 eligible patients were identified from the GP record from 4 practices and contacted by the 
research team to enquire about their interest in participating in a survey about knowledge and 
attitude to viral hepatitis infection.  Patients were contacted by an invitation letter and follow-up 
phone-call.  Patients were unable to participate in the study for various reasons including declining 
participation and not being contactable for an invitation by letter or phone. The full list of reasons 
for eligible patient drop-out and the numbers this included are outlined in the Flow Chart 1. 
At the end of the recruitment process, a total of 377 of 1935 eligible patients (19.1%) agreed to 
complete a pre-screening survey. Of those who did not participate, 208 declined participation, and a 
further n=1350 did not respond to attempted contacts from the study team (see flowchart 1). 
The survey was conducted by postal survey (self-completed by the patient) or by telephone 
interview (with the researcher collecting the responses). 
Of the 377 patients who agreed, 7 patients returned postal surveys which did not have any 
responses to the demographics or knowledge base questions.  These 7 were not included in the 
analysis. 
A sample of the survey questions is included in Appendix 11. 
Interviewees were asked about their demographics (age, gender, ethnicity, birthplace) and 
understanding and knowledge of viral hepatitis (including symptoms, transmission, knowledge of 
treatments and vaccinations).  The respondents were also asked questions regarding mood and 
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anxiety in order to assess PHQ and GAD scores.  Finally, participants were asked about their 
willingness to test for viral hepatitis having been informed of their eligibility for testing. 
Outcomes of the data were assessed with the primary outcome being the number of patients who 
took-up the screening invitation by close of recruitment at their practice.  Testing outcomes for the 













































No phone number 
N=7 (0.36%) 
Total number interviewed 
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N=465 (24%) 





























 No longer 






Did not receive 
invitation letter 
N=9 (0.46) 





N= 223 (11.5%) 
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6.3 Survey Results 
Of 377 patients who consented to be interviewed, 370 completed the survey in full.   
377 patient identifiers were collated on the OpenClinica database, of which 370 had survey data 
collected.  7 patients returned postal surveys which did not have any responses to the demographics 
or knowledge base questions. 
The 370 patient identifiers were cross-checked with the HepFREE screening data.  147 participants 
were from Bradford, 192 were from South London and 31 were from East London.   
92/370 participants attended for HepFREE screening for viral hepatitis.  In Bradford 73/147 (49.6%) 
participants attended, in South London 13/192 (7.3%) attended, and 6/31 (19.4%) of East London 
participants attend. 
None of the 92 screened participants tested positive for HBsAg or HCV AB. 
 
Table 28: Survey Respondents and Attendance for HepFREE Screening 
Location Survey 
Respondents 






77 25 (32.5%) 0 
Bradford  
Practice 2 
70 48 (68.5%)  
Bradford 
TOTAL 
147 73(49.6%) 0 
East 
London 
31 6 (19.4%) 0 
South 
London 















Table 29: Comparison of Pre-Screening Testing Uptake with total HepFREE Screening Trial Outcomes 
 
Group Tested in 
HepFREE 
Pre-Screen Interviewees 
At Intervention Practices 
(2014) 
 HepFREE 
Outcomes at Intervention Practices 
(2014-2017) 
Total Tested 92/370 = 24.9% 11,929/58,512 = 19.5% 
<40 years tested 35/194 = 18% 5151 / 36,115 = 14.3 % 
≥40 years tested 57/176 = 32.4% 6,235/22,397 = 27.8% 
African tested 16/177 = 9% 545/6866 = 11.7% 
Pakistani tested 38/120 = 31.7%  6,841 / 19,001 = 32.5% 
 
It is notable how similar the outcomes of screening uptake were in the pre-screening survey 
population compared with the main HepFREE outcomes in all the parameters above. 
 
6.3.1 Demographics 





• Place of birth 
• Average PHQ-7 score 
• Average GAD score 
 
Responses to personal history and knowledge of viral hepatitis screening and treatment were also 
analysed.  Parameters in these fields were 
• A personal history of testing for viral hepatitis 
• A personal history of being vaccinated against hepatitis B infection 
• A family history of viral hepatitis infection 






Table 30: Demographics of Respondents 
Demographics TESTED (n=92) DID NOT TEST (n=278) 
Gender Male 40 (43%) 120 (43%) 
Female 52 (57%) 158 (57%) 
 
Ethnicity African 18 (19.6%) 161 (57.9%) 
Pakistani 73 (79.3%) 82 (29.5%) 
Chinese ---- 26 (9.4%) 
White ---- 7 (2.5%) 
Indian 1 (1.1%) 2 (0.7%) 
 
Place of Birth South Asia 50 (54.3%) 53 (19.1%) 
UK & Ireland 22 (23.9%) ----- 
Africa 18 (19.6%) 166 (59.7%) 
Middle East 2 (2.2%) 1 (0.36%) 
China ---- 26 (9.4%) 
Europe ---- 32 (11.5%) 
 
Age 18-39 years 35 (38%) 158 (57%) 
40+ years 57 (62%) 110 (39.7%) 
Not recorded ---- 10 (3.6%) 
---------------------------- ---------------------------- ---------------------------- 
Mean Age 45.4 years 38.8 years 
Mode by decade 50-59 years 30-39 years 
  
 
Place of birth: 
For the purposes of descriptive analysis, country of birth was collapsed to continents as below: 
• South Asia (Pakistan, India)  
• Africa (Ghana, Somalia, Eritrea, DRC, Ivory Coast, Nigeria, Sierra Leone, South Africa, Guinea, 
Algeria, Zimbabwe, Uganda, Senegal, Kenya, Gambia, Ethiopia, Cameroon, Angola) 
• Middle East (Saudi Arabia, Afghanistan)  
• UK & Ireland  
• China  






















6.3.2 Depression and Anxiety Scores of Respondents 
Table 31: PHQ-9 and GAD-7 Scores of respondents 
 
Depression & Anxiety Score TESTED (n=92) DID NOT TEST (n=277) 
PHQ-9 Score 0-4 – No depression 57 (58.7%) 194 (69.8%) 
5-9 – Mild depression 19 (20.7%) 45 (16.2%) 
10-14 – Moderate 
depression 
9 (9.8%) 19 (6.8%) 
15-20 – Moderate to 
severe depression 
6 (6.5%) 15 (5.4%) 
20+ Severe depression 1 (1.1%) 5 (1.8%) 
 
GAD-7 Score 0-4 – No anxiety 64 (69.5%) 210 (75.5%) 
5-9 – Mild anxiety 11 (12%) 34 (12.2%) 
10-14 – Moderate 
anxiety 
9 (9.8%) 18 (6.5%) 
15+ - Severe Anxiety 8 (8.7%) 16 (5.8%) 
 
 
6.4 Regressive Analysis 
I was interested in whether the likelihood in attendance for testing could be predicted according to 
demographics such as ethnicity or place of birth, and if there was a relation to other factors such as 
mental health status, or knowledge related to viral hepatitis. 
A cross-tabulation of the data allowed a binary logistic regression to be performed against the 
outcome of uptake vs non-uptake.  
Data was prepared as follows: 
Binary Data (0/1 according to no/yes response) was prepared for the following variables to be 
analysed using the Stata program: 
21 x symptoms variable  
25 x consequences 
19 x perceived treatments 
34 x perceived causes 
5 x historical items (including previous screening, familial risk, HCP recommendation)  
1 x screened/not screened 
 
PHQ and GAD scores were categorised for sensitivity analyses and descriptive tests.  
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Ethnicity was categorised dependent on the most common values.  
Frequencies for each variable were run for screening uptake and screening drop-out. 
 
An assumption of logistic regression analyses is a minimum expected cell count of 5.  After an initial 
descriptive analysis for these variables, it was found that some categories needed collapsing down 
before the counts could be run as logistic regressions.   
As a result of this the consequences variables were converted to binaries instead (i.e. a score of 1 to 
8 will collapse to 1). 
- Perceived biological consequences (0-8; sum of liver cancer, liver cirrhosis, death, lifelong infection, 
exhaustion, high blood pressure, stomach ulcer, depletion of energy) 
- Perceived social consequences (0-8; loss of employment, loss of future income, stigma, shame, not 
being able to marry, killed by family, discrimination, isolation)  
- Perceived psychological consequences (0-7; worry, stress, fear, anxiety, sadness, depression, fear 
of getting liver cancer) 
Other variables were also collapsed as outlined in Table 32. 
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 Table 32 Collapsed Demographic and PHQ/GAD variables for logistic regression analysis  


















































































Age Range 18-79 18-39 / 40-79  




























Married / Living as 
Married / Engaged 





Yes / Unsure / No Yes / No   
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6.4.1 Binary Logistic Regression Analysis  
Regression analysis was run on the variables in the following groupings: 
(i) Demographics 
(ii) PHQ9 and GAD-7 Scores 
(iii) History of personal viral hepatitis testing or family member with infection or tested 
(iv) Willingness to test or be vaccinated (vs HBV) 
(v) Understanding of viral transmission, symptoms and treatments 
(vi) Perception of consequences of viral infection. 
These analyses were run for the interview participants who subsequently tested in the HepFREE trial 
(n = 92), and for those who stated they were willing to test but subsequently did not test (n=226). 
Results are presented in Tables 33-38. 
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Table 33 Logistic Regression Analysis of Demographics of Participants 
Variable  Tested (n=92)  Willing to Test but Did Not Test 
(n=226) 
 n OR p 95% CI n OR p 95% CI 
Age (at 
2014) 
18-39 (REF) 35 -----
- 
------ ----- ----- 111 ------ ------ ----- ----- 
 40-79 57 2.21 0.00 1.36 3.59 115 0.63 0.11 0.35 1.12 
Gender Male 40 1.01 0.96 0.63 1.63 100 1.21 0.52 0.68 2.17 
Female (REF) 52 -----
- 
------ ----- ------ 126 ------ ------ ----- ----- 
Ethnic 
Group 
African (REF) 16 -----
- 
------ ----- ----- 97 ------ ------ ----- ----- 
Pakistani 73 8.51 0.00 4.67 15.50 111 0.13 0.00 0.06 0.27 
Other 3 0.61 0.52 0.13 2.76 18 0.80 0.79 0.16 4.06 
Birthplace Africa 16 0.14 0.00 0.07 0.30 99 6.86 0.00 2.82 16.67 
Pakistan/India 50 1.33 0.40 0.68 2.60 75 0.93 0.85 0.43 2.02 
Other 4 0.10 0.00 0.02 0.47 13 ------ ------ ----- ----- 

















8 2.45 0.07 0.92 6.54 21 0.55 0.15 1.97  
Location Bradford (REF) 72 -----
- 
------ ----- ----- 103 ------ ------ ----- ----- 
East London 6 0.27 0.01 0.10 0.69 19 2.85 0.06 0.96 8.51 
South London 14 0.08 0.00 0.04 0.15 104 10.76 4.91 23.60  
 
Where Odds Ratio >1.00 and p<0.05: 
- Over 40s are more likely to screen 
- Pakistani pts are more likely to screen than African respondents; those born in Pakistan are less 
likely to drop out of screening after invitation than those born in the UK. 







Table 34 Logistic Regression Analysis of PHQ9 & GAD7 Scores of Participants 
Variable Tested (n=92)  Willing to Test but Did Not Test 
(n=226) 
  N OR p 95% CI n OR p 95% CI 
PHQ9 None (REF) 58 ------- ------ ----- ----- 139 ------
- 
------ ----- ----- 
Mild 18 1.44 0.25 0.78 2.65 46 0.71 0.34 0.35 1.44 
Moderate 9 1.61 0.27 0.69 3.76 21 0.75 0.57 0.28 2.01 
Moderate/Severe 7 1.19 0.71 0.48 2.96 20 1.13 0.83 0.38 3.32 
GAD7 None (REF) 63 ------- ------ ----- ----- 159 ------
- 
------ ----- ----- 
Mild 12 1.06 0.87 0.51 2.21 30 1.30 0.58 0.52 3.23 
Moderate 9 1.64 0.25 0.70 3.83 19 0.54 0.20 1.44  
Severe 8 1.14 0.76 0.49 2.67 18 0.79 0.66 0.28 2.23 
 
There was no statistically significant correlation between presence (or absence) of symptoms of low 
mood or anxiety and subsequent attendance for screening. 
 
 Table 35 Logistic Regression Analysis of History of Testing Scores of Participants 
 
*Four respondents (screened) and four respondents (did not screen) did not complete this 
question. 
Participants with a family member living with viral hepatitis were more likely to attend for 
screening after invitation than those without.   
 
Variable Tested (n=92)  Willing to Test but Did Not Test 
(n=226) 





60 ----- ----- ----- ----- 133 ----- ----- ----- ----- 
Yes 13 0.42 0.01 0.22 0.82 29 1.66 0.28 0.66 4.18 
Don’t 
Know* 





58 ----- ----- ----- ----- 131 ----- ----- ----- ----- 
Yes 13 0.69 0.28 0.35 1.37 22 1.22 0.70 0.44 3.37 
Don’t 
Know 






59 ----- ----- ----- ----- 160 ----- ----- ----- ----- 
Yes 17 3.58 0.00 1.72 7.43 25 0.37 0.03 0.16 0.88 
Don’t 
Know 
16 1.14 0.68 0.61 2.15 41 0.74 0.43 0.35 1.57 
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Table 36 Logistic regression of Willingness to test/vaccinate/follow recommendation 
Variable Tested  Did Not Screen 
  n OR p 95% CI n OR p 95% CI 











Yes 226 1.24 0.62 0.53 2.90      




----- ----- ----- ---- ---- 
Willing to 
vaccinate 




6 ----- ----- ---- ---- 
Yes 235 1.64 0.33 0.60 4.47 179 0.90 0.75 0.45 1.78 




12 ----- ----- ---- ---- 
Recommended 
by HCP 




213 ----- ----- ---- ---- 
Yes 45 0.64 0.28 0.29 1.44 8 1.20 0.82 0.24 6.13 









Table 37 Logistic Regression of Knowledge 
Variable Tested (n=92)  Willing to Test but Did Not Test 
(n=226) 






66 -------- ------- ----- -----
- 
49     
Yes 26 1.18 0.84 0.22 6.24 23 1.07 0.94 0.18 6.32 






57 -------- ------- ----- -----
- 
146     






40 -------- ------- ----- -----
- 
104     





36 -------- ------- ----- -----
- 
122     
Yes 51 1.87 0.01 1.16 3.02 96 0.55 0.04 0.31 0.97 
Unsure 5 -------- ------- ----- -----
- 





52 -------- ------- ----- -----
- 
127     





82 -------- ------- ----- -----
- 
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74 -------- ------- ----- -----
- 
186     




Table 38 Perception of Consequences of Viral Hepatitis Infection 
Variable Tested (n=92)  Willing to Test but Did Not Test 
(n=226) 






39 ------- ------- ----- ---- 87 ------
- 
------- ----- ---- 






53 ------- ------- ----- ----- 127 ------
- 
------- ----- ---- 






57 ------- ------- ----- ----- 141 ------
- 
------- ----- ---- 
Yes 35 1.08 0.75 0.67 1.76 85 0.98 0.96 0.54 1.78 
 
Looking at the variables associated with knowledge of viral hepatitis and perceptions of the 
consequences of infection, only one variable was associated with screening uptake which was 
knowledge of treatments.  This indicates that improving patient knowledge of new therapies should 
improve screening uptake and should be prioritised over other knowledge areas. 
 
 
Figure 24 Forest Plot of Odds Ratio with Confidence Intervals against statistically significant variables















6.4.2 Stratified Regressive Analysis 
 
Finally, the significant bivariate regressions were analysed by location and ethnicity strata groups.  
These stratified regressions showed that significant effects when accounting for location strata are 
mostly explained by ethnicity. 
 
 
Table 39 Descriptives for Ethnicity groups by intervention location 
 
 Location African Pakistani Chinese/Other Total 
n Bradford 2 146 6 154 
%  1.30 94.81 3.90 100.00 
n East London 16 13 2 31 
%  51.61 41.94 6.45 100.00 
n South London 158 0 33 191 
%  82.72 0.00 17.28 100.00 
n Total 176 159 41 376 
%  46.81 42.29 10.90 100.00 
 
The majority of Bradford participants identified as Pakistani. 
East London participants mostly identified as African or Pakistani. 
The majority of South London participants identified as African. 
 
 
Table 40 Awareness of treatments and likelihood of screening 
 
Screened OR Std Err Z P>z 95% CI 
Aware of 
treatments 
      
Yes 1.87 0.45 2.59 0.01 1.16 3.02 



















Table 41 Awareness of Treatments, Ethnicity and Location on likelihood of Screening 
 
Screened  OR Std Err Z P>z 95% CI 
Aware of 
Treatments 
      
Yes 1.06 0.29 0.19 0.85 0.61 1.82 
Ethnicity  
Pakistani 8.68 2.73 6.87 0.00 4.69 16.08 
Chinese/other 0.90 0.59 -0.17 0.87 0.24 3.27 
African (REF)       
Location  
Bradford 1.06 0.30 0.22 0.83 0.61 1.84 
East London 0.25 0.12 -2.89 0.00 0.09 0.64 
South London 0.07 0.03 -7.63 0.00 0.04 0.15 
 
The association of awareness of treatments was significantly explained by those who identified as 
Pakistani (where z-score is < -1.96 or > 1.96 and p-value <0.05), and also significantly explained by 








OR Std Err Z P.z 95% CI 
Aware of 
Treatments 
      
Yes 0.55 0.16 -2.05 0.04 0.31 0.97 




Table 43 Awareness of treatment and ethnicity on dropout rates 
 
No screened OR Std Err Z P.z 95% CI 
Aware of 
treatments 
      
Yes 0.92 0.31 -0.26 0.79 0.47 1.78 
- Ethnicity  
Pakistani 0.13 0.05 -5.21 0.00 0.06 0.28 
African 0.56 0.40 -0.80 0.42 0.14 2.31 
 
 
Those aware of treatments were less likely to drop out. 
The association of awareness of treatments on drop out was significantly explained by those who 





This analysis of 370 participants eligible for the HepFREE Screening trial prior to the initiation of 
testing gives us an insight into the potential facilitators and barriers to patients agreeing to testing.  
The population is representative of the final screened population, with male/female, <40 years and 
>40 years and Pakistani and African patients well matched.  Predictors for attending for testing were 
being Pakistani, over 40 years of age, knowing a family member with viral hepatitis and awareness of 
treatments. 
24.9% of the interviewees attended for screening, compared to a 19.5% uptake in intervention 
practices in the main HepFREE screening trial.  It is striking how similar the uptakes rates were in the 
pre-screening population with the general eligible population in the HepFREE trial, not only overall 
but also amongst <40 years and ≥40 years age groups and the African and Pakistani populations. 
Pakistani patients attended for screening in 3:1 ratio compared to African (or Black) patients.  The 
ratio was similar in the pre-screen population and suggests that patients from Pakistani backgrounds 
are more likely to be motivated to attend for viral hepatitis testing.  Several reasons could explain 
this: (i) living in Bradford, Pakistani patients were more likely to be invited at uncapped intervention 
practices by their GP (ii) Pakistani patients may be more likely to know a familiar member with HBV 
or HCV.  However, on the latter point, viral hepatitis positivity rates were similar in both ethnicities 
in the HepFREE trial (2.0% in Pakistani population, 1.7% in Black/African populations), so it may be 
that fewer Black African patients have an awareness of an affected family member. 
Knowledge of treatments was another strong predictor of attendance for screening, and this may be 
more commonly found in patients who have already been aware of a family member or friend 
treated for viral hepatitis.  Again, this was associated with Pakistani populations.  Mood and 
perception of illness did not show any significant correlation with screening uptake.   




















As the main HepFREE screening trial recruitment came to a close, it became apparent that there was 
a wide variability in recruitment figures between practices (ranging from 3-30% of eligible patients).  
In order to understand this, the HepFREE Provider Substudy identified 12 intervention practices who 
would be invited to participate in qualitative research interviews.  These practices were selected on 
the basis of their recruitment outcomes, as I wanted to interview participants from practices that 
had recruited >20% of eligible patients (high recruiters), <10% of eligible patients (low recruiters) 
and between 10-20% (intermediate recruiters). 
These practices were identified as in Table 44.   
HepFREE Screening Trial Recruitment Determinants 
High:  >/ = 20% of eligible patients 
Intermediate: between 10.1-19.9% of eligible patients 
Low: </= 10.0 % of eligible patients 
 
7.2 Recruitment of HCPs for Qualitative Research 
An initial email was sent to 14 HepFREE intervention practices for the recruitment of HCPs for 
interview.  This email explained the role of qualitative research as part of the HepFREE trial and 
invited staff to participate in an anonymised 20-30min interview conducted either face to face or by 
phone for the purposes of understanding the facilitators and barriers to providing viral hepatitis 
screening in primary care.   
Recruitment was extremely slow.  After the initial email, and follow-up emails after two weeks and 
four weeks later, none of the practices responded with interest and on further questioning by 
telephone and in person while discussing other aspects of the trial, two respondents (practice 
managers) advised that many HCPs did not feel they had the time to provide further participation in 
the HepFREE Trial outside of the provision of screening intervention.   
Therefore to encourage participation, ethical approval was sought for the provision of a £50 
shopping voucher incentive to individual HCPs for their participation in the qualitative study. 
From the initial contact of 12 practices, 9 practices responded to the call for interviewees.  One 
practice HCP agreed to be interviewed but prior to signing the consent form was informed by their 
practice that the incentive should be a cash payment to the practice managers.  As we did not have 
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ethical approval for this, the participant was asked if they would be happy to be interviewed in their 
own time at the HepFREE office.  The participant initially agreed to this, but then withdrew before 
consenting to interview.  Two other interested participants did not respond to further emails 
requesting a suitable interview time. 
This left 8 interested respondents from 6 practices, and face to face and telephone interviews were 


















GP May 2017 
East London Stratford 
Village 
Oct 2015 Intermediate 
74/650 
11.4% 
Stuart Declined  
East London Jubilee 
Street 
Practice 










East London Royal Docks July 2016 Low 
50/500 
10% 
Dania Declined  













Sir John Kirk June 2016 High 
117/500 
23.4% 

















Crown Dale Feb 2016 Low 
40/500 
8% 


























Bradford Primrose Dec 2015 High 
1836/2984 
61.5% 
Stuart Declined  
Bradford Picton Dec 2015 High 
1696/1842 
92.1% 
Stuart Declined  











Bradford  Moorside 
Surgery 
Feb 2016 Intermediate 
79/600 
13.1% 







1. Practice Involvement in research 
2. Technical Set-Up 
3. Training in Intervention Delivery 
4. Delivering the Intervention 
























Topic 1 Practice Background 
1.1 Research Experience at the Practice 
1.2 Awareness of Hepatitis at the Practice 
 
Theme 2 HepFREE Set-Up 
2.1 Specific leads (designated) 
2.2 Technical set-up and prep 
2.3 Funding 
Theme 3 Delivering the Intervention 
3.1 Process 
Theme 4 Recruitment to the Study 
4.1 Staggered recruitment 
4.2 views on recruitment letter 
4.3 Opportunistic testing 
4.4 telephoning /texting patients 
4.5 language support provided 
4.6 communication with HepFREE team 
4.7 patient response 
4.8 consenting patients 
 
Theme 5 Perceptions of benefits and 
Outcomes 
5.1 Perception of Outcome 
5.2 Perceived benefits to patients & staff 
Theme 6 Perceptions of Challenges 
6.1 Demands on time/workload
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7.3 2017 End of Trial Interviews 
Seven interviews with eight healthcare practitioners were recorded over a four month period 
between February and May 2017 (see Table 44).  One interview was a joint discussion with a 
practice nurse and receptionist; the others were one-to one interviews.  Four interviews were via 
telephone and three were face to face.   
Four interviews were performed by Interviewer 1 (myself) and three by Interviewer 2 (Dr Dania 
Shoeb, a GP trained in Qualitative Research). Both researchers had no previous direct contact with 
their allocated primary care practices.  
The interview duration ranged from 6 min 46s to 24 min 28s.  The interviews were subsequently 
transcribed and thematic analysis was used to identify important commonalities and differences 
within provider accounts. 
7.4 2014 Pre-Trial Interviews  
I wanted to use my 2017 end of trial interviews data to expand upon data from interviews 
conducted by the Qualitative Researcher Lorna Sweeney in July-October 2014 with 20 primary care 
staff from 14 practices (6 practices in Bradford, 8 practices in London).  Nineteen were telephone 
interviews, with one participant interviewed face-to-face.  Participants included: 
• 5 General practitioners 
• 4 Practice managers 
• 4 Practice administrators 
• 3 Healthcare assistants 
• 2 Practice nurses 
• 2 Practice IT leads 
All study procedures were approved by the Research Ethics Committee at Queen Mary, University of 
London (No. QMREC2012/02). All participants provided verbal consent to the recording of their 
interview. Topic Guide for these interviews is in Box 2.  Recordings were transcribed by Lorna 
Sweeney and identifying information removed for written transcripts. However, primary care 
practice identification was made available to me and one practice (Practice C) provided staff for 






7.5 Thematic Analysis 
I explored the key topics from the responses to my 2017 end of trial interviews, and then used these 
to expand on the similar topics covered in the 2014 responses to build a thematic analysis of 
interviews with interventional practice staff at two timepoints in the trial. 
The topics that were explored in both sets of interviews are found in the Interview Topics Box-out. 
 
7.6 Theme 1 Practice Background in Research 
7.6.1 2014 Interviews 
2014 participants were asked about the motivators for the practice to become involved in the 
HepFREE trial.  For many interviewees, stated that the practices viewed the study as being very 
relevant to their patient population as they had a high volume of patients who met the eligibility 
criteria, and that this intervention had a role in reducing long-term health problems for their 
patients.  There were anticipated benefits to patients which outweighed the burden of introducing a 
new screening programme.  Some staff were surprised by the number of eligible patients identified 
at their practices: 
 “I think we were shocked really at how many people from such a wide range of countries it would 
affect. And we have quite a high Asian population, but we’re also getting lots of new patients from 
Eastern Europe as well. So we thought it would be really useful for our patients and help them before 
things get too bad.” 
Practice administrator, Bradford primary care practice ‘2’ 
Another primary motivator was additional funding attained by being part of a research study and 
that this trial was suitable for their practice as it provided financial incentive for recruitment and 
acknowledged the extra strain on time and resources it would involve. 
 “And then the funding has to, it has to cover costs, plus a little bit to be honest. No GP at the 
moment is going to do something for goodwill, purely in research. Because we’re so 
stretched, we just can’t fit in anything else. And money is being eroded left, right and 
centre.” 
GP, London primary care practice 7 
At the time of the Early Interviews, practice staff voiced concerns that other regular duties of the 
clinic would take priority over a research project.  Some interviewees noted that the study activation 
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had been delayed at their location until practice targets (such as annual flu vaccinations) had been 
completed.   
 “We had a lot of other things going on and a lot of changes going on for primary care…And 
so we had to keep switching between that and back onto the Hep and that sort of thing. But 
that was more to do with the timing of how it landed with other national requirements that 
were going on.” 
Practice manager, Bradford primary care practice A 
“We’ve only sent a hundred [letters] out, because obviously with it being flu season, flu 
immunisations and stuff have to take priority.” 
Practice administrator, Bradford primary care practice N 
 
7.6.2 2017 Interviews 
Interview participants were asked about how much experience their practice and they themselves 
had in clinical research.  Two interviewees described their practices as research practices, with one 
identifying their surgery as part of a primary care research network.  Their previous experience in 
participating in clinical trials was a particular help in consenting patients for testing.  For some of the 
healthcare providers the HepFREE trial was their first personal experience of providing care in the 
context of a clinical trial.  This did not appear to impact recruitment outcomes – practices with no 
previous research experience were among the intermediate and high recruiters.  One lead GP felt 
that as a research practice (who delivered a high recruitment outcome) they were especially 
interested as the topic was relevant to their patient population.      
"I like breaking myths of “you can’t do research with people who don’t speak English as a second 
language, or who don’t speak English, or that Bengali populations are not going to come forward”.  
"Research is a challenge... What went well was it was a topic that is topical and relevant to this area" 
Lead GP, London, Practice C 
 
In the 2017 interviews, the benefit of the practices being part of a research network was 
highlighted, and although the extra work caused by the HepFREE trial was noted, most 




7.7 Theme 2 HepFREE Trial Set-Up 
7.7.1 2014 Interviews 
Technical problems in developing the bespoke search terms the HepFREE team used to identify 
eligible patients on electronic patient records led to a delay in initiating the trial at some practices.  
There were further problems in and then monitoring screening uptake of recruited patients which 
meant search terms changed several times, causing confusion amongst primary care staff.   
In 2014, several interviewees voiced frustration at some the early search design problems and felt 
this led to additional workload for practice staff.  One IT lead created their own solution 
 “The searches that they built were totally incorrect; they haven’t been able to identify the 
patients or taken into account anyone who declined to be tested for the study, or anyone 
who has already got hepatitis diagnosis. Now I’ve reported that to them and to our IT 
department multiple times, but they’ve not bothered to update the searches to take any 
consideration for...So we’ve had patients being rung three or four times to come for 
appointments and they’ve got a hepatitis diagnosis already, or they’ve already declined to be 
in the programme. It’s quite a big problem really and I don’t think we’ve got feedback or help 
regarding that at all…I ended up having to build my own searches to filter all this stuff out” 
Practice IT lead, Bradford primary care practice C 
Some participants voiced concern that the research team did not have a good understanding of the 
software already used in primary care practices and had not adequately tested the search terms in 
advance of implementing them at the practice.    
“There seems to be some sort of issue with the software, but I think that really should have 
been sorted out initially. And one issue is they clearly don’t have access to an EMIS computer 
so they can’t really even test it on fake patients”.  
GP, London primary care practice M 
 
7.7.2 2017 Interviews 
In the end of trial interviews, participants reflected upon how the trial set-up had affected delivery 
of the study at the practice.  Many interviewees felt having a specific lead GP was beneficial to 
provide direction.  As the trial intervention was delivered over an 18 month period at each practice, 
the range of staff allocated to the study included Healthcare assistants, Data Quality mangers and 
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practice nurses as well as the Practice Manager.  At one practice a medical student was recruited to 
assist with phlebotomy, and their duties included blood draws for the HepFREE trial.  This had the 
effect of more staff groups feeling involved in trial delivery. 
The HepFREE team provided a training session to each practice prior to activation in the trial.  This 
included training on viral hepatitis, the consent process and explanation of the trial objectives.  Lead 
GPs were tasked with cascading this information to new staff involved in the trial, and the HepFREE 
team were also available to repeat the training session if required. 
Some variability was noted in the interviewees’ experiences of the training process.  Most of the 
participants reported a good training experience, highlighting that staff felt well informed about the 
trial and the consent process. 
“We were well informed… training felt well done from start to finish.” 
Healthcare Assistant, Bradford, Practice A. 
“Training experience was good… it was education, plus highlighting the importance of the research 
and how to do it” 
Lead GP, London, Practice E 
However HCP participants at one practice recognised that there were some gaps in their training – 
highlighting that this made it more difficult to explain the reasons for the trial to patients.  At this 
particular practice the Lead GP recognised that cascading training model had not worked for them, 
and although the practice felt well supported by the HepFREE team, they struggled to ensure all staff 
were aware of the trial intervention and how to recruit patients. 
 "We had no training… (I'd have liked) a half day telling us the reason why we're doing it.  Even 
though I've read it up, tell us why we're doing it - what we're capturing and how it will benefit the 
patients.  So we can express it a bit more to them." 
Practice Nurse, London, Practice C 
"The only people that were trained were me, (plus) the deputy practice manager.  So if (staff) say 
they didn't have any training, cos the training will have been a bit slapdash probably from me.  Was I 
supported?  Yes.  Was the rest of the team supported?  Probably no."  
Lead GP, London, Practice C 
At some practices, the HepFREE team were able to provide additional support from Clinical Research 
Nurses to consent and draw blood from recruited patients.  This staff at Practice C felt that extra 
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support staff were helpful in providing the intervention, but this was not necessarily due to a lack of 
funding but staffing resources.    
“(The HepFREE team) helped us by finding extra support.  It wasn’t usually a money thing, it was time 
thing, and a priority thing.  Would we be happy to take part in a study like this again? Honest answer 
is no.  The amount of work, time, extra effort that I did, I don’t think I’ve got that time now.” 
Lead GP, London, Practice C 
As well as a training session, practice leads for HepFREE were left a “site pack” with information on 
the study which included a manual for the practice and contact numbers of the HepFREE team.  
However, some interviewees felt that this was impractical, too long and not suitable for using to 
consult during the consent process.  Some participants suggested as one-page summary poster to 
simplify the intervention would have been more practical for primary care. 
Key messages from these responses were that all staff groups should be included in training sessions 
to minimise knowledge gaps for HCPs, and the provision of summery posters would be good 
reminders of the key aims of the intervention. 
 
7.8 Theme 3 Delivering the Intervention 
7.8.1 2014 Interviews 
In the early stages of the trial, the process of delivering the intervention, after the initial eligibility 
searches had been completed, was described by the interviewees as “straightforward” and easy”.  
Most practices used a healthcare assistant or nurse as the primary healthcare provider to consent 
and test patients.  These duties were conducted as part of their regular clinic slots. 
The extra workload was noted by some participants as a potential barrier to recruitment, but others 
felt it was less onerous than other previous studies they had been involved in.  Some particularly 
liked that after training and electronic searches had been set-up, the practice was left alone to carry 
out the intervention and valued this autonomous direction. 
 “…it was well communicated. Even from the very start, of putting out the interest, to us 
accepting, to them coming and doing a talk, to then actually doing the clinics, getting trained 
up to do them, and then leaving us alone then, just to do it, and then feedback and the 
results. It’s all been pretty straightforward and smooth.” 
Practice IT lead, Bradford primary care practice E 
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However, not all practices had the staff and resources to match the demand that HepFREE placed on 
their time.  One participant voiced a concern that the HepFREE team should be providing external 
staff to carry out consent and testing at the practice, and if this was not available it may be difficult 
undertake for staff to manage the additional workload of recruiting patients.   
 
7.8.2 2017 Interviews 
Three years later at the end of trial recruitment, interviewees reflected on the resources needed by 
the practices and individual staff members to deliver the interventional screening. A wide range of 
expertise was mentioned, from administrative and IT skills to understanding date input and 
collection.   
The role of an interpreter, or access to translating services at the practice, was one area several 
respondents viewed as being very important for screening migrant populations.   
Languages offered by staff at practices included Bengali, Punjabi and Urdu, and other services 
included a local interpreters and patient advocates as well as the translation service Language Line.  
The absence of an interpreter was identified as reason that patients were not invited to test, as this 
would lead to a longer consultation and or another appointment. 
"If it was a patient that didn’t speak English, obviously we rely on language line, so it would mean 
having a consultation over the phone, which would we mean we would really need a longer 
appointment.  Sometimes patients would come with a relative prepared to translate for them" 
Specialist Nurse, London, Practice D 
Collecting data from the trial involved coding patients as having consented to the trial and provided 
a blood sample with bespoke HepFREE Trial codes.  The results from the blood screening would also 
be recorded in patient records and positive outcome were referred onto the HepFREE team for 
follow-up to be arranged.  Data collection proved more burdensome for some practices than others, 
particularly those without a data manager.  Collection of HepFREE recruitment and outcomes was 
described as “straightforward” by two of the interviewees, both of whom were from practices were 
administrative staff were used to inputting data, or had a data quality manager.  Another practice 
respondent felt the process took longer to document than non-trial data, and another respondent 





7.9 Theme 4 Recruitment to the Study 
7.9.1 2014 Interviews 
Recruiting patients for screening 
One of the biggest challenges faced by primary care practices was patient recruitment to the trial.  
At each practice, all identified eligible patients were invited by letter to screen for viral hepatitis. 
Practices were randomised to a standard invitation letter or an enhanced invitation letter which 
included a Patient information Leaflet (PIL) on viral hepatitis.  Letters and PILs were written in the 
spoken language of the individual patients (according to their demographic data at the practice).   
At the early stage interviews, the screening invitation letter was not perceived to be the most 
effective way to recruit patients. Participant felt that the patients are generally unlikely to read or 
act upon screening invitations, and also voiced a concern that this particular target population (at 
risk migrants) were likely to be mobile and may not receive the letter.  Interviewees also thought 
knowledge of viral hepatitis to be poor amongst the target populations and therefore recipients may 
not identify themselves as being at risk of the infections, especially if they have UK residents for 
some time.    
Interviewees felt that the HepFREE enhanced letter invitation was too lengthy and dense in its 
content. 
Telephone invitations and opportunistic testing were highlighted as being more efficient and 
successful methods of recruitment to screening tests and health engagement generally.   
“So what we did was we sent out letters to anybody that was in this list. But some patients 
didn’t even read it. Because when we said, “Oh, you would have got the letter”, they didn’t 
know what we were talking about. Because we find that at our surgery, that letters don’t 
make much of a difference. We find that if we ring somebody up and talk to them about 
something or we talk to them face-to-face, that makes more of an impact. So with regards 
to, I’ll give you an example, our flu uptake is 97 per cent…So we don’t write to anybody at all. 
It’s done through, when they come to see either myself or the nurse, if it’s coming up to flu 
season we’ll say, “Oh, you need to see the nurse at this time”. The practice manager is quite 
good at getting people to come in for things. So that’s what we were doing, what we’ve been 
doing for HepFREE as well.” 
GP, London primary care practice H 
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Other participants felt that the HepFREE screening invitation letter needed to be tailored to the 
needs of their local patient population, and should include contact numbers of specific individuals at 
the practice who could be contacted for more information.   
One participant expressed frustration that he had asked the research if the letter could be altered 
but was advised this would require a protocol amendment to be assessed by the ethics committee 
for only one individual practice.  Another participant mentioned making changes to the letter but did 
not say if permission from the research team had been sought for this.   
“We would not send this quality of letter out to our patients normally. [In previous studies] 
we’ve been able to comment on letters that went out of the practice and we have made 
suggestions which have been adopted”.  
GP, London primary care practice L 
“We made a few very tiny changes to the letter. We personalised it…we put the healthcare 
assistant’s name in it. And then we specified who they should contact if they had any 
problems” 
GP, London primary care practice M 
 
Practices differed in whether they sent patients translated versions of the screening invitation letter 
in their spoken language, which is likely to have influenced uptake.   
 
Some practices were enthusiastic about opportunistic testing, which the research team were able to 
facilitate by providing a prompt on the practices’ electronic patients records software.    
Interviewees who had used opportunistic testing for other screening tests said the prompt reminded 
them to ask eligible patients if they would like to participate, and felt this face-to-face approach 
worked better in encouraging patients to participate.  They also felt it would be easier to offer 
HepFREE testing if it was bundled with other blood tests the patients required. 
 “For all those people who we were going to invite, we asked Y for the HepFREE people to put 
an alert on the computer to say that they are eligible for having this. So it makes much more 
sense if they’re in front of you, or you’re speaking to them to say, “If we’re doing your 
diabetes, would you also like this blood test?” So I think that’s helped.” 
GP, London primary care practice F 
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“I mean most people would require a routine blood test at some point anyway and then we 
would just ask them whether they wouldn’t mind adding an extra one onto it. So that way we 
could just integrate it into our usual practice really”.  
GP, London primary care practice M 
 
However, one participant pointed out that their practices would not have the capacity to 
opportunistically carry out screening for the HepFREE study, because staff would not have the time 
to go through the consenting procedure with every patient who appeared eligible.  
Consenting patients for the study 
Concern was voiced by some participants that the consent procedure was too arduous for the 
patient population as individuals had to provide initials to multiple paragraphs and a final signature 
at the bottom of the consent form.  Problems arose with those patients who did not speak English as 
a first language and led to longer consultations and a patient who may have placed an X instead of 
their initials.  However the majority of interviewees felt of patients were happy to provide consent 
once the study had been explained to them, and were comfortable with providing a blood sample 
for the study.   
Two of the interview participants suggested that patients may not fully realise that they are signing 
up to be part of a study, as the intervention simply consisted of a blood test taken by the practice 
healthcare assistant or nurse, as per usual, rather than by an external party or research team.   As a 
result it may be more difficult to obtain written consent than verbal consent. 
“…if we say, “Look, are you happy to do this? And you sign the blood test to say you’re fine to 
be in the trial”. They look a bit perplexed as to why I’m asking them to sign a piece of paper 
to have a blood test, because you never do that normally for a blood test. So at times I think 
we might be missing that consent. But verbal consent is certainly there and putting out your 
arm, and they’ve turned up with this letter in their hand, saying they want to have a blood 
test and be part of the study.” 






7.9.2 2017 Interviews 
7.9.2.1 Recruitment methods 
In 2017, the interviewees were asked to reflect on the recruitment experience, which was ongoing 
throughout the 18 months screening period at each practice.  In anticipation of a large number of 
responses to the letter, some practices opted to stagger the letter mail-outs.  One interviewee felt 
this was a good way to manage a potentially large number of trial participants. 
"Rather than sending them all at once we staggered it, so we would say I don't know, a hundred a 
month, but rather than sending out the whole lot at once and being inundated” 
Specialist Nurse, London, Practice D  
Interviewees felt that although some patients responded to the letter, it did not necessarily 
encourage them to consider testing.  Sometimes the response was to enquire why the letter had 
been sent to them, or what the patient information leaflet meant. 
"A few came in with the letter asking "What does this mean?", so yeah the letters had a response".   
Practice Nurse, London, Practice B 
 
"There was quite a lot of information for them to take in.  Now if we’d sent out a letter saying they 
need a blood test for this, we’d have got a phone call and they’d have booked in straight away.  So 
from a patient’s perspective I think it was too much information for them.” 
Healthcare Assistant, Bradford, Practice A. 
 
If patients did not respond to an initial letter, some practices opted to send out the letter invitation a 
second time.  Others preferred to use a text invitation, or to phone patients directly.  Due to a 
HepFREE screening prompt on the GP electronic patient records, eligible patients were also offered 
opportunistic screening if they attended the practice for another reason.  Interviewees were asked 
about their perception of the success of each of these methods in recruiting patients.  Some felt that 
literacy may limit understanding of a letter invitation, or that patients may ignore letters, and 
therefore opportunistic screening would be a better recruitment method for those patients who did 
not respond to letter invitation. 
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 “(Patients responded to) opportunistic testing, because a lot of them do not speak English very well, 
so they don't understand the letters." 
Healthcare Assistant, Bradford, Practice A. 
"I don't think the letter worked because all we did was batch and print the letter.  I think where 
they'd come in for something else, and we'd spoken to them, that's what made more of a difference."   
Lead GP, London, Practice B 
"We did it opportunistically.  We have an alert on the computer and it says “Patient eligible for 
HepFREE study”.  So at the end of my consultation with them, I would ask them about it.  The 
prompts were for people that ignore letters, they don't do letters.  Either they can't read it, or they 
can't be bothered." 
Specialist Nurse, London, Practice C 
In contrast, telephone and text reminders were not felt to be a good way of inviting patients to 
participate in a study, with only one of the represented practices using text reminders, and one 
other practice using a telephone reminder.  
“With such a huge list of eligible patients it would have been difficult to arrange phone calls." 
Practice Manager, London, Practice F 
Some of the interviewees felt that although the practice offered tests for viral hepatitis prior to the 
HepFREE study, this trial increased the awareness amongst the local patient population, noting that 
some patients had asked to be tested due a relative or friend telling them about the trial.   
“Patients have spoken to one another and then actually come in and asked for the test”. 
Lead GP, London, Primary Care Practice B 
 
The electronic prompt on patient records was helpful in reminding clinical staff of patients’ eligibility 
for the study 
"Our role was to look at the alert, and encourage patients to go for the screen." 





7.9.2.2 Process of Recruitment 
During the recruitment process, primary care teams were encouraged to liaise with the HepFREE 
Trial team for any support required in delivering the intervention.  This included administrative 
issues in sending out letter and texts in order to invite patients for testing, referring positive viral 
hepatitis outcomes to the HepFREE team for a secondary care appointment, and additional IT and 
phlebotomy support if required.  Interviewees were asked to comment on their communication with 
the Trial team regarding recruitment and follow-up for patients who tested positive for viral 
hepatitis.   
At some practices, a data quality manager facilitated the referral to the HepFREE team. At others, 
the practice manager was tasked with ensuring the administration of the referral process was 
completed in a timely fashion.  One practice manager noted that the IT support from the research 
team helped to modify the HepFREE trial search so that positive patients were not identified, which 
made her daily duties more efficient: 
“(The trial manager) showed me something on the computer to tweak the search.  That made my job 
a lot easier." 
Practice Manager, London, Practice F 
The three GPs interviewed all commented that they appreciated confirmation of a referral (including 
date and time of appointment) when it was made. 
"I would generate a referral on the EMIS system and I emailed it across … and I got a response back 
to say we’ve got your referral.  I think that’s one of the things that’s useful, just an email back to say 
that we’ve got your referral and the patient is booked in on this date.  The reason why it was useful 
was that then I can make sure that the patient went to that appointment, if I know when it is.  
Because you’d given us a pre-populated… like a template we could use that we could populate 
ourselves, the referrals process was very easy. " 
Lead GP, London, Practice E 
 
7.9.2.3 Consenting Patients for Recruitment 
As part of the ethical approval for the HepFREE trial, patients were required to provide written 
consent as part of the recruitment process.  This involved a healthcare professional explaining the 
trial, the reasons that an individual patient was eligible for recruitment, the process of providing a 
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blood sample for testing and how results would be delivered, as well referral for further assessment 
at the local hospital if the test result was positive.   
If the patient was agreeable to participation, they were required to provide initials and signature to 
a written consent form outlining the above.   
Although most of the practices had reported previous research experience, for individual staff 
members, consenting was a new process.   
"At first it seemed very long, it was new to us.  So, because (the HepFREE research fellow) was very 
informative with us, we wanted to be making sure they (patients) understood it all.  So yeah, first 
week it seemed like it takes ages, after that it was very quick."  
HCA, Bradford, Practice A  
At other practices, staff were more comfortable with consenting patients and one nurse and one GP 
both described the process as “straightforward”.  Having written information in patient’s own 
languages was highlighted as allowing a smooth consenting process.  
 
“The patients were given the information leaflet to read and where it was in different languages, 
that was the best thing about this study.  All of the documentation was available in different 
languages, I think that was a really big deal, because patients were able to read things for 
themselves.” 
GP, London, Practice B 
Although staff generally found the consenting process straightforward, they did note a small number 
of patient declined at this stage.  Interviewees perceived that the reasons for declining were (i) 
language barrier, (ii) poor understanding of the study, (iii) paperwork created a more formal 
approach and therefore patients declined to provide a signature. 
The majority of patients were not put off by having a blood test as part of the study, and some GPs 
felt that patients were encouraged by the fact of having a blood test as part of the study. 
"Patients were quite happy to have the blood test and thought it was very valuable.  Some patients 
like screening.  You either get a group of patients who don't like to be screened, who don't want to 
know about their health.  And then you've got the other group of patients who are really proactive, 
who want every test you can offer them." 
Specialist Nurse, London, Practice D 
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"Patients from Asian-type countries, they like to have a blood test!  The fact it was a blood test 
wasn't an issue. Some patients didn't go to do the blood test, I don't think that they didn't go because 
it was a blood test, I think they've not gone because they just did not have time to go." 
GP, London, Practice B 
"Here people like a blood test, they don't mind.  That’s what I sold.  “You will get a blood test and it 
will either be a positive or a negative.  Hopefully it will be negative.  We assume it will be negative.  
However, if it’s positive there are things we can do.”  So I think that they did not mind a blood test." 
GP, London, Practice C. 
 
Across the 2014 and 2017 responses, it is notable there is a lot of similar themes emerging.  
One aspect was that the letter may not have encouraged patients to test, either being 
ignored or not fully understood, and including too much information.  Opportunistic 
screening was again highlighted as a preferred method of recruitment, whereas texts and 
telephone calls were felt to be too laborious for staff.  Support from the HepFREE team and 
confirmation of receipt of referrals were also highlighted as being important aspects of the 





7.10 Theme 5 Perceptions of Benefits and Outcomes 
This topic was only covered in the 2017 interviews.  Practice staff members were asked about their 
perception of the outcome of the trial at their practice. 
Staff from high-performing practices recognised that their practice recruited patients throughout the 
trial period and as a result some patients were newly diagnosed with viral hepatitis. 
"I think we participated well as a practice, and I think our patients were quite engaged, and we were 
able to engage the patients very well.  (We were able to) let them know what Hepatitis is" 
GP, London, Practice B 
"It was one of the ones where we could really see the benefits of doing it, because we were detecting 
patients who had Hepatitis B or C" 
Specialist Nurse, London, Practice D 
 
One interviewee from an intermediate performing practice perceived their recruitment to be good, 
reporting many patients attending for screening, in response to over 2,500 invitation letters.  At a 
lower performing practice, the lead GP felt that the practice’s low involvement in the study was due 
to other priorities.   
"(Practice) participation was pretty minimal really.  GPs have so many things to juggle from HIV to 
diabetes to depression, there's always something we need to be thinking about with every patient.  
So I don't think it's had any long term benefit". 
GP, London, Practice E 
 
When HCPs were asked of their opinion on the benefits of screening study to patients, responses 
were mixed and may have reflected the practice’s outcomes.   
“(That’s) hard to measure.  Because we're in a high prevalence area, (viral hepatitis) is on our minds 
anyway.” 




Other HCPs felt there was material benefit to those individuals who tested positive as part of the 
study: 
"I think this was a study that benefitted the practice, and the patients and the general population in 
the area. Patients that we screened as positive, if it wasn't for the study, they wouldn't have been 
picked up... (such as) Asian housewives that have only had one partner, no high risk activity, no 
operations, had been here for 20 plus years, no reason for us to test them for hepatitis" 
GP, London, Practice B 
"I think it's really beneficial, obviously hepatitis is serious isn't it? Any study that picks up a condition 
that is probably going to impact a person's life later on is really important". 
Specialist Nurse, London, Practice D 
Other interviewees commented that this study was an opportunity to not only test for viral hepatitis, 
but also to educate the local migrant population about liver health.   
"Educating them about … another problem that can occur later on in life." 
Practice Nurse, London, Practice C 
"We have a lot of South Asian patients, people from Pakistan.  I think that in certain areas of where 
we live and for this population here…we should screen.” 
Healthcare Assistant, Bradford, Practice A 
 
The practices were updated on their recruitment numbers on a monthly basis during the HepFREE 
trial.  Interviewees reflected on the perceived benefits to practice staff as the results emerged, and 
at the end of the trial.  
"Since doing the study I think about it (testing) more than I used to.  So if I’m doing sexual health 
screening, doing a blood test for HIV, I’ll ask them, the patients, about hepatitis b and c as well”.  





"And I think it’s…  sort of normalising it – it’s an infection that’s out there, it can treated, it can be 
managed and it’s not something you need to be asking for testing for in secret or be ashamed to ask 
for."   
GP, London, Practice B 
"For us it was more work!  It was good to interact with the patients, find out a bit more about their 
family life, where their parents are from.  For the nurse to get a bit more understanding of the 
patient and where they come from.  But it was extra work." 
Nurse, London, Practice C 
"I'm from a Bengali background, so it made me think “Oh my Mum could be one as well”, so I 
encourage patients that way.  So it's taught me on a personal level." 
Receptionist, London, Practice C 
Some of the GPs however did not feel the trial would have a long-term impact on primary care 
screening, or that the trial provided a new testing approach for their patients. 
"We're already screening for viral hepatitis.  Are we opportunistically screening every Asian, first 
generation in the practice?  No.  And that’s because we’re told how much money it costs to do blood 
tests and to try and reduce that, and we’ve been saying “Don’t do LFTs, do ALT”. " 
GP, London, Practice C 
"The study was fine.  There was nothing special about it.  It was just another study that we 
participated in." 




7.11 Theme 6 Perceptions of challenges 
This topic was only covered in the 2017 interviews.  Interviewees were asked about their views on 
the challenges of recruiting to a screening study in primary care, and of providing viral hepatitis 
screening for migrant patients registered to their practice.  Healthcare Providers were asked about 
the level of staff involvement because of the research trial at the practice.  All interviewees reported 
that local staff were involved in the study – at one practice a medical student was also a member of 
the research team.   
"All the clinical team were involved.  Healthcare assistant saw patients.  Practice manager sent out 
invites, HCA did consent and blood test.” 
Practice Manager, London, Practice F 
Participation was pretty minimal.  The manager and the data person did the searches and liaised 
with GPs when the results came back.” 
GP, London, Practice E 
"Medical student would do the consent, explain to patient what it was, do the blood test, fill out the 
template.  The results went to the doctor…if there was a problem he would come to me… I did most 
of the follow-up.” 
Specialist Nurse, London, Practice D 
 
Increased demands on time were highlighted as one aspect of the trial experience that could have 
been improved for clinical staff, although at the same practice administrative staff were able to 
balance the research workload with their usual duties. 
"It could have gone better if we had the time to implement it, because most of the patients we saw 
didn’t come for that appointment, they came for other things." 
Practice Nurse, London, Practice C 
 
"From my side it went well, because I have the time to do it.  I had time to call up each patient and 
explain to them and everyone in reception was supporting as well.  They were doing their own thing, 
looking at the alerts as well.” 
Receptionist, London, Practice C 
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One GP interviewee from a high-performing practice was very positive about the experience of being 
involved in the trial. 
"I think it’s something that should be part of a national programme because it’s raising awareness 
and I think it’s reducing rates of certain diseases. I think that the hepatitis screening should be made 
as part of your standard health check and the GP practice is the ideal place to do it." 
7.12 Discussion 
This qualitative study of healthcare professionals’ opinion on testing for viral hepatitis in primary 
care across two timepoints gives us a unique insight into the challenges in providing this type of 
screening in GP practices.  Over the course of these interviews across three years, pre and post 
screening at intervention practices, healthcare professionals have been able to share their 
experiences of engaging patients in a clinical trial, their understanding of viral hepatitis, and their 
opinions on the barriers and facilitators to testing in this setting. 
Several key themes linked into what Primary Care services need to provide viral hepatitis screening – 
financial incentive, appropriate skillset and numbers of staff, and provision of training.  Across both 
sets of interviews, HCPs alluded to the challenges in providing screening with limited resources and 
time. 
The main HepFREE screening outcomes showed that incentivising practices financially leads to 
higher uptake than practices in the control arm, but even within the intervention arm there was 
considerable variation in uptake.    Recruitment of patients was challenging for practices, despite the 
perception of staff from the intermediate or lower performing practices that they had performed 
well.  Essentially their perception was within a vacuum as the staff had no insight into the 
recruitment outcomes for any other practice in the study.  Financial incentives may help practices 
identify ways in which their particular service can be more successful at recruiting patients for a viral 
hepatitis blood test. 
One key aspect of the post-trial interviews is that a wide range of staff were involved in delivering 
screening, and all the practices required the involvement of dedicated healthcare assistants as well 
as admin staff.  Some participants felt their practice was hampered without a data manger, 
underlining the importance of good information governance and IT support for a large scale 
intervention such as this.  The role of the HealthCare Assistant can often been overlooked in Primary 
Care, but at several practices they were key member of the research team – responsible for 
recurring and consenting patients as well venepuncture and sample collection. 
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Additional staff resources would undoubtedly help many of the services we interviewed, but for this 
particular patient population, an interpreter (or a staff member with the appropriate language skills) 
was a real boon to the recruitment and consenting process, making the trial accessible to the key 
population of first generation migrant. 
There was little enthusiasm for the invitation letter as a method of recruitment either before or after 
the screening period, with most practitioners stating that they preferred an opportunistic approach, 
prompted by an electronic records alert.  The simple, cheap and straightforward intervention of 
identifying at risk patients and setting an electronic alert for their blood test was a familiar aspect of 
care for clinicians.   
One potential barrier to recruitment in the HepFREE trial which would not be present in real life 
screening was written consent.  Small numbers of patients were reported as declining the consent 
process due to language barriers and poor understanding of the trial.  This data was not collected as 
part of the trial dataset but may have been a factor in poor recruitment in some practices without 
interpreter facilities on site. 
Interestingly, opinions were mixed on the benefits of screening, indicating that even after training 
sessions and an extended period of incentivised screening, many primary care practitioners do not 
perceive screening to be beneficial for their local population, although several noted benefits to 
individual patients. 
The main limitations of this study were the limited responses to call for interview participants, even 
after the offer of £50 incentive.  There may have been an element of “HepFREE fatigue” across the 
14 invited GP practices.  All of them had been involved with the HepFREE study over a three year 
basis this point and staff had had multiple contact with the HepFREE research team.  They may have 
felt their contribution to the study was at end after data collection and closure.  Also, the interviews 
were recorded between 1-2 years after the trial had concluded at the practices, and in some cases 
recall of experiences may have been affected by the passage of time. 
The HepFREE provider study shows that the voices of primary care clinicians and healthcare 
professional should play an important role in the shaping of future viral hepatitis case-finding 
programmes at both national and local level.  GPs have a key insight into the ability for their services 
to provide the service delivery needed to test migrant populations in their care, and any additional 
workload for primary care should be attached to a financial incentive and / or the provision of 


















The HepFREE trial was developed to determine the feasibility of testing migrant populations for viral 
hepatitis in primary care and to determine the best location of follow-up for those testing positive 
for HBV or HCV infection.   
My role in the trial was as Clinical Research Fellow for the East London and South London sites.  I 
was also trial manager for the trial in its latter two years. 
I have presented the data analysis of the whole HepFREE trial which I collaborated on with the 
HepFREE statistics team.  I have also presented my own analysis of other HepFREE data outcomes 
for disease staging, community vs standard follow-up clinics, pre-trial surveys of eligible patients and 
their subsequent testing uptake, and qualitative interviews of healthcare professionals delivering 
testing. 
In this chapter I will summarise the findings of the HepFREE trial and associated sub-studies and 
discuss how this adds to our current knowledge of viral hepatitis testing strategies.  I will explore 
what the research findings tell us about barriers and facilitators to screening for viral hepatitis in the 
migrant population. 
I will also discuss how the HepFREE outcomes can inform future plans to achieve the WHO goal of 
viral hepatitis elimination by 2030 (1). 
The objectives of my research were: 
1. To determine the screening rate at practices where GPs are supported and incentivised to 
screen migrants for viral hepatitis, compared to standard screening rates 
and through my own sub study analysis 
2. To determine the range of disease staging of those testing positive for viral hepatitis in 
primary care  
3. To determine if community-based follow-up and management is superior to standard 
hospital-based follow-up 
4. To analyse the outcomes of the pre-trial survey of eligible patients on their understanding 
and knowledge of viral hepatitis, and if this influenced their attendance for screening 
5. to explore the views and opinions of healthcare professionals on their experience in 




8.2 Outcomes of the HepFREE Trial 
Previous studies and modelling data have suggested that screening immigrants for viral hepatitis is 
both clinically effective as well as cost-effective (114)(86)(43).  However these studies were 
performed on a small scale in local populations with well-motivated clinicians.  Similarly sized studies 
have also shown that (between 40-75 %) of patients would be referred for therapy(5).  This evidence 
prompted the UK National Institute for Health and Care Excellence  NICE) to issue guidance in 2012 
recommending the testing of migrant patients for viral hepatitis in primary care settings (3).  
However the uptake of this guidance has not been tested in the UK.  HepFREE was the first national, 
large scale randomised control trial to assess primary care testing rates of migrants in the UK. 
 
8.3 AIM 1: To determine the screening rate at practices where GPs are supported and incentivised 
to screen migrants for viral hepatitis, compared to standard screening rates 
8.3.1 The HepFREE Screening Trial 
HepFREE was a large-scale randomised control cluster trial designed to measure the frequency of 
viral hepatitis testing in primary care in England and compare this to the uptake from the 
intervention of incentivising GPs to invite patients to test.  Other outcomes looked at the current 
prevalence of viral hepatitis in immigrants and outcomes in a secondary trial of comparing 
attendance at follow-up standard of care hospital setting versus follow-up in a community based 
service.   
Overall testing uptake was 1% in control practices (where only educational updates were provided) 
and 19.5% in interventional practices (funding and support provided), indicating that incentivising 
GPs with financial rewards and providing additional resources can make a considerable impact on 
testing rates.  Indeed, without such incentives, the national guidance(3) for viral hepatitis screening 
is not adhered to.  However even with incentives testing rates were lower than testing projections 
(estimating 40% of the population would be tested).  
This uptake is a new finding which has not been previously determined for this population in primary 
care. 
People from Pakistan were more likely to attend for testing, perhaps reflecting engagement of 
general practitioners based in high density areas with such patients (especially Bradford) but across 
all the sites, testing of patients from other ethnicities was poor.  Older patients (age > 40 years) were 
also more likely to agree to testing, perhaps reflecting their higher attendance at primary care. 
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Prevalence rates for both HBV and HCV were around 1%, however viraemic HCV was 0.3%.  This is 
lower than previous estimates for HCV(174) in the migrant population in the UK and in relation to 
previous prevalence studies listed in Table 3, the prevalence rates in the HepFREE trial sit at the 
lower end of the scale for both HBsAg and HCV RNA.  This is a new finding for migrant populations in 
the UK and would suggest that in this country the overall viral hepatitis burden amongst immigrants 
is lower than expected.  However, there is higher prevalence in particular sub-groups, such as  
patients from Pakistan.  Despite the lower than anticipated prevalence, these values still justify 
screening in the UK migrant population with the advent of the new cost-effective DAA therapies.  Of 
note the HepFREE prevalence rates were most similar to those found in screening migrant patients 
with tuberculosis (99), suggesting that a combined infectious disease screening of targeted migrant 
populations could be time-efficient as well as cost-effective. 
 
8.3.2 Invitation Letter 
The HepFREE trial also tested the use of a bespoke invitation letter (including details of viral 
hepatitis, risks of hepatocellular carcinoma and reasons for the invite) versus a standard invitation 
letter.  This was the first (to my knowledge) large-scale randomised trial of specifically tailored 
invitation letters in a primary care setting.  An enhanced letter did not encourage of uptake of 
testing compared to a standard letter (3.7% vs 4.5% response within 31 days), and of note the 
invitation letter overall had a poor response from invitees.  As providing an enhanced letter was a 
costly intervention, it is not a recommended approach in inviting eligible patients. 
 
8.3.3 HepFREE Community vs Standard Follow-up Trial 
The HepFREE trial design included an embedded study of community treatment vs standard 
treatment, to my knowledge the first such study of viral hepatitis management for migrant 
populations.  
However setting up community clinics in busy GP practices proved to be more challenging than 
originally anticipated, with logistical problems such as room availability, local agreement with GPs 
and transport of expensive DAA therapy from secondary care centres delaying the initiation of this 
part of the trial. 
Patients who were allocated via cluster randomisation to the community care arm and asked to wait 
until treatment could be arranged in their local centre were either not willing to delay therapy and 
management or would not consent to community therapy.  Along with the incremental availability 
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of new DAA therapy for treatment of HCV during the HepFREE trial, these difficulties prevented the 
completion of a fully powered study. 
 
However the outcomes of the adherence to medical advice and therapy in the immigrant population 
screened in primary care were excellent, whether attending hospital or community based clinics.   
 
Although this sub study was statistically underpowered, the data suggests engagement with hospital 
based clinics (85.4% attendance) was excellent and there are very unlikely to be any benefits to 
offering community based clinics instead (81.1% attendance).  Given the extra costs, staffing and 
logistical arrangements required to provide community clinics it cannot be recommended for 
immigrant patients with HBV or HCV infection. 
Community based therapy would be better targeted at other populations at risk of viral hepatitis 
such as people who inject drugs(175). 
 
8.3.4 Strengths and Limitations of the HepFREE Trial 
The strengths of the HepFREE trial were the large study population (a total of 90,250 eligible patients 
across control and interventional practices) and the large number of GP practices involved in 
recruitment at Bradford, East London, South and Oxfordshire (for the low prevalence study, data not 
reported in this thesis).  The use of cluster randomisation also provides benefits such as increased 
administrative efficiency for a population of this size, and reduced risk of experimental 
contamination (with practices being randomised to either interventional screening or control, or 
standard or enhanced invitation letters)(176). 
The very low testing rates in control practices was an unexpected finding and reduced value of the 
power calculation for the trial.  However, this did provide a very clear signal that testing for viral 
hepatitis in primary care without financial incentives occurs at background levels, and the provision 








8.4 AIM 2: To determine the range of disease staging of those testing positive for viral hepatitis in 
primary care  
 
The HepFREE trial found a positivity rate of 1.06% for HBsAg and 0.93% for HCV Ab (0.3% were 
viraemic) in a population of 11,929 tested patients from 58,512 eligible migrants living in Bradford 
and London.  Of the 220 positive patients, 128 engaged in diagnostic and imaging assessments.  
 
The 220 positive patients were all identified as part of HepFREE invitation to testing, and therefore 
had not been offered testing based on abnormal liver function tests or clinical evidence of liver 
disease. It is reasonable to infer that these patients were asymptomatic and may not have been 
otherwise tested by their GPs for viral hepatitis. 
 
Of the 128 patients who engaged in diagnostic and imaging assessments, 13 (10.1%) were found to 
have severe fibrosis or cirrhosis, putting them at increased risk of hepatocellular carcinoma.  An 
additional 7 (5.5%) were either HDV co-infected or HBeAg positive, also putting them at increased 
risk of HCC.  These are notable findings and underline that the migrant population is at risk of 
developing asymptomatic severe liver disease due to undiagnosed viral hepatitis infection.  Other 
studies have recognised the trend in increased risk of liver disease in this population due to viral 
hepatitis infection (90,177,178), but this is the first time an asymptomatic population has been 
diagnosed via a primary care testing program.  
 
Since control practices had very low testing rates, asymptomatic viral hepatitis infection may be a 
considerable barrier to testing in primary care, as has been noted in previous research (115).   
 
Prevalence of viraemic HCV infection (0.3%) was lower than expected(2) and skewed towards the 
under 50 years age group, a factor future testing strategies should take into consideration, 
particularly as testing and curing younger patients will have impactful QALYs. 
Engagement with diagnostic and imaging appointments in the positive population was high, perhaps 
indicating that this is a health-aware group who have already responded to the invitation to testing 
and therefore are more likely to follow-up on the result.  These results should be contrasted to the 
outcomes of opt-out testing engagement outcomes (40,100) which are typically lower in 




8.5 AIM 3: To determine if community-based follow-up and management is superior to standard 
hospital-based follow-up 
128 patients who attended their diagnostic and imaging appointments were eligible for 
randomisation for follow-up in the HepFREE follow-up trial.  The 38 patients who tested positive in 
London were analysed in my substudy.  16 were randomised to community care with 22 followed up 
in standard (hospital) setting.   
The data shows that there is no significant difference in engagement between the standard care 
(85.4% attending) and community care (81.1%) arms of the follow-up trial.   
One of the strengths of the study was the opportunity to follow these groups through from testing 
to diagnosis to staging to treatment and management.  The longitudinal nature of this data gives a 
good indication that patient engagement continues beyond the initial diagnosis and that patients 
referred from primary care will remain engaged in follow-up long-term if appropriate. 
The excellent engagement rates in the HepFREE trial are in stark contrast to previous findings of 
undertreatment and poor engagement in migrant populations (79–83) where underdiagnosis was 
felt to be an important contributor.  From the HepFREE outcomes, I would argue that we are seeing 
the ongoing engagement of a health-conscious group of patients: those who have already agreed to 
be tested will continue to engage if they are diagnosed positive and are aware that treatment and 
management is available. 
The main limitation of this analysis is the small numbers of patients who consented to randomisation 
and were seen in the community care arm (16 patients).  Even with this relatively small number, 
arranging community-based care proved to be a logistical challenge.  It should also be noted that 
during 2015-2017 the new DAA therapies were available incrementally on the NHS and therefore 
some patients opted to pursue therapy with interferon (the only available option for HCV Genotype 
3 during 2015 and most of 2016) or wait  until DAAs were available.  Fortunately, since 2018 all 
people diagnosed with Hepatitis C can now access DAA therapy via the NHS. 
This is the first such randomised control trial for standard vs community therapy for immigrant 
patients.  Other trials have found good outcomes for community based therapies for PWIDs, but 
none have previously investigated their role for immigrant patients (179,180). 
From the overall outcomes of the follow-up trial, the data suggests that community-based care is of 
no benefit to this population, and with the difficulty in setting up such a service, would be wasteful 
of valuable staffing and time resources. 
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8.6 AIM 4: To analyse the outcomes of the pre-trial survey of eligible patients on their 
understanding and knowledge of viral hepatitis, and if this influenced their attendance for 
screening 
Previous analysis of the knowledge of immigrants regarding viral hepatitis showed that awareness of 
viral hepatitis and its causes and sequalae was poor (131).  This was supported by qualitative 
interviews with GPs and key informants around knowledge amongst at risk immigrant 
communities(132). 
These qualitative studies examined background knowledge of viral hepatitis in immigrant 
communities and found considerable misinformation about these conditions with confusion about 
symptoms and modes of transmission.  
I analysed the responses of 370 participants eligible for HepFREE screening in pre-screening surveys 
of their knowledge and understanding of viral hepatitis.  In this analysis I was particularly interested 
in understanding if any demographic or knowledge parameters indicated an increased likelihood to 
test.   
Most striking was the similarity of uptake in this group of 370 eligible patients compared with the 
58,000 invited patients in the intervention arm (24.9% and 19.5% respectively).  There were also 
similarities in age groups (32.4%, 27.8% in age >40 years group) and particularly in ethnicities (31.7% 
and 32.5% for Pakistani population, 9% and 11.7% in African populations).   
Other indicators of likelihood to attend for testing were knowledge of treatments and having a 
friend or family member treated for viral hepatitis.  These were statistically significant and may have 
been driven by a better awareness of viral hepatitis amongst the Pakistani population.  However, it is 
important to note that positivity rates for viral hepatitis are similar amongst Pakistani (2.0%) and 
African populations (1.7%) and so more should be done to improve understanding of viral hepatitis 
risks in the African population.  Mood and illness perceptions did not have an impact on screening 
uptake. 
A strength of this study was that the population was representative of the final screened population, 
with male/female, <40 years and >40 years and Pakistani and African patients well matched. 
However, the African population was made up of individuals originally from a wide spread of 
territories from across the continent and it is not clear if certain African states or cultures are better 
informed regarding viral hepatitis than others. 
There is limited similar data on the predictors for testing in migrant populations.  Previous studies 
highlighted a lack of information on disease and stigmatisation, as well as language being an 
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additional barrier to testing (79).  One qualitative study in the US found that predictors for African 
Americans to attend for testing included having a blood transfusion prior to 1992, perceptions of 
benefits, severity, and subjective norms (181). 
Information campaigns focussing on new hepatitis treatments and the potential risks of undiagnosed 
infection should be targeted at the African community to increase testing rates in this population.  
Such campaigns could be part of a wider drive to educate at-risk populations on the commoner 
causes of liver disease, such as alcohol misuse and metabolic syndrome.   
Previous studies(132) have suggested that low viral hepatitis screening rates may be due to focus on 
employment and limited access to healthcare professionals who can speak the same language. 
Therefore testing campaigns should be led by community advocates who speak appropriate 
languages.  Testing should be made available out of working hours to improve uptake rates in this 
population. 
 
8.7 AIM 5: To explore the views and opinions of healthcare professionals on their experience in 
delivering the HepFREE trial.   
My qualitative study sought the opinions of healthcare professionals on delivering a viral hepatitis 
screening program in primary care.   
Several key themes emerged from these interviews – that GPs require IT and staffing support to 
deliver hepatitis testing, and financial incentives motivate the practice to achieve targets.  
Perception of outcome can be different to the reality, and so comparison with other local testing 
centres may be helpful in supporting underperforming sites.   
For those providing training to primary care it is important to include all staff groups in training, and 
to identify a testing champion.  At various HepFREE practices this was as likely to have been a 
practice manager, healthcare assistant, or specialist nurse as well as a GP. 
The importance of an interpreter was also highlighted as a key concern for primary care staff, in 
order to make screening more accessible to first generation migrants. 




Training sessions should also focus on the benefits of screening, prevention of chronic liver disease 
and HCC and the curative rates of the new DAA drugs.  There were mixed opinions on the benefits of 
screening and it may be that HCPs need persuading that their local population can benefit. 
The strength of this study was the semi-structured interview across two time-points which gives a 
strong sense of how the trial delivery was viewed at the beginning and end of the testing period. 
The main limitation of the study was the poor response to the call for interviewees, with eight 
participants at the end of the trial, compared to twenty before the trial was fully implemented.  GPs.  
This meant that very few of the original participants were interviewed at the start and end of the 
trial to give a true longitudinal view of the provider experience. 
Previous data has suggested that testing outcomes, referral pathways and patient education are all 
more likely to be successful when the GP voice is part of strategy planning for viral hepatitis testing 
(121,182,183), and this qualitative study supports those findings. 
 
8.8 Future Research and Investigation 
The HepFREE Trial and its associated substudies show there is still some considerable work to be 
done to achieve viral hepatitis elimination in migrant populations by 2030.  From the findings, I 
would not recommend there is further research into offering this population community based 
treatment centres.  This would be time-consuming and wasteful of resources.  However we still have 
much to learn about strategies for case-finding eligible immigrant patients from their GP records.  
The use of electronic record searches will be crucial in processing a large amount of data in ne 
efficient and timely way.  Missing data on electronic records will be a barrier to finding patients and 
more work should be done to understand why key demographic parameters such as country of birth 
and ethnicity may be absent in primary care records. 
The testing rate increase seen in HepFREE intervention practices compared to standard practices 
was 1850%, a vast improvement compared with the 60% increase seen in a previous interventional 
study in Australia. (122)  However, as in the Australian study, rates amongst Asian and African 
immigrant patients could be higher.   Future studies should focus on ways of improving primary care 
testing rates in these populations (perhaps by increasing GP training, engaging community leaders 
and offering more education to at-risk populations) rather than care delivery.  Enthusiastic GP 
champions and peer navigators could be a source of local knowledge and support for both 




We did not investigate the role of patient incentivisation for viral hepatitis testing, but other studies 
have looked at the role of financial compensation and travel stipends to encourage testing and 
engagement in at-risk populations, particularly PWIDs (184,185).  However, this has not been 
specifically studied in migrant populations, and it would be worthy of further investigation, perhaps 
in the context of other interventions aimed to improve testing rates.  From the results of our pre-
screening survey I would argue that engaging peer support workers for screening programmes may 
be more effective than financial incentives for a population where improved knowledge of viral 
hepatitis and those affected has an impact on testing uptake.  In the HepFREE trial, patients who 
tested positive went on to engage well in follow-up at both community and standard care settings, 
and I conclude that this population do not require further intervention to support ongoing 
engagement 
It would be valuable to do more work with healthcare professionals to understand the drivers 
behind offers of viral hepatitis testing, particularly in opt-in settings.  Conversations between 
clinicians and patients may be framed by unconscious bias, and I expect that this played a role in 
which patients were offered testing at our GP practices.  Fitzgerald and Hurst (186) highlighted the 
dangers of implicit bias in healthcare which may lead to disparities, and healthcare research carries 
its own cycle of bias (187).  Unconscious bias of the healthcare professionals within a large real-
world cluster-randomised trial such as HepFREE may have led to some patients not being offered 
testing as that process also involved providing written consent.  GPs I interviewed felt that some 
patients were actively seeking blood tests and would be agreeable to testing, whereas other 
healthcare professionals judged the information sheets and consent process to be challenging for 
patients.  The opportunity to explore this through unconscious bias training may help individuals 
reflect upon their own affinity and conformity biases, as well as understanding institutional bias that 











The HepFREE trial data shows that to improve viral hepatitis screening rates in primary care, GPs 
need to be incentivised and should also be offered training and staffing support.  Such interventions 
are clinically effective and cost-effective.  The target population has a prevalence of around 1% for 
HBV and 0.3% for viraemic HCV, which is lower than expected.  However, they are at risk of 
developing asymptomatic severe liver fibrosis or cirrhosis and may not be tested in primary care 
without invitation.   
Barriers to testing uptake include poor knowledge in the target population (particularly regarding 
the new HCV treatments), limited resources in primary care, and lack of priority for viral hepatitis 
testing amongst both the target population and primary care HCPs.  HCPs should be educated on the 
risks of asymptomatic, undiagnosed viral hepatitis. 
Facilitators to testing include a testing champion and training resource at primary care practices, 
financial incentivisation and knowledge of peers who have been treated amongst the target 
population. 
Other models of primary care screening for HCV in the US used similar support mechanisms for GP 
practices, including Healthcare assistant-initiated testing, reflex laboratory-based HCV tests, and 
electronic health record modifications to prompt, track, and facilitate reimbursement for tests 
performed(115).  Future elimination strategies should consider implementing these tools. 
Community based care is of no benefit to the migrant population, although it has been shown to be 
successful for other high risk groups.  In the interests of cost-saving it should not be implemented for 
this population. 
Given the large scale nature of the HepFREE trial, these findings are applicable to immigrant testing 
in the UK and around the rest of the globe.  However, despite the increase in uptake in the 
interventional arm, attendance for testing was less than 20%.  With the WHO’s target to eliminate 
viral hepatitis by 2030, additional measures will be needed to encourage GPs to roll out testing for 
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STUDY SUMMARY/SYNOPSIS  
 
TITLE Chronic viral hepatitis in first and  second generation 
immigrants from ‘at risk’ countries. A controlled randomised 
cross sectional  cluster trial to assess the impact of  identifying, 
screening and treating immigrants with viral hepatitis.  
 
SHORT TITLE HepFREE 
Protocol Version Number 
and Date 
 
8.0 dated 18th August 2016 
Methodology 
 
A controlled randomised cross sectional cluster trial to 
determine how to effectively identify and screen immigrants 
from ‘at risk’ ethnic minority communities as well as assessing 
the impact of primary care on engagement of targeted newly 




5 years  
Study Centre 
 
There will be 58 centres to be utilised over old Primary care 
trusts (including Bradford as well as South and East London), 
known to have a high density of immigrant populations from 




Primary objectives  
• To assess the most cost effective method of screening for 
chronic viral hepatitis in primary care patients within ‘at risk’ 
ethnic minority communities. 
 
• To assess the impact of the interventional approach based 
strategy to screening.  
 
• To establish whether the involvement of community therapy 
is likely to have an impact on a patient’s engagement after 




• To assess differences in treatment adherence between 
patients groups receiving treatment within the community 




• It is postulated that up to 48,000 prospective patients could 
be approached to be screened, with demographic data from 
the control practices to be provided for another prospective 
4,000 patients.  
 
• Up to 3500 of these prospective patients will be contacted 
prior to screening by their GP, to try and collect baseline 
information relating to explanatory models of viral hepatitis 
as well as demographics and other contextual variables that 
relate to screening uptake and subsequent treatment 
engagement, using 2 different questionnaires.  
 
• Estimates indicate that up to approximately 19,200 will 
screened with 3% testing positive for viral hepatitis.   
 
• Up to approximately 580 infected patients will likely be used 
to assess the impact of community care or standard hospital 
care for patient engagement.    
 
Main Inclusion Criteria 
 
• Female and male patients who have been identified as first 
generation immigrants born in a country of high risk or 
second generation immigrants. Please see appendix 2 – for 
the complete listing of countries that deemed high risk (as 
outlined by WHO classification of HBV prevalence >2%). 






For this clustered trial, it is assumed an intra-cluster correlation 
co-efficient of 0.05 for all outcomes and a coefficient of 
variation of cluster size of 0.65.  
We are making three comparisons in this two-stage trial: 
 
Stage 1  
Comparison A: Control vs Interventional screening practices 
gives >80% power to detect a difference from 15% to 40% in 
testing rates at 5% significance level). 
 
Comparison B: Standard invitation vs enhanced invitation gives 
88% power to detect a difference from 32% to 42% in testing 
rates at 5% significance level). 
 
Stage 2  
Comparison C: Standard hospital treatment vs treatment in 
community gives 90% power to detect a difference from 50% 
to 70% in engagement rates assuming 40% of eligible patients 
will be screened and 3% test positive).  
 
Analyses will use appropriate methods to take account of 
clustering. Because of the nature of the outcomes we 
anticipate few missing values so that generalised estimating 
equations should produce unbiased results. For comparison A 
we will also conduct a cluster-level analysis as a sensitivity 
analysis because of the imbalance in the number of clusters per 





Glossary of Terms and Abbreviations  
 
AE   Adverse Event    
AR   Adverse Reaction 
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ASR   Annual Safety Report 
CA   Competent Authority 
CI   Chief Investigator 
CRF   Case Report Form 
CRO   Contract Research Organisation 
DMC   Data Monitoring Committee 
EC   European Commission 
GAfREC Governance Arrangements for NHS Research Ethics Committees 
HRA Health Research Authority  
ICF   Informed Consent Form 
ISRCTN   International Standard Randomised Controlled Trial Number 
JRMO   Joint Research Management Office 
MA   Marketing Authorisation 
MS   Member State 
Main REC  Main Research Ethics Committee 
NHS R&D  National Health Service Research & Development   
PI   Principle Investigator 
QA   Quality Assurance 
QC   Quality Control 
Participant  An individual who takes part in a clinical trial 
PCTU   Pragmatic Clinical Trials Unit  
RCT   Randomised Controlled Trial 
REC   Research Ethics Committee 
SAE   Serious Adverse Event 
SDV   Source Document Verification 
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SOP   Standard Operating Procedure  
SSA   Site Specific Assessment 
SVR12 Sustained Viral Response 12 weeks after treatment (i.e. virus not detected 
12 weeks after treatment for viral hepatitis). 
TMG   Trial Management Group 
TSC   Trial Steering Committee 
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1. Introduction  
 
 
 1.1  Background  
 
Chronic viral hepatitis is common in people born outside the UK and involves persistent infection with 
either hepatitis B or hepatitis C virus. The disease can cause asymptomatic disease that leads to 
cirrhosis or potentially hepatocellular carcinoma as well as death in a large proportion of those who 
are infected.  
 
Hepatitis C virus is a blood borne single strand RNA virus which exists in a number of different 
genotypes. Chronic infection (defined as infection for more than 6 months) is usually asymptomatic 
and patients usually remain unaware that they are infected until the disease has progressed. However, 
disease progression and severity is highly likely.  
 
Hepatitis B is a blood borne DNA virus that may also be transmitted sexually or by maternofetal 
transmission. Chronic HBV is defined by the presence of hepatitis B surface antigen (HBsAg) for six 
months or more after acute infection.  The disease persists in a number of different, convertible 
phases. The two major phases are defined by the presence or absence of the hepatitis B e antigen 
(HBeAg) in the circulation.  
 
These often asymptomatic diseases require multifaceted diagnostic testing, which includes serial 
testing for antibodies, RNA/DNA as well as liver function tests to ensure patients are accurately 
diagnosed. 
 
The prevalence rate of viral hepatitis currently stands at approximately 0.5% within the UK. However, 
statistics for first and second generation immigrants from ‘at risk’ countries indicates a higher 
prevalence, perhaps approaching 5%.  Current data relating to immigrant populations within the UK 
is limited. However, it is believed that 7 million first and second generation immigrants from high 
prevalence countries currently reside in the UK.  It is believed that certain ‘at risk’ communities have 
a prevalence level similar to their country of origin, as demonstrated by studies conducted in the 
Somali community in Liverpool as well as the Pakistani community in London, (Brabin et al., 2002 and 
Uddin et al., 2010). Hence  
the prevalence of viral hepatitis is at least ten fold greater in immigrants than in the indigenous 
community. 
 
The UK has one of the lowest rates of therapy for viral hepatitis in Europe and this is undoubtedly 
contributing to the observed rising mortality from liver disease in the UK. This is, in contradistinction 
to the rest of Europe, where mortality from liver disease is decreasing. Previous UK studies have shown 
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that access to therapy for patients known to have viral hepatitis is poor with only a tiny minority of 
diagnosed patients going on to receive treatment.  
 
Current statistics indicate that of the total UK population that have been infected with hepatitis C, 
only 17% have been diagnosed and less than 2% go on to receive treatment (Ryder., S, 2004). Hepatitis 
B is known to be the cause of 50% of primary liver cancer cases within the UK, in which patients are 
100 times more likely to develop hepatocellular carcinoma than those who are not infected. Strategies 
culminating in improved access to treatment are thought likely to have a major impact on treatment 
uptake and to reduce morbidity. However, currently alternatives to hospital based treatment have 
not been studied. 
 
Current data indicates that approximately 25% of those with chronic viral hepatitis will die in their fifth 
decade as a result of their infection, indicating that up to 50,000 immigrants living in the UK may 
develop cirrhosis and/or liver cancer. The subsequent care of patients with these conditions will add 
a significant financial burden to the NHS. Further analysis of the current demographics of the 
immigrant population shows that over 80% are less than 50 years old (Foster, G – unpublished data).  
It is therefore anticipated that there will be a sharp rise in the number of immigrant deaths associated 
with viral hepatitis over the coming decade. 
 
Therapy for chronic viral hepatitis is available and is clinically and cost effective as indicated by NICE 
approval. For chronic HCV infection therapy involves a combination of a long acting interferon 
combined with ribavirin and, increasingly a direct acting antiviral agent (such as telaprevir or 
boceprevir). For chronic HBV infection a number of different treatment options are available including 
interferon based immunomodulatory regimes or perpetual viral suppression with a third generation 
nucleotide derived antiviral agent, either entecavir or tenofovir.  The current model of care involves 
specialist centres with highly trained staff administering therapy at some distance from the patient’s 
home.  
 
Given the poor uptake of antiviral therapy under current conditions it has been suggested that 
alternative treatment models should be developed but these have not been assessed or tested in a 






2.      Trial Objectives and Design 
 
2.1    Trial Objectives 
 
The central objective of the study is to determine whether screening for chronic viral hepatitis in 
immigrants living in the UK by testing all registered immigrants in GP surgeries is feasible, 
effective, and cost effective.  
 
We will examine the costs and benefits of screening compared to current ‘standard practice’ 
and evaluate whether an enhanced patient information invitation letter (as opposed to 
‘standard patient information invitation letter’) enhances engagement as well as determining 
whether local delivery of therapy improves compliance with clinical management plan when 
compared to conventional delivery of care. 
 
Prior to the commencement of screening, we will also look at the contextual variables and 
health literacy that will have an impact and influence the uptake of screening  and subsequent 
engagement in treatment. This will be done with a population-based survey of knowledge of 
viral hepatitis in conjunction with  other questionnaires, Patient Health Questionnaire [PHQ-9] 
and Generalised Anxiety Disorder 7-item [GAD-7] . The survey questionnaire is to determine the 
range and prevalence of different beliefs, attitudes and barriers to screening.  
 
The specific study objectives are listed below:_ 
 
 Primary Objectives 
 
Stage 1 
• To determine whether interventional screening is more cost-effective than control 
screening in the detection of viral hepatitis in ethnic minority patients in primary care 
(comparison A).  
• To determine the screening rate of intervention practices compared to the screening 
rate in control GP practices (comparison A.) 
 
To determine whether the provision of an enhanced patient information invitation 
letters increases attendance for testing when compared to standard information 








• To determine whether community based therapy is superior to conventional delivery of 
treatment (based on referral to local hospital treatment centres) as measured by 
engagement with management (comparison C).  
 
         
 Secondary Objectives  
 
• To determine the range and prevalence of different beliefs, attitudes and barriers to 
screening. 
• To assess the impact of contextual variables and demographics as well as health literacy 
in the uptake rate of screening and subsequent treatment engagement. 
• To assess treatment adherence between patient groups receiving treatment within the 
community care setting against standard hospital care. 
• To determine the cost effectiveness of the interventions 
• To determine the prevalence of viral hepatitis in different ethnic groups living in the UK 
• To determine the number of eligible patients across the participating GP practices 
• To determine the overall level of compliance with diagnostic and prognostic events for 
all patients that test viral hepatitis positive as part of this trial (overall outcome D). 
• To determine the level of compliance with the management plan for patients that test 
positive for viral hepatitis.  
•  
 
 Primary outcomes 
 
• In control GP practices, the proportion of patients eligible to be screened (determined 
by a review of the number of immigrants registered at the GP practice at the initiation 
of the study).  In intervention GP practices: The proportion of patients eligible for this 
study that are invited to screen (determined by a review of the number of invitation 
letters sent to eligible immigrants registered at the GP practice at the initiation of the 
study ).  
• The proportion of potential participants that attend for testing (for comparisons A & B)  
• The proportion of potential participants that engage in therapy in the different 
treatment arms. Engagement is defined as:  
o  Attending  at least 3 different occasions  
o For patients who are HCV antibody positive or equivocal but HCV RNA negative 
attending the GP practice or the local hospital on two separate occasions. 
 
• The costs associated with delivering the intervention will be recorded and used for the 
cost effectiveness analysis.  
 




• Proportion of new registrants who agree to undergo testing for viral hepatitis. Patients 
who are newly registered with the practice during the study period and who are eligible 
for screening will be offered screening if they attend a practice with ‘unrestricted’ 
testing or one of the control practices. Rates of testing in ‘new registrants’ will be 
reported along with compliance with treatment outcomes.  
 
• The proportion of viral hepatitis positive participants that comply with the clinical 
diagnostic and prognostic assessment in secondary care. Engagement with diagnostic 
and prognostic assessment is defined as completion of three diagnostic and prognostic 
events (including diagnostic assessment visit, a Fibroscan® and/or ultrasound and a 
statement of clinical management plan from the hepatology team). The schedule of 
these events will be dictated by local policy. For patients who are HCV antibody positive 
but HCV RNA negative attending the GP practice or the local hospital on two separate 
occasions will be deemed as compliance with diagnostic and prognostic 
assessments(for overall outcome D) 
• The proportion of patients that are compliant with their prescribed clinical management 
plan in the different treatment arms (community care Vs Standard hospital care). 
Compliance with the clinical management plan is defined as:  
o  Attending  at least 1 visit after the management plan has been agreed by the 
participant and the clinicians (for comparison C)  
 
• Patients that test positive for viral hepatitis and are prescribed medication to treat their 
viral hepatitis will be monitored for their adherence to therapy. Patients will be 
considered to have adhered to therapy if they successfully complete 80% or more of 
their prescribed therapy.  
• The ‘outcome of therapy’ will also be monitored. A successful outcome of therapy will 
be defined as sustained viral response 12 weeks after treatment completion for 
hepatitis C patients. The definition of successful outcome of therapy for hepatitis B 




2.2    Trial Design  
 
It is a two stage cluster randomised trial. The first stage (two arms) determines how to effectively 
identify and screen immigrants from ‘at risk’ ethnic minority communities for chronic viral hepatitis. 
Within the first stage of the trial we will determine whether or not patients who receive an enhanced 
patient information invitation letter agree to participate in testing at the same rate as patients who 
receive a standard patient information invitation letter. 
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The second stage (two arms) investigates the overall engagement rates for positive patients with 
diagnostic and prognostic consultations and compliance with their clinical management plan. It also 
explores if treatment in primary care (community based therapy) impacts on the adherence to 
therapy.   
There will be an in-depth investigation into a small subset of these participants to assess 
impact of contextual variables and demographics as well as health literacy in the uptake rate of 


























 interventional screening practices   control screening  practices 
Standard care (patients not aware of 
allocation at screening) 
 
Community care (patients not aware 

























































Comparison A: Red vs orange practices 
Comparison B: White vs yellow practices 












3.      Subject Selection 
 
3.1    Number of Subjects and Subject Selection  
 
Pre-screening Component (Survey) 
 
Prior to the commencement of screening, 4 ‘intervention’ GP practices will be involved in the Pre-
screening component of this trial. The GP practice will be involved in generating a representative 
random sample identified by ethnicity group, based on the inclusion criteria specified in section 3.2. 
The sample will reflect the wider population of those that are potentially eligible for Stage 1 of 
HepFREE. Up to 3500 of the pool of potential participants will be contacted to take part in the pre-




Up to 48,000 prospective patients from known ethnic minority populations will be contacted 
(interventional screening). First and second generation immigrants from known ‘at risk’ 
communities (as detailed in appendix 2) will be identified utilising GP practice list definitions of 
ethnicity.  
 
Potential participants from GP practices employing interventional screening will be approached in a 
number of different methods in accordance with local clinical practice. Patients will be contacted 
either by letter, text message or opportunistically when visiting the GP.  
 
Patients will then be tested using standard local testing approaches – in practices with on-site 
phlebotomy we will use local phlebotomy and for practices that refer patients for blood testing the 
usual referral policy will be followed. Once the results are available, the patient will be contacted.  
If tested positive for viral hepatitis, the patient will be invited to re-attend the GP practice to receive 
their result and patients will then be offered a referral to the local hepatology department to receive 
appropriate therapy. Once referred, patients who have tested positive for infection will be offered 
the choice of continuing with standard management (i.e. treatment within hospital) or taking part 
in Stage 2 of the study in which standard management is compared with community care (see 
section 4.1.3 for full detail of the invitation and consent procedures) 
 
In the control practices patients will be offered a screening test opportunistically, as per standard of 
care. There is no intervention at the control GP practices. 
Immigrant demographics from control GP practices for a further 4,000 potential participants will be 
monitored with regards to testing for viral hepatitis, and the total number of viral hepatitis positive 
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patients will be noted. The total number of positive patients that engage with subsequent care will 
be noting by looking at the total number of positive patients that have further diagnostic tests. This 
will be fully anonymised prior to data being exported and sent to the data management team for 
data collection. Aggregated ethnicity data on patients that fit our inclusion criteria will be provided 
to the data manager.  
 
Screening and treatment of the identified patients will last for 2 - 3 years with a staggered approach 
to GP site initiations to ensure a consistent flow of patients. 
 
 
Stage 2  
 
GP practices employing interventional screening will be randomised into two different arms, 
hospital treatment (standard care) or community care treatment. In both GP practices, participants 
found to be viral hepatitis positive will be referred to their local hospital where they will have the 
option to start stage 2 of the HepFREE study. In secondary care, participants will have further 
diagnostic and prognostic consultations to ascertain the severity of their liver disease. Once an 
appropriate clinical management plan has been agreed between the clinical team and the patient, 
the patients will then be able to start their prescribed treatment or active monitoring in either their 
local hospital (standard of care) or in community care. Full details of the consent procedures for this 
arm of the trial is detailed in section 4.1.3 and details of stage 2 of the trial are listed in section 4.2.  
 
 
3.2 Inclusion Criteria 
 
Stage 1  
• ≥18 years old  
• First and Second Generation immigrants of appropriate ethnicity (born or born to 
parents that originate from a country of high prevalence (Please see Appendix 2 for 
comprehensive list of countries listed by WHO as >2% HBV prevalence) 
Stage 2  
• Inclusion is as for Stage 1 , with the additional criteria: 
• Patient who test positive for viral hepatitis during screening  
 
3.3 Exclusion Criteria 
 
Stage 1 
• <18 years old  




Stage 2  
• Exclusion is as for Stage 1 , with the additional exclusion criteria: 
• Patients that screen negative for viral hepatitis  
 
3.4 Premature withdrawal 
 
Withdrawal of informed consent.  
Data up to the point of withdrawal will be retained and used in the analysis. 
  
 
4.      Study Procedures  
 
4.1 Informed Consent Procedures  
 
4.1.1 Consent for the Pre-screening Component (Survey) 
 
For the subset of participants to be approached for this survey completion, it is proposed that verbal 
consent be sought. The fundamental principles that underlie both verbal and written consent are, 
in essence, the same. The main issue surrounds informing the potential participant as to the nature 
of the research, their rights and safety as participants and making explicit that participation is 
voluntarily and can be revoked at any time without reprisal. From our previous work, we discovered 
that ethnic minorities were often willing to participate but concerned about signing anything, 
perhaps if there literacy problems or concerns about ‘authorities’ not acting in their interest which 
is common amongst refugees, for example, or recent migrant who may be settling into a new life.  
 
There is an element of culturally sensitivity that should be observed within this potential participant-
population as many will see the signing of forms as an official act with subsequent retributions in 
the future. This may be seen as having negative connotations, bringing about considerable 
scepticism relating to participation. Verbal consent may be deemed as a less threatening act. It is 
known that there is incidence of illiteracy and semi-illiteracy in this particular population 
demographic.  
 
The main concerns are to not discriminate against participation by using a methodology that 
reduced their chances of participation because of language or cultural factors, or issues related to 
social exclusion; for example, postal addresses may chance if the population are mobile, or shared 
accommodation, or loss of post may be factors in non-response.  
 
HRA guidance ‘Consent & Participation Information Sheet Preparation Guidance’ released on March 
3rd 2014, details that participants can give ‘written, oral or non-verbal’ consent. The objective is to 




It is likely that the vast majority of the interviews are likely to be conducted via telephone as to 
create minimal intrusion or disruption on account of participation, written consent may not be seen 
as the most practical route of obtaining consent. However, it will be made explicit that the consent 
can be withdrawn at any point during the course of the interview. This methodology has been tested 
previously and worked successfully with ethnic groups in primary care.  
 
As detailed by NRES Guidance, Annex 5: Consent and its problems – the stipulation of written 
informed consent could be act as a barrier to recruitment, particularly when there is an imperative 
need  to obtain a representative sample, with the potential benefit deemed significant. 
 
The intended mechanism, as discussed with the sponsor, is to use patient information letter and 
using the HRA template consent form as a means of obtaining informed verbal consent, at minimum 
at the start and the end of the interview. The participant will be allowed to ask any further questions 
to ensure that they have understood what is involved and their participation is voluntary, and can 
be withdrawn at any time. This demonstrates that consent an ongoing process and not a one off 
event. If required, it will be repeated and enforced during the course of the interview.  Although, in 
the first instance, the crucial time points are at the commencement of the interview and at the end. 
This process has been discussed with the sponsor, and they have indicated their approval for the 
research team to proceed. 
 
In each instance, verbal consent will be taken in the presence of an independent witness and 
adequately documented. A similar methodology has been used in previous studies of East London 
immigrants, within a survey in primary care of different ethnic groups (Rudell, K. et al., 2009). 
 
4.1.2 Consent for Stage 1 of the Trial 
 
Stage 1 of the trial is investigating two different methods of screening, i.e targeted screening which 
takes place at intervention practices or current standard practice at control practices.  
 
In the intervention practices, it is the responsibility of the investigator, or a person delegated this 
task by the investigator, to obtain consent for the blood test and written informed consent from 
each subject to data collection for further analyses (specifically they will be asked if they agree to 
allow the HepFREE trial team to access their medical records and for data held by The Health and 
Social Care Information Centre to be made available to the research team).  The investigator will 
adequately explain the aims, methods, anticipated benefits, and potential hazards of these 
procedures. In the case where the patient is unable to read, an impartial witness should be present 
during the entire informed consent discussion. After the subject has orally consented to 
participation in the trial, the witness’ signature on the form will attest that the information in the 
consent form was accurately explained and understood. The investigator or designee must also 
explain that the subjects are completely free to not to be tested or to withdraw consent for data 
collection at any time. If participants do not wish to allow certain aspects of their data to be collected 
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this can be indicated in the consent form.  They will still be able to enter the study but in this case 
only anonymised aggregate data will be collected for analysis. 
 
 
4.1.3 Consent for Stage 2 of the trial  
 
Patients eligible for stage 2 of the trial (testing positive for viral hepatitis in the screening 
intervention practices) will be invited to participate by a member of the clinical hepatology team. 
patient information sheet will provide a comprehensive account of the treatment/monitoring  phase 
(stage 2) of the trial enabling the participant to make an informed decision as to whether they would 
like to remain on the trial or not. The patient information sheet will not indicate whether the 
patient’s GP practice was randomised to standard care (care in hospital as per standard practice) or 
intervention (care at a local community care practice) arm. The investigator, or delegated member 
of the HepFREE team, consenting the eligible patients will not be aware of the patient’s practice’s 
allocation at the time when consent is sought (see section 4.2.4). Participants that consent to take 
part in stage 2 of the trial, will subsequently be informed of their treatment/monitoring allocation 
by the doctor or health care practitioner who will manage their treatment/active monitoring. 
Participants that do not wish to take part in the second stage of the trial will be treated as per 
standard care. Treatment allocation will be concealed until after consent to participate in the trial 
has been obtained, in an effort to prevent bias between recruitment into the two arms of the trial 
(community vs hospital care).  Patients will be explicitly informed of their right to withdraw from 
the study if they are not comfortable with their treatment allocation at any point. If a participant 
subsequently withdraws consent to the trial they will be treated as per standard of care (see section 
above). Supplementary consent to remain on the study will be sought at the first visit to secondary 
care subsequent to a referral. Supplementary consent can be sought at following visits to secondary 
care only if conditions do not allow for the consent to be sought at the first visit to the local hospital. 
However, it is a pre-requisite that the consent must be stated (written) prior to the patient adopting 
their trial allocation (community care Vs Hospital care). 
 
4.2 Study Procedure Overview 
  
Practice selection for invitation to this study will be based on an established patient population of 
first and second generation immigrants from ‘at risk’ countries. Following invitations to a larger 
group of practices we expect 58 GP practices across East London, South London and Bradford to be 
randomized in this study. The GP practices will either be allocated to one of the following five 
groups:  
 
A) Control screening practices 
B) Intervention screening practices with standard hospital treatment, standard invitation  
C) Intervention screening practices with standard hospital treatment, enhanced invitation  
D) Intervention screening practices with community care to be offered, standard invitation 




In the first stage of the trial to assess screening methods we will compare group A with all the others 
combined.(comparison A) 
In the second stage trial to assess treatment options we will compare groups B & C with groups D & 
E(comparison C)  
In a supplementary analysis to assess the effect of the enhanced invitation on testing rates we will 
compare groups B & D with groups C & E (comparison B) 
 
4.2.1 Pre-screening Component (survey)  
 
A small subset of up to 3500  potential participants from up to 4 of  targeted screening practices, 
form the sample for a population based survey of those eligible for screening, in order to assess 
characteristics of take or decline, at all stages of the project. 
 
The patients will be asked about their illness perceptions and narratives (called explanatory models) 
about hepatitis using an adapted version of the Barts Explanatory Model Interview checklists. These 
have been developed from focus groups and literature review information, following the methods 
set out in the original development for use in common mental disorders. Three other validated  
patient-reported outcomes will be completed by interview: patient health questionnaire (PHQ-9) 
and the generalized anxiety disorder 7-item (GAD-7) scale. 
 
Some information about the individual will be available from primary care electronic databases, that 
will help establish the need for translated material or not. Potential participants will be contacted 
by a letter of invitation to participate within the survey, with further information detailing the 
project (in English or appropriate translation).  
 
The letter would detail what is involved and that agreement or not to complete questionnaires is 
completely voluntary. In the first instance, telephone interviews will be the primary choice used for 
completion. However, the invitation letter will detail and accommodate if the participant prefers to 
receive an interview face to face, or if they prefer a postal survey. The letter will also indicate that 
contact after 2 weeks will be made to ascertain if they would be willing to participate. 
 
After 2 weeks, potential participants will be contacted from the GP practice, via telephone (up to 3 
times) to confirm if they received the letter and If they have any questions for the GP or the research 
team, indicating that they are happy to continue and participate. 
 
If the participant indicates that they are willing to be interviewed over the phone, verbal consent in 
the presence of a witness will be sought with appropriate language translation (as required) and 
documented. It will be highlighted that participation is voluntary and the interview can be stopped 





If the participant details that they would prefer to complete the surveys via post, all documents with 
instructions will be forwarded with a self-addressed envelope with a contact telephone number for 
any enquiries. If, the participant details that they would prefer face to face interview, a suitable time 
will be arranged with appropriate language translation (as required) to attend the GP practice. 
 
Data collected from the pre-screening database will be linked, using the pseudonymised identifier 
generated by the GP database, to screening data collected as part of stage 1 of HepFREE. This is to 
ascertain whether there are certain beliefs of perceptions about hepatitis that indicate whether a 
patient is more or less likely to screen for viral hepatitis when offered a screen and therefore answer 
our primary objective detailed in this protocol. This linkage will not lead to identification of patients.  
 
4.2.2 Screening in Control GP Practices  
 
In the control group arm, existing GP registers of patients will be screened to identify patients that 
fit the HepFREE eligibility criteria, by their country of birth or their parents’ country of birth. In 
conjunction with this, a local hepatologist or a trained member of the study team will visit the GP 
practices, highlighting the study to the GPs and their teams and educating them about hepatitis B 
and C. These practices will continue with their standard care policy relating to screening over the 18 
months of screening. 
 
4.2.3 Screening at Intervention Practices 
 
In the intervention practices, existing GP registers of patients will be screened to identify eligible 
patients by recorded ethnicity, country of birth or their parents’ country of birth and first language 
spoken. Potential participants identified as first or second generation immigrants without HBV or 
HCV status, will either be contacted or approached to take part in the trial .  
 
Potential participants for screening will be invited by their GP practices to have a blood test for viral 
hepatitis.  The GP, or delegated and trained members of staff, will provide a copy of the patient 
information sheet and informed consent form (in English or appropriate translation, if applicable). 
This will explain the details of the study relating to screening and if they test positive for viral 
hepatitis. Details of the consent process is detailed in section 4.1.2. 
 
After up to 4 weeks, participants that have been sent an invitation letter may be contacted to ensure 
receipt of the letter. If they wish to attend, an appointment will be made. Alternatively, participants 
can also contact or attend their GP to discuss further and decide whether to be tested.  
 
Approximately 48,000 ‘targeted’ patients from ‘at risk’ countries will be approached over a 
maximum 18 month period. All those screened and tested positive for viral hepatitis will either be 
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offered treatment in the specialist out patients clinic in their local hospital or in an ‘intervention 
practice’ as part of community care. The location of where patients receive their treatment will be 
dependent on the interventional cluster allocation. 
 
During the screening period, a hepatitis awareness campaign will be set up and conducted by a local 
community group within East London during the screening period. It will involve a series of 
awareness videos to be broadcast on local immigrant channel/ stations as well as producing 
awareness posters to be displayed in local community centres to try and raise awareness and local 
knowledge about Hepatitis B and C. The impact of this awareness campaign will be assessed by 
looking at screening uptake rates of the practices within the area. This awareness campaign will also 
be fed into the cost benefit analysis of screening. 
 
4.2.4 Participants with Chronic Viral Hepatitis 
 
Participants who test positive for viral hepatitis are offered a referral to the local specialist 
hepatology team. All participants that are referred will initially be seen at their local outpatient’s 
hepatology clinic, by the HepFREE Clinical Research Fellow or a delegated clinician, to ascertain their 
diagnostic and prognostic status which will determine the treatment or level of monitoring that is 
required. It also ensures that community care, as a potential treatment location, is appropriate for 
the patient. Supplementary consent is sought from all patients that are referred as part of the 
HepFREE trial (section 4.1.3). To reduce the chance of bias between the two arms, consent to be 
part of the second stage trial will be sought for both arms in the same way, by a member of the 
direct clinical care team, who, ideally, will be blinded to allocation. The status of the person seeking 
consent will be documented. If the participant consents to remain on the study, they will be 
unblinded to  their treatment allocation. Patients who wish to enter stage 2 of HepFREE will receive 
treatment/monitoring in the specialist out patients clinic in their local hospital or in a local 
community care practice as part of community care. The treatment option for each patient will 
depend on the allocation of their practice, whether to the treatment intervention (local community 
care practice) or control arm (standard hospital). 
 
Patients who test positive for viral hepatitis will be monitored for their level of engagement and 
compliance which will be monitored in two separate ways.  
1) Overall engagement with diagnostic and prognostic consultations measured by completion 
of the following events as three separate entities: i) a diagnostic assessment consultation ii) 
an ultrasound/ Fibroscan® assessment iii) receipt of a management plan  
2) Compliance  with the agreed clinical management plan, measured by attending at least one 
visit after the receipt of a clinical management plan.  
These definitions will allow an assessment of engagement in patients who do not wish to receive 
or are not suitable for antiviral therapy at this time. 
 
Data relating to engagement (outcome D), compliance with management plan (Comparison C) 
and data relating to the secondary outcome will continue to be monitored until the end of data 
collection in February 2017 for all patients that screen positive as part of Stage 1 of HepFREE. 
Due to due to fast developments in treatment availabilities for hepatitis C and change in NHS 
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policy, with regards to prescribing new hepatitis therapies, the ‘clinical management plan’ for 
some patients may change throughout the course of the trial. Continuing to collect outcome 
data for all HepFREE patients that screen positive until Feb 2017 will enable us to obtain 
‘adherence to therapy’ and ‘response to therapy’ (secondary outcomes) information for 
patients whose treatment options change during the trial period.   
 
For patients who are randomised to community care, they will continue to receive their 
hepatology care, if appropriate, in the community until the HepFREE data collection stops in 
February 2017. This is to allow the patients enough time to adjust to their treatment regimes in 
the community before moving their care back to ‘standard of care’ based at the local hospital 
once their study visits have been completed. 
 
Adherence to therapy will be analysed as a secondary study outcome. Adherence to therapy will be 
defined as having taken 80% or more of the prescribed medication as described in section 2.1.   
 
 
In ‘community care’ practices, patients who agree to undergo therapy in the community will be 
asked to attend a designated GP practice where a specialist viral hepatitis nurse and/or hepatologist 
will attend and deliver care in the community in accordance with a community treatment algorithm 
established and supervised by the local secondary care centre (see section 4.4).  
 
4.2.5 Investigating Barriers to Screening in Primary Care. “The HepFREE Provider Experience” 
Qualitative Research 
 
 This is a qualitative substudy linked to the screening rates in Stage 1 of the HepFREE trial.  
Data collected so far from stage 1 of the HepFREE study shows that screening rates differ vastly 
across different GP practices (from 2%-90%) and the purpose of this substudy is to determine why 
some GP practices are effective at engaging with patients, and others are not. This will enable the 
HepFREE team to make future recommendations about key GP practice characteristics that 
indicate the hepatitis B/C screening intervention would be most effective.  
This substudy follows on from previous pre-trial research into the attitudes of primary care 
healthcare workers towards screening patients for viral hepatitis. (Study approved through the 
Queen Mary Research Ethics Committee - Ref no: QMREC2012/02).  Healthcare workers of various 
grades were interviewed at 14 GP practices in Bradford, East London and South London between 
July-October 2014. Since then, all 14 GP practices have participated in the 18 months of 
“HepFREE” viral hepatitis screening programme. 
 
In this qualitative substudy we will interview a general practitioner, practice nurse, healthcare 
administrator and/or practice manager at 12-14 practices to assess their attitudes to screening in 
primary care following completion of the screening programme. All interviewees are adult 
healthcare workers, and many of them will also have contributed to the pre-trial qualitative 
research. Written informed consent will be sought from GP practice staff who agree to be 
interviewed. A participant information sheet will be provided detailing the aims of the interviews. 
All interviewees will be made aware that participation is voluntary and they can stop the 
interview, or refuse to answer questions, at any time. If the interviewee was part of the pre-trial 
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research then they will be asked for permission to link information provided as part of this 
interview with information provided prior to the HepFREE trial commencing.  Interviewees can opt 
out of this link if they so wish. Participation in the interviews will be kept confidential. The 
interviewer will not have access to identifiable research material from the pre-trial interviews until 
the interviewees provide elicit consent for this. As a reimbursement for their time, all interviewees 
will be offered a shopping voucher to the value of £50. 
 
Interviews will be either face-to-face or by telephone and last approximately 30 minutes and will 
be conducted between September 2016 – June 2017. All interviews will be audio-recorded and 
responses will be anonymised. Interviews will be conduct by trial staff who have had no previous 
direct contact with the primary care practice. No patient data will be used. 
Questions will explore specific quantitative data collection such as practice staff to patient ratios, 
staff to room ratios, patient recruitment levels and the presence of onsite phlebotomy services. 
Other question will explore motivations and challenges of running a screening programme 
(perceived benefits to patients and to practice, impact on time and resources, impact of payment 
and the prioritisation of the study in a busy practice), the practical implications of being involved in 
a research study (local trial training, use of trial dataset) and the challenges of recruiting and 
consenting patients to the trial. 
The anonymised responses will be collated along with the previous pre-trial responses to assess 
attitudes before and after the 18 month screening programme and to identify potential barriers to 
viral hepatitis screening in the primary care setting. With consent, the ethnicity and country of 
birth of the interviewer will be recorded.  
 
4.3 Screening/Randomisation Procedure  
 
Each GP practice will be randomised to one of the five arms at the outset. See section 4.2 for detail. 
Randomisation is undertaken by the Pragmatic Clinical Trials Unit. 56 Practices will be stratified by 
region and minimised by the number of eligible patients.  
 
4.4   Schedule of Treatment 
  
Standard therapy for chronic viral hepatitis will be provided as described in Section 4.2.4  
 
Treatment and any related decisions will be overseen by a named local specialist 
consultant, with GP input and nurse management, in line with usual standard of care.  
  
 
4.5  Schedule of Assessment  
 
Patients who fit the eligibility criteria will be invited to attend for hepatitis B and C screening. If an 
eligible patient attends their GP practice during the HepFREE screening period, they may be 
opportunistically offered hepatitis B and C screening, providing informed consent is sought. Once 
written informed consent is in place, the patient will provide a blood sample for testing, following 
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local phlebotomy services and provisions. The patient will be re-contacted to receive the test results. 
To meet the primary objectives of this study the viral hepatitis screening outcome will be collected 
by the research team and this data will be provided to the research team in an anonymised format, 
linked only to an anonymised identifier.  Thus the participant’s identity could not be deduced from 
the HepFREE database. The identity of the participant will not be known to anyone outside the direct 
clinical care of the participant, or members of the virology team, as per standard practice.    
 
Patients, who test positive will be contacted, to visit their practice to receive their result. If 
unsuccessful, these patients will be recorded as being ‘non-attenders’ 
 
If the patient tests positive, the patient will be treated at either their local hospital specialist centre 
or will receive treatment in community care under supervision of the hepatology consultant and 
nurse at the ‘community care practices’. On a regular basis, a member of the team will conduct 
review of specific referral forms or accesses the patient’s electronic records via CRS/PAS/EMIS Web 
as well as review of the appointment system to capture patient engagement as defined in section 
4.1.3.  
 
For HCV or HBV patients that require immediate therapy, oral and injectable medication adherence 
will be  monitored and logged  as detailed by clinical assessment of the patient’s condition. Overall 
assessment of anti-viral adherence to therapy will be logged at the SVR 12 follow-up visit.  
Definitions of ‘adherence to therapy’ and ‘outcome of therapy’ are detailed in section 2.1. 
 
 
4.6   Laboratory Assessments (see section 5 for further information) 
 
4.7 End of Study Definition 
The end of study will be defined when the final patient has been assessed for engagement, 
and is documented engaged or not with the diagnostic and prognostic consultations.  
 
4.8    Subject Withdrawal  
 Subjects have the right to withdraw consent at any time and those who do so will have no 
further contact with the study team. Where feasible, reason for withdrawal will be 
documented. 
 
4.9 Data Collection and Follow up for Withdrawn Subjects  
Patients that withdraw consent or drop out will be replaced and the withdrawal will be 




5.      Laboratories  
 
5.1 Local Laboratories  
 
 Blood samples will be taken from local sites phlebotomy and sent to local virology laboratories 
for analysis.  
 Blood samples will be measured for HbsAg and Anti-HCV as part of the screening process.  
 GP practices and local virology laboratory teams will liaise closely to ensure that participants 
that screen receive their result, as per standard practice. GPs will make the virology team 
aware of patients that consent to the HepFREE trial. As the screening outcome directly relates 
to the primary objective of this study, the HepFREE research team will liaise with both the GP 
practices and virology laboratories to ensure that screening outcome is captured accurately 
for participants. The identity of the participants will not be disclosed to the HepFREE research 
team as the screening results will be linked to an anonymised number. For Control GP 
practices, the HepFREE team may liaise with local laboratory teams to obtained anonymized 
screening outcomes of Hepatitis B and C for eligible participants, where this information is not 
available at GP practices. In this case, any information shared to the HepFREE team will be 
aggregated and anonymous.   
 
 
6. Safety Reporting 
 
6.1    Serious Adverse Event Reporting  
 
In non-CTIMPs a serious adverse event (SAE) is defined as an untoward occurrence that: 
 
a) Results in death 
b) Is life threatening 
c) Requires hospitalization or prolongation of existing hospitalization  
d) Results in persistent of significant disability or incapacity 
e) Consists of a congenital abnormality of birth defect 
f) Is otherwise considered medically significant by the investigator 
 
 
An SAE occurring to a research participant should be reported to the main REC (i.e. the REC that 




a) Related – that is, it resulted from administration of any of the research procedures 
and 
b) Unexpected – that is, the type of event is not listed in the protocol as an expected 
occurrence 
 
Any hospitalization or other SAE that in the opinion of the CI is related to the trial and expected for 
this population will not be reported to the sponsor or the REC. 
 
SAEs however that are deemed to be related to the trial and/or unexpected will be reported to both 
the sponsor within 24 hours of the CI becoming aware of the event and the REC within 15 days of 
the CI becoming aware of the event. 
 
6.2   Adverse event reporting 
 
In non-CTIMPs, an adverse event (AE) is any untoward medical occurrence in a patient or clinical 
investigation subject exposed to a research procedure which does not necessarily have a causal 
relationship with that procedure.  
 
An adverse event can therefore be any unfavourable and unintended sign or symptom of disease 




7. Statistical Considerations   
 
7.1   Sample Size  
 
We have assumed an intra-cluster correlation co-efficient of 0.05 for all outcomes and a coefficient 
of variation of cluster size of 0.65. The sample size is driven by the second stage trial, primary 
comparison, since this involves a smaller number of practices and patients.  We assume that 40% of 
patients will be screened and of these 3% will test positive. To detect a difference from 50% to 70% 
engaged; with 90% power at the 5% significance level requires 56 practices which also accounts for 
drop outs. With the number of practices in each of the standard care/community care arms, the 
control practices will be able to detect an increase in screening from 15% to 40% with 90% power 
(first stage of the trial) which will allow for drop outs.   
 




No interim analyses are planned. A 5% level of significance will be used. Due to the nature of the 
outcomes we anticipate few missing values. We will use available case analysis, i.e. all individuals 
on whom we have outcome data. 
 
Baseline comparisons of both cluster and individual characteristics will be presented. We will report 
separate analyses using generalized estimating equations for the main analyses for our three 




7.3   Primary Endpoint Effectiveness Analyses 
 
Stage 1:  
A) Control vs intervention screening, outcome = testing rates 
Generalised estimating equations using logit link to account for binary outcome as primary analysis, 
accounting for region, cluster size (number of individuals eligible to be tested),  A cluster-level t-test 
as sensitivity analysis. 
 
B)   Standard invitation v enhanced invitation (outcome = testing rates 
Generalised estimating equations using logit link to account for binary outcome, accounting for 
region, cluster size (number of individuals eligible to be tested).  
 
Qualitative data collected as part of the pre-screening questionnaire will be linked to stage 1 of 
HepFREE to determine whether there are specific beliefs or perceptions that determine whether a 
patient is more or less likely to screen for viral hepatitis.  
 
Stage 2:  
Main comparison: Overall engagement rates = engagement with diagnostic and prognostic 
consultations (section 4.2.4). Standard treatment v treatment in community outcome = attendance 
to at least one visit following the agreement of the clinical management plan. Generalised 
estimating equations using logit link to account for binary outcome as primary analysis, accounting 




 We will use the intention to treat principle when identifying which clusters and arms to analyse 





7.4 Cost Effectiveness Analysis 
 
Data collected as part of HepFREE will be used to determine the cost effectiveness of the screening 
intervention, as per the primary objective (section 2.1).   
The economic model that will drive the cost effectiveness analysis will be based on a Markov 
Model. The main focus will be to determine cost-effectiveness for a range of NHS policy options in 
hepatitis screening, as well as understand the uncertainty and sensitivities associated with these 
estimates. Modelling will be associated with the whole study population rather than individual 
cases although sub-group analysis may require that we can identify key population groups (e.g. 
ethnic or age related).  
 
 
7.5 Disease Progression Modelling 
 
The team will use data collected as part of HepFREE on prevalence of hepatitis B and C and disease 
severity to model the current burden of disease in different local communities. In particular, the 
team will look at the distribution of fibrosis and cirrhosis in relation to demographic factors like age, 
gender and ethnicity. This will enable the team to provide an estimate of future impact of hepatitis 
in order to recommend prioritisation strategies for screening in communities at higher risk of 
developing viral hepatitis related complications. Data input for this analysis will be based of hepatitis 
positive patients who gave full informed consent to the HepFREE study.   
       
7.6 Analysis of Barriers to Viral Hepatitis Screening in Primary Care 
 
The team will use descriptive statistics to describe key characteristics of practices with low, medium 
and high screening rates. A detailed qualitative analysis will be performed on themes arising from 




8.        Data Handling & Record Keeping 
 
8.1 Data Management 
 
For stage 1 of the trial electronic data capture will be supported by the in-house GP practice 
database, such as EMIS WEB and SystmOne, by a HepFREE specific template. Only authorized 
personnel will have access to the EMIS/SystmOne database at the practice level. Data relating to the 
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primary outcome will be collected in an identical way between control and intervention practices. 
In intervention practices data from participants who have agreed to share personal data with the 
trial team will be included in the cost effectiveness analysis. 
 
Data files containing HepFREE specific data will be transferred from the GP practices to the HepFREE 
data management team via a method deemed secure and in accordance to information governance 
policy.   
Once HepFREE data files are securely received by the data manager they will be uploaded onto a 
dedicated folder on the secure virtualised environment at the Barts Cancer Centre (BCC).  This is 
where all data analysis of PCTU trial data is carried out.  The BCC environment requires a two factor 
authentication to access the portal via Citrix and the folders where the data is stored are only 
accessible to the appropriate members of the PCTU and HepFREE trial team. 
 
The data files will be imported into a template Access database, within the BCC network,  where 
various data integration steps will be performed to remove any duplication, standardise and ensure 
data quality. 
 
For Stage 2 of the trial, trial specific data will be collected using Case Report Forms within an 
electronic data capture program hosted by a secure online data management system called 
OpenClinica. The CRFs can be accessed via an encrypted and secure uniform resource locator (URL) 
using a unique username and password, which is externally validated, and the details of the 
validation will be held in electronic files by the PCTU. Only authorised members of the HepFREE 
team, who are fully trained, will be granted user accounts. A full audit trail will be accessible to data 
managers at the PCTU and relevant members of the HepFREE team.   The OpenClinica software is 
provided by OpenClinica and is hosted on a server by their hosting partner in the UK. 
The trial statistician will receive a fully integrated dataset which is blinded to GP trial allocation and 
GP location (South or East London or Bradford).   
 
 For the Pre-screening survey paper questionnaires will be used in the first instance. Data from these 
questionnaires will be entered into an OpenClinica database in the same way as described for Stage 
2 of the trial above. The electronic survey will be designed to mirror the paper survey to ensure data 
is transferred accurately. Pseudonymised data collected as part of the pre-screen survey will be 
linked to Stage 1 of HepFREE screening data using a patient ID that does not identify the patient. 
Consent to collect both datasets is a pre-requisite for collecting both survey data (oral consent) and 
screening data (written consent) as detailed in section 4.1.1.   
 
Interview data collected as part of the qualitative sub-study described in section 4.2.5 will be stored 
in password protected files within a secure Barts Trust network, only accessible to authorised 





The HepFREE team will implement a data management plan, which will be approved and overseen 
by the PCTU, to ensure data security, quality and accuracy.  
 
8.1.1     Confidentiality  
 
The Investigator has a responsibility to ensure that patient anonymity is protected and maintained. 
They must also ensure that their identities are protected from any unauthorised parties. Information 
with regards to study patients will be kept confidential and managed in accordance with the Data 
Protection Act, NHS Caldicott Guardian, The Research Governance Framework for Health and Social 
Care and Research Ethics Committee Approval. 
 
All documentation containing patient identifiable data (PID), such as informed consent forms and 
contact details, will be stored separately from case report forms, adverse event logs. 
 
8.2    Study Documents   
 
• A signed protocol and any subsequent amendments 
• Current/Superseded Patient Information Sheets (as applicable) 
• Current/Superseded Consent Forms (as applicable)Indemnity documentation from 
sponsor/Conditions of Sponsorship from sponsor (Conditional)/Final R&D Approval 
Ethics submissions/approvals/correspondence/CVs of CI and site staff 
• Laboratory accreditation letter, certification and normal ranges for all laboratories to be 
utilised in the study Delegation log, Enrolment log  
• Study specific and PCTU SOPs  
 
8.3 Case Report Form  
 
All parameters relating to testing outcome, disease severity, engagement with diagnostic and 
prognostic tests, compliance with clinical management plan, adherence to therapy and 
outcome of therapy will be captured on eCRFs. Additional parameters relating to the cost 
effectiveness of the intervention will be documented. For example: 
- Rate of missed appointments 
- Location of consultation  
- Duration of each consultation 
- Job role of each health care professional providing care (specialist 
nurse/consultant/registrar) 
 All CRF data will be pseudonymised and will not be identifiable to anyone outside of the clinical care 
team.   
  
 




During the course of research, all records are the responsibility of the Chief Investigator and must 
be kept in secure conditions. When the research trial is complete, it is a requirement of the Research 
Governance Framework and Trust Policy that the records are kept for a further 20 years. For trials 
involving BLT Trust patients, undertaken by Trust staff, or sponsored by BLT or QMUL, the approved 
repository for long-term storage of local records is the Trust Modern Records Centre which is based 
at 9 Prescot Street. Site files from other sites must be archived at that external site and cannot be 
stored at the Modern Records Centre. 
 
8.5   Compliance 
 
The CI will ensure that the trial is conducted in compliance with the principles of the Declaration of 
Helsinki (1996), and in accordance with all applicable regulatory requirements including but not 
limited to the Research Governance Framework, Trust and Research Office policies and procedures 
and any subsequent amendments. 
 
8.6          Clinical Governance Issues 
 
8.6.1      Ethical Considerations 
 
This protocol and any subsequent amendments, along with any accompanying material provided to 
the patient in addition to any advertising material will be submitted by the Investigator to an 
Independent Research Ethics Committee. Written Approval from the Committee must be obtained 
and subsequently submitted to the JRO to obtain Final R&D approval. 
 
8.7      Quality Control and Quality Assurance 
 
8.7.1       Summary Monitoring Plan 
 
Will be in accordance with the sponsor based risk assessment and monitoring will follow sponsor 
and PCTU SOPs. 
 
8.7.2      Audit and Inspection 
 
Auditing: Definition “A systematic and independent examination of trial related activities and 
documents to determine whether the evaluated trial related activities were conducted, and the data 
were recorded, analysed and accurately reported according to the protocol, sponsor's standard 





A study may be identified for audit by any method listed below:  
1. A project may be identified via the risk assessment process. 
2. An individual investigator or department may request an audit. 
3. A project may be identified via an allegation of research misconduct or fraud or a suspected 
breach of regulations. 
4. Projects may be selected at random. The Department of Health states that Trusts should be 
auditing a minimum of 10% of all research projects. 
5. Projects may be randomly selected for audit by an external organisation. 
 
Internal audits will be conducted by the sponsor as per their SOPs and by the PCTU Quality 
Assurance Management team.  
 
8.8 Non-Compliance   
      
A noted systematic lack of both the CI and the study staff adhering to sponsor and PCTU   
SOPs and the protocol leads to prolonged collection of deviations, breaches or suspected fraud.) 
These non-compliances may be captured from a variety of different sources including monitoring 
visits, CRFs, communications and updates. The PCTU  will maintain a log of the non-compliances to 
ascertain if there are any trends developing which to be escalated. The sponsor will assess the non-
compliances and action a timeframe in which they need to be dealt with. Each action will be given 
a different timeframe dependent on the severity. If the actions are not dealt with accordingly, the 
JRO will agree an appropriate action, including an on-site audit. 
 
9.      Trial Committees  
 
9.1  Trial Steering Committee 
 
There are plans to have a steering committee in place for the study. It is intended that the committee 
will meet at least twice a year to review progress. They will have the authority to halt the program 
for reasons of non-progression or unacceptable ethical/safety issues. 
 
9.2  Trial Management Committee 
 
There will also be a management group put in place for this study which will meet three times 
annually. The management group will monitor progress and will implement any modifications the 




9.3  Trial Team Meetings  
 
HepFREE team meetings will be scheduled on a weekly basis to review study progress and address 
any issues that may arise. If necessary the trial team will report the Trial Management Committee 
and the Trial Steering Committee.    
 
10.     Publication Policy  
All publications from the study will be published with joint authorship. No member of the study 




• Progression of hepatic fibrosis in patients with hepatitis C:  a prospective repeat liver 
biopsy study. Stephen Ryder Gut 2004;53:451-455 
• Cluster randomised trials: Methodological and ethical considerations MRC clinical trials 
series November 2002 
• Uddin et al (2010) Prevalence of chronic viral hepatitis in people of south Asian ethnicity 
living in England: the prevalence cannot necessarily be predicted from the 
prevalence in the country of origin. J Viral Hepat;17(5):327-35 







Appendix 1– Information with regards to Safety Reporting in Non-CTIMP Research 
 
 
 Who When How To Whom 
SAE Chief 
Investigator 
-Report to Sponsor 
within 24 hours of 
learning of the event 
-Report to the MREC 
within 15 days of 
learning of the event 
SAE Report form for 
Non-CTIMPs, 
available from NRES 
website. 





Contact the Sponsor 
and MREC 
Immediately 




giving notice in 
writing setting out 
Main REC and 
Sponsor  
Main REC with a 
copy also sent to 
the sponsor. The 
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the reasons for the 
urgent safety 
measures and the 
plan for future action. 
MREC will 
acknowledge this 
within 30 days of 
receipt.  
Progress Reports  Chief 
Investigator  
Annually (starting 12 
months after the date 




from the NRES 
website 
Main REC 
Declaration of the 
conclusion or early 




Within 90 days 
(conclusion) 
Within 15 days (early 
termination) 
The end of study 
should be defined in 
the protocol 
End of Study 
Declaration form 
available from the 
NRES website 
Main REC with a 
copy to be sent to 
the sponsor  




Within one year of 
conclusion of the 
Research 
No Standard Format 
However, the 
following Information 
should be included:- 
Where the study has 
met its objectives, 




including feedback to 
participants 
Main REC with a 






Appendix 2: Countries listed by WHO as having >2% HBV prevalence 
 
AFRICA 
North Africa East Africa Southern Africa West Africa Central Africa 
Algeria Burundi Botswana  Benin Angola 
Egypt Comoros Lesotho Burkina Faso Cameroon 
Libyan Arab 
Jamahiriya 
Djibouti Namibia Cape Verde Central African 
Republic 
Morocco Eritrea South Africa Cote d’Ivoire Chad 
Tunisia Ethiopia Swaziland Gambia Congo 
 Kenya Zimbabwe Ghana D.R of the 
Congo 
 Madagascar  Guinea Equatorial 
Guinea 
 Malawi  Guinea-Bissau Gabon 
 Mauritius  Liberia Sudan 
 Mozambique  Mali Zambia 
 Reunion  Mauritania  
 Rwanda  Niger  
 Seychelles  Nigeria  
 Somalia  Sao Tome and 
Principe 
 
 Uganda  Senegal  
 United R. of 
Tanzania 
 Sierra Leone  






Eastern Europe and Newly Independent 






Bosnia and Herzegovina Spain 
Bulgaria  
Croatia  








Republic of Moldova  
Romania  
Russian Federation  
Slovakia  
Tajikistan  







Mexico and Central America Temperate South America Tropical South America 
Belize Argentina Bolivia 
Guatemala  Brazil 
Honduras  Ecuador 
Mexico  Guyana 
Panama  Suriname 







The Caribbean Australia and the South Pacific Islands 
Antigua and Barbuda American Samoa 
Dominica C.N. Mariana Islands  
Dominican Republic Cook Islands 
Grenada Fiji 
Haiti French Polynesia 
Jamaica Guam 
Puerto Rico Kiribati 
Saint Kitts and Nevis Marshall Islands 
Saint Lucia Micronesia 
St Vincent & Grenadines Nauru 
Trinidad and Tobago New Caledonia 
Turcs and Caicos Islands Niue 
 Palau 
 Papua New Guinea 
 Samoa  




 Wallis and Futuna Islands 
 
Asia 
East Asia South East Asia 
China Brunei 
Japan Cambodia 
Dem. People’s Rep. of Korea Indonesia 
Republic of Korea Lao People’s Dem. Rep. 
Mongolia Malaysia 
 Myanmar (Burma) 
Indian Subcontinent and South Asia Philippines 











Iran (Islamic Republic of) Qatar 
Iraq Saudi Arabia 
Israel Syrian Arab Republic 
Jordan Turkey 


















































































Appendix 4 Trial Invitation Letters – Standard and Enhanced Versions 
Dear Sir or Madam, 
 
We are writing to you, from your local GP surgery, to ask if you would take part in a research project 
that we are undertaking.  
 
We know that people who were born outside the UK and their children have a higher rate of 
infection with Hepatitis B and C Virus. Unfortunately, they are often “silent” diseases, and people 
are unaware that they are infected. These viruses can cause more serious liver illness that needs 
treatment. At the moment, we do not know the best way to identify the people who have 
Hepatitis B and C from amongst those who are at risk. This practice has therefore agreed to take 
part in a research project that will try to answer this question. 
 
We are offering you a blood test for Hepatitis B and C. This will involve a short visit to your GP where 
a member of our team will discuss Hepatitis B and C. You can then decide what you would like to 
do. The blood taking itself takes only a few minutes. You will be informed about the results of all 
your tests. Should you be infected you will receive advice and will be assessed at your local specialist 
clinic and offered treatment, if necessary.  
 
If you would like to talk about the project further or ask questions please contact the GP surgery. A 
member of the team may contact you to see if you would like to book an appointment to take part 
in the project, or you can call or attend your GP surgery.  You can leave this project whenever you 
want without giving a reason and this will not affect your medical care.  
 
Yours sincerely,  
 
 
_________________                                                           _____________________ 




[GP surgery address/ headed notepaper] 
 
Dear [Name of patient],  
We are writing to tell you that your GP surgery is working on a new project with a research team 
from Queen Mary University of London. The aim of the project is to encourage more people in 
London and Bradford to get a free test for Hepatitis B and Hepatitis C. These are viruses that can 
affect the liver and may need treatment. It is very important that the Hepatitis B and C viruses are 
found and treated early, so that people can live a longer and healthier life. Your GP surgery and the 
research team hope to test people for Hepatitis B and C, so that we can offer advice and free 
treatment to people who test positive for Hepatitis B/C. 
We would like to offer you the opportunity to have a free, simple blood test for Hepatitis B and C 
organised by your GP surgery. Receiving this letter does not mean that the GP thinks you are ill. 
Many other people from the GP surgery have also received this letter and have been offered the 
test. We hope as many people as possible will take this opportunity for an important free health 
check.  
If you agree to have a Hepatitis B/C test, this will involve a 10 minute visit to your GP surgery. The 
GP will discuss hepatitis with you and organise the test. The test will draw a small amount of blood 
from your arm and this blood will only be tested for Hepatitis B/C.  
Included on the back of this letter is an information sheet to tell you more about Hepatitis B and C. 
If you would like to talk about the project further or ask questions please contact the GP surgery. 
A member of the team may contact you to see if you would like to book an appointment to take 
part in the project, or you can call or attend your GP surgery.  You can leave this project whenever 
you want without giving a reason and this will not affect your medical care.  
Yours sincerely,  
 
 
_________________                                                           _____________________ 




WHY HAVE I BEEN INVITED FOR A TEST?  
Receiving this letter does not mean that the GP thinks you are ill. We have sent 
this letter to many other people from the GP surgery in order to encourage as many 
people as possible to have a test for Hepatitis B and C.  
Many people around the world are infected with Hepatitis B and Hepatitis C. There 
are high rates of these viruses in countries in Asia, Africa and Eastern Europe, 
so people who move from these regions to the UK may be at increased risk of 
having these viruses. It is very important that these viruses are found and treated, 
to promote healthy living and save lives. 
WHAT WILL HAPPEN IF I GO FOR A TEST? 
If you agree to have a test for Hepatitis B and C, this will involve a 10 minute visit 
to your GP surgery. The GP will discuss hepatitis with you and take a small amount 
of blood to test for Hepatitis B and C. The test will be free of charge. 
WHAT WILL HAPPEN AFTER THE TEST? 
Within 3 weeks, you will be contacted by the GP surgery, in order to receive the 
results of your test. If the test shows that you have Hepatitis B or C then you 
will be offered advice and free treatment. Your GP will discuss with you whether 
you will need to take medication to treat or manage the infection. Any treatment 
provided will be free of charge. 
CONFIDENTIALITY 
Like all appointments at the GP surgery, if you decide to come for a test for 
Hepatitis B and C, your appointment will be completely confidential. The results of 
your test will be completely confidential and none of your family members or anyone 
else will be told.  
 
WHAT IS HEPATITIS B AND C?  
Many people in the world are infected with Hepatitis B and/or Hepatitis C. 
These are viruses that can infect the liver. When some people are infected 
with Hepatitis B or Hepatitis C they recover from the virus, but for many 
people the virus will stay in their body for years. This is then called chronic 
viral hepatitis.  
HOW DOES SOMEONE GET HEPATITIS B/ HEPATITIS C?  
If a mother has the Hepatitis B virus, her child may be infected with the virus 
during or after birth. Hepatitis B can also be passed from one person to 
another through sexual contact.  
Both Hepatitis B and Hepatitis C can also be passed from person to person by 
blood- through sharing razorblades, toothbrushes and non-sterilised needles. 
People may get Hepatitis B or C from medical treatment in a country where 
equipment is not properly sterilised.  
WHAT DAMAGE DOES HEPATITIS B AND C CAUSE?  If the Hepatitis B or C virus 
remains in the person’s body it slowly causes damage to their liver and the liver 
is damaged over many years. If it is not treated, eventually it can cause 
liver cirrhosis (scarring of the liver and poor liver function), liver cancer 
and liver failure.  
WHAT ARE THE SYMPTOMS OF HEPATITIS B AND C? Some people with Hepatitis 
B or C might experience symptoms like tiredness, but many people who are 
infected with the viruses do not have symptoms, and will not know that 
they are infected. The only way to know for sure whether you have 
Hepatitis B or C is to have a blood test for hepatitis. 
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Appendix 5 – Patient Information Sheet version 5.0 
Chronic Viral Hepatitis in First and Second Generation Immigrants from ‘At Risk’ Countries: The HepFREE 
study 
 
Patient Information Sheet for Patient Screening  
 
We would like to invite you to take part in our research study. Before you decide we would like you to 
understand why the research is being done and what it would involve for you. It will tell you what will happen 
if you take part and what the risks might be. One of our team will go through the information sheet with you 
and answer any questions you have.  It is entirely your choice whether or not you take part. Talk to others 
about the study if you wish. 
 
1.0 Nature and purpose of the study  
From previous research, we know that people who were born or whose parents were born in certain 
countries are often infected with viruses that can cause liver disease. But many people will be unaware of 
their infection, as the viruses often remain silent. We would like to identify people who have these viruses, 
so we can offer them treatment to try to prevent more serious liver disease. We do not yet know the best 
way to identify within certain ‘at risk’ populations, who are infected with chronic hepatitis and who are not, 
and this study is designed to answer this question.  
 
Chronic Viral hepatitis – what is it and what does it do? 
Chronic viral hepatitis is commonly caused by two viruses – hepatitis B and hepatitis C. Both of these viruses 
travel in blood and can be passed on by contact with another person’s blood. Both viruses can be passed on 
by unsterile medical equipment and they can be passed on by mothers to their children. Chronic viral 
hepatitis may be a mild illness that does not cause any problems but sometimes chronic viral hepatitis causes 
liver disease that may need treatment. We have drugs that we can use to treat viral hepatitis and these work 
for most infected patients. Unfortunately, chronic viral hepatitis usually causes a silent disease and people 
who are infected often don’t realise that they are infected until serious liver damage has occurred. 
 
2.0 Why have I been invited? 
We know from previous work that patients within certain communities have a higher likelihood/ are more at 
risk of having chronic hepatitis. 
 
3.0 Do I have to take part? 
 It is up to you to decide to join the study. We will describe the study and go through this information sheet. 
If you agree to take part, we will then ask you to sign a consent form. You are free to withdraw at any time, 




4.0 What will happen to me if I take part? 
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In your GP practice, all selected patients will be invited. You may be contacted by your GP surgery to book an 
appointment for testing.  If you would like to participate, one of the doctors will talk to you about viral 
hepatitis. You will then be asked to allow yourself to be tested for viral hepatitis. This will involve a small 
needle prick in one of your veins to draw 4 teaspoons (5 to 10ml) of blood which will then be sent to a local 
laboratory for testing. After testing the sample will be kept for the duration of the study as well as additional 
2 years (to allow clinical tests to be performed in line with normal clinical management). Your visit to the 
practice should not take more than 10 minutes all together.  Your GP will be informed of the results, and 
patients will be re-contacted to receive their results. If you don’t have viral hepatitis no further action is 
needed. We will test only for viral hepatitis.  
If you do have viral hepatitis you will be asked to attend a clinic where one of the doctors will talk to you 
about further tests that are needed. You may need treatment to protect your liver and the doctor who sees 
you in the clinic will explain this. You will be treated just like every other patient with viral hepatitis. 
This is going to be a long term project and we will be collecting data and information held and managed by 
the Health and Social Care Information Centre and other central UK NHS bodies. This information may be 
used to provide information about your health status. This will not require us to contact you directly. If you 
do not wish to have long term data about you collected you are free to decline to take part in this part of the 
study. 
 
5.0 What are the possible disadvantages and risks of taking part? 
The study involves 10 minutes of your time to learn about viral hepatitis and you will be asked to allow us to 
take a blood sample. This is an uncomfortable procedure. You will have to wait for the results of the test and 
this can cause anxiety.  
 
6.0 What are the possible benefits of taking part? 
The aim of this study will hopefully tell us how best to identify people from high risk communities, who are 
infected with viral hepatitis.  
Patients who participate in the study will learn whether or not they have viral hepatitis and if they do have 
viral hepatitis then they will be able to get treatment which may be helpful.  
If you test positive for viral hepatitis, in line with standard practice, your GP will recommend your children to 
get tested for viral hepatitis. As part of the study, we would like to collect information about testing rates in 
children and so ask for your permission for access to this data.  
 
7.0 What happens when the research study stops?  
Nothing, you will continue to receive your clinical standard of care for your viral hepatitis. 
 
8.0 What if there is a problem? 
We believe that this study is safe and do not expect you to suffer any harm because of your participation. 
However, Queen Mary University of London has agreed that if you are harmed as a result of your participation 
in the study, you will be compensated, provided that, on balance of probabilities, an injury was caused as a 
direct result of interventions or procedures you received during the course of the study. These special 
compensation arrangements apply where an injury is caused to you that would have not happen if you were 
not participating in the study.  These arrangements do not affect your right to pursue a claim through legal 
action. If you wish to complain, or have any concerns about any aspect of the way you have been approached 
or treated during the course of this study, the normal National Health Service complaints mechanisms should 
be available to you and you can obtain advice on this, or any other aspect of the study from :- 
Patient Advice and Liaison Service (PALS) Telephone: is available Monday to Friday, 9.30am-4.30pm 




9.0 Will my taking part be kept confidential? 
Your participation in this study will be kept confidential and your name will not be made known to anyone 
other than people working on the study. All information which is collected about you during the course of 
the research will be kept strictly confidential.   
Your patient details and details about your health will be transferred from your GP practice to the study team 
at Queen Mary University of London, in a secure and confidential manner. The study team will comply with 
information governance policy. Data collected as part of this study will be kept in a secure database and will 
only be accessible to authorised members of the HepFREE Team. Professor Graham Foster will be responsible 
for the data that is collected as part of this trial (data custodian). 
If you consent to take part in the research the people conducting the study will abide by the Data Protection 
Act 1998, and the patient rights you have under this Act.   
 
10.0 What will happen to any samples I give? 
All patients will need to have blood taken (about 4 teaspoons) in order to be tested for viral hepatitis.  The 
sample will be sent to a local laboratory where it will be tested to see if you have ever been exposed to viral 
hepatitis and the length of time that you have had it. After completion of the study, it will be kept for 2 years 
(to allow clinical tests to be performed in line with normal clinical management).  
 
11.0 Who is organising, funding and reviewing the research? 
This study is being sponsored by Queen Mary, University of London and the funder is Department of Health. 
This research study has been reviewed by an independent group of individuals known as a Research Ethics 
Committee, to protect your interests. This study has been reviewed and given favourable opinion by NRES 
Committee London - Fulham Research Ethics Committee. 
  
12.0 Further information and contact details  
You are encouraged to ask questions at any time in the study.  If you have a problem or concerns about the 







Appendix 6 – HepFREE Screening Trial Consent Form  
Chronic Viral Hepatitis in First and Second Generation Immigrants from ‘At Risk’ Countries:  
The HepFREE Study 
Consent Form Version 5.0 dated 27Mar2015 
 
Centre (GP practice):     Participant ID for this study: 
 
Please initial box to indicate agreement INITIAL BELOW 
I confirm that I have read and understand the information sheet dated 27Mar2015 
 (version 5.0) for the above study. I have had the opportunity to consider the 
information, ask questions and have these answered satisfactorily. 
 
I understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving any reason, without my medical care or legal rights being affected. 
 
I understand that relevant sections of any of my medical notes and data collected 
during the study, may be looked at by responsible individuals from the Primary Care 
Trust/ Barts Health NHS Trust/Queen Mary, University of London or from regulatory 
authorities, where it is relevant to my taking part in this research. I give permission 
for these individuals to have access to my records.  
 
 
I understand that data collected as part of the study has to be stored for 20 years and 
agree to this. 
 
 
I understand that if I test positive for viral hepatitis, it will recommended that all 
immediate family members get tested including children (if applicable). If this is 
applicable, I give permission for these individuals to have access to data to gather 
further information about testing rates in children.  
 
I understand and agree that information held and managed by The Health and Social 
Care Information Centre and other central NHS bodies may be used in order to 
provide information about my health status.  
 
I agree to take part in the above study.  
 
____________________  ________________               
 ________________ 
Name of Participant Date Signature 
_________________________ ________________                ________________ 
Name of Person taking consent Date  Signature 
(if different from investigator) 
_________________________ ________________                 ________________ 






Appendix 7 – Supplementary Patient Information Sheet for Community Care 
Chronic Viral Hepatitis in First and Second Generation Immigrants from ‘At Risk’ Countries: The HepFREE 
study 
 
 Supplementary Patient Information Sheet for Community Care therapy 
 
We would like to invite you to continue to take part in our research study. Before you decide we would like 
you to understand what research is being done and what it would involve for you. It will tell you what will 
happen if you take part. One of our team will go through the information sheet with you and answer any 
questions you have.  It is entirely your choice whether or not you take part. Talk to others about the study if 
you wish. 
 
2.0 Nature and purpose of the study  
 
You have previously read the patient information sheet for the screening component of this study, in which 
the nature and the purpose of the study have been previously highlighted. If you are reading this 
supplementary patient information sheet, it is because you have tested positive for viral hepatitis and have 
remained on study. 
 
2.0 Do I have to take part? 
It is up to you to decide to remain on study. We will describe the next stage of the study in this information 
sheet. If you agree to take part, we will then ask you to sign a consent form. You are free to withdraw at 
any time, without giving a reason. This would not affect the standard of care you receive.  
 
4.0 What will happen to me if I take part? 
In your GP practice, all patients that test positive for viral hepatitis are to be referred to a community care 
practice for treatment, where you will be under the care of your GP, a specialist hepatitis nurse and a 
hepatology consultant.  At this community based clinic, you will receive the same treatment as if you were 
referred to your local hospital specialist unit, like every other patient with viral hepatitis. This will not affect 
your treatment or subsequent medical care. 
 
5.0 What are the possible benefits/disadvantages of taking part? 
Patients that have viral hepatitis then they will be able to get treatment which may be helpful. You can 
receive your hepatitis treatment within a community based practice, or you can withdraw and continue 
treatment at your local hospital, as per standard of care.  
 
6.0 What happens when the research study stops?  
Nothing, you will continue to receive your clinical standard of care for your viral hepatitis. 
 
7.0 What if there is a problem? 
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Provisions are the same as the screening component, regardless of this, if you wish to complain, or have 
any concerns about any aspect of the way you have been approached or treated during the course of this 
study, the normal National Health Service complaints mechanisms should be available to you and you can 
obtain advice on this, or any other aspect of the study from :- 




8.0 Will my taking part be kept confidential? 
Your continued participation, as before, will be kept confidential and your name will not be made known to 
anyone other than people working on the study.  If you consent to take part the study will abide by the 
Data Protection Act 1998, and the patient rights you have under this Act.   
 
12.0 Further information and contact details  
You are encouraged to ask questions at any time in the study.  If you have a problem or concerns about the 









Appendix 8 – Supplementary Informed Consent Form 
Chronic Viral Hepatitis in First and Second Generation Immigrants from ‘At Risk’ countries: The HepFREE Study 
Supplementary Informed Consent Form for Viral Hepatitis Positive Patients 
Consent Form Version 3.0 dated 12 March 15 
 




Please INITIAL box to indicate agreement Initial below 
 
I confirm that I have read and understood the ‘Supplementary Patient Information 
Sheet for Viral Hepatitis Positive Patients’ information sheet dated 12 March 2015 
(version 3.0) for the above study. I have had the opportunity to consider the 
information, ask questions and these have been answered satisfactorily. 
 
I agree to remain on the HepFREE Study which will involve randomly (by chance) 
being assigned to receive treatment at a local hospital or at a local community 
care practice. I understand that the clinical care I receive will be the same, 




____________________  ________________               
 ________________ 
Name of Participant Date Signature 
 
_________________________ ________________                ________________ 
Name of Person taking consent Date Signature 
(if different from investigator) 
 
_________________________ ________________                 ________________ 









Appendix  9 – Standard Operating Procedure Document for East London HepFREE Clinics 
Chronic Viral Hepatitis in First and  Second Generation Immigrants from 
‘At Risk’ Countries . A controlled randomised cross sectional  cluster trial 
to assess the impact of  identifying, screening and treating immigrants 









Standard operating procedure document for the treatment of 






This will act as a standard operating procedure document designed as an aid for the assessment, treatment 
and management of patients diagnosed with chronic hepatitis B or hepatitis C virus (HBV and HCV) 
infection through the HepFREE trial, and assigned to the community based treatment arm of the study.  The 
flow charts will provide time lines to indicate key follow up appointments required in the treatment of HBV 
and HCV and appointments required to meet the primary objectives set by the study.  The document is 
designed to use in conjunction with Barts Health NHS Trust clinical guidelines for the management of 
chronic viral hepatitis. 
 
Study objectives 
• One of the primary objectives of the HepFREE study is to determine whether community based 
therapy is superior to conventional delivery of treatment as measured by engagement with 
management and treatment. 
• Engagement with the study is defined completion of at least three visits for diagnosis, investigation 
and management in a 12 month period: 
o For patients who test HBsAg positive, or HCV Antibody, RNA positive this is attending (i) 
diagnostic visit (i) prognostic investigation: ultrasound and/or Fibroscan® (iii) management 
visit 
o NB Patients who test HCV antibody positive or equivocal but HCV RNA negative 
engagement is defined as attending the GP practice or the local hospital on two separate 
occasions. 
• Compliance with the clinical management plan is defined as attending at least one visit after the 
management plan is agreed by participant and clinicians. 
• Adherence to therapy in the study is defined as 80% completion of prescribed therapy. 
• The outcome of therapy will also be monitored. A successful outcome of therapy will be defined as 
sustained viral response 12 weeks after treatment completion for HCV infected patients. The 
definition of successful outcome of therapy for HBV treatment is a reduction in viral load to <80% 







ALT Alanine transaminase 
AST Aspartate aminotransferase 
DNA Did Not Attend (appointment) 
FBC Full blood count 
FU Follow up 
G1 Genotype 1 hepatitis C virus infection 
G3 Genotype 3 hepatitis C virus infection 
GCSF Granulocyte-colony stimulating factor 
GP General Practitioner 
HBV Hepatitis B infection 
HCV Hepatitis C Infection 
LFTs Liver function tests 
MDT Multidisciplinary team 
ODN Operational Delivery Network 
PC Primary care 
PCR Polymerase chain reaction 
SC Secondary care 
SOC Standard of care 
SVR Sustained virological response 
TBA To be arranged 
TFTs Thyroid function tests 
Tx Treatment 
U&E Urea and electrolytes 
VHS Viral Hepatitis Service (clinical fellow and nurse 
specialists) 





Inclusion and exclusion criteria 
Care of patients allocated to community based treatment will be coordinated by the viral hepatitis service 
clinical fellow and clinic nurse specialists (VHS), supervised in the community by a named GP and 
supervised remotely by a named hepatologist.  Exclusion criteria exist to ensure patient safety. 
 
Community based treatment is contraindicated in the following groups (for whom it may be unsuitable also 
to treat within secondary care) 
• Pregnancy, considering pregnancy or breast feeding 
• Significant psychiatric history, severe depressive illness or para-suicide 
• Co-existent autoimmune hepatitis or other autoimmune conditions 
• Pre-existing thyroid disease, not controlled on medications 
• Severe, unstable or poorly controlled cardiac disease 
• Poorly controlled or unstable epilepsy. 
• Retinopathy 
• Evidence of decompensated liver disease or a documented previous episode of decompensation 
• Alcohol intake exceeding recommended guidelines 
• Evidence of impending cirrhosis: 
o Platelet count <150 x109/l  
o Albumin <35g/L 
o Evidence of portal hypertension on imaging or endoscopy. 
• A low neutrophil count 
• Chronic renal failure or a creatinine clearance of less than 50mls/min 
• Haemoglobinopathies 





Figure 1: Algorithm for the Assessment and Treatment of Patients with Chronic HBV or HCV infection  
 
  
Primary Care Screening Test 
HBsAg positive  
or Hepatitis C Antibody positive and Hepatitis C RNA positive 
Visit 1: Secondary care 
Appointment time 30 minutes 
1. Obtain secondary stage consent for continuation in the HepFREE trial.   
2. Un-blind participant to treatment allocation.   If patient declines community treatment 
they default to SOC. 
3. Medical assessment and physical examination 
4. Initial verbal and written information provided on possible treatment and prognosis, 
including observation, antiviral therapy and follow-up. 
5. Request fibrosis assessment: ultrasound liver, Fibroscan® 
6. Request blood tests and provide stickers to take to phlebotomy. 
7. Letter to GP with summary and to request vaccination against hepatitis A and B pre-
treatment (if appropriate). 
Bloods 
FBC, U&E, LFTs  Immunoglobulins HIV test 
Liver autoantibodies Ferritin/folate/B12 Alpha-fetoprotein 
For HBsAg positive – eAg, eAb, cAb, HBV DNA 
For HCV Ab, RNA positive - HCV genotype and viral load  
Visits 2 & 3: Fibrosis assessment in secondary care 
Ultrasound abdomen  
Fibroscan® 
Visit 4: VHS assessment in secondary care 
Visit time: 30 minutes 
• Review of pre-treatment bloods and fibrosis assessment with patient 
• If prescribed Interferon: Near patient urine pregnancy test (for female patients) 
and baseline  FBC, U&E, LFTs and  TFTs 
• Arrange provisional date to commence treatment if patient agrees with treatment 
plan 
Multidisciplinary review of patient pathway in SC (patient not present) 
• MDT discussion as part of ODN (includes Lead Consultant, Clinical Fellow, 
Specialist Nurse, Pharmacist) 
• Review of pre-treatment bloods and fibrosis assessment 
• Discuss treatment plan – observation or antiviral treatment  
• Discuss antiviral agent selection for treatment of HBV or HCV 
• Highlight and discuss potential problems associated with treatment 
• Set date for treatment initiation 




Visit 5: Initiation of treatment (visit 1 in primary care) 
Visit time: 45 minutes 
• Prior to visit: VHS to prescribe antiviral therapy, processing and 
checking for drug-drug interactions and dispensing of the 
medications from the hospital pharmacy. 
• VHS to collect prescription for weeks 1-4 of treatment from the 
hospital pharmacy and take to patient in PC. 
• Agree time, date and location of Weeks 2 & 4 visits with 
patient and GP practice. 
• If prescribed interferon: Teaching session on administration of 
interferon, safe disposal of sharps and storage of interferon 
therapy  
• Administer first interferon injection during consultation 
Subsequent visits (follow up): Weeks 2 & 4 
Visit time: 45 minutes 
• Review of patient and treatment side effects. 
• Check adherence to prescribed medication 
• Named GP for review of acute symptoms not associated to treatment 
• Prescription for symptomatic medications if required. 
• At week 4 VHS to collect prescription for weeks 5-8 of treatment from the hospital pharmacy 
and take to patient in PC. 
• Agree time, date and location of Weeks 8, 12, 24 visits with patient and GP practice. 
Venepuncture by VHS for 
Week 2 & 4: FBC, U&E, LFTs  
Addition al Week 4 Bloods  
• for Interferon Treatment: TFTs 
• for HBV Infection : HBV DNA level 
• for HCV Infection: HCV RNA level   
Blood samples to be returned in person for processing at Royal London Hospital.   
MDT review of week 4 blood results in SC 
HBV infected patients on anti-virals 
<1 Log drop in HBV viral load – STOP TREATMENT AND RE-REFER TO SC 
  
HCV infected patients on treatment 
<1 Log drop in HCV viral load – STOP TREATMENT AND RE-REFER TO SC 
If patient has DNA’d x 2 attendances – STOP COMMUNITY FOLLOW-UP and RE-REFER TO SC 
2. HBV Infection on 
treatment 
1. HBV Infection 
for observation 





1. HBV Infection for Observation 
Treatment follow up for participants under observation for HBV infection 
Follow up visits: 30 minutes 
Weeks:  12 & 24 
• Patient review 
• Venepuncture: 
 Week 12: FBC, U&E, LFTs 
 Week 24: FBC, U&E, LFTs, AFP, HBV DNA, and request US Liver 
If blood results within normal limits and US Liver shows no cirrhosis and no 
hepatoma, patient can be followed-up on a six-monthly basis in Community Clinic 
until study end. 
If blood results or ultrasound report abnormal - STOP COMMUNITY FOLLOW-UP 
and RE-REFER TO SC 
If patient has DNA’d x 2 attendances – STOP COMMUNITY FOLLOW-UP and RE-
REFER TO SC 
2. HBV Infection on Antivirals 
Treatment follow up for participants prescribed antiviral therapy for HBV 
infection 
Follow up visits: 30 minutes 
Weeks:  12 & 24 
• Patient review 
• Venepuncture: 
 Week 12: FBC, U&E, LFTs 
 Week 24: FBC, U&E, LFTs, AFP, HBV DNA, and request US Liver 
 Additional bloods for Interferon Treatment: TFTs 
If blood results within normal limits and US Liver shows no cirrhosis and no 
hepatoma, patient can be followed-up on a six-monthly basis in Community Clinic 
until study end. 
If blood results or ultrasound report abnormal - STOP COMMUNITY FOLLOW-UP 
and RE-REFER TO SC 
If patient has DNA’d x 2 attendances – STOP COMMUNITY FOLLOW-UP and RE-




3A. HCV Infection on DAA Therapy 
Genotype 1 HCV infection treatment regimens 
  
Treatment follow up for participants receiving HARVONI therapy 
Weeks:  1, 2, 4 as above 
Week 8 
Visit time: 30 minutes 
• VHS to collect and supply 4 weeks of antiviral therapy 
• Review of patient and treatment side effects. 
• Check adherence to prescribed medication 
• Named GP for review of acute symptoms not associated to treatment 
• Prescription for symptomatic medications if required. 
Venepuncture by VHS for 
FBC, U&E, LFTs, HCV RNA level 
Blood samples to be returned in person for processing at Royal London Hospital. 
  
Week 12: End of Treatment 
Stop HARVONI 
Patient review 
Venepuncture: FBC, LFT, U&E, HCV PCR 
Week 16: SVR4 Monitoring Visit 
Patient review 
Venepuncture: FBC, LFT, U&E, HCV PCR 
Week 24: End of Monitoring 
Patient review 
Venepuncture: FBC, LFT, U&E, TFTs, HCV PCR 
If HCV DNA level = 0, and baseline imaging showed NO CIRRHOSIS: 
SVR12 achieved and patient can be followed-up at Week 48 for repeat HCV DNA prior 
to discharge (as per NHSE guidelines).  Patient should be advised they have been CURED 
of HCV. 
If HCV DNA level = 0 and baseline imaging showed CIRRHOSIS (compensated): 
SVR12 achieved and patient can be followed-up at Week 48 and 6 monthly thereafter 
for repeat HCV DNA and Ultrasound level for HCC surveillance.  Patient should be 




3B. HCV Infection on Interferon therapy  
Genotype 3 HCV infection treatment regimen 
 Treatment follow up for participants receiving Interferon and Ribavirin therapy 
Weeks:  1, 2, 4 as above 
Week 8 
• VHS to collect and supply 4 weeks of antiviral therapy 
• Patient review 
• Venepuncture: FBC, LFT, U&E, TFTs 
• Pregnancy test if appropriate 
  
Week 12 
• If intention to treat for 12 weeks: stop all therapy 
• Patient review 
• Venepuncture: FBC, LFT, U&E, TFTs, HCV RNA level 
• If intention to treat 24weeks: 
• VHS nurse to supply a further 4 weeks of medication 
  
Week 12 PCR review: IF LESS THAN 2 LOG DROP IN HCV VIRAL LOAD OR INCREASE IN VIRAL LOAD 
CONSIDER STOPPING ALL THERAPY AND REFER TO SC 
  
Weeks 16 & 20 
• VHS to collect and supply 4 weeks of antiviral therapy 
• Patient review 
• Venepuncture as per table below 
• Pregnancy test if appropriate 
  
Week 24: end of treatment 
• Patient review 
• Venepuncture: FBC, LFT, U&E, TFTs, HCV RNA level 
• Pregnancy test if appropriate 
Week 28: SVR4 Monitoring Visit 
• Patient review 
• Venepuncture: FBC, LFT, U&E, HCV RNA level 
Week 36: SVR12 Monitoring Visit 
• Patient review 
• Venepuncture: FBC, LFT, U&E, TFTs, HCV RNA level 
Week 48: SVR24 Monitoring Visit 
• Patient review 
• Venepuncture: FBC, LFT, U&E, TFTs, HCV RNA level 
If HCV DNA level = 0, and baseline imaging showed NO CIRRHOSIS: 
SVR24 achieved and patient can be advised they have been CURED of HCV and discharged to GP care. 
If HCV DNA level = 0 and baseline imaging showed CIRRHOSIS (compensated): 
SVR24 achieved and patient can be followed-up 6 monthly thereafter for repeat HCV DNA and Ultrasound 




Additional supportive measures 
  
Use of erythropoietin or granulocyte-colony stimulating factors (GCSF) 
• The follow up frequency will change to one encounter once every two 
weeks for patients requiring darbepoetin or GCSF for the management 
of anaemia or neutropenia. 
• Abnormal blood tests prompting the use of these products are 
discussed with the named hepatologist prior to commencement, after 
dose reduction of ribavirin has occurred. 
• G-CSF and darbepoetin will be taken to the appointment by VHS and 
administered during the consultation. 
  
  
Issue of MED3 sickness certification 
• A patient receiving antiviral therapy may require a period of time off 
work due to either 
• Side effects of treatment or n acute medical problem. 
• If the time off is due to an acute medical problem which is addressed 
and managed by the named GP, a MED3 certificate will be provided by 
the clinician. 
• If the time off is due to side effects of antiviral treatment the case will 
be discussed at the SC MDT and a certificate issued if appropriate. 
  
Non-attendance ‘DNA’ 
• If a patient receiving antiviral therapy fails to attend follow up in the 
community during a week required for receiving prescribed medication, 
the patient should be contacted by phone and offered a SC 
appointment. 
• If a patient receiving antiviral therapy fails to attend follow up in the 
community during a week required for monitoring of therapy the 
patient should be contacted by phone and offered another 
appointment the following week in the community centre. 
• If they patient DNAs the second appointment slot, a SC appointment 







Secondary Care Visits 
The purpose of starting the treatment pathway in secondary care is because the participant, at the 
point of entering the HepFREE trial is ‘blind’ to their allocation of either SOC or community based 
treatment.   
At the index diagnostic assessment supplementary consent will be sought and participants un-
blinded to their treatment allocation.  
If consent is with-held the patient will be removed from the study and subsequent management 
performed as SOC. 
The fibrosis assessment and initial viral hepatitis clinical nurse specialist assessment will be carried 
out in secondary care to ensure all participants have standard work up and characterisation of 
their liver disease prior to consideration of antiviral therapy.   
Once these visits have been completed, cases will be discussed at the SC MDT meeting and a 
treatment pathway signed with intention to treat details. 
At this point the participants contact with secondary care ends unless: 
• They develop a complication preventing on-going treatment in the community 
• They have evidence of significant fibrosis or cirrhosis on Fibroscan® (F3-F4) which 
will require follow up post treatment (at which point they will be offered a SC 
appointment in Hepatology Outpatient Clinic). 
  
Location of community based treatment service 
The community based treatment services in East London will be held at: 
• Jubilee Street Practice, 367-374 Commercial Road, London E1 0LS 
• Dr Abiola Practice, Lord Lister Health Centre, 121 Woodgrange Road, London E7 0EP 
• St Andrews Health Centre, 2 Hannaford Walk Bow, London E3 3FF 
Record Keeping 
The individual treatment pathway will be kept in SC with VHS and taken in a secure bag to the 
clinic.  An entry will be made in the medical record at the associated SC centre (Cerner Millennium 
Electronic Patient Record at the Royal London Hospital).  
  
Emergency contact details 




Appendix  10 – Standard Operating Procedure Document for South London HepFREE Clinics 
Chronic Viral Hepatitis in First and  Second Generation Immigrants from 
‘At Risk’ Countries . A controlled randomised cross sectional  cluster trial 
to assess the impact of  identifying, screening and treating immigrants 









Standard operating procedure document for the treatment of 






This will act as a standard operating procedure document designed as an aid for the assessment, treatment 
and management of patients diagnosed with chronic hepatitis B or hepatitis C virus (HBV and HCV) 
infection through the HepFREE trial, and assigned to the community based treatment arm of the study.  The 
flow charts will provide time lines to indicate key follow up appointments required in the treatment of HBV 
and HCV and appointments required to meet the primary objectives set by the study.  The document is 
designed to use in conjunction with Barts Health NHS Trust clinical guidelines for the management of 
chronic viral hepatitis. 
 
Study objectives 
• One of the primary objectives of the HepFREE study is to determine whether community based 
therapy is superior to conventional delivery of treatment as measured by engagement with 
management and treatment. 
• Engagement with the study is defined completion of at least three visits for diagnosis, investigation 
and management in a 12 month period: 
o For patients who test HBsAg positive, or HCV Antibody, RNA positive this is attending (i) 
diagnostic visit (i) prognostic investigation: ultrasound and/or Fibroscan® (iii) management 
visit 
o NB Patients who test HCV antibody positive or equivocal but HCV RNA negative 
engagement is defined as attending the GP practice or the local hospital on two separate 
occasions. 
• Compliance with the clinical management plan is defined as attending at least one visit after the 
management plan is agreed by participant and clinicians. 
• Adherence to therapy in the study is defined as 80% completion of prescribed therapy. 
• The outcome of therapy will also be monitored. A successful outcome of therapy will be defined as 
sustained viral response 12 weeks after treatment completion for HCV infected patients. The 
definition of successful outcome of therapy for HBV treatment is a reduction in viral load to <80% 







ALT Alanine transaminase 
AST Aspartate aminotransferase 
DNA Did Not Attend (appointment) 
FBC Full blood count 
FU Follow up 
G1 Genotype 1 hepatitis C virus infection 
G3 Genotype 3 hepatitis C virus infection 
GCSF Granulocyte-colony stimulating factor 
GP General Practitioner 
HBV Hepatitis B infection 
HCV Hepatitis C Infection 
LFTs Liver function tests 
MDT Multidisciplinary team 
ODN Operational Delivery Network 
PC Primary care 
PCR Polymerase chain reaction 
SC Secondary care 
SOC Standard of care 
SVR Sustained virological response 
TBA To be arranged 
TFTs Thyroid function tests 
Tx Treatment 
U&E Urea and electrolytes 
VHS Viral Hepatitis Service (clinical fellow and nurse 
specialists) 





Inclusion and exclusion criteria 
Care of patients allocated to community based treatment will be coordinated by the viral hepatitis service 
clinical fellow and clinic nurse specialists (VHS), supervised in the community by a named GP and 
supervised remotely by a named hepatologist.  Exclusion criteria exist to ensure patient safety. 
 
Community based treatment is contraindicated in the following groups (for whom it may be unsuitable also 
to treat within secondary care) 
• Pregnancy, considering pregnancy or breast feeding 
• Significant psychiatric history, severe depressive illness or para-suicide 
• Co-existent autoimmune hepatitis or other autoimmune conditions 
• Pre-existing thyroid disease, not controlled on medications 
• Severe, unstable or poorly controlled cardiac disease 
• Poorly controlled or unstable epilepsy. 
• Retinopathy 
• Evidence of decompensated liver disease or a documented previous episode of decompensation 
• Alcohol intake exceeding recommended guidelines 
• Evidence of impending cirrhosis: 
o Platelet count <150 x109/l  
o Albumin <35g/L 
o Evidence of portal hypertension on imaging or endoscopy. 
• A low neutrophil count 
• Chronic renal failure or a creatinine clearance of less than 50mls/min 
• Haemoglobinopathies 





Figure 1: Algorithm for the Assessment and Treatment of Patients with Chronic HBV or HCV infection  
 
  
Primary Care Screening Test 
HBsAg positive  
or Hepatitis C Antibody positive and Hepatitis C RNA positive 
Visit 1: Secondary care 
Appointment time 30 minutes 
1. Obtain secondary stage consent for continuation in the HepFREE trial.   
2. Un-blind participant to treatment allocation.   If patient declines community treatment 
they default to SOC. 
3. Medical assessment and physical examination 
4. Initial verbal and written information provided on possible treatment and prognosis, 
including observation, antiviral therapy and follow-up. 
5. Request fibrosis assessment: ultrasound liver, Fibroscan® 
6. Request blood tests and provide stickers to take to phlebotomy. 
7. Letter to GP with summary and to request vaccination against hepatitis A and B pre-
treatment (if appropriate). 
Bloods 
FBC, U&E, LFTs  Immunoglobulins HIV test 
Liver autoantibodies Ferritin/folate/B12 Alpha-fetoprotein 
For HBsAg positive – eAg, eAb, cAb, HBV DNA 
For HCV Ab, RNA positive - HCV genotype and viral load  
Visits 2 & 3: Fibrosis assessment in secondary care 
Ultrasound abdomen  
Fibroscan® 
Visit 4: VHS assessment in secondary care 
Visit time: 30 minutes 
• Review of pre-treatment bloods and fibrosis assessment with patient 
• If prescribed Interferon: Near patient urine pregnancy test (for female patients) 
and baseline  FBC, U&E, LFTs and  TFTs 
• Arrange provisional date to commence treatment if patient agrees with treatment 
plan 
Multidisciplinary review of patient pathway in SC (patient not present) 
• MDT discussion as part of ODN (includes Lead Consultant, Clinical Fellow, 
Specialist Nurse, Pharmacist) 
• Review of pre-treatment bloods and fibrosis assessment 
• Discuss treatment plan – observation or antiviral treatment  
• Discuss antiviral agent selection for treatment of HBV or HCV 
• Highlight and discuss potential problems associated with treatment 
• Set date for treatment initiation 




Visit 5: Initiation of treatment (visit 1 in primary care) 
Visit time: 45 minutes 
• Prior to visit: VHS to prescribe antiviral therapy, processing and 
checking for drug-drug interactions and dispensing of the 
medications from the hospital pharmacy. 
• VHS to collect prescription for weeks 1-4 of treatment from the 
hospital pharmacy and take to patient in PC. 
• Agree time, date and location of Weeks 2 & 4 visits with 
patient and GP practice. 
• If prescribed interferon: Teaching session on administration of 
interferon, safe disposal of sharps and storage of interferon 
therapy  
• Administer first interferon injection during consultation 
Subsequent visits (follow up): Weeks 2 & 4 
Visit time: 45 minutes 
• Review of patient and treatment side effects. 
• Check adherence to prescribed medication 
• Named GP for review of acute symptoms not associated to treatment 
• Prescription for symptomatic medications if required. 
• At week 4 VHS to collect prescription for weeks 5-8 of treatment from the hospital pharmacy 
and take to patient in PC. 
• Agree time, date and location of Weeks 8, 12, 24 visits with patient and GP practice. 
Venepuncture by VHS for 
Week 2 & 4: FBC, U&E, LFTs  
Addition al Week 4 Bloods  
• for Interferon Treatment: TFTs 
• for HBV Infection : HBV DNA level 
• for HCV Infection: HCV RNA level   
Blood samples to be returned in person for processing at King’s College London   
MDT review of week 4 blood results in SC 
HBV infected patients on anti-virals 
<1 Log drop in HBV viral load – STOP TREATMENT AND RE-REFER TO SC 
  
HCV infected patients on treatment 
<1 Log drop in HCV viral load – STOP TREATMENT AND RE-REFER TO SC 
If patient has DNA’d x 2 attendances – STOP COMMUNITY FOLLOW-UP and RE-REFER TO SC 
2. HBV Infection on 
treatment 
1. HBV Infection 
for observation 





1. HBV Infection for Observation 
Treatment follow up for participants under observation for HBV infection 
Follow up visits: 30 minutes 
Weeks:  12 & 24 
• Patient review 
• Venepuncture: 
 Week 12: FBC, U&E, LFTs 
 Week 24: FBC, U&E, LFTs, AFP, HBV DNA, and request US Liver 
If blood results within normal limits and US Liver shows no cirrhosis and no 
hepatoma, patient can be followed-up on a six-monthly basis in Community Clinic 
until study end. 
If blood results or ultrasound report abnormal - STOP COMMUNITY FOLLOW-UP 
and RE-REFER TO SC 
If patient has DNA’d x 2 attendances – STOP COMMUNITY FOLLOW-UP and RE-
REFER TO SC 
2. HBV Infection on Antivirals 
Treatment follow up for participants prescribed antiviral therapy for HBV 
infection 
Follow up visits: 30 minutes 
Weeks:  12 & 24 
• Patient review 
• Venepuncture: 
 Week 12: FBC, U&E, LFTs 
 Week 24: FBC, U&E, LFTs, AFP, HBV DNA, and request US Liver 
 Additional bloods for Interferon Treatment: TFTs 
If blood results within normal limits and US Liver shows no cirrhosis and no 
hepatoma, patient can be followed-up on a six-monthly basis in Community Clinic 
until study end. 
If blood results or ultrasound report abnormal - STOP COMMUNITY FOLLOW-UP 
and RE-REFER TO SC 
If patient has DNA’d x 2 attendances – STOP COMMUNITY FOLLOW-UP and RE-




3A. HCV Infection on DAA Therapy 
Genotype 1 HCV infection treatment regimens 
  
Treatment follow up for participants receiving HARVONI therapy 
Weeks:  1, 2, 4 as above 
Week 8 
Visit time: 30 minutes 
• VHS to collect and supply 4 weeks of antiviral therapy 
• Review of patient and treatment side effects. 
• Check adherence to prescribed medication 
• Named GP for review of acute symptoms not associated to treatment 
• Prescription for symptomatic medications if required. 
Venepuncture by VHS for 
FBC, U&E, LFTs, HCV RNA level 
Blood samples to be returned in person for processing at Royal London Hospital. 
  
Week 12: End of Treatment 
Stop HARVONI 
Patient review 
Venepuncture: FBC, LFT, U&E, HCV PCR 
Week 16: SVR4 Monitoring Visit 
Patient review 
Venepuncture: FBC, LFT, U&E, HCV PCR 
Week 24: End of Monitoring 
Patient review 
Venepuncture: FBC, LFT, U&E, TFTs, HCV PCR 
If HCV DNA level = 0, and baseline imaging showed NO CIRRHOSIS: 
SVR12 achieved and patient can be followed-up at Week 48 for repeat HCV DNA prior 
to discharge (as per NHSE guidelines).  Patient should be advised they have been CURED 
of HCV. 
If HCV DNA level = 0 and baseline imaging showed CIRRHOSIS (compensated): 
SVR12 achieved and patient can be followed-up at Week 48 and 6 monthly thereafter 
for repeat HCV DNA and Ultrasound level for HCC surveillance.  Patient should be 




3B. HCV Infection on Interferon therapy  
Genotype 3 HCV infection treatment regimen 
 Treatment follow up for participants receiving Interferon and Ribavirin therapy 
Weeks:  1, 2, 4 as above 
Week 8 
• VHS to collect and supply 4 weeks of antiviral therapy 
• Patient review 
• Venepuncture: FBC, LFT, U&E, TFTs 
• Pregnancy test if appropriate 
  
Week 12 
• If intention to treat for 12 weeks: stop all therapy 
• Patient review 
• Venepuncture: FBC, LFT, U&E, TFTs, HCV RNA level 
• If intention to treat 24weeks: 
• VHS nurse to supply a further 4 weeks of medication 
  
Week 12 PCR review: IF LESS THAN 2 LOG DROP IN HCV VIRAL LOAD OR INCREASE IN VIRAL LOAD 
CONSIDER STOPPING ALL THERAPY AND REFER TO SC 
  
Weeks 16 & 20 
• VHS to collect and supply 4 weeks of antiviral therapy 
• Patient review 
• Venepuncture as per table below 
• Pregnancy test if appropriate 
  
Week 24: end of treatment 
• Patient review 
• Venepuncture: FBC, LFT, U&E, TFTs, HCV RNA level 
• Pregnancy test if appropriate 
Week 28: SVR4 Monitoring Visit 
• Patient review 
• Venepuncture: FBC, LFT, U&E, HCV RNA level 
Week 36: SVR12 Monitoring Visit 
• Patient review 
• Venepuncture: FBC, LFT, U&E, TFTs, HCV RNA level 
Week 48: SVR24 Monitoring Visit 
• Patient review 
• Venepuncture: FBC, LFT, U&E, TFTs, HCV RNA level 
If HCV DNA level = 0, and baseline imaging showed NO CIRRHOSIS: 
SVR24 achieved and patient can be advised they have been CURED of HCV and discharged to GP care. 
If HCV DNA level = 0 and baseline imaging showed CIRRHOSIS (compensated): 
SVR24 achieved and patient can be followed-up 6 monthly thereafter for repeat HCV DNA and Ultrasound 




Additional supportive measures 
  
Use of erythropoietin or granulocyte-colony stimulating factors (GCSF) 
• The follow up frequency will change to one encounter once every two 
weeks for patients requiring darbepoetin or GCSF for the management 
of anaemia or neutropenia. 
• Abnormal blood tests prompting the use of these products are 
discussed with the named hepatologist prior to commencement, after 
dose reduction of ribavirin has occurred. 
• G-CSF and darbepoetin will be taken to the appointment by VHS and 
administered during the consultation. 
  
  
Issue of MED3 sickness certification 
• A patient receiving antiviral therapy may require a period of time off 
work due to either 
• Side effects of treatment or n acute medical problem. 
• If the time off is due to an acute medical problem which is addressed 
and managed by the named GP, a MED3 certificate will be provided by 
the clinician. 
• If the time off is due to side effects of antiviral treatment the case will 
be discussed at the SC MDT and a certificate issued if appropriate. 
  
Non-attendance ‘DNA’ 
• If a patient receiving antiviral therapy fails to attend follow up in the 
community during a week required for receiving prescribed medication, 
the patient should be contacted by phone and offered a SC 
appointment. 
• If a patient receiving antiviral therapy fails to attend follow up in the 
community during a week required for monitoring of therapy the 
patient should be contacted by phone and offered another 
appointment the following week in the community centre. 
• If they patient DNAs the second appointment slot, a SC appointment 






Secondary Care Visits 
The purpose of starting the treatment pathway in secondary care is because the participant, at the 
point of entering the HepFREE trial is ‘blind’ to their allocation of either SOC or community based 
treatment.   
At the index diagnostic assessment supplementary consent will be sought and participants un-
blinded to their treatment allocation.  
If consent is with-held the patient will be removed from the study and subsequent management 
performed as SOC. 
The fibrosis assessment and initial viral hepatitis clinical nurse specialist assessment will be carried 
out in secondary care to ensure all participants have standard work up and characterisation of 
their liver disease prior to consideration of antiviral therapy.   
Once these visits have been completed, cases will be discussed at the SC MDT meeting and a 
treatment pathway signed with intention to treat details. 
At this point the participants contact with secondary care ends unless: 
• They develop a complication preventing on-going treatment in the community 
• They have evidence of significant fibrosis or cirrhosis on Fibroscan® (F3-F4) which 
will require follow up post treatment (at which point they will be offered a SC 
appointment in Hepatology Outpatient Clinic). 
  
Location of community based treatment service 
The community based treatment services in East London will be held at: 
• Albion Street Group Practice, 87 Albion St, London SE16 7JX 
• Manor Place Surgery, 1 Manor Place, London, SE17 3BD 
• Sir John Kirk Close Surgery, 3 Sir John Kirk Close, London, SE5 0BB 
• Crown Dale Medical Centre, 61 Crown Dale, London, SE19 3NY 
 
Record Keeping 
The individual treatment pathway will be kept in SC with VHS and taken in a secure bag to the 
clinic.  An entry will be made in the medical record at the associated SC centre (Sunrise Electronic 
Patient Record at the King’s College Hospital).  
  
Emergency contact details 




Appendix 11: Pre-Screening Survey Questionnaire 
 
 
VIRAL HEPATITIS B & C Survey 
 
Date of interview:  ………………………………………….. 
 
Subject ID: ………………………………………… 
 
 







1: Year of birth:   
 
2: Gender  
Are you:                      Male 
                                
                                      Female    
                              








4: If you were born outside UK, what year did you first come to live in the UK?   …………………………………………. 
 
 















































8: What is your ethnic group? 






Other Asian Background  
 






Other African background  
 












Other European ………………………………………………………………. 
 
Mixed / multiple ethnic groups   
 
White / Pakistani 
 
White  / Black African 
  
White / Chinese  
 
White / Somali  
 








































12: Which of these qualifications do you have?  
• Tick every box that applies if you have any other qualifications listed 
• If your qualification is not listed, tick the box that contains its nearest equivalent 
If you have qualifications gained outside the UK, tick the ‘Foreign qualifications’ box and the nearest UK 
equivalents (if known) 
 
1-4 O levels /CSEs/GSEs (any grades), Entry level, Foundation diploma 
 
NVQ Level 1, Foundation GNVQ, Basic Skills 
 
5+ O level (passes) / CSEs (grade1) / GCSEs (grades A*-C), School Certificate, 1A levels/ 2-3 AS levels / 
VCEs, Higher Diploma 
 
NVQ Level 2, Intermediate GNVQ, City and Guilds Advanced Craft, BTEC First / General National, RSA 
Diploma 
 
Apprenticeship   
 
2+ A levels/VCEs, 4+ AS levels, Higher School certificate, Progression / Advanced Diploma 
 
NVQ Level 3, Advanced GNVQ, City and Guilds Advanced Craft, ONC, OND, BTEC national, RSA Advanced 
Diploma 
 
Degree (for example BA, BSc), Higher Education (For example, MA, PhD, PGCE) 
 
NVQ Level 4-5, HNC, HND, RSA Higher Diploma, BTEC Higher Level 
 
Professional qualifications (For example teaching, nursing, accountancy)  
 
Other vocational / work-related qualifications 
 
Foreign qualifications  
 





















14: What type housing do you live in? 
 
A council flat / house 
 
A privately rented flat /  house 
 





15: Would you mind estimating the approximate total income of your household members during the last year? 
Income includes money from things like state benefits (income support, housing benefit, child benefit, disability 
living allowances), and wages.  
 
Less than £10,000 
 
Between £10,000 and £20,000 
 
Between £20,000 and £30,000 
 
Between £30,000 and £40,000 
 









































19: Have you ever been tested for viral hepatitis B or C?  
 
Yes            Which one?.................................. [Go to question 20] 
 
No              [Go to question 24] 
      
Do not know          [Go to question 24] 
 




20: If yes: 




Do not know 
 




Country of origin 
 





ii. Why were you tested? 
 




Community screening programme (specify)…………… 
 
Ordered by hospital ( because of my other illness)   
 
As part of occupational health / employment  
 
As part of a requirement for course / training  
 
Family member tested positive - for:  hepatitis B and / or hepatitis C …..(specify)……………… 
 
Family member having liver disease 
 
Facilitated by self, to check if having viral hepatitis 
 





21: What was the outcome of the test?  
 
Negative   
 
Positive   
 
Do not know  
 
Other …………………………………  
       
 
 




















































































 No [go to question 27] 
 
Other ………………………………………………..[go to question 27] 
 
 












 26: If yes,  
 




Do not know 
 




Country of origin 
 
Other country  
 
Why were you vaccinated? 
 
As part of a routine health check 
 
Afraid of being infected with viral hepatitis B 
 
As part of antenatal care  
 
As part of occupational health for employment 
 
As part of a requirement for a course / training  
 
To prevent viral hepatitis B 
 


























29: Do you have a family member who has viral hepatitis B or C?  
 
Yes, hepatitis B 
 
























VIRAL HEPATITIS CHECKLIST 
 
This is part of the interview is about how people understand and perceive viral hepatitis B and C 
infections. It is totally anonymous and confidential. We will keep no reference to your name and your 
answers will be combined with others before they are analysed. We are very much interested in your 
personal views, thoughts, and understanding. This means there is no wrong or right answers to the 































1. Please could you tick any of the following boxes, what you think are the symptoms of viral hepatitis (B & C)  
 
Jaundice 
Yellow eyes  
Greenish-yellow eyes 
Not tolerating food with too much butter  / fat  





Fatigue (looking tired)  
Nausea (vomiting)  
Tough liver  
Swollen liver  
Loss of appetite  

















2. Please could you tick any of the following boxes, what you think are the causes of viral 
hepatitis (B & C)  
 
Damaged / weak liver  
 
Weak body  
Food not cooked properly  
Unclean / contaminated food  
Fried food  
Fatty food 
New foods  
Spicy food  
Seafood  
Dirty / contaminated vegetables / salads  
Butter (sheep fat) 
Milk  
Hard work / labour 
Alcohol  




Heat / sun  
Dirty / contaminated khat  









Poor hygiene  
Raw  food  
Poverty 
Physical deprivation  
Migration  
Lack of rest  









3. Please could you tick any of the following boxes, what you think about how viral hepatitis 
(B & C) is spread / transmitted?  
 
Sexual transmission  
Oral sex 
Tasting food while cooking 
Sleeping together   
During birth  
Hereditary (genes)  
Kissing 
Holding  / Shaking hands 
Hugging  
Contact with open wound or open / cut skin   
Tattooing  
Body piercing  
Traditional healing practices 
Smoking 
Alcohol  
Sharing food & drinks with an infected 
person 
Sharing eating / drinking utensils 
Dental surgical equipment  
Poor hygiene practices  
Sharing earrings 
Coughing and sneezing 
Eating food prepared  / cooked by an infected 
person 
Raw food  
Dirty food  
Contaminated food  
Eating pre-chewed food  
 
Mosquitoes  
Dirty water  
Not washing hands 
Sharing water  
Lancet therapy 
Blood and body fluids   (including sweat & 
saliva) 
Sharing razor blades  
Sharing tooth brush 
Sharing water wells 
Organ transplant  
Blood transfusion 
Close contact with the infected 
Drug injecting paraphernalia  – (spoon, 
filter, & needles) 
Surgical procedures  
Breast feeding  
Sharing towels 
Poor hygiene practices  
Sharing (/contaminated) syringes and 
needles for medical  injections  








4. Please could you tick any of the following boxes, what you think can prevent / control the 





Regular check-ups / test / screenings   
Good hygiene 
Clean food  
Properly cooked food  
Balanced diets 
Not sharing food and drinks  
Avoid eating in restaurants   
Not sharing utensils 
Cleanliness 
Not sharing clothes 
Wear clean clothes  
Personal hygiene / cleanliness 
Avoid butter / sheep fat 
Avoid sesame oil with beans  
Clean water 
No sex before marriage 
No extramarital sex 
Regular exercise 
Not sharing razor blades  
Sharing tooth brush 
Avoid travelling in a bus 





No contact with infected individuals 
No kissing  
Cover open wounds 
Enough rest  
Stress reduction  
Adequate sleep  
Indigenous  (herbal) medicines 
Not smoking 
Avoid illicit drugs 
Avoid alcohol  
Avoid blood contact  
Avoid bodily contact 
Use a condom 
Avoid drinking contaminated water  
Healthy living 
Not sharing soap  
Quarantine / isolation for the infected   








5. Please could you tick any of the following boxes, what you think is the course (sequelae) of 
viral hepatitis (B & C)  
 
Liver cancer 





6. Please could you tick any of the following boxes, what you think is the consequences of viral 
hepatitis (B & C)  
 
Liver cancer 
Liver cirrhosis  
Death  








Loss of employment 
Loss of future work / income / financial  security  
Stigma  
Shame  
Fear of getting cancer / death  
Not able to marry / be married  
Being killed by family (honour killing) 
Discrimination  








7. Please could you tick any of the following boxes, what you think are the ways of treating / 
managing viral hepatitis (B & C)  
 
Testing / screening   
Enough rest 
Regular exercise  
Good nutrition (balanced diet)  
Treatment using alternative medicine such as Traditional Chinese Medicine, & other indigenous / 
traditional  medicines   
Watermelon 
Clean water  
Blood transfusion  
Burning area above the liver (parietal area), hands, behind knees, & head  
Drinking camel milk  
Eating lamb / sheep meat   
Hospital treatment with medication / tablets  
Spiritual healing  
Sugar  








































Study title: The provider experience of the ‘HepFREE’ viral hepatitis screening and 
treatment intervention in primary care – follow-up after completion of screening period 
 
We would like to invite you to be part of this research project.  You should only agree to 
take part in this project if you want to; it is entirely up to you.  
Please read the following information before deciding to take part; this will tell you why 
the research is being done and what you will be asked to do if you take part. Please ask if 
there is anything that is not clear or if you would like more information. If you decide to 
take part you will be asked to sign the attached form to say that you agree. You are still 
free to withdraw at any time and without giving a reason. 
 
Purpose of the study: 
The purpose of the research is to explore the experiences of primary care practices 
following the completion of the ‘HepFREE’ intervention of targeted screening and 
treatment for chronic viral hepatitis in high-risk immigrant communities. We are 
interested in gathering perspectives from GPs, practice nurses, and practice managers who 
were involved in the ‘HepFREE’ study. You are being invited to participate in an 
interview as part of this research in order to explore your views on barriers and supports 
to delivering the intervention, and suggestions for improving the national roll-out of the 
service model. We hope that the results of the study will inform us in developing 
recommendations and resources to support primary care services in delivering 
interventions to manage chronic viral hepatitis in immigrant patients.  
 
 
Details of participation: 
If you are willing to participate in the research, you will be invited to take part in an interview 
with a researcher. The timing and length of this interview will be dependent upon your 
availability. The interview can be held by telephone if that is more convenient. As a thank you for 




Do I have to take part?  
It is up to you to decide to join the research interview. We will describe the aims of the research 
interview and go through this information sheet. If you agree to take part, we will then ask you to 
sign a consent form and begin to conduct the interview at a time/place of convenience to you. You 
are free to withdraw at any time, without giving a reason. 
 
Previous HepFREE Research Interview - “implementing and delivering the ‘HepFREE’ 
intervention” 
 
In July – October 2014, the HepFREE team commissioned a very similar research interview called 
“implementing and delivering the ‘HepFREE’ intervention”. You may or may not have 
participated in that research interview at the beginning of the HepFREE study in 2014. The 
procedures for conducting the interviews in 2014 were fully approved by the Research Ethics 
Committee at Queen Mary, University of London (No. QMREC2012/02). Participation in that 
research interview is confidential and the current research interviewer does not know whether you 
have previously been interviewed or not.  
We are interested in linking answers from interviews conducted in 2014, as part of the 
“implementing and delivering the ‘HepFREE’ intervention” study, to these new interviews being 
conducted in 2016/2017, but require your explicit consent to do so.  
If you have previously been interviewed and would like to provide consent for a member of the 
interviewing team to have access to the interview transcripts from 2014 please state your explicit 
consent in the consent form. If you provide consent, a member of the team analysing the 
interviews will analyse answers from both of the interviews but will NOT disclose your name or 
the GP practice where you work. If you would NOT like for the interviewer to have access to the 
interview conducted in July - October 2014 this does not compromise your participation in this 
study. You can still take part in this research interview even if you have not previously been 
interviewed in 2014.  If you did not take part in the 2014 interviews or wish not to disclose your 





Will my taking part be kept confidential? 
Your participation in this study will be kept confidential. All information which is collected about 
you during the course of the research will be kept strictly confidential. The interview will be audio-
recorded, but all names and identifying information will be changed upon transcription of 
recordings. The study will abide by the Data Protection Act 1998, and the rights you have under this 




Who is organising, funding and reviewing the research? 
This study is being sponsored by Queen Mary, University of London and the funder is 
Department of Health. This research study has been reviewed by an independent group of 
individuals known as a Research Ethics Committee, to protect your interests. This study has 
been reviewed and given favourable opinion by NRES Committee London - Fulham 
Research Ethics Committee. 
 
 Further information and contact details  
You are encouraged to ask questions at any time in the study.  If you have a problem or 
concerns about the study or your rights as a subject, please contact: 
 
Dr. Stuart Flanagan - 0207882 3854/ stuart.flanagan@nhs.net 
Hepatology Unit, 
Blizard Institute 
Queen Mary University of London  
4 Newark Street, 
London E1 2AT 
 
If you have any questions or concerns about the manner in which the study was 
conducted please, in the first instance, contact the researcher above responsible for the 
study.  If this is unsuccessful, or not appropriate, please contact the Principal Investigator 





Appendix 13 – HepFREE Provider Experience Participant Consent Form version 1.0 
Title of Study: The provider experience of the ‘HepFREE’ viral hepatitis screening and treatment intervention 
in primary care – follow-up after completion of screening period 
Consent form V1.0_dated_11Aug2016 
Please complete this form after you have read the Information Sheet and/or have received an explanation about 
the research. 
Thank you for considering taking part in this research.  
 
Please initial box to indicate agreement                
           INITIAL BELOW 
I confirm that I have read and understand the information sheet dated 11Aug2016 (version 1.0) 
for the above study. I have had the opportunity to consider the information, ask questions and 
have these answered satisfactorily. 
 
I understand that if I decide at any other time during the research that I no longer wish to 
participate in this project, I can notify the researchers involved and be withdrawn from it 
immediately.  
 
I consent to the processing of my personal information for the purposes of this research study. I 
understand that such information will be treated as strictly confidential and handled in 
accordance with the provisions of the Data Protection Act 1998. 
 
I wish to voluntarily disclose that I took part in the research interviews called “implementing 
and delivering the ‘HepFREE’ intervention” in 2014. I wish to give consent to the current 
interviewers to have access to the interview transcript from 2014 providing that they do not 
disclose my name or the GP Practice where I work. Transcripts from interviews held in 2014 
will be held in strict confidence and in accordance with the provisions of the Data Protection 
Act 1998. If you did not take part in the 2014 interviews or wish not to disclose this 
information please do not initial this statement. You can still take part in the research interview 
even if you do not initial this statement. 
 
I understand that the interview transcripts have to be archived for 20 years and agree to this.  
 
I agree that the research project named above has been explained to me to my satisfaction and I 




____________________ ________________                             ________________ 
Name of Participant Date Signature 
_________________________ ________________                ________________ 






Appendix 14 HepFREE Provider Experience Semi-Structured Interview Questions  
QUESTIONS 
 
1. Motivations & Challenges 
Could you tell me how the practice’s participation in the HepFREE trial has gone?  
Do you think there were any benefits of the trial? (either for the practice, staff or patients) 
- What were they? 
Were there aspects of the trial that staff found problematic? 
Were there aspects of the trial that patients found problematic? 
 
2. Study Set-Up at Practice 
Did someone take the lead for looking after HepFREE at the practice?
- We know this study required inputting of data codes on patient records - how did you and 
other staff member find the process of collecting data? 
- Any comments on how this process compared to collection of other routine data in the 
practice?   
- Was it straightforward or problematic?   
- Why was that? 
- Can you tell me more about your training experience?  How do you think the training 
experience could be improved? 
 
3. Patient Recruitment 
What was the trial recruitment process at your practice? 
Did it include  
- Invitation texts?  
- invitation phone calls? 
- Prompted by Doctor or Nurse testing? 
What was the patient response to  
- Invitation letter? 
- Invitation text? 
- Invitation phone calls? 
- Prompted by Doctor or Nurse testing? 
Were other methods used to recruit patients?  What were they?  Why were they used?  Do you think they 
were successful?
 
4. Consenting Patients to the Trial 
How did you find the consent process (as a staff member)? 
On average how long did it take to explain the trial and consent patients? 
- What were the patients’ reactions to the consent process? 
- What were patients’ reactions to having a blood test as part of the trial? 
372 
 
Did you personally refer patients to the HepFREE team if they tested positive?   
- If yes - could you tell me about the referral process?  Was it fairly easy or difficult? 
- If no, do you know who did? 
 
5. Other Questions: 
Based on your experience of HepFREE which aspects went well?
Which did not go well?
Are there any changes you would suggest? 
- For staff 
- For patients 
 
On balance, would you be happy to take part in this type of study again? 
- Why do you say that? 
 
Would you be happy to screen for viral hepatitis routinely? 
- Why do you say that?
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